

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
11 March 2004 (11.03.2004)

PCT

(10) International Publication Number
WO 2004/019878 A2

(51) International Patent Classification⁷:

A61K

(21) International Application Number:

PCT/US2003/026937

(22) International Filing Date: 27 August 2003 (27.08.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/406,517	27 August 2002 (27.08.2002)	US
60/423,754	5 November 2002 (05.11.2002)	US
60/430,001	27 November 2002 (27.11.2002)	US

(71) Applicant (for all designated States except US): **COMPOUND THERAPEUTICS, INC.** [US/US]; 40 Bear Hill Road, Waltham, MA 02451 (US).

(71) Applicant and

(72) Inventor (for US only): **AEYAN, Noubar, B.** [US/US]; 1 Sunset Ridge, Lexington, MA 02421 (US).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **BAYNES, Brian** [US/US]; 125 Josephine Avenue, Apt.1, Somerville, MA 02144 (US). **DASGUPTA, Ruchira** [IN/US]; 143 Rowe Street, Auburndale, MA 02466 (US). **LEE, Frank, D.** [US/US]; 6 Norfolk Road, Chestnut Hill, MA 02467 (US). **WONG, Gordon, G.** [CA/US]; 134 Clinton Road, Brookline, MA 02445 (US).

(74) Agents: **QUISEL, John, D.** et al.; Ropes & Gray LLP, One International Place, Boston, MA 02110-2624 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

[Continued on next page]

(54) Title: ADZYMES AND USES THEREOF



(57) **Abstract:** Disclosed is a family of novel protein constructs, useful as drugs and for other purposes, termed "adzymes," comprising an address moiety and a catalytic domain. In some types of disclosed adzymes, the address binds with a binding site on or in functional proximity to a targeted biomolecule, e.g., an extracellular targeted biomolecule, and is disposed adjacent the catalytic domain so that its affinity serves to confer anew specificity to the catalytic domain by increasing the effective local concentration of the target in the vicinity of the catalytic domain. The present invention also provides pharmaceutical compositions comprising these adzymes, methods of making adzymes, DNA's encoding adzymes or parts thereof, and methods of using adzymes, such as for treating human subjects suffering from a disease, such as a disease associated with a soluble or membrane bound molecule, e.g., an allergic or inflammatory disease.

WO 2004/019878 A2



LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,

SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

ADZYMES AND USES THEREOF

Related Applications

This application claims priority to U.S. Provisional Patent Application Serial No. 60/406,517, filed August 27, 2002, U.S. Provisional Patent Application Serial No. 60/423,754, filed November 5, 2002, and U.S. Provisional Patent Application Serial No. 60/430,001, filed November 27, 2002, the entire contents of each of which are incorporated herein by reference.

Background of the Invention

This invention relates to synthetic protein constructs useful in modulating a variety of targeted molecules *in situ*. In particular aspects, it relates to a family of constructs employing linked molecular parts which target and modulate the activity of a biomolecule catalytically to induce a therapeutic effect.

Many diseases are caused by or associated with biomolecules, either free in solution in body fluids or exposed to extracellular body fluids such as membrane-bound proteins and polysaccharides, such as cytokines or growth factors, and it is widely recognized that it is possible to develop therapies for such diseases by modulating the activity of the biomolecule.

For example, overproduction of TNF- α and/or TNF- β is closely linked to the development of many diseases, including septic shock, adult respiratory distress syndrome, rheumatoid arthritis, selective autoimmune disorders, graft-host disease following bone marrow transplantation and cachexia. Other diseases associated with excessive TNF- α and/or TNF- β production include hemorrhagic shock, asthma and post-renal dialysis syndrome. The multiplicity of actions of TNF- α and TNF- β can be ascribed to the fact that TNF- α and/or TNF- β actions result in activation of multiple signal transduction pathways, kinases, transcription factors, as well as an unusually large array of cellular genes. (Walajtys-Rode, Elizbieta, Kosmos (Warsaw), 44, 451-464, 1995, C.A. 124:199735a, 1995). TNF α has also been linked to the development of autoimmune disorders.

Current therapies for combating the foregoing disorders include the administration of a binding agent, such as an antibody or soluble receptor, that binds to and thereby inhibits a targeted biomolecule that causes or is associated with the disease. However, there are many drawbacks associated with this approach. For example, binding agents, by their very nature, can only inhibit the biomolecules(s) to which they are bound, and can neither catalytically inactivate a series of biomolecules nor chemically alter the bound biomolecules(s). It is probably for these reasons that relatively large doses of binding

agents are often needed to achieve therapeutic effectiveness, exposing the subject to dangerous and often toxic side-effects. Moreover, production of such large quantities of antibodies and other binding agents is expensive.

Targeted therapeutic agents with greater effectiveness than traditional binding agent therapeutics would be a desirable improvement.

Summary of the Invention

In certain aspects, the invention provides a new class of engineered protein constructs, referred to herein as “adzymes”, as well as methods and compositions related to the use and production of adzymes. Adzymes are chimeric protein constructs that join one or more catalytic domains with one or more targeting moieties (or “addresses”). A catalytic domain of an adzyme has an enzymatically active site that catalyzes a reaction converting a pre-selected substrate (the “target” or “targeted substrate”) into one or more products, such as by cleavage, chemical modifications (transformations) or isomerization. Such products may have an altered activity relative to the substrate, optionally having an increased or decreased activity or an activity that is qualitatively different.

In certain aspects, the invention provides adzymes comprising a catalytic domain and a targeting moiety, wherein the catalytic domain catalyzes a chemical reaction converting a substrate into one or more products, and wherein the targeting moiety reversibly binds to an address site that is either on the substrate or in functional proximity with the substrate. Preferably, the targeting moiety binds reversibly to the address site. Optionally, said targeting moiety and said catalytic domain are heterologous with respect to each other. Generally, said targeting moiety, when provided separately, binds to the substrate, and said catalytic domain, when provided separately, catalyzes the chemical reaction converting said substrate to one or more products.

In certain embodiments, a catalytic domain and a targeting domain of the adzyme are joined by a polypeptide linker to form a fusion protein. A fusion protein may be generated in a variety of ways, including chemical coupling and cotranslation. In a preferred embodiment, the fusion protein is a cotranslational fusion protein encoded by a recombinant nucleic acid. In certain embodiments the linker for the fusion protein is an unstructured peptide. Optionally, the linker includes one or more repeats of Ser₄Gly or SerGly₄. In preferred embodiments, the linker is selected to provide steric geometry between said catalytic domain and said targeting moiety such that said adzyme is more effective against the substrate than either the catalytic domain or targeting moiety alone. For example, the linker may be selected such that the adzyme is more potent than said catalytic domain or targeting moiety with respect to the reaction with said substrate. The

linker may be selected such that the targeting moiety presents the substrate to the enzymatic domain at an effective concentration at least 5 fold greater than would be present in the absence of the targeting moiety.

In certain embodiments, the adzyme is an immunoglobulin fusion, wherein the 5 catalytic domain and the targeting moiety are joined, in a geometry consistent with effectiveness against substrate, to at least a portion of an immunoglobulin comprising a constant domain of an immunoglobulin. For example, the adzyme may comprise a first fusion protein and a second fusion protein, wherein the first fusion protein comprises a constant portion of an immunoglobulin heavy chain and a catalytic domain, and wherein 10 the second fusion protein comprises a constant portion of an immunoglobulin heavy chain and a targeting domain that reversibly binds with an address site on or in functional proximity to the substrate. Preferably the immunoglobulin portions are Fc portions that dimerize by disulfide bonds.

In certain embodiments, an adzyme is designed so as to have one or more desirable 15 properties, with respect to the reaction with said substrate. In many instances, such properties will be significant for achieving the desired effect of the adzyme on the substrate. For example, an adzyme may have a potency at least 2 times greater than the potency of catalytic domain or the targeting moiety alone, and preferably at least 3, 5, 10, 20 or more times greater than the potency of the catalytic domain or targeting moiety 20 alone. An adzyme may have a k_{on} of $10^3 \text{ M}^{-1}\text{s}^{-1}$ or greater, and optionally a k_{on} of $10^4 \text{ M}^{-1}\text{s}^{-1}$, $10^5 \text{ M}^{-1}\text{s}^{-1}$, $10^6 \text{ M}^{-1}\text{s}^{-1}$, $10^7 \text{ M}^{-1}\text{s}^{-1}$ or greater. An adzyme may have a k_{cat} of 0.1 sec^{-1} or greater, and optionally a k_{cat} of 1 sec^{-1} , 10 sec^{-1} , 50 sec^{-1} or greater. An adzyme may have a K_D that is at least 5, 10, 25, 50 or 100 or more fold less than the K_m of the catalytic 25 domain. An adzyme may have a k_{off} of 10^{-4} sec^{-1} or greater, and optionally a k_{off} of 10^{-3} sec^{-1} , 10^{-2} sec^{-1} , or greater. An adzyme may have a catalytic efficiency that is at least 5 fold greater than the catalytic efficiency of the catalytic domain alone, and optionally a catalytic efficiency that is at least 10 fold, 20 fold, 50 fold or 100 fold greater than that of the catalytic domain. An adzyme may have a K_m at least 5 fold, 10 fold, 20 fold, 50 fold, or 100 fold less than the K_m of the catalytic domain alone. An adzyme may have an 30 effective substrate concentration that is at least 5 fold, 10 fold, 20 fold, 50 fold or 100 fold greater than the actual substrate concentration. In certain preferred embodiments, an adzyme will be designed so as to combine two or more of the above described properties.

A catalytic domain may include essentially any enzymatic domain that achieves 35 the desired effect on a selected substrate. The catalytic domain may be selected so as to modify one or more pendant groups of said substrate. The substrate may include a chiral atom, and said catalytic domain may alter the ratio of stereoisomers. The catalytic domain may alter the level of post-translational modification of the polypeptide substrate, such as

a glycosylation, phosphorylation, sulfation, fatty acid modification, alkylation, prenylation or acylation. Examples of enzymatic domains that may be selected include: a protease, an esterase, an amidase, a lactamase, a cellulase, an oxidase, an oxidoreductase, a reductase, a transferase, a hydrolase, an isomerase, a ligase, a lipase, a phospholipase, a phosphatase, 5 a kinase, a sulfatase, a lysozyme, a glycosidase, a nuclease, an aldolase, a ketolase, a lyase, a cyclase, a reverse transcriptase, a hyaluronidase, an amylase, a cerebrosidase and a chitinase. Regardless of the type of catalytic domain, it may be desirable that the adzyme be resistant to autocatalysis (e.g., inter- or intra-molecular reactions), particularly at an adzyme concentration that is about equal to the concentration of adzyme in a solution 10 to be administered to a subject. In certain embodiment, the adzyme acts on the substrate such that a product of the chemical reaction is an antagonist of the substrate.

In certain preferred embodiments, the catalytic domain of an adzyme includes a protease domain that, when active, cleaves at least one peptide bond of a polypeptide substrate. In general it will be desirable to design the adzyme such that it is resistant to 15 cleavage by the protease catalytic domain. The protease domain may be generated as a zymogen (an inactive form) and then activated prior to use. The adzyme may be purified from a cell culture in the presence of a reversible protease inhibitor, and such inhibitor may be included in any subsequent processing or storage activities.

A targeting moiety may include essentially any molecule or assembly of molecules 20 that binds to the address site (e.g., on the substrate in the case of direct adzymes or on a molecule that occurs in functional proximity to the substrate, in the case of proximity adzymes). In many embodiments, a targeting moiety will comprise a polypeptide or polypeptide complex, and particularly an antibody or polypeptide(s) including an antigen binding site of an antibody. For example, a targeting moiety may include a monoclonal 25 antibody, an Fab and F(ab)2, an scFv, a heavy chain variable region and a light chain variable region. Optionally, the targeting moiety is an artificial protein or peptide sequence engineered to bind to the substrate. In certain embodiments, the targeting moiety is a polyanionic or polycationic binding agent. Optionally, the targeting moiety is an oligonucleotide, a polysaccharide or a lectin. In certain embodiments, the substrate is a 30 receptor, and the targeting moiety includes a ligand (or binding portion thereof) that binds to the receptor. In certain embodiments, the substrate is a ligand of a receptor, and the targeting moiety includes a ligand binding portion of the receptor, particularly a soluble ligand binding portion.

An adzyme may be used to target essentially any amenable substrate in a variety of 35 technological applications, including therapeutic uses, industrial uses, environmental uses and uses in microfabrications. In a preferred embodiment, an adzyme substrate is from a mammal, such as a rodent, a non-human primate or a human. In a preferred embodiment,

the substrate is endogenous to a human patient. In certain embodiments, the substrate is a biomolecule produced by a cell, such as a polypeptide, a polysaccharide, a nucleic acid, a lipid, or a small molecule. In certain embodiments, the substrate is a diffusible extracellular molecule, and preferably an extracellular signaling molecule that may act on an extracellular or intracellular receptor to triggers receptor-mediated cellular signaling. Optionally, the extracellular signaling molecule is an extracellular polypeptide signaling molecule, such as an inflammatory cytokine. In a preferred embodiment, the substrate is an interleukin-1 (e.g., IL-1 α , IL-1 β) or TNF- α . In certain embodiments, the substrate is a polypeptide hormone, a growth factor and/or a cytokine, especially an inflammatory cytokine. Optionally, the adzyme acts to reduce a pro-inflammatory activity of a substrate. A substrate may be selected from among the following: four-helix bundle factors, EGF-like factors, insulin-like factors, β -trefoil factors and cysteine knot factors. In certain embodiments, the substrate is a receptor, particularly a receptor with some portion exposed to the extracellular surface. Optionally, the substrate is a unique receptor subunit of a heteromeric receptor complex. In certain embodiments, the substrate is a biomolecules that is a component of a biomolecular accretion, such as an amyloid deposit or an atherosclerotic plaque. In certain embodiments, the substrate is an intracellular biomolecule, and in such instances, it may be desirable to use an adzyme that is able to enter the targeted cells, such as an adzyme that further comprises a transcytosis moiety that promotes transcytosis of the adzyme into the cell. In certain embodiments, the substrate is a biomolecule produced by a pathogen, such as a protozoan, a fungus, a bacterium or a virus. The substrate may be a prion protein. In a preferred embodiment, the substrate is endogenous to a human patient. In such an embodiment, the adzyme is preferably effective against the substrate in the presence of physiological levels of an abundant human serum protein, such as, serum albumins or an abundant globin.

In a preferred embodiment, the substrate for an adzyme is TNF α . In the case of a direct adzyme, the targeting moiety binds to TNF α . Preferably, the catalytic domain comprises a protease that decreases TNF α activity. For example, the protease is may be selected from among: MT1-MMP; MMP12; tryptase; MT2-MMP; elastase; MMP7; chymotrypsin; and trypsin. The targeting moiety may be selected from among, a soluble portion of a TNF α receptor and a single chain antibody that binds to TNF α , although other targeting moieties are possible. A preferred targeting moiety is an sp55 portion of TNF α Receptor 1 (TNFR1).

In another preferred embodiment, the substrate for an adzyme is an interleukin-1, such as IL-1 α or IL-1 β . In the case of a direct adzyme, the targeting moiety binds to the interleukin-1 substrate. Preferably, the catalytic domain comprises a protease that decreases an IL-1 bioactivity.

In one aspect, the invention provides an adzyme for enzymatically altering a substrate, the adzyme comprising: a catalytic domain that catalyzes a chemical reaction converting said substrate to one or more products, and a targeting moiety that reversibly binds with an address site on said substrate or with an address site on a second molecule

5 that occurs in functional proximity to the substrate, wherein said targeting moiety and said catalytic domain are heterologous with respect to each other, said targeting moiety, when provided separately, binds to the substrate, said catalytic domain, when provided separately, catalyzes the chemical reaction converting said substrate to one or more products, and said adzyme has one or more desirable properties, with respect to the

10 reaction with said substrate. For example, in this aspect, the adzyme may have a potency at least 2 times greater than the catalytic domain or the targeting moiety alone, and preferably at least 3, 5, 10, 20 or more times greater than the potency of the catalytic domain or targeting moiety alone. The adzyme may have a k_{on} of $10^3 \text{ M}^{-1}\text{s}^{-1}$ or greater, and optionally a k_{on} of $10^4 \text{ M}^{-1}\text{s}^{-1}$, $10^5 \text{ M}^{-1}\text{s}^{-1}$, $10^6 \text{ M}^{-1}\text{s}^{-1}$, $10^7 \text{ M}^{-1}\text{s}^{-1}$ or greater. The adzyme

15 may have a k_{cat} of 0.1 sec^{-1} or greater, and optionally a k_{cat} of 1 sec^{-1} , 10 sec^{-1} , 50 sec^{-1} or greater. The adzyme may have a K_D that is at least 5, 10, 25, 50 or 100 or more fold less than the K_m of the catalytic domain. The adzyme may have a k_{off} of 10^{-4} sec^{-1} or greater, and optionally a k_{off} of 10^{-3} sec^{-1} , k_{off} of 10^{-2} sec^{-1} , or greater. The adzyme may have a catalytic efficiency that is at least 5 fold greater than the catalytic efficiency of the

20 catalytic domain alone, and optionally a catalytic efficiency that is at least 10 fold, 20 fold, 50 fold or 100 fold greater than that of the catalytic domain. The adzyme may have a K_m at least 5 fold, 10 fold, 20 fold, 50 fold, or 100 fold less than the K_m of the catalytic domain alone. The adzyme may have an effective substrate concentration that is at least 5 fold, 10 fold, 20 fold, 50 fold or 100 fold greater than the actual substrate concentration.

25 In certain preferred embodiments, the adzyme will be designed so as to combine two or more of the above described properties.

In certain embodiments of an adzyme having one or more of such properties with respect to the reaction with the substrate molecule, a catalytic domain and a targeting domain of the adzyme are joined by a polypeptide and linker to form a fusion protein.

30 The fusion protein may be generated in a variety of ways, including chemical coupling and cotranslation. In a preferred embodiment, the fusion protein is a cotranslational fusion protein encoded by a recombinant nucleic acid. In certain embodiments the linker for the fusion protein is an unstructured peptide. Optionally, the linker includes one or more repeats of Ser₄Gly or SerGly₄. In preferred embodiments, the linker is selected to provide

35 steric geometry between said catalytic domain and said targeting moiety such that said adzyme is more effective against the substrate than either the catalytic domain or targeting moiety alone. For example, the linker may be selected such that the adzyme is more potent than said catalytic domain or targeting moiety with respect to the reaction with said

substrate. The linker may be selected such that the targeting moiety presents the substrate to the enzymatic domain at an effective concentration at least 5 fold greater than would be present in the absence of the targeting moiety.

In certain embodiments of an adzyme having one or more of such properties, the 5 adzyme is an immunoglobulin fusion, wherein the catalytic domain and the targeting moiety are joined, in a geometry consistent with effectiveness against substrate, to at least a portion of an immunoglobulin comprising a constant domain of an immunoglobulin. For example, the adzyme may comprise a first fusion protein and a second fusion protein, wherein the first fusion protein comprises a constant portion of an immunoglobulin heavy 10 chain and a catalytic domain, and wherein the second fusion protein comprises a constant portion of an immunoglobulin heavy chain and a targeting domain that reversibly binds with an address site on or in functional proximity to the substrate. Preferably the immunoglobulin portions are Fc portions that dimerize by disulfide bonds.

In certain embodiments of an adzyme having one or more of such properties, a 15 catalytic domain may include essentially any enzymatic domain that achieves the desired effect on a selected substrate. The catalytic domain may be selected so as to modify one or more pendant groups of said substrate. The substrate may include a chiral atom, and said catalytic domain may alter the ratio of stereoisomers. The catalytic domain may alter the level of post-translational modification of the polypeptide substrate, such as a 20 glycosylation, phosphorylation, sulfation, fatty acid modification, alkylation, prenylation or acylation. Examples of enzymatic domains that may be selected include: a protease, an esterase, an amidase, a lactamase, a cellulase, an oxidase, an oxidoreductase, a reductase, a transferase, a hydrolase, an isomerase, a ligase, a lipase, a phospholipase, a phosphatase, a kinase, a sulfatase, a lysozyme, a glycosidase, a nuclease, an aldolase, a ketolase, a 25 lyase, a cyclase, a reverse transcriptase, a hyaluronidase, an amylase, a cerebrosidase and a chitinase. Regardless of the type of catalytic domain, it may be desirable that the adzyme be resistant to autocatalysis (e.g., inter- or intra-molecular reactions), particularly at an adzyme concentration that is about equal to the concentration of adzyme in a solution to be administered to a subject. In certain embodiment, the adzyme acts on the substrate 30 such that a product of the chemical reaction is an antagonist of the substrate.

In certain preferred embodiments of an adzyme having one or more of the properties described above with respect to the reaction with the substrate, the adzyme includes a protease domain that, when active, cleaves at least one peptide bond of a polypeptide substrate. In general it will be desirable to design the adzyme such that it is 35 resistant to cleavage by the protease catalytic domain. The protease domain may be generated as a zymogen (an inactive form) and then activated prior to use. The adzyme

may be purified from a cell culture in the presence of a reversible protease inhibitor, and such inhibitor may be included in any subsequent processing or storage activities.

In certain embodiments of an adzyme having one or more of the properties described above with respect to the reaction with the substrate, a targeting moiety may 5 include essentially any molecule or assembly of molecules that binds to the address site (e.g., on the substrate in the case of direct adzymes or on a molecule that occurs in functional proximity to the substrate, in the case of proximity adzymes). In many embodiments, a targeting moiety will comprise a polypeptide or polypeptide complex, and particularly an antibody or polypeptide(s) including an antigen binding site of an antibody. 10 For example, a targeting moiety may include a monoclonal antibody, an Fab and F(ab)2, an scFv, a heavy chain variable region and a light chain variable region. Optionally, the targeting moiety is an artificial protein or peptide sequence engineered to bind to the substrate. In certain embodiments, the targeting moiety is a polyanionic or polycationic binding agent. Optionally, the targeting moiety is an oligonucleotide, a polysaccharide or 15 a lectin. In certain embodiments, the substrate is a receptor, and the targeting moiety includes a ligand (or binding portion thereof) that binds to the receptor. In certain embodiments, the substrate is a ligand of a receptor, and the targeting moiety includes a ligand binding portion of the receptor, particularly a soluble ligand binding portion.

In certain embodiments of an adzyme having one or more of the properties 20 described above with respect to the reaction with the substrate, the substrate is a biomolecule produced by a cell, such as a polypeptide, a polysaccharide, a nucleic acid, a lipid, or a small molecule. In certain embodiments, the substrate is a diffusible extracellular molecule, and preferably an extracellular signaling molecule that may act on an extracellular or intracellular receptor to triggers receptor-mediated cellular signaling. 25 Optionally, the extracellular signaling molecule is an extracellular polypeptide signaling molecule, such as an inflammatory cytokine. In a preferred embodiment, the substrate is an interleukin-1 (e.g., IL-1 α , IL-1 β) or a TNF- α . In certain embodiments, the substrate is a polypeptide hormone, a growth factor and/or a cytokine, especially an inflammatory cytokine. Optionally, the adzyme acts to reduces a pro-inflammatory activity of a 30 substrate. A substrate may be selected from is selected from the group consisting of four-helix bundle factors, EGF-like factors, insulin-like factors, β -trefoil factors and cysteine knot factors. In certain embodiments, the substrate is a receptor, particularly a receptor with some portion exposed to the extracellular surface. Optionally, the substrate is a unique receptor subunit of a heteromeric receptor complex. In certain embodiments, the 35 biomolecule is a component of a biomolecular accretion, such as an amyloid deposit or an atherosclerotic plaque. In certain embodiments, the substrate is an intracellular biomolecule, and in such instances, it may be desirable to use an adzyme that is able to

enter the targeted cells, such as an adzyme that further comprises a transcytosis moiety that promotes transcytosis of the adzyme into the cell. In certain embodiments, the substrate is a biomolecule produced by a pathogen, such as a protozoan, a fungus, a bacterium or a virus. The substrate may be a prion protein. In a preferred embodiment, the 5 substrate is endogenous to a human patient. In such an embodiment, the adzyme is preferably effective against the substrate in the presence of physiological levels of an abundant human serum protein, such as, serum albumins or an abundant globin.

In a preferred embodiment of an adzyme having one or more of the properties described above with respect to the reaction with the substrate, the substrate for an adzyme 10 is TNF α . In the case of a direct adzyme, the targeting moiety binds to TNF α . Preferably, the catalytic domain comprises a protease that decreases TNF α activity. For example, the protease is may be selected from among: MT1-MMP; MMP12; tryptase; MT2-MMP; elastase; MMP7; chymotrypsin; and trypsin. The targeting moiety may be selected from among, a soluble portion of a TNF α receptor and a single chain antibody that binds to 15 TNF α , although other targeting moieties are possible. A preferred targeting moiety is an sp55 portion of TNF α Receptor 1 (TNFR1).

In another preferred embodiment of an adzyme having one or more of the properties described above with respect to the reaction with the substrate, the substrate for an adzyme is an interleukin-1, such as IL-1 α or IL-1 β . In the case of a direct adzyme, the 20 targeting moiety binds to the interleukin-1 substrate. Preferably, the catalytic domain comprises a protease that decreases an IL-1 bioactivity.

In one aspect, the invention provides an adzyme for enzymatically altering a substrate, the adzyme comprising: a catalytic domain that catalyzes a chemical reaction converting said substrate to one or more products, and a targeting moiety that reversibly 25 binds with an address site on said substrate or with an address site on a second molecule that occurs in functional proximity to the substrate, wherein the substrate is an extracellular signaling molecule, said targeting moiety and said catalytic domain are heterologous with respect to each other, said targeting moiety, when provided separately, binds to the substrate, said catalytic domain, when provided separately, catalyzes the 30 chemical reaction converting said substrate to one or more products, and said chimeric protein construct is more potent than said catalytic domain or targeting moiety with respect to the reaction with said substrate.

In certain embodiments of an adzyme that targets an extracellular signaling molecule, a catalytic domain and a targeting domain of the adzyme are joined by a 35 polypeptide and linker to form a fusion protein. A fusion protein may be generated in a variety of ways, including chemical coupling and cotranslation. In a preferred embodiment, the fusion protein is a cotranslational fusion protein encoded by a

recombinant nucleic acid. In certain embodiments the linker for the fusion protein is an unstructured peptide. Optionally, the linker includes one or more repeats of Ser₄Gly or SerGly₄. In preferred embodiments, the linker is selected to provide steric geometry between said catalytic domain and said targeting moiety such that said adzyme is more effective against the substrate than either the catalytic domain or targeting moiety alone. For example, the linker may be selected such that the adzyme is more potent than said catalytic domain or targeting moiety with respect to the reaction with said substrate. The linker may be selected such that the targeting moiety presents the substrate to the enzymatic domain at an effective concentration at least 5 fold greater than would be present in the absence of the targeting moiety.

In certain embodiments of an adzyme that targets an extracellular signaling molecule, the adzyme is an immunoglobulin fusion, wherein the catalytic domain and the targeting moiety are joined, in a geometry consistent with effectiveness against substrate, to at least a portion of an immunoglobulin comprising a constant domain of an immunoglobulin. For example, the adzyme may comprise a first fusion protein and a second fusion protein, wherein the first fusion protein comprises a constant portion of an immunoglobulin heavy chain and a catalytic domain, and wherein the second fusion protein comprises a constant portion of an immunoglobulin heavy chain and a targeting domain that reversibly binds with an address site on or in functional proximity to the substrate. Preferably the immunoglobulin portions are Fc portions that dimerize by disulfide bonds.

In certain embodiments of an adzyme that targets an extracellular signaling molecule, the adzyme is designed so as to have one or more desirable properties with respect to the reaction with said substrate. In many instances, such properties will be significant for achieving the desired effect of the adzyme on the substrate. For example, an adzyme may have a potency at least 2 times greater than the catalytic domain or the targeting moiety alone, and preferably at least 3, 5, 10, 20 or more times greater than the potency of the catalytic domain or targeting moiety alone. The adzyme may have a k_{on} of 10^3 M⁻¹s⁻¹ or greater, and optionally a k_{on} of 10^4 M⁻¹s⁻¹, 10^5 M⁻¹s⁻¹, 10^6 M⁻¹s⁻¹, 10^7 M⁻¹s⁻¹ or greater. The adzyme may have a k_{cat} of 0.1 sec⁻¹ or greater, and optionally a k_{cat} of 1 sec⁻¹, 10 sec⁻¹, 50 sec⁻¹ or greater. The adzyme may have a K_D that is at least 5, 10, 25, 50 or 100 or more fold less than the K_m of the catalytic domain. The adzyme may have a k_{off} of 10^{-4} sec⁻¹ or greater, and optionally a k_{off} of 10^{-2} sec⁻¹, k_{off} of 10^{-2} sec⁻¹, or greater. The adzyme may have a catalytic efficiency that is at least 5 fold greater than the catalytic efficiency of the catalytic domain alone, and optionally a catalytic efficiency that is at least 10 fold, 20 fold, 50 fold or 100 fold greater than that of the catalytic domain. The adzyme may have a K_m at least 5 fold, 10 fold, 20 fold, 50 fold, or 100 fold less than the

K_m of the catalytic domain alone. The adzyme may have an effective substrate concentration that is at least 5 fold, 10 fold, 20 fold, 50 fold or 100 fold greater than the actual substrate concentration. In certain preferred embodiments, an adzyme will be designed so as to combine two or more of the above described properties.

5 In certain embodiments of an adzyme that targets an extracellular signaling molecule, a catalytic domain may include essentially any enzymatic domain that achieves the desired effect on a selected substrate. The catalytic domain may be selected so as to modify one or more pendant groups of said substrate. The substrate may include a chiral atom, and said catalytic domain may alter the ratio of stereoisomers. The catalytic domain
10 may alter the level of post-translational modification of a polypeptide substrate, such as a glycosylation, phosphorylation, sulfation, fatty acid modification, alkylation, prenylation or acylation. Examples of enzymatic domains that may be selected include: a protease, an esterase, an amidase, a lactamase, a cellulase, an oxidase, an oxidoreductase, a reductase, a transferase, a hydrolase, an isomerase, a ligase, a lipase, a phospholipase, a phosphatase,
15 a kinase, a sulfatase, a lysozyme, a glycosidase, a nuclease, an aldolase, a ketolase, a lyase, a cyclase, a reverse transcriptase, a hyaluronidase, an amylase, a cerebrosidase and a chitinase. Regardless of the type of catalytic domain, it may be desirable that the adzyme be resistant to autocatalysis (e.g., inter- or intra-molecular reactions), particularly at an adzyme concentration that is about equal to the concentration of adzyme in a solution
20 to be administered to a subject. In certain embodiment, the adzyme acts on the substrate such that a product of the chemical reaction is an antagonist of the substrate. In certain embodiment, the adzyme acts on the substrate such that a product of the chemical reaction is an antagonist of the substrate.

25 In certain preferred embodiments of an adzyme that targets an extracellular signaling molecule, the adzyme includes a protease domain that, when active, cleaves at least one peptide bond of a polypeptide substrate. In general it will be desirable to design the adzyme such that it is resistant to cleavage by the protease catalytic domain. The protease domain may be generated as a zymogen (an inactive form) and then activated prior to use. The adzyme may be purified from a cell culture in the presence of a
30 reversible protease inhibitor, and such inhibitor may be included in any subsequent processing or storage activities.

35 In certain embodiments of an adzyme that targets an extracellular signaling molecule, a targeting moiety may include essentially any molecule or assembly of molecules that binds to the address site (e.g., on the substrate in the case of direct adzymes or on a molecule that occurs in functional proximity to the substrate, in the case of proximity adzymes). In many embodiments, a targeting moiety will comprise a polypeptide or polypeptide complex, and particularly an antibody or polypeptide(s)

including an antigen binding site of an antibody. For example, a targeting moiety may include a monoclonal antibody, an Fab and F(ab)2, an scFv, a heavy chain variable region and a light chain variable region. Optionally, the targeting moiety is an artificial protein or peptide sequence engineered to bind to the substrate. In certain embodiments, the 5 targeting moiety is a polyanionic or polycationic binding agent. Optionally, the targeting moiety is an oligonucleotide, a polysaccharide or a lectin. In certain embodiments, the substrate is a ligand of a receptor, and the targeting moiety includes a ligand binding portion of the receptor, particularly a soluble ligand binding portion.

In certain embodiments of an adzyme targeted to an extracellular signaling 10 molecule, the substrate is preferably an extracellular signaling molecule that acts on an extracellular or intracellular receptor to triggers receptor-mediated cellular signaling. Optionally, the extracellular signaling molecule is an extracellular polypeptide signaling molecule, such as an inflammatory cytokine. In a preferred embodiment, the substrate is an interleukin-1 (e.g., IL-1 α , IL-1 β) or a TNF- α . In certain embodiments, the substrate is 15 a polypeptide hormone, a growth factor and/or a cytokine, especially an inflammatory cytokine. Optionally, the adzyme acts to reduces a pro-inflammatory activity of a substrate. A substrate may be selected from is selected from the group consisting of four-helix bundle factors, EGF-like factors, insulin-like factors, β -trefoil factors and cysteine knot factors. In a preferred embodiment, the substrate is endogenous to a human patient. 20 In such an embodiment, the adzyme is preferably effective against the substrate in the presence of physiological levels of an abundant human serum protein, such as, serum albumins or an abundant globin.

In a preferred embodiment of an adzyme targeted to an extracellular signaling molecule, the substrate for the adzyme is TNF α . In the case of a direct adzyme, the 25 targeting moiety binds to TNF α . Preferably, the catalytic domain comprises a protease that decreases TNF α activity. For example, the protease is may be selected from among: MT1-MMP; MMP12; tryptase; MT2-MMP; elastase; MMP7; chymotrypsin; and trypsin. The targeting moiety may be selected from among, a soluble portion of a TNF α receptor and a single chain antibody that binds to TNF α , although other targeting moieties are 30 possible. A preferred targeting moiety is an sp55 portion of TNF α Receptor 1 (TNFR1).

In another preferred embodiment of an adzyme targeted to an extracellular signaling molecule, the substrate for an adzyme is an interleukin-1, such as IL-1 α or IL-1 β . In the case of a direct adzyme, the targeting moiety binds to the interleukin-1 substrate. Preferably, the catalytic domain comprises a protease that decreases an IL-1 35 bioactivity.

In one aspect, the invention provides adzymes for enzymatically altering a substrate, the adzyme comprising a polypeptide comprising: a catalytic domain that

catalyzes a chemical reaction converting said substrate to one or more products, a targeting domain that reversibly binds with an address site on said substrate or with an address site on a second molecule that occurs in functional proximity to the substrate, and a linker joining said catalytic domain and said targeting domain, wherein said substrate is
5 a receptor, said targeting moiety and said catalytic domain are heterologous with respect to each other, said targeting domain, when provided separately, binds to the substrate, said catalytic domain, when provided separately, catalyzes the chemical reaction converting said substrate to one or more products, and said chimeric protein construct is more potent than said catalytic domain or targeting moiety with respect to the reaction with said
10 substrate.

In certain embodiments of an adzyme that targets a receptor, a catalytic domain and a targeting domain of the adzyme are joined by a polypeptide and linker to form a fusion protein. A fusion protein may be generated in a variety of ways, including chemical coupling and cotranslation. In a preferred embodiment, the fusion protein is a
15 cotranslational fusion protein encoded by a recombinant nucleic acid. In certain embodiments the linker for the fusion protein is an unstructured peptide. Optionally, the linker includes one or more repeats of Ser₄Gly or SerGly₄. In preferred embodiments, the linker is selected to provide steric geometry between said catalytic domain and said targeting moiety such that said adzyme is more effective against the substrate than either
20 the catalytic domain or targeting moiety alone. For example, the linker may be selected such that the adzyme is more potent than said catalytic domain or targeting moiety with respect to the reaction with said substrate. The linker may be selected such that the targeting moiety presents the substrate to the enzymatic domain at an effective concentration at least 5 fold greater than would be present in the absence of the targeting
25 moiety.

In certain embodiments of an adzyme that targets a receptor, the adzyme is an immunoglobulin fusion, wherein the catalytic domain and the targeting moiety are joined, in a geometry consistent with effectiveness against substrate, to at least a portion of an immunoglobulin comprising a constant domain of an immunoglobulin. For example, the
30 adzyme may comprise a first fusion protein and a second fusion protein, wherein the first fusion protein comprises a constant portion of an immunoglobulin heavy chain and a catalytic domain, and wherein the second fusion protein comprises a constant portion of an immunoglobulin heavy chain and a targeting domain that reversibly binds with an address site on or in functional proximity to the substrate. Preferably the immunoglobulin
35 portions are Fc portions that dimerize by disulfide bonds.

In certain embodiments of an adzyme that targets a receptor, the adzyme is designed so as to have one or more desirable properties adzyme has one or more desirable

properties, with respect to the reaction with said substrate. In many instances, such properties will be significant for achieving the desired effect of the adzyme on the substrate. For example, an adzyme may have a potency at least 2 times greater than the catalytic domain or the targeting moiety alone, and preferably at least 3, 5, 10, 20 or more times greater than the potency of the catalytic domain or targeting moiety alone. The adzyme may have a k_{on} of $10^3 \text{ M}^{-1}\text{s}^{-1}$ or greater, and optionally a k_{on} of $10^4 \text{ M}^{-1}\text{s}^{-1}$, $10^5 \text{ M}^{-1}\text{s}^{-1}$, $10^6 \text{ M}^{-1}\text{s}^{-1}$, $10^7 \text{ M}^{-1}\text{s}^{-1}$ or greater. The adzyme may have a k_{cat} of 0.1 sec^{-1} or greater, and optionally a k_{cat} of 1 sec^{-1} , 10 sec^{-1} , 50 sec^{-1} or greater. The adzyme may have a K_D that is at least 5, 10, 25, 50 or 100 or more fold less than the K_m of the catalytic domain. The adzyme may have a k_{off} of 10^{-4} sec^{-1} or greater, and optionally a k_{off} of 10^{-2} sec^{-1} , k_{off} of 10^{-2} sec^{-1} , or greater. The adzyme may have a catalytic efficiency that is at least 5 fold greater than the catalytic efficiency of the catalytic domain alone, and optionally a catalytic efficiency that is at least 10 fold, 20 fold, 50 fold or 100 fold greater than that of the catalytic domain. The adzyme may have a K_m at least 5 fold, 10 fold, 20 fold, 50 fold, or 100 fold less than the K_m of the catalytic domain alone. The adzyme may have an effective substrate concentration that is at least 5 fold, 10 fold, 20 fold, 50 fold or 100 fold greater than the actual substrate concentration. In certain preferred embodiments, an adzyme will be designed so as to combine two or more of the above described properties.

In certain embodiments of an adzyme that targets a receptor, a catalytic domain may include essentially any enzymatic domain that achieves the desired effect on a selected substrate. The catalytic domain may be selected so as to modify one or more pendant groups of said substrate. The substrate may include a chiral atom, and said catalytic domain may alter the ratio of stereoisomers. The catalytic domain may alter the level of post-translational modification of a polypeptide substrate, such as a glycosylation, phosphorylation, sulfation, fatty acid modification, alkylation, prenylation or acylation. Examples of enzymatic domains that may be selected include: a protease, an esterase, an amidase, a lactamase, a cellulase, an oxidase, an oxidoreductase, a reductase, a transferase, a hydrolase, an isomerase, a ligase, a lipase, a phospholipase, a phosphatase, a kinase, a sulfatase, a lysozyme, a glycosidase, a nuclease, an aldolase, a ketolase, a lyase, a cyclase, a reverse transcriptase, a hyaluronidase, an amylase, a cerebrosidase and a chitinase. Regardless of the type of catalytic domain, it may be desirable that the adzyme be resistant to autocatalysis (e.g., inter- or intra-molecular reactions), particularly at an adzyme concentration that is about equal to the concentration of adzyme in a solution to be administered to a subject. In certain embodiment, the adzyme acts on the substrate such that a product of the chemical reaction is an antagonist of the substrate. In certain embodiment, the adzyme acts on the substrate such that a product of the chemical reaction is an antagonist of the substrate.

In certain preferred embodiments of an adzyme that targets a receptor, the adzyme includes a protease domain that, when active, cleaves at least one peptide bond of a polypeptide substrate. In general it will be desirable to design the adzyme such that it is resistant to cleavage by the protease catalytic domain. The protease domain may be 5 generated as a zymogen (an inactive form) and then activated prior to use. The adzyme may be purified from a cell culture in the presence of a reversible protease inhibitor, and such inhibitor may be included in any subsequent processing or storage activities.

In certain embodiments of an adzyme that targets a receptor, a targeting moiety may include essentially any molecule or assembly of molecules that binds to the address 10 site (e.g., on the substrate in the case of direct adzymes or on a molecule that occurs in functional proximity to the substrate, in the case of proximity adzymes). In many embodiments, a targeting moiety will comprise a polypeptide or polypeptide complex, and particularly an antibody or polypeptide(s) including an antigen binding site of an antibody. For example, a targeting moiety may include a monoclonal antibody, an Fab and F(ab)2, 15 an scFv, a heavy chain variable region and a light chain variable region. Optionally, the targeting moiety is an artificial protein or peptide sequence engineered to bind to the substrate. In certain embodiments, the targeting moiety is a polyanionic or polycationic binding agent. Optionally, the targeting moiety is an oligonucleotide, a polysaccharide or a lectin. The targeting moiety may include a ligand (or binding portion thereof) that binds 20 to the receptor.

In certain embodiments of an adzyme that targets a receptor, the substrate is a receptor with some portion exposed to the extracellular surface. Optionally, the substrate is a unique receptor subunit of a heteromeric receptor complex. In a preferred embodiment, the substrate is endogenous to a human patient. In such an embodiment, the 25 adzyme is preferably effective against the substrate in the presence of physiological levels of an abundant human serum protein, such as, serum albumins or an abundant globin.

In a preferred embodiment of an adzyme targeted to a receptor, the substrate for the adzyme is a TNF α receptor, such as TNFR1 or TNFR2. In the case of a direct adzyme, the targeting moiety binds to the receptor. Preferably, the catalytic domain 30 comprises a protease that decreases the TNF α stimulated activity of the receptor. The targeting moiety may be selected from among, a receptor binding portion of TNF α and a single chain antibody that binds to the receptor, although other targeting moieties are possible.

In another preferred embodiment of an adzyme targeted to a receptor, the substrate 35 for an adzyme is an interleukin-1 receptor (IL-1R). In the case of a direct adzyme, the targeting moiety binds to the IL-1R. Preferably, the catalytic domain comprises a protease that decreases an IL-1R bioactivity.

In a further aspect, the invention provides an adzyme for enzymatically altering a substrate, the adzyme comprising: a catalytic domain that catalyzes a chemical reaction converting said substrate to one or more products, and a targeting moiety that reversibly binds with an address site on said substrate or with an address site on a second molecule 5 that occurs in functional proximity to the substrate, wherein one or more of said products is an antagonist of an activity of said substrate.

In certain embodiments of an adzyme that generates an antagonist of the substrate, a catalytic domain and a targeting domain of the adzyme are joined by a polypeptide and linker to form a fusion protein. A fusion protein may be generated in a variety of ways, 10 including chemical coupling and cotranslation. In a preferred embodiment, the fusion protein is a cotranslational fusion protein encoded by a recombinant nucleic acid. In certain embodiments the linker for the fusion protein is an unstructured peptide. Optionally, the linker includes one or more repeats of Ser₄Gly or SerGly₄. In preferred embodiments, the linker is selected to provide steric geometry between said catalytic 15 domain and said targeting moiety such that said adzyme is more effective against the substrate than either the catalytic domain or targeting moiety alone. For example, the linker may be selected such that the adzyme is more potent than said catalytic domain or targeting moiety with respect to the reaction with said substrate. The linker may be selected such that the targeting moiety presents the substrate to the enzymatic domain at 20 an effective concentration at least 5 fold greater than would be present in the absence of the targeting moiety.

In certain embodiments of an adzyme that generates an antagonist of the substrate, the adzyme is an immunoglobulin fusion, wherein the catalytic domain and the targeting moiety are joined, in a geometry consistent with effectiveness against substrate, to at least 25 a portion of an immunoglobulin comprising a constant domain of an immunoglobulin. For example, the adzyme may comprise a first fusion protein and a second fusion protein, wherein the first fusion protein comprises a constant portion of an immunoglobulin heavy chain and a catalytic domain, and wherein the second fusion protein comprises a constant portion of an immunoglobulin heavy chain and a targeting domain that reversibly binds 30 with an address site on or in functional proximity to the substrate. Preferably the immunoglobulin portions are Fc portions that dimerize by disulfide bonds.

In certain embodiments of an adzyme that generates an antagonist of the substrate, the adzyme is designed so as to have one or more desirable properties adzyme has one or more desirable properties, with respect to the reaction with said substrate. In many 35 instances, such properties will be significant for achieving the desired effect of the adzyme on the substrate. For example, an adzyme may have a potency at least 2 times greater than the catalytic domain or the targeting moiety alone, and preferably at least 3, 5, 10, 20 or

more times greater than the potency of the catalytic domain or targeting moiety alone. The adzyme may have a k_{on} of $10^3 \text{ M}^{-1}\text{s}^{-1}$ or greater, and optionally a k_{on} of $10^4 \text{ M}^{-1}\text{s}^{-1}$, $10^5 \text{ M}^{-1}\text{s}^{-1}$, $10^6 \text{ M}^{-1}\text{s}^{-1}$, $10^7 \text{ M}^{-1}\text{s}^{-1}$ or greater. The adzyme may have a k_{cat} of 0.1 sec^{-1} or greater, and optionally a k_{cat} of 1 sec^{-1} , 10 sec^{-1} , 50 sec^{-1} or greater. The adzyme may have a K_D that is at least 5, 10, 25, 50 or 100 or more fold less than the K_m of the catalytic domain. The adzyme may have a k_{off} of 10^{-4} sec^{-1} or greater, and optionally a k_{off} of 10^{-2} sec^{-1} , k_{off} of 10^{-2} sec^{-1} , or greater. The adzyme may have a catalytic efficiency that is at least 5 fold greater than the catalytic efficiency of the catalytic domain alone, and optionally a catalytic efficiency that is at least 10 fold, 20 fold, 50 fold or 100 fold greater than that of the catalytic domain. The adzyme may have a K_m at least 5 fold, 10 fold, 20 fold, 50 fold, or 100 fold less than the K_m of the catalytic domain alone. The adzyme may have an effective substrate concentration that is at least 5 fold, 10 fold, 20 fold, 50 fold or 100 fold greater than the actual substrate concentration. In certain preferred embodiments, an adzyme will be designed so as to combine two or more of the above described properties.

In certain embodiments of an adzyme that generates an antagonist of the substrate, a catalytic domain may include essentially any enzymatic domain that achieves the desired effect on a selected substrate. The catalytic domain may be selected so as to modify one or more pendant groups of said substrate. The substrate may include a chiral atom, and said catalytic domain may alter the ratio of stereoisomers. The catalytic domain may alter the level of post-translational modification of a polypeptide substrate, such as a glycosylation, phosphorylation, sulfation, fatty acid modification, alkylation, prenylation or acylation. Examples of enzymatic domains that may be selected include: a protease, an esterase, an amidase, a lactamase, a cellulase, an oxidase, an oxidoreductase, a reductase, a transferase, a hydrolase, an isomerase, a ligase, a lipase, a phospholipase, a phosphatase, a kinase, a sulfatase, a lysozyme, a glycosidase, a nuclease, an aldolase, a ketolase, a lyase, a cyclase, a reverse transcriptase, a hyaluronidase, an amylase, a cerebrosidase and a chitinase. Regardless of the type of catalytic domain, it may be desirable that the adzyme be resistant to autocatalysis (e.g., inter- or intra-molecular reactions), particularly at an adzyme concentration that is about equal to the concentration of adzyme in a solution to be administered to a subject. In certain embodiment, the adzyme acts on the substrate such that a product of the chemical reaction is an antagonist of the substrate. In certain embodiment, the adzyme acts on the substrate such that a product of the chemical reaction is an antagonist of the substrate.

In certain preferred embodiments of an adzyme that generates an antagonist of the substrate, the adzyme includes a protease domain that, when active, cleaves at least one peptide bond of a polypeptide substrate. In general it will be desirable to design the

adzyme such that it is resistant to cleavage by the protease catalytic domain. The protease domain may be generated as a zymogen (an inactive form) and then activated prior to use. The adzyme may be purified from a cell culture in the presence of a reversible protease inhibitor, and such inhibitor may be included in any subsequent processing or storage 5 activities.

In certain embodiments of an adzyme that generates an antagonist of the substrate, a targeting moiety may include essentially any molecule or assembly of molecules that binds to the address site (e.g., on the substrate in the case of direct adzymes or on a molecule that occurs in functional proximity to the substrate, in the case of proximity 10 adzymes). In many embodiments, a targeting moiety will comprise a polypeptide or polypeptide complex, and particularly an antibody or polypeptide(s) including an antigen binding site of an antibody. For example, a targeting moiety may include a monoclonal antibody, an Fab and F(ab)2, an scFv, a heavy chain variable region and a light chain variable region. Optionally, the targeting moiety is an artificial protein or peptide 15 sequence engineered to bind to the substrate. In certain embodiments, the targeting moiety is a polyanionic or polycationic binding agent. Optionally, the targeting moiety is an oligonucleotide, a polysaccharide or a lectin. The targeting moiety may include a ligand (or binding portion thereof) that binds to the receptor.

In certain embodiments of an adzyme that generates an antagonist of the substrate, 20 the substrate is a biomolecule produced by a cell, such as a polypeptide, a polysaccharide, a nucleic acid, a lipid, or a small molecule. In certain embodiments, the substrate is a diffusible extracellular molecule, and preferably an extracellular signaling molecule that may act on an extracellular or intracellular receptor to triggers receptor-mediated cellular signaling. Optionally, the extracellular signaling molecule is an extracellular polypeptide 25 signaling molecule, such as an inflammatory cytokine. In a preferred embodiment, the substrate is an interleukin-1 (e.g., IL-1 α , IL-1 β) or a TNF- α . In certain embodiments, the substrate is a polypeptide hormone, a growth factor and/or a cytokine, especially an inflammatory cytokine. Optionally, the adzyme acts to reduces a pro-inflammatory activity of a substrate. A substrate may be selected from is selected from the group 30 consisting of four-helix bundle factors, EGF-like factors, insulin-like factors, β -trefoil factors and cysteine knot factors. In certain embodiments, the substrate is a receptor, particularly a receptor with some portion exposed to the extracellular surface. Optionally, the substrate is a unique receptor subunit of a heteromeric receptor complex. In certain embodiments, the biomolecule is a component of a biomolecular accretion, such as an 35 amyloid deposit or an atherosclerotic plaque. In certain embodiments, the substrate is an intracellular biomolecule, and in such instances, it may be desirable to use an adzyme that is able to enter the targeted cells, such as an adzyme that further comprises a transcytosis

moiety that promotes transcytosis of the adzyme into the cell. In certain embodiments, the substrate is a biomolecule produced by a pathogen, such as a protozoan, a fungus, a bacterium or a virus. The substrate may be a prion protein. In a preferred embodiment, the substrate is endogenous to a human patient. In such an embodiment, the adzyme is 5 preferably effective against the substrate in the presence of physiological levels of an abundant human serum protein, such as, serum albumins or an abundant globin.

In a preferred embodiment, the substrate for an adzyme is TNF α . In the case of a direct adzyme, the targeting moiety binds to TNF α . Preferably, the catalytic domain comprises a protease that decreases TNF α activity. For example, the protease is may be 10 selected from among: MT1-MMP; MMP12; tryptase; MT2-MMP; elastase; MMP7; chymotrypsin; and trypsin. The targeting moiety may be selected from among, a soluble portion of a TNF α receptor and a single chain antibody that binds to TNF α , although other targeting moieties are possible. A preferred targeting moiety is an sp55 portion of TNF α Receptor 1 (TNFR1).

15 In another preferred embodiment, the substrate for an adzyme is an interleukin-1, such as IL-1 α or IL-1 β . In the case of a direct adzyme, the targeting moiety binds to the interleukin-1 substrate. Preferably, the catalytic domain comprises a protease that decreases an IL-1 bioactivity.

In one aspect, the invention provides adzymes for enzymatically altering a 20 substrate, the adzyme comprising: a catalytic domain that cleaves at least one peptide bond of said substrate to produce one or more products, and a polypeptide targeting domain that reversibly binds with an address site on said substrate or with an address site on a second molecule that occurs in functional proximity to the substrate, wherein said adzyme is resistant to cleavage by the catalytic domain, said targeting moiety, when 25 provided separately, binds to the substrate, said catalytic domain, when provided separately, cleaves at least one peptide bond of said substrate to produce one or more products, and said chimeric protein construct is more potent than said catalytic domain or targeting moiety with respect to the reaction with said substrate.

In certain embodiments of a proteolytic adzyme, a catalytic domain and a targeting 30 domain of the adzyme are joined by a polypeptide and linker to form a fusion protein. A fusion protein may be generated in a variety of ways, including chemical coupling and cotranslation. In a preferred embodiment, the fusion protein is a cotranslational fusion protein encoded by a recombinant nucleic acid. In certain embodiments the linker for the fusion protein is an unstructured peptide. Optionally, the linker includes one or more 35 repeats of Ser₄Gly or SerGly₄. In preferred embodiments, the linker is selected to provide steric geometry between said catalytic domain and said targeting moiety such that said adzyme is more effective against the substrate than either the catalytic domain or targeting

moiety alone. For example, the linker may be selected such that the adzyme is more potent than said catalytic domain or targeting moiety with respect to the reaction with said substrate. The linker may be selected such that the targeting moiety presents the substrate to the enzymatic domain at an effective concentration at least 5 fold greater than would be 5 present in the absence of the targeting moiety.

In certain embodiments of a proteolytic adzyme, the adzyme is an immunoglobulin fusion, wherein the catalytic domain and the targeting moiety are joined, in a geometry consistent with effectiveness against substrate, to at least a portion of an immunoglobulin comprising a constant domain of an immunoglobulin. For example, the adzyme may 10 comprise a first fusion protein and a second fusion protein, wherein the first fusion protein comprises a constant portion of an immunoglobulin heavy chain and a catalytic domain, and wherein the second fusion protein comprises a constant portion of an immunoglobulin heavy chain and a targeting domain that reversibly binds with an address site on or in functional proximity to the substrate. Preferably the immunoglobulin portions are Fc 15 portions that dimerize by disulfide bonds.

In certain embodiments of a proteolytic adzyme, the adzyme is designed so as to have one or more desirable properties adzyme has one or more desirable properties, with respect to the reaction with said substrate. In many instances, such properties will be significant for achieving the desired effect of the adzyme on the substrate. For example, 20 an adzyme may have a potency at least 2 times greater than the catalytic domain or the targeting moiety alone, and preferably at least 3, 5, 10, 20 or more times greater than the potency of the catalytic domain or targeting moiety alone. The adzyme may have a k_{on} of $10^3 \text{ M}^{-1}\text{s}^{-1}$ or greater, and optionally a k_{on} of $10^4 \text{ M}^{-1}\text{s}^{-1}$, $10^5 \text{ M}^{-1}\text{s}^{-1}$, $10^6 \text{ M}^{-1}\text{s}^{-1}$, $10^7 \text{ M}^{-1}\text{s}^{-1}$ or greater. The adzyme may have a k_{cat} of 0.1 sec^{-1} or greater, and optionally a k_{cat} of 1 sec^{-1} , 25 10 sec^{-1} , 50 sec^{-1} or greater. The adzyme may have a K_D that is at least 5, 10, 25, 50 or 100 or more fold less than the K_m of the catalytic domain. The adzyme may have a k_{off} of 10^{-4} sec^{-1} or greater, and optionally a k_{off} of 10^{-2} sec^{-1} , k_{off} of 10^{-2} sec^{-1} , or greater. The adzyme may have a catalytic efficiency that is at least 5 fold greater than the catalytic efficiency of the catalytic domain alone, and optionally a catalytic efficiency that is at 30 least 10 fold, 20 fold, 50 fold or 100 fold greater than that of the catalytic domain. The adzyme may have a K_m at least 5 fold, 10 fold, 20 fold, 50 fold, or 100 fold less than the K_m of the catalytic domain alone. The adzyme may have an effective substrate concentration that is at least 5 fold, 10 fold, 20 fold, 50 fold or 100 fold greater than the actual substrate concentration. In certain preferred embodiments, an adzyme will be 35 designed so as to combine two or more of the above described properties.

In certain embodiments of the proteolytic adzyme, the substrate is a polypeptide produced by a cell. In certain embodiments, the substrate is a diffusible extracellular

polypeptide, and preferably an extracellular polypeptide signaling molecule that may act on an extracellular or intracellular receptor to triggers receptor-mediated cellular signaling. Optionally, the substrate is an inflammatory cytokine. In a preferred embodiment, the substrate is an interleukin-1 (e.g., IL-1 α , IL-1 β) or a TNF- α . In certain 5 embodiments, the substrate is a polypeptide hormone, a growth factor and/or a cytokine, especially an inflammatory cytokine. Optionally, the adzyme acts to reduces a pro-inflammatory activity of a substrate. A substrate may be selected from is selected from the group consisting of four-helix bundle factors, EGF-like factors, insulin-like factors, β -trefoil factors and cysteine knot factors. In certain embodiments, the substrate is a 10 receptor, particularly a receptor with some portion exposed to the extracellular surface. Optionally, the substrate is a unique receptor subunit of a heteromeric receptor complex. In certain embodiments, the biomolecule is a component of a biomolecular accretion, such as an amyloid deposit or an atherosclerotic plaque. In certain embodiments, the substrate is an intracellular biomolecule, and in such instances, it may be desirable to use an adzyme 15 that is able to enter the targeted cells, such as an adzyme that further comprises a transcytosis moiety that promotes transcytosis of the adzyme into the cell. In certain embodiments, the substrate is a biomolecule produced by a pathogen, such as a protozoan, a fungus, a bacterium or a virus. The substrate may be a prion protein. In a preferred embodiment, the substrate is endogenous to a human patient. In such an embodiment, the 20 adzyme is preferably effective against the substrate in the presence of physiological levels of an abundant human serum protein, such as, serum albumins or an abundant globin.

In general, with a proteolytic adzyme, it will be desirable to design the adzyme such that it is resistant to cleavage by the protease catalytic domain. The protease domain may be generated as a zymogen (an inactive form) and then activated prior to use. The 25 adzyme may be purified from a cell culture in the presence of a reversible protease inhibitor, and such inhibitor may be included in any subsequent processing or storage activities.

In certain embodiments of a proteolytic adzyme, a targeting moiety may include essentially any molecule or assembly of molecules that binds to the address site (e.g., on 30 the substrate in the case of direct adzymes or on a molecule that occurs in functional proximity to the substrate, in the case of proximity adzymes). In many embodiments, a targeting moiety will comprise a polypeptide or polypeptide complex, and particularly an antibody or polypeptide(s) including an antigen binding site of an antibody. For example, a targeting moiety may include a monoclonal antibody, an Fab and F(ab)2, an scFv, a 35 heavy chain variable region and a light chain variable region. Optionally, the targeting moiety is an artificial protein or peptide sequence engineered to bind to the substrate. In certain embodiments, the targeting moiety is a polyanionic or polycationic binding agent.

Optionally, the targeting moiety is an oligonucleotide, a polysaccharide or a lectin. In certain embodiments, the substrate is a receptor, and the targeting moiety includes a ligand (or binding portion thereof) that binds to the receptor. In certain embodiments, the substrate is a ligand of a receptor, and the targeting moiety includes a ligand binding portion of the receptor, particularly a soluble ligand binding portion.

In a preferred embodiment, the substrate for an adzyme is TNF α . In the case of a direct adzyme, the targeting moiety binds to TNF α . Preferably, the catalytic domain comprises a protease that decreases TNF α activity. For example, the protease is may be selected from among: MT1-MMP; MMP12; tryptase; MT2-MMP; elastase; MMP7; chymotrypsin; and trypsin. The targeting moiety may be selected from among, a soluble portion of a TNF α receptor and a single chain antibody that binds to TNF α , although other targeting moieties are possible. A preferred targeting moiety is an sp55 portion of TNF α Receptor 1 (TNFR1).

In another preferred embodiment, the substrate for an adzyme is an interleukin-1, such as IL-1 α or IL-1 β . In the case of a direct adzyme, the targeting moiety binds to the interleukin-1 substrate. Preferably, the catalytic domain comprises a protease that decreases an IL-1 bioactivity.

In one aspect, the invention provides adzymes for enzymatically altering a substrate, the adzyme comprising a polypeptide comprising: a catalytic domain that catalyzes a chemical reaction converting said substrate to one or more products, a targeting domain that reversibly binds with an address site on said substrate or with an address site on a second molecule that occurs in functional proximity to the substrate, and a linker joining said catalytic domain and said targeting domain, wherein said substrate is an extracellular polypeptide signaling molecule, said targeting moiety and said catalytic domain are heterologous with respect to each other, said targeting domain, when provided separately, binds to said substrate, said catalytic domain, when provided separately, catalyzes the chemical reaction converting said substrate to one or more products, and said adzyme is more potent than said catalytic domain or targeting moiety with respect to the reaction with said substrate.

In certain aspects, the invention provides an adzyme for inhibiting receptor-mediated signaling activity of an extracellular substrate polypeptide, the adzyme being a fusion protein comprising a protease domain that catalyzes the proteolytic cleavage of at least one peptide bond of the substrate polypeptide so as to inhibit the receptor-mediated signaling activity of the polypeptide, and a targeting domain that reversibly binds with an address site on said substrate polypeptide, wherein said targeting domain and said protease domain are discrete and heterologous with respect to each other. Optionally, the adzyme is resistant to cleavage by said protease domain. Optionally, the protease domain is a

zymogen. Optionally, the protease domain is selected from among: a serine proteinase, a cysteine protease, a threonine protease, an aspartate protease and a metalloproteinase. Optionally, the adzyme is purified from a cell culture in the presence of a reversible protease inhibitor that inhibits the protease activity of the protease domain. In certain 5 embodiments, the adzyme has one or more properties, with respect to the reaction with said substrate. In many instances, such properties will be significant for achieving the desired effect of the adzyme on the substrate. For example, an adzyme may have a potency at least 2 times greater than the catalytic domain or the targeting moiety alone, and preferably at least 3, 5, 10, 20 or more times greater than the potency of the catalytic 10 domain or targeting moiety alone. The adzyme may have a k_{on} of $10^3 \text{ M}^{-1}\text{s}^{-1}$ or greater, and optionally a k_{on} of $10^4 \text{ M}^{-1}\text{s}^{-1}$, $10^5 \text{ M}^{-1}\text{s}^{-1}$, $10^6 \text{ M}^{-1}\text{s}^{-1}$, $10^7 \text{ M}^{-1}\text{s}^{-1}$ or greater. The adzyme may have a k_{cat} of 0.1 sec^{-1} or greater, and optionally a k_{cat} of 1 sec^{-1} , 10 sec^{-1} , 50 sec^{-1} or greater. The adzyme may have a K_D that is at least 5, 10, 25, 50 or 100 or more fold less than the K_m of the catalytic domain. The adzyme may have a k_{off} of 10^{-4} sec^{-1} or greater, 15 and optionally a k_{off} of 10^{-2} sec^{-1} , k_{off} of 10^{-2} sec^{-1} , or greater. The adzyme may have a catalytic efficiency that is at least 5 fold greater than the catalytic efficiency of the catalytic domain alone, and optionally a catalytic efficiency that is at least 10 fold, 20 fold, 50 fold or 100 fold greater than that of the catalytic domain. The adzyme may have a K_m at least 5 fold, 10 fold, 20 fold, 50 fold, or 100 fold less than the K_m of the catalytic 20 domain alone. The adzyme may have an effective substrate concentration that is at least 5 fold, 10 fold, 20 fold, 50 fold or 100 fold greater than the actual substrate concentration. In certain preferred embodiments, an adzyme will be designed so as to combine two or more of the above described properties. Optionally, the substrate is an inflammatory cytokine. In a preferred embodiment, the substrate is an interleukin-1 (e.g., IL-1 α , IL-1 β) 25 or a TNF- α . In certain embodiments, the substrate is a polypeptide hormone, a growth factor and/or a cytokine, especially an inflammatory cytokine. Optionally, the adzyme acts to reduce a pro-inflammatory activity of a substrate. A substrate may be selected from is selected from the group consisting of four-helix bundle factors, EGF-like factors, insulin-like factors, β -trefoil factors and cysteine knot factors. In a preferred embodiment, the 30 substrate is endogenous to a human patient. In such an embodiment, the adzyme is preferably effective against the substrate in the presence of physiological levels of an abundant human serum protein, such as, serum albumins or an abundant globin. The fusion protein adzymes may be generated in a variety of ways, including chemical coupling and cotranslation. In a preferred embodiment, the fusion protein is a 35 cotranslational fusion protein encoded by a recombinant nucleic acid. In certain embodiments the linker for the fusion protein is an unstructured peptide. Optionally, the linker includes one or more repeats of Ser₄Gly or SerGly₄. In preferred embodiments, the linker is selected to provide steric geometry between said catalytic domain and said

targeting moiety such that said adzyme is more effective against the substrate than either the catalytic domain or targeting moiety alone. For example, the linker may be selected such that the adzyme is more potent than said catalytic domain or targeting moiety with respect to the reaction with said substrate. The linker may be selected such that the 5 targeting moiety presents the substrate to the enzymatic domain at an effective concentration at least 5 fold greater than would be present in the absence of the targeting moiety. A targeting domain may include essentially any molecule or assembly of molecules that binds to the address site (e.g., on the substrate in the case of direct adzymes or on a molecule that occurs in functional proximity to the substrate, in the case of 10 proximity adzymes). In many embodiments, a targeting domain will comprise an antigen binding site of an antibody, such as a single chain antibody. Optionally, the targeting moiety is an artificial protein or peptide sequence engineered to bind to the substrate. In a preferred embodiment, the substrate for the adzyme is TNF α . In the case of a direct adzyme, the targeting moiety binds to TNF α . Preferably, the catalytic domain comprises a 15 protease that decreases TNF α activity. For example, the protease is may be selected from among: MT1-MMP; MMP12; tryptase; MT2-MMP; elastase; MMP7; chymotrypsin; and trypsin. The targeting moiety may be selected from among, a soluble portion of a TNF α receptor and a single chain antibody that binds to TNF α , although other targeting moieties are possible. A preferred targeting moiety is an sp55 portion of TNF α Receptor 1 20 (TNFR1). In another preferred embodiment, the substrate for the adzyme is an interleukin-1, such as IL-1 α or IL-1 β . In the case of a direct adzyme, the targeting moiety binds to the interleukin-1 substrate. Preferably, the catalytic domain comprises a protease that decreases an IL-1 bioactivity.

In one aspect, the invention provides an adzyme for inhibiting receptor-mediated 25 signaling activity of an extracellular substrate polypeptide, the adzyme being an immunoglobulin fusion complex. For example, such an adzyme may comprise: a first fusion protein bound to a second fusion protein, wherein the first fusion protein comprises a constant portion of an immunoglobulin heavy chain and a protease domain that catalyzes the proteolytic cleavage of at least one peptide bond of the substrate polypeptide so as to 30 inhibit the receptor-mediated signaling activity of the polypeptide, and wherein the second fusion protein comprises a constant portion of an immunoglobulin heavy chain and a targeting domain that reversibly binds with an address site on said substrate polypeptide, wherein said targeting domain and said protease domain are discrete and heterologous with respect to each other.

35 In certain aspects, the invention provides adzyme preparations for use in a desired application, such as a therapeutic use, an industrial use, an environmental use or in a microfabrication. Such preparations may be termed adzyme preparations. In certain embodiments, the invention provides an adzyme preparation for therapeutic use in a

human patient, the preparation comprising any adzyme disclosed herein. Optionally, the preparation further comprising a pharmaceutically effective carrier. Optionally, the adzyme preparation is formulated such that autocatalytic modification of the adzyme is inhibited. Optionally, the adzyme comprises a catalytic domain that is a protease, and in 5 certain embodiments, the preparation comprises a reversible inhibitor of said protease, preferably a reversible inhibitor that is safe for administration to a human patient. Optionally, an adzyme preparation for therapeutic use is substantially pyrogen free. An adzyme preparation may be packaged along with instructions for use. For example, an adzyme preparation for therapeutic use may be packaged with instructions for 10 administration to a patient.

In certain aspects, the invention provides methods for making a medicament for use in treating a disorder that is associated with an activity of the substrate of any adzyme disclosed herein, the method comprising formulating the adzyme for administration to a patient, preferably a human patient. In certain embodiments, the invention provides a 15 method of making a medicament for use in treating an inflammatory or allergic disorder, the method comprising formulating an adzyme for administration to a human patient in need thereof, wherein the substrate of the adzyme is an inflammatory cytokine.

In certain aspects, the invention provides methods of treating a disorder that is associated with an activity of the substrate of an adzyme, the method comprising 20 administering a therapeutically effective dose of an adzyme to a human patient in need thereof. In certain embodiments, an adzyme may be used in a method of treating an inflammatory or allergic disorder, the method comprising administering a therapeutically effective dose of an adzyme to a human patient in need thereof, wherein the substrate of the adzyme is an inflammatory cytokine.

25 In certain aspects, the invention provides nucleic acids encoding any of the various polypeptide portions of an adzyme, and particularly recombinant nucleic acids encoding a fusion protein adzyme. Such nucleic acids may be incorporated into an expression vector wherein the expression vector directs expression of the adzyme in a suitable host cell. The invention further provides cells comprising such nucleic acids and vectors. In certain 30 embodiments, the invention provides cells comprising a first nucleic acid comprising a first coding sequence and a second nucleic acid comprising a second coding sequence, wherein the first coding sequence encodes a first fusion protein comprising an immunoglobulin heavy chain and a catalytic domain, and wherein the second coding sequence encodes a second fusion protein comprising an immunoglobulin heavy chain and a targeting domain. Preferably, such as cell, in appropriate culture conditions, secretes an 35 adzyme comprising an Fc fusion protein construct that is a dimer of the first fusion protein and the second fusion protein.

In certain aspects, the invention provides methods for manufacturing an adzyme. Such methods may include expression of polypeptide components in cells. Such methods may include chemical joining of various adzyme components. In one embodiment, a method comprises culturing a cell having an expression vector for producing a fusion protein adzyme in conditions that cause the cell to produce the adzyme encoded by the expression vector; and purifying the adzyme to substantial purity. In one embodiments, a method comprises culturing a cell designed to produce an immunoglobulin fusion in conditions that cause the cell to produce the adzyme encoded by the expression vector; and purifying the adzyme to substantial purity. In certain embodiments, purifying an adzyme to substantial purity includes the use of a reversible inhibitor that inhibits autocatalytic activity of the catalytic domain, and particularly, wherein the catalytic domain of the adzyme is a protease domain, and wherein purifying the adzyme to substantial purity includes the use of a reversible protease inhibitor that inhibits the protease activity of the catalytic domain.

In further aspects, the invention provides methods for designing and producing adzymes with desirable properties, and methods for operating a business that involves designing and selling adzymes with desirable properties, such as therapeutically effective adzymes.

The embodiments and practices of the present invention, other embodiments, and their features and characteristics, will be apparent from the description, figures and claims that follow.

Brief Description of the Drawings

Figures 1A-1J are schematic representations of the structure of a series of different exemplary constructs embodying the invention. The boxes represent moieties having binding or catalytic properties, and can be embodied as true protein domains, *i.e.*, bonded sequences of amino acids forming structures characterized by folding of the peptide chain into alpha helices, beta pleated sheets, random coils, etc., to form separate binding surfaces or enzymatically active sites, and including catalytic moieties (CAT), address moieties (ADD), and protein domains serving to associate these parts together in various operative configurations. Lines connecting boxes represent a covalent bond linking together amino acid sequence defining the respective functional regions, or linkers comprising, for example, a flexible linear linker such as a string of peptide bonded amino acids or a poly(ethylene glycol) chain. Lines between boxes represent non covalent, reversible attachments wherein the parts are held together by a combination of forces such

as hydrogen bonding, hydrophobic-hydrophobic interaction, opposite charge matching, etc., for example, ligand-receptor interactions.

Figure 1K is a schematic diagram illustrating the basic concept of a contingent adzyme.

5 *Figures 2A-2J* are cartoons illustrating various exemplary embodiments of adzyme constructs at various types of targeted biomolecules in position to initiate an enzymatic reaction on the substrate site of the target. The address is designated as AD, the catalytic domain as CD.

10 *Figures 3A-3G* are cartoons illustrating various exemplary embodiments of contingent adzyme constructs in the absence of and in the vicinity of their respective intended targeted biomolecules.

Figure 4 is a cartoon illustrating components of a pre thrombin scFv α HA adzyme.

Figure 5 is electrophoretic analysis of purified model adzyme.

Figure 6 is Western blot analysis of model adzyme activated using Factor Xa.

15 *Figure 7* shows proteolytic activity of thrombin and model adzyme before and after activation on standard thrombin tripeptide substrate.

Figure 8 shows that enhanced adzyme activity is driven by the presence of an address domain.

20 *Figure 9* shows that enhanced adzyme activity requires cotranslational linkage of the domains.

Figure 10 shows proteolytic inactivation of TNF α cytotoxicity.

Figure 11 shows that soluble TNF α receptor p55 address domain binds TNF α .

25 *Figure 12* is a representative expression of several adzyme constructs as analyzed by Western blotting with anti-myc antibody. Lane 1: trypsinogen expressed in the absence of stabilizing benzamidine, Lane 2: trypsinogen, Lane 3: trypsinogen-0aa-sp55, Lane 4: trypsinogen-20aa-sp55; Lane 5: trypsinogen-3aa-sp55, Lane 6: sp55. Material in lanes 2 through 6 was expressed in the presence of 1 mM benzamidine.

30 *Figure 13* shows a snapshot of representative experiments where the fluorescence detected at the end of 2 hours of incubation is compared for the different recombinant adzymes and other control proteins.

Figure 14 shows normalization of trypsin activities.

Figure 15 shows detection of TNF α binding of adzymes by ELISA.

Figure 16 shows kinetic model results comparing the performance of an adzyme, an address, and an enzyme.

Detailed Description of the Invention

5 I. Overview

The invention provides a new class of engineered protein constructs, referred to herein as “adzymes”, as well as methods and compositions related to the use and production of adzymes. Adzymes are chimeric protein constructs that join one or more catalytic domains with one or more targeting moieties (or “addresses”). A catalytic 10 domain of an adzyme has an enzymatically active site that catalyzes a reaction converting a pre-selected substrate (the “target” or “targeted substrate”) into one or more products, such as by cleavage, chemical modifications (transformations) or isomerization. Generally, the catalytic domain is selected such that one or more of the product(s) of the adzyme-mediated reaction have a qualitatively or quantitatively different activity relative 15 to the selected substrate. Merely to illustrate, the adzyme may alter such functional characteristics of a selected substrate as affinity, potency, selectivity, solubility, immunogenicity, half-life, clearance (such as by renal or hepatic function), biodistribution or other pharmacokinetic properties. In certain instances, the product of an adzyme-mediated reaction is itself an antagonist of an activity of the selected substrate.

20 The targeting moiety (or “address”) is a moiety capable of recognizing and reversibly binding to a pre-determined “address binding site” (also herein “address site”), such as, for example, a soluble or membrane-bound biomolecules, or a component of a biomolecular accretion (e.g., a plaque or other insoluble protein-containing aggregate). In certain types of adzymes (termed “direct adzymes”), the targeting moiety binds to the 25 target molecule. In certain types of adzymes (termed “proximity adzymes”) the targeting moiety binds to a molecule that tends to occur in functional proximity to the target. The term “moiety” should be understood as including single molecules or portions thereof (e.g., a polypeptide or sugar that binds to the address binding site), as well as combinations of molecules (e.g., an antibody that binds to an address binding site).

30 In an adzyme, at least one targeting moiety is operatively associated with at least one catalytic domain. An adzyme may be a single polypeptide chain (e.g., a fusion protein) or an assembly of polypeptide chains and/or other molecules that are joined through covalent or non-covalent bonds. Regardless of how the constituent portions of an adzyme are associated, at least one targeting moiety and one catalytic domain should be 35 operatively associated. The term “operatively associated”, as used herein to describe the relationship between a catalytic domain and a targeting moiety, means that the

effectiveness of the associated catalytic domain and targeting moiety in chemically altering or otherwise affecting the activity of the pre-selected substrate is greater than the effectiveness of either the targeting moiety or the catalytic domain alone, and also greater than the effectiveness of both the targeting moiety and the catalytic domain when provided 5 in combination but not in association with each other (e.g., where the target is simultaneously contacted with both a discrete catalytic domain and a discrete targeting moiety). As described below, the adzyme may include other components as well, such as linkers, moieties that influence stability or biodistribution, and the like.

The effectiveness of an adzyme relative to its constituent parts may be assessed in 10 a variety of ways. For example, effectiveness may be assessed in terms of potency of the adzyme, as compared to its component parts, to affect a biological activity of the pre-selected substrate. As another example, effectiveness may be assessed in terms of a comparison of kinetic or equilibrium constants that describe the reaction between the adzyme and the pre-selected substrate to those that apply to the reaction between the 15 component parts and the targeted substrate. In embodiments where an adzyme is intended for use in a mammal, at least one catalytic domain and at least one targeting moiety of an adzyme will be associated such that these portions are operatively associated under physiological conditions (e.g., in whole blood, serum, cell culture conditions, or phosphate buffered saline solution, pH 7). Where the adzyme is intended for other purposes (e.g., the 20 modification of an environmental pollutant or the modification of a component of a molecular reaction), at least one catalytic domain and at least one targeting moiety of an adzyme will be associated such that these portions are operatively associated under the expected or desired reaction conditions.

Merely to illustrate, an adzyme may comprise a catalytic domain that cleaves or 25 otherwise modifies TNF- α , converting it into one or more products having reduced activity, no activity or antagonist activity, thereby ameliorating a disease state associated with TNF- α , such as rheumatoid arthritis or other conditions associated with TNF- α activity.

While not wishing to be bound to any particular mechanism of action, it is 30 expected that a targeting moiety will bind to the pre-selected targeted substrate (direct adzyme) or to another molecule that occurs in the same vicinity as the pre-selected targeted substrate (proximity adzyme), and thereby functions to increase the concentration of the catalytic domain at or near the targeted substrate. In this way, the adzyme is self-concentrating at or in the vicinity of a targeted substrate and has an enhanced effectiveness 35 for reacting with and altering the activity of the targeted substrate, relative to the catalytic or binding domains alone. As a consequence to the improved effectiveness of the targeted

reaction, the adzyme has a greater selectivity and/or catalytic efficiency for the targeted substrate as compared to other non-targeted (potential) substrates of the catalytic domain.

Again, while not wishing to be bound to any particular theory, for certain adzymes it is expected that a relatively fast k_{on} rate for the targeted substrate will be desirable. A k_{on} 5 of at least $10^3 \text{ M}^{-1}\text{s}^{-1}$ may be desirable. Other kinetic and performance parameters that may be useful in certain embodiments are described below.

In most embodiments, the modular components of an adzyme are heterologous with respect to each other, meaning that these domains are not found naturally as part of a single molecule or assembly of molecules, and accordingly, adzymes of these 10 embodiments are not naturally occurring substances. Each of the various domains and moieties that are present in an adzyme may themselves be a naturally occurring protein or protein fragment, or other naturally occurring biomolecule (e.g., a sugar, lipid or non-proteinaceous factor), or an engineered or wholly synthetic molecule.

In most embodiments, a catalytic domain will comprise a polypeptide having 15 enzymatic activity. In certain preferred embodiments, a targeting moiety will comprise a polypeptide. In general, at least one catalytic domain and at least one targeting moiety of the adzyme are selected from amongst "modular" entities, i.e., able to function as a catalyst or binding agent independently. To exemplify, an adzyme may be a single fusion protein comprising (1) a catalytic domain that comprises a polypeptide and has enzymatic 20 activity and (2) a targeting domain that comprises a polypeptide and binds to an address binding site, and, optionally, (3) a polypeptide linker configured such that the catalytic domain and targeting domain are operatively associated. As another example, an adzyme may be a type of immunoglobulin fusion construct, wherein a first fusion protein comprises a catalytic domain fused to a first Fc chain and a second fusion protein 25 comprises a targeting domain fused to a second Fc chain, and wherein the first and second Fc chains are associated in such a way as to cause the catalytic domain and the targeting domain to be operatively associated.

Within the broad category of adzymes, various subcategories or classes of 30 adzymes may be identified. As noted above, two such classes are termed herein "direct" adzymes and "proximity" adzymes. In a direct adzyme the targeting moiety binds to a targeted substrate. The catalytic domain acts on the same type of molecule as the targeting moiety has bound. In certain embodiments, this will require the targeting moiety to dissociate from the targeted substrate in order for the catalytic domain to alter that molecule. Depending on a variety of conditions, such as the concentration of the direct 35 adzyme and the concentration of the targeted substrate, the catalytic domain of a direct adzyme may primarily act on the targeted substrate that is or was bound by the targeting moiety, or the direct adzyme may act on one substrate while the targeting moiety is bound

to another. While not wishing to be bound to mechanism, it is generally expected that when the targeted substrate is present in relatively low concentrations (as is the case for most extracellular signaling molecules in the extracellular fluids of a multicellular organism), a direct adzyme will primarily act on the targeted substrate that is or was

5 bound by the targeting moiety. In a proximity adzyme, the targeting moiety binds to a molecule that is not covalently part of the targeted substrate. Instead, the targeting moiety binds to a molecule that is expected to be found in functional proximity to the targeted substrate. By "functional proximity" is meant that the address binding site is present at sufficient concentration or with sufficient stability in the proximity of targeted substrates

10 that the adzyme reacts with the targeted substrate with greater effectiveness than the catalytic domain and targeting moiety alone or in non-associated combination. While the existence of functional proximity between an address binding site and a targeted substrate is most accurately assessed in the milieu in which the adzyme is intended for use (e.g., in the human body, in a contaminated soil site), an adzyme may be considered a proximity

15 adzyme if it shows the appropriate effectiveness in a reasonable experimental system, such as a culture of cells related to the type of cells that are predicted to be targeted by the adzyme, or in a purified protein mixture where the address binding site and the adzyme are present at concentrations that fairly approximate those that are expected in the intended milieu. In certain embodiments, the targeting moiety binds to a molecule which

20 is diffusionaly constrained with respect to the targeted substrate, meaning that, for whatever reason, the targeted substrate and the address binding site are neither covalently attached nor free to diffuse apart. For example, the targeting moiety may bind one protein in a receptor complex while the catalytic domain acts on another protein in the receptor complex. As another example, the targeting moiety may bind to a protein that is lodged in

25 cell membranes and the targeted substrate may also be lodged in or attached to cell membranes. The terms "direct adzyme" and "indirect adzyme", while distinct concepts that raise different issues in adzyme design, may not, in practice, be entirely mutually exclusive. For example, a targeting moiety may bind to both the targeted substrate and a separate molecule that occurs in functional proximity to the targeted substrate.

30 An additional discernible class of adzymes are the "contingent adzymes". The term "contingent adzymes" refers to adzyme constructs that are catalytically activated or up-regulated in the vicinity of the targeted substrate but less active, such as by inhibition, elsewhere. Both direct and proximity adzymes can be modified to be contingent adzymes, in which the interaction of the targeting domain with its cognate partner alters the activity

35 of the catalytic domain, such as by allosteric, competitive, or non-competitive mechanisms.

As a descriptive example, a variety of antibodies with affinity for particular targets (e.g., anti-TNF- α and anti-EGF receptor) have been used as effective therapeutic agents for certain disorders, and it is expected, in accordance with the teachings herein, that adzymes with greater potency than the antibodies alone may be designed.

5 In a further aspect, the present invention provides pharmaceutical compositions comprising an adzyme of the invention and a pharmaceutically acceptable carrier, as well as methods for making a medicament for use in a human by combining an adzyme with a pharmaceutically acceptable carrier.

In another aspect, the present invention provides a method for treating a subject, 10 e.g., a human, suffering from a disease. The method includes administering (e.g., using a pharmaceutical formulation) a therapeutically, prophylactically or analgesically effective amount of an adzyme, thereby treating a subject suffering from a disease. In one embodiment, the disease is associated with a soluble molecule and the adzyme is administered to the subject in an amount effective to render the soluble molecule 15 biologically inactive.

II. Definitions

For convenience, certain terms employed in the specification, examples, and appended claims are collected here. Unless defined otherwise, all technical and scientific 20 terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

As used herein, the term "aptamer", when referring to a targeting moiety, encompasses an oligonucleotide that interacts with a targeted substrate or associated molecule, e.g., binds to the address site for an adzyme.

25 As used herein, the term "biologically inactive" as it relates to a targeted biomolecule is intended to mean that its biological function is down-regulated, e.g., suppressed or eliminated. For example, if the target is TNF α , biological inactivation would include modifying TNF α such that the inflammatory response mediated by NFkB is inhibited, there is inhibition of the secretion of other pro-inflammatory cytokines, the 30 induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumor and tumor regression activities of the TNF are enhanced; and/or the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumor cells. For example, a catalytic domain capable of methylating TNF α (e.g., methylating TNF α on 35 15 His as described in Yamamoto R. et al. (1989) *Protein Engineering* 2(7):553-8) would inactivate TNF α .

The term “ k_{cat} ”, or the “turnover number”, is the number of substrates converted to product per enzyme molecule per unit of time, when E is saturated with substrate.

The term “ k_{cat}/K_m ”, is an apparent second-order rate constant that is a measure of how the enzyme performs when the concentration of substrate is low (e.g., not saturating).

5 The upper limit for k_{cat}/K_m is the diffusion limit – i.e., the rate at which enzyme and substrate diffuse together. k_{cat} / K_m is also known as the “catalytic efficiency” for the enzyme.

The term “catalytic efficiency”, as applied to an adzyme, is the apparent second-order rate constant of the adzyme when the concentration of substrate is substantially (at least ten-fold) lower than the Michaelis-Menten constant (K_m) for the adzyme (i.e., when $[S] \ll K_m$), at least with respect to those adzymes that can be reasonably modeled using Michaelis-Menten kinetic modeling theories. In the case of many simple catalytic domains taken in isolation, the catalytic efficiency may be defined as the ratio k_{cat}/K_m (see above).

In most cases where Michaelis-Menten modeling applies, the catalytic efficiency 15 will be different for the adzyme and for its component enzyme, i.e. the adzyme’s catalytic efficiency is not k_{cat} / K_m . Both v_{max} and K_m are also different for the adzyme. For a case where the Michaelis-Menten pseudo-steady state analysis is valid (generally $[AE]_0 \ll [S]_0$, wherein $[AE]_0$ is the initial adzyme concentration) and substrate holdup is negligible, simple closed-form expressions for these quantities can be derived:

$$v_{max}^{AE} = \frac{k_{off}^{AS}}{k_{cat}^{ES} + k_{off}^{AS} K_m^E / [S]_{eff} + k_{off}^{AS}} v_{max}^E$$

$$20 K_m^{AE} = \frac{(k_{off}^{AS} K_m^E / [S]_{eff} + k_{cat}^{ES}) k_{off}^{AS}}{(k_{cat}^{ES} + k_{off}^{AS} K_m^E / [S]_{eff} + k_{off}^{AS}) k_{on}^{AS}}$$

wherein v_{max}^{AE} and v_{max}^E are the maximum velocity for the adzyme and its enzyme component, respectively; K_m^{AE} and K_m^E are the K_m for the adzyme and its enzyme component, respectively. The superscript “AS” indicates that the kinetic constant is that of an address / targeting moiety, which is determined by independent experiments on the address; the superscript “ES” indicates that the kinetic constant is that of an enzyme / catalytic moiety, which is determined by independent experiments on the enzyme. $[S]_{eff}$ or the “effective concentration” of the targeted substrate is a geometric parameter of the adzyme with concentration units.

30 The catalytic efficiency for an adzyme is:

$$\begin{aligned}
 \text{Catalytic Efficiency} &= \frac{v_{\max}^{AE}}{K_m^{AE}[AE]_o} \\
 &= \frac{k_{on}^{AS} k_{cat}^{ES}}{k_{off}^{AS} K_m^E / [S]_{\text{eff}} + k_{cat}^{ES}}
 \end{aligned}$$

5 A “chimeric protein construct” is an assemblage comprising at least two heterologous moieties, e.g., a catalytic domain and an address that are heterologous with respect to each other, that are covalently or non-covalently associated to form a complex. A chimeric protein construct may comprise non-proteinaceous molecules.

10 “Differentiation” in the present context means the formation of cells expressing markers known to be associated with cells with different functional properties or cells that are more specialized and closer to becoming terminally differentiated cells incapable of further division or differentiation.

A “fusion protein” is a chimeric protein wherein at least two heterologous amino acid sequences are covalently joined through an amide backbone bond, e.g., to form one contiguous polypeptide.

15 As used herein, the terms “modulate” or “alter” the activity of the targeted substrate are intended to include inhibiting, stimulating, up-regulating, down-regulating, activating, inactivating, or modifying the activity of the target in any other way.

20 A polynucleotide sequence (DNA, RNA) is “operatively linked” to an expression control sequence when the expression control sequence controls and regulates the transcription and translation of that polynucleotide sequence. The term “operatively linked” includes having an appropriate start signal (e.g., ATG) in front of the polynucleotide sequence to be expressed, and maintaining the correct reading frame to permit expression of the polynucleotide sequence under the control of the expression control sequence, and production of the desired polypeptide encoded by the polynucleotide sequence.

25 The term “pharmaceutically acceptable salts” refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention, i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.

30 The terms “polynucleotide sequence” and “nucleotide sequence” are also used interchangeably herein.

As used herein, "protein" is a polymer consisting essentially of any of the 20 amino acids. Accordingly, a protein may include various modifications (e.g., glycosylation, phosphorylation) or non-amino acids. Although "polypeptide" is often used in reference to relatively large polypeptides, and "peptide" is often used in reference to small polypeptides, usage of these terms in the art overlaps and is varied.

As used herein, "proliferating" and "proliferation" refer to cells undergoing mitosis.

The International Union of Biochemistry and Molecular Biology (1984) has recommended to use the term "peptidase" for the subset of peptide bond hydrolases (Subclass E.C 3.4.). The widely used term protease is synonymous with peptidase. Peptidases comprise two groups of enzymes: the endopeptidases and the exopeptidases. Endopeptidases cleave peptide bonds at points within a protein, and exopeptidases remove amino acids sequentially from either the N- or C-terminus.

The term "proteinase" is also used as a synonym for endopeptidase. Proteinases are classified according to their catalytic mechanisms. Five mechanistic classes have been recognized by the International Union of Biochemistry and Molecular Biology: serine proteinases, cysteine proteinases, aspartic proteinases, threonine proteinases, and metalloproteinases.

This classification by catalytic types has been suggested to be extended by a classification by families based on the evolutionary relationships of proteases (Rawlings, N.D. and Barrett, A.J., (1993), *Biochem. J.*, 290, 205-218). This classification is available in the SwissProt database.

In addition to these five mechanistic classes, there is a section of the enzyme nomenclature which is allocated for proteases of unidentified catalytic mechanism. This indicates that the catalytic mechanism has not been identified, and the possibility remains that novel types of proteases do exist.

The class "serine proteinases" comprises two distinct families: the chymotrypsin family which includes the mammalian enzymes such as chymotrypsin, trypsin or elastase or kallikrein, and the subtilisin family which includes the bacterial enzymes such as subtilisin. The general three-dimensional structure is different in the two families but they have the same active site geometry and catalysis proceeds via the same mechanism. The serine proteinases exhibit different substrate specificities which are related to amino acid substitutions in the various enzyme subsites (see the nomenclature of Schechter and Berger) interacting with the substrate residues. Three residues which form the catalytic triad are essential in the catalytic process: His-57, Asp-102 and Ser-195 (chymotrypsinogen numbering).

The family of "cysteine proteinases" includes the plant proteases such as papain, actininidin or bromelain, several mammalian lysosomal cathepsins, the cytosolic calpains (calcium-activated), and several parasitic proteases (e.g., Trypanosoma, Schistosoma). Papain is the archetype and the best studied member of the family. Like the serine proteinases, catalysis proceeds through the formation of a covalent intermediate and involves a cysteine and a histidine residue. The essential Cys-25 and His-159 (papain numbering) play the same role as Ser-195 and His-57 respectively. The nucleophile is a thiolate ion rather than a hydroxyl group. The thiolate ion is stabilized through the formation of an ion pair with neighboring imidazolium group of His-159. The attacking nucleophile is the thiolate-imidazolium ion pair in both steps and then a water molecule is not required.

Most of the "aspartic proteinases" belong to the pepsin family. The pepsin family includes digestive enzymes such as pepsin and chymosin as well as lysosomal cathepsins D, processing enzymes such as renin, and certain fungal proteases (penicillopepsin, rhizopuspepsin, endothiapepsin). A second family comprises viral proteinases such as the protease from the AIDS virus (HIV) also called retropepsin. In contrast to serine and cysteine proteinases, catalysis by aspartic proteinases does not involve a covalent intermediate, though a tetrahedral intermediate exists. The nucleophilic attack is achieved by two simultaneous proton transfers: one from a water molecule to the dyad of the two carboxyl groups and a second one from the dyad to the carbonyl oxygen of the substrate with the concurrent CO-NH bond cleavage. This general acid-base catalysis, which may be called a "push-pull" mechanism leads to the formation of a non-covalent neutral tetrahedral intermediate.

The "metalloproteinases" are found in bacteria, fungi as well as in higher organisms. They differ widely in their sequences and their structures but the great majority of enzymes contain a zinc (Zn) atom which is catalytically active. In some cases, zinc may be replaced by another metal such as cobalt or nickel without loss of the activity. Bacterial thermolysin has been well characterized and its crystallographic structure indicates that zinc is bound by two histidines and one glutamic acid. Many enzymes contain the sequence HEXXH (SEQ ID NO:), which provides two histidine ligands for the zinc whereas the third ligand is either a glutamic acid (thermolysin, neprilysin, alanyl aminopeptidase) or a histidine (astacin). Other families exhibit a distinct mode of binding of the Zn atom. The catalytic mechanism leads to the formation of a non-covalent tetrahedral intermediate after the attack of a zinc-bound water molecule on the carbonyl group of the scissile bond. This intermediate is further decomposed by transfer of the glutamic acid proton to the leaving group.

In discussing the interactions of peptides with proteinases, e.g., serine and cysteine proteinases and the like, the present application utilizes the nomenclature of Schechter and Berger [(1967) Biochem. Biophys. Res. Commun. 27:157-162)]. The individual amino acid residues of a substrate or inhibitor are designated P1, P2, etc. and the corresponding 5 subsites of the enzyme are designated S1, S2, etc. The scissile bond of the substrate is P1-P1'.

The binding site for a peptide substrate consists of a series of "specificity subsites" across the surface of the enzyme. The term "specificity subsite" refers to a pocket or other site on the enzyme capable of interacting with a portion of a substrate for the enzyme.

10 "Recombinant," as used herein with respect to a protein, means that the protein is derived from the expression of a recombinant nucleic acid by, for example, a prokaryotic, eukaryotic or in vitro expression system. A recombinant nucleic acid is any non-naturally occurring nucleic acid sequence or combination of nucleic acid sequences that was generated as a result of human intervention.

15 The term "substrate" refers to a substrate of an enzyme which is catalytically acted on and chemically converted by the enzyme to product(s).

The term "stereoisomers" refers to compounds which have identical chemical 20 constitution, but differ with regard to the arrangement of the atoms or groups in space. In particular, "enantiomers" refer to two stereoisomers of a compound which are non- superimposable mirror images of one another. "Diastereomers", on the other hand, refers to stereoisomers with two or more centers of asymmetry and whose molecules are not mirror images of one another. With respect to the nomenclature of a chiral center, terms "D" and "L" configuration are as defined by the IUPAC Recommendations. As to the use 25 of the terms, diastereomer, racemate, and enantiomer will be used in their normal context to describe the stereochemistry of peptide preparations.

"Transcriptional regulatory sequence" is a generic term used throughout the specification to refer to nucleic acid sequences, such as initiation signals, enhancers, and promoters, which induce or control transcription of protein coding sequences with which they are operably linked. In some examples, transcription of a recombinant gene is under 30 the control of a promoter sequence (or other transcriptional regulatory sequence) which controls the expression of the recombinant gene in a cell-type in which expression is intended. It will also be understood that the recombinant gene can be under the control of transcriptional regulatory sequences which are the same or which are different from those sequences which control transcription of the naturally-occurring form of a protein.

35 As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. Preferred vectors are those

capable of autonomous replication and/or expression of nucleic acids to which they are linked. Vectors capable of directing the expression of genes to which they are operatively linked are referred to herein as “expression vectors”.

5 **III. Exemplary Embodiments**

An adzyme comprises at least two modular moieties: a targeting moiety and a catalytic domain. With respect to altering the activity of a targeted substrate, the adzyme is more potent relative to either the catalytic domain or targeting moiety alone.

The catalytic domain will often be protein-based, though even then may include 10 other components, such as organic ligands or co-factors, or metal ions. It comprises a catalytically active site that reacts with a substrate without itself being consumed in the reaction. A catalytic domain will generally alter one or more bonds of a substrate, e.g., breaking the bond, removing one or more atoms across the bond (including oxidizing or reducing), and/or altering the stereochemistry of an atom participating in the bond. The 15 site of chemical modification on the targeted substrate is referred to herein as the “substrate site”.

The targeting moiety recognizes and binds to a pre-determined molecule, *i.e.*, an address binding site such as on a soluble or membrane bound intracellular or extracellular targeted biomolecule, which molecule is the same as or associated with the targeted 20 substrate. The effect in both instances is to impart “addressability” to the adzyme construct, that is, to increase the local concentration of the construct in the vicinity of the targeted substrate so as to increase the proximity of the catalytic domain to the targeted substrate and thereby increase the catalytic efficiency for that substrate.

The targeting moiety and catalytic domain may be covalently attached or 25 associated by non-covalent means. For instance, the moieties can be covalently attached as by fusion of two protein domains, with or without intervening sequences, to form a single polypeptide chain, or through derivation of the amino or carboxy terminus, or a sidechain of a polypeptide chain. In certain preferred embodiments, the targeting moiety and catalytic domain are produced as a cotranslational fusion by expression of a single 30 recombinant nucleic acid construct. The various moieties may also be associated by non-covalent interactions, such as between protein domains, interaction with a common cross-linking ligand, etc.

The adzyme concept can be exploited in appropriate circumstances using a recruitment approach. Here, a multispecific binder is administered. An address of the 35 multispecific binder complexes with a binding site on or near the intended targeted biomolecule. A chaperone protein or other structure of the multispecific binder, linked to

or constituting a part of the address, displays a surface which complexes with a catalytic domain such as an enzyme already present in the body, or a co-administered enzymatically active moiety. The multispecific binder thereby induces complex formation between the address and a catalytic domain. The affinity of the address for the binding site 5 serves to increase the effective concentration of the catalytic domain in the vicinity of the targeted biomolecule.

The address and catalytic domain of an adzyme often cooperate to produce synergistic behavior. The target may be modulated, e.g., inhibited by cleavage, by a catalytic domain used alone at a potency determined by its K_m and k_{cat} . The target may 10 also be inhibited by binding with a molecule defining an address used alone at a potency determined by its K_a , acting simply as a conventional drug. The amount of modulation of the target often may be objectively measured by standard assays. Thus modulation induced independently through each mechanism often can be at least roughly quantitated. It often will be found, at least in some adzyme constructs, that an adzyme comprising an 15 optimized combination of a catalytic domain having the same K_m and k_{cat} , and an address having the same K_a will have a potency at least 10, 10^2 , 10^3 , or even 10^4 times the sum of the potency of the individual components (catalytic and targeting) acting alone.

Another way to express the functional improvement of the adzyme in a pharmaceutical setting, relative to the targeting moiety and/or catalytic domain alone, is 20 that in certain preferred embodiments the adzyme will have an effective dose (ED_{50}) for altering the activity of the targeted substrate *in vivo* at least 2 times less than the catalytic domain and/or targeting moiety (e.g., if a neutralizing moiety) alone, and more preferably at least 5, 10 or even 100 times less.

In the case of embodiments in which the targeted substrate is degraded to an 25 inactive form by the adzyme, the potency may be expressed in terms of “ HL_{50} ”, e.g., the concentration of adzyme required to reduce the half-life ($T_{1/2}$) *in vivo* of the targeted substrate by 50 percent. The more potent and selective the adzyme is, the lower the HL_{50} concentration is relative to the catalytic domain alone. In certain preferred embodiments, the HL_{50} of the adzyme is at least 2 times less than the catalytic domain alone, and more 30 preferably at least 5, 10 or even 100 times less.

In certain embodiments, the adzyme has a catalytic efficiency for the catalyzed reaction with the targeted substrate of at least $10^4 M^{-1}sec^{-1}$, and even more preferably at least $10^5 M^{-1}sec^{-1}$ or even at least $10^6 M^{-1}sec^{-1}$.

In certain embodiments, the adzyme has a catalytic efficiency for the catalyzed 35 reaction with the targeted substrate at least 5 times greater than the catalytic domain alone, and even more preferably at least 10, 50 or even 100 times greater.

In certain therapeutic applications, it will be important to balance the potency and specificity of an adzyme. A good balance of potency and specificity can be achieved through the following design criterion:

5 $k_{cat}^{ES} / K_m^E = k_{off}^{AS} / [S]_{eff}$

In adzyme embodiments designed with this criterion, the catalytic domain will be very weak, in some cases having a catalytic efficiency as low as 100, 10, or 1 M⁻¹s⁻¹, or even lower. Thus, adzymes designed to balance potency and specificity should be derived from 10 weak enzyme domains.

In certain embodiments, the k_{off} rate of the targeting moiety will be similar for the substrate and the adzyme reaction product, and it will be desirable to optimize the k_{off} rate for high substrate affinity and rapid release of the product when bound to the address. In these embodiments, the optimal k_{off} rate may be 0.001 sec⁻¹, 0.01 sec⁻¹, 0.1 sec⁻¹, or greater, 15 and can be approximated by:

$$k_{off, optimal}^{AS} \approx \sqrt{k_{on}^{AS} \frac{k_{cat}^{AS}}{K_m^E} [S]_{eff} [S]}$$

when $[S]_{eff} \ll K_m^E$, wherein K_m^E is the enzyme's K_m (not the adzyme's). The k_{on}^{AS} (k_{on} of adzyme) above is the same as k_l in Equation 2 below.

For a fusion protein of two domains both of which independently bind the 20 substrate, the "effective concentration of a substrate," $[S]_{eff}$, is the quotient of the overall association equilibrium constant for the fusion protein binding to its substrate and the product of the association equilibrium constants for the two, independent address domains binding to the substrate. This definition follows Figure 1 and Equation 2 in Zhou, *J. Mol. Biol.* (2003) 329, 1-8. Each of the three equilibrium constants required to determine $[S]_{eff}$ 25 can be measured via standard binding assays. In performing kinetic analysis, it is further assumed that the microscopic off rates for each domain in a fusion protein are not affected by the presence of the linker.

In certain embodiments, the adzyme has a K_m for catalyzed reaction with the targeted substrate at least 5 times less than the catalytic domain alone, and even more 30 preferably at least 10, 50 or even 100 times less.

Broadly, the adzyme may be designed to interact with any biomolecule target provided the site of enzymatic attack and the binding site for the address are solvent accessible. Thus, both the targeted biomolecule and the binder for the address may be a soluble biomolecule or a membrane-bound biomolecule. The target may be intracellular,

although extracellular targets are more accessible to protein constructs and are therefore preferred.


Referring to Figure 1, schematic diagrams illustrative of various structures which can exploit the invention are set forth as Figs. 1A through 1K. In 1A, perhaps the simplest 5 adzyme, an address (ADD) is covalently linked to a catalytic domain (CAT). Such a construct may be embodied as two separate globular protein domains attached by a flexible or rigid linker as illustrated, or by a single globular protein wherein one portion of the molecular surface functions as the address and another as a catalytically active site. In Figure 1B, the domains are complexed, i.e., each comprises a surface that reversibly 10 binds to a surface on its partner. In Figures 1C through 1F, the address and catalytic domains are associated via a chaperone protein, with either or both linked to the chaperone via covalent bonds such as a linker or noncovalent protein-protein complexation. In Figures 1G and 1H, each of the address and catalytic domains is linked, covalently or non 15 covalently, to a chaperone protein domain, and the chaperone domains are noncovalently complexed together.

Figures 1I and 1J illustrate one way to exploit the recruitment embodiment of the invention. These constructs, as illustrated, comprises an address linked (covalently or non 20 covalently) to a chaperone protein, which defines a binding surface specific for a predetermined catalytic domain, i.e., an enzyme either already present in a body fluid or one co administered with the construct. This type of construct functions by recruiting the 25 enzyme to the vicinity of the targeted biomolecule, mediated by the affinity of the address for the target so that the fully functional adzyme is assembled *in vivo*. Of course, such enzyme recruiting constructs could also be embodied in other forms provided they have a binding surface serving as an address that binds to the binding site on or adjacent the 30 target, and a binding surface that serves to bind specifically to an enzyme. For example, a recruitment construct may be embodied as a single globular protein, or as a globular protein defining a binding surface for a catalytic domain and a small molecule with affinity for the target linked to it through a length of biocompatible polymer.


After the enzymatic reaction is complete, the adzyme disassociates from the target 35 (now converted to a product) and moves on to bind to and act on another molecule of the target, creating turnover. As a result of this feature of the adzymes, the potency of the drug constructs is not dependant directly on drug/target stoichiometry. This provides a significant engineering advantage and can permit avoidance of toxicity issues associated with the use of antibodies or small molecule drugs inhibiting soluble biomolecules associated with a disease.

The equations below illustrates two possible adzyme (A—E) interactions between an address (A) and its binding site on a targeted biomolecule (S), and between the adzyme's enzymatically active site (E) and the targeted substrate (S) to make product (P).

5



10



15 Reaction 1 is the normal catalytic reaction, where the address is not involved, such as might occur with a substrate that does not display a binding site for the address. In the presence of a local concentration of both the adzyme (A—E) and the biomolecule (S) the targeted substrate has an on rate k_1 for the enzyme pocket (E), forms a complex A—E—S with the pocket, and is converted at a rate dependent on k_{cat} to product P and released.

20 Reaction 2 occurs when the binding site on the targeted substrate S binds to the adzyme through formation of an address: binding site interaction (with an affinity that may be higher than the E—S affinity), forming a complex S—AE with on rate k_1 . Presuming a suitable structure of the adzyme, e.g., the length of the linker or stereochemistry of the complex and its target permits, this complex can enter an 25 intermediate state at rate k_2 where the targeted substrate interacts simultaneously with the address and the enzyme pocket. In this state the targeted substrate is converted to product P at a rate governed by k_{cat} , and then disassociates from the adzyme at rate k_3 .

The functioning and structure of various forms of adzymes may be understood better with reference to Figures 2A-2J. Figure 2A depicts an adzyme in situ at a moment 30 when it has bound to its intended biomolecule. In this case the adzyme is embodied as a single globular protein which defines a catalytic domain (CD) having an enzymatically active site and an address (AD) defined by a separate surface on the protein. The address binds reversibly with a binding site, in this case embodied as a surface on the targeted

biomolecule. The targeted substrate site is vulnerable to immediate enzymatic attack by the enzymatically active site of the catalytic domain.

Figure 2B shows a construct similar to Figure 2A except that the address is a small molecule attached to the catalytic domain by a flexible linker that binds reversibly directly 5 with a binding site on the intended targeted biomolecule.

Figure 2C is an adzyme similar to 2B in which the address and the catalytic domain are attached by a flexible leash. Binding of the address domain to the binding site, here again illustrated as a portion of the targeted biomolecule, serves effectively to increase the local concentration of the catalytic domain in the region of the target, as 10 illustrated. The address domain and the catalytic domain may be linked via a flexible linker, or a more rigid structure (not shown) such that binding of the address domain serves to pose the catalytic domain in position to induce chemical change in its targeted biomolecule.

The adzyme of Figure 2D is similar to Figure 2C, except that the binding site and 15 the targeted biomolecule are separate molecular species, here illustrated as being lodged in a membrane, such as a cell membrane. As in the embodiments of Figures 2A-2C, binding of the address domain to the recognition site of what here functions as a attractant molecule serves to effectively increase the local concentration of the catalytic domain in the region of the target. Where the concentration of two proteins on a cell is significant, 20 especially in cases where they are known to interact in lipid rafts or the like, one molecule can be used as the binding site to attract the construct to the other molecule that will be catalytically modulated.

The adzyme of Figure 2E is similar to Figure 2C, except that the address domain and the catalytic domain are non-covalently associated directly to each other. Examples of 25 this type of association include dimerization, optionally stabilized by disulfide linkages, hybridization of complementary nucleotides, or protein-protein complexation of the type that is ubiquitous within cells.

Figure 2F shows an embodiment of an adzyme similar to Figure 2E, except that the address domain is designed to bind to an attractant biomolecule separate from but 30 complexed to the targeted biomolecule. Nevertheless, binding increases the effective concentration of the target and its substrate site in the vicinity of the catalytic domain as shown.

Figure 2G is the same as Figure 2F except that the targeted biomolecule is complexed with a separate protein displaying the binding site through a third, complexing 35 protein.

Figure 2H illustrates an embodiment of an adzyme in which the address and the catalytic domain are non-covalently associated through a third, chaperone protein, to form an active complex. Its intended targeted biomolecule is illustrated as being embedded in a lipid bilayer, and the binding site is illustrated as residing on a separate molecule in the 5 lipid bilayer, similar to Figure 2D. Again, binding nevertheless increases the effective concentration of the target and its substrate site in the vicinity of the catalytic domain.

Figure 2I illustrates an embodiment of an adzyme similar to Figure 2H, except that the address domain binds to a binding site directly on the targeted biomolecule.

Figure 2J is similar to Figure 2G, except that the address domain and catalytic 10 domain of the adzyme are held together via complexation with a chaperone protein. In all construct where the AD and CD are non covalently complexed, the surface on the address domain that binds to the catalytic domain (or a chaperone protein) may be the same or different from the one that binds to the binding site on the target or trigger molecule.

A further optional feature of adzymes is “engineered contingency,” that is, creation 15 of a family of adzymes that *become* capable of reacting with their target in the presence of the target or another triggering or attractant molecule having an affinity for the address. Figure 1K illustrates the fundamental idea behind the contingent adzyme. As illustrated, the address has an affinity for the catalytic domain and is configured so that it can bind to it and inhibit its enzymatic activity. In the presence of the target, a competition for the 20 address ensues, freeing the catalytic domain to induce chemical change in its intended target.

Stated differently, contingent adzyme constructs are inactive (have low enzymatic 25 activity) in the absence of a triggering molecule, but become active in the presence of the triggering molecule, e.g., the target (see Legendre D. *et al.* (1999) *Nature Biotechnology* 17:67-72; Legendre D. *et al.* (2002) *Protein Science* 11:1506-1518; Soumillion P. and Fastrez J. (2001) *Current Opinion in Biotechnology* 12:387-394). This type of adzyme also requires a catalytic domain and an address. However, in this case, binding of the address has the effect of freeing up the catalytic site of the catalytic domain to enhance its activity. This may be achieved in several ways, illustrated by way of example in Figures 30 3A through 3G, which are described in more details in the contingent adzyme section.

In addition to the address and catalytic domains, and the optional chaperone 35 proteins, linkers and other structures defining the relationship of these parts, an adzyme may further comprise one or more fusion partners operatively linked to any of its components, e.g., N-terminal or C-terminal fusions, or added or substituted sequences in loops on protein domains. Adzymes may also include polymeric side chains, small molecules, or metal ions. These moieties may, for example, restrict the adzyme to a

conformationally restricted or stable form; serve as a targeting sequence allowing the localization of the adzyme into a sub-cellular or extracellular compartment; assist in the purification or isolation of either the adzyme or the nucleic acids encoding it; serve to confer a desired solubility on the adzyme; or confer stability or protection from degradation to the adzyme or the nucleic acid molecule(s) encoding it (e.g., resistance to proteolytic degradation). The adzyme may comprise one or any combination of the above fusion partners as needed.

The fusion partners can, for example, be (histidine)₆-tag, glutathione S-transferase, protein A, dihydrofolate reductase, Tag•100 epitope (IETARFQPGYRS; SEQ ID NO:1), c-myc epitope (EQKLISEEDL; SEQ ID NO:2), FLAG[®]-epitope (DYKDDDK; SEQ ID NO:3), lacZ, CMP (calmodulin-binding peptide), HA epitope (YPYDVPDYA; SEQ ID NO:4), protein C epitope (EDQVDPRLLDGK; SEQ ID NO:5) or VSV epitope (YTDIEMNRLGK; SEQ ID NO:6).

The fusion partner may also be a membrane translocation domain, *i.e.*, a peptide capable of permeating the membrane of a cell and which is used to transport attached peptides into or out of a cell *in vivo*. Membrane translocation domains that may be used include, but are not limited to, the third helix of the *antennapedia* homeodomain protein and the HIV-1 protein Tat or variants thereof. Additional membrane translocation domains are known in the art and include those described in, for example, Derossi *et al.*, (1994) *J. Biol. Chem.* 269, 10444-10450; Lindgren *et al.*, (2000) *Trends Pharmacol. Sci.* 21, 99-103; Ho *et al.*, *Cancer Research* 61, 474-477 (2001); U.S. Patent No. 5,888,762; U.S. Patent No. 6,015,787; U.S. Patent No. 5,846,743; U.S. Patent No. 5,747,641; U.S. Patent No. 5,804,604; and Published PCT applications WO 98/52614, WO 00/29427 and WO 99/29721.

25

A. Exemplary Targeting Moieties

It will be appreciated that a wide range of entities can be used as targeting moieties in the subject adzymes. Fundamentally, the targeting moiety reversibly binds to a pre-determined feature (“address site”) associated with the targeted substrate. The targeting moiety presents one or more surfaces having chemical characteristics (e.g., hydrophobic, steric and/or ionic) which permit it to bind selectively, or relatively selectively, with the address site. In many embodiments, the address will be a modular protein (including peptide) domain which is provided in association with the catalytic domain. For example, the targeting moiety can be an antibody, or a fragment of an antibody which retains the ability to bind to the address site. Accordingly, the targeting moiety can be derived from such antibody and antibody fragments as monoclonal antibodies, including Fab and F(ab)2

fragments, single chain antibodies (scFv), diabodies, and even fragments including the variable regions of an antibody heavy or light chain that binds to the address site.

Other examples of proteins that can be suitably adapted for use in the subject adzymes including ligand binding domains of receptors, such as where the targeted 5 substrate of the adzyme is the receptor ligand. Conversely, the targeting moiety can be a receptor ligand where the adzyme is directed to the receptor as the targeted substrate. Such ligands include both polypeptide moieties and small molecule ligands.

In still other embodiments, the targeting moiety can be an engineered polypeptide sequence that was selected, e.g., synthetically evolved, based on its kinetics and selectivity 10 for binding to the address site.

The targeting moiety can also be a polyanionic or polycatonic binding agent, such as an oligonucleotide, a polysaccharide, a polyamino peptide (such as poly-aspartate, poly-glutamate, poly-lysine or poly-arginine). In certain embodiments, such targeting moieties maintain a number of either negative or positive charges over their structure at 15 physiological pH. The address may also be a protein nucleic acid (PNA), a lock nucleic acid (LNA) or a nucleotide sequence, such as a single strand of DNA or RNA.

The targeting moiety may also be a small molecule that has been selected based on the kinetics and selectivity it displays for binding to an address site associated with the targeted substrate.

20 There are a variety of well-known techniques for generating libraries of polypeptide/peptide, nucleic acid (aptamer) and small molecule moieties that can be used to identify molecules having the appropriate specificity, selectivity and binding kinetics for use in any particular adzyme. For example, such techniques as described in US Patents 6258558 titled "Method for selection of proteins using RNA-protein fusions" and 5837500 25 titled "Directed evolution of novel binding proteins" can be readily adapted for use in identifying peptide or polypeptide targeting moieties for use in generating the subject adzymes. Likewise, the preparation of aptamers previously described in the art can be adapted for generating appropriate targeting moieties. See, for example, Tuerk Science 249:505-510 (1990); Klug Mol Biol Reports 20:97-107 (1994); and Morris et al, PNAS 30 95:2902-2907 (1998), as well as U.S. Patents 5,843,701 and 5,843,653.

The address may be at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90 or 100 amino acid residues long. Ranges using a combination of any of the foregoing recited values as upper and/or lower limits are intended to be included in the present invention.

35 In certain preferred embodiments, the dissociation constant (K_d) for binding to the address site is lower (higher affinity) and/or the K_{off} rate is slower when the address site is

bound to the unmodified targeted substrate relative to when it is bound to the adzyme reaction product (e.g, the targeted substrate that has been acted on by the catalytic domain). That is, conversion of the targeted substrate to an adzyme reaction product reduces the affinity of the targeting moiety for the address binding site and promotes 5 dissociation of the adzyme from the reaction product. In certain embodiments: the K_d of the targeting moiety for the adzyme reaction product relative to the targeted substrate is at least 5 times greater, and even more preferably 10, 100 or even 1000 times greater; and/or the K_{off} rate of the targeting moiety for the adzyme reaction product is at least 5 times faster, and even more preferably 10, 100 or even 1000 times faster relative to the K_{off} rate 10 for the targeted substrate.

In certain embodiments of direct adzymes, the address site and substrate site are overlapping in the sense that binding of the targeting moiety to the targeted substrate interferes with the ability of the catalytic domain to act on the targeted substrate site. This interference may be the result of steric occlusion, or the lack of flexibility in the adzyme 15 and/or targeted substrate to permit both portions of the adzyme to simultaneously interact with the targeted substrate. In other embodiments, the address and substrate sites are spaced sufficiently apart, and the adzyme has sufficient steric flexibility, that dissociation of the targeting moiety is not required for the adzyme to modify the targeted substrate. In many embodiments, the adzyme will be designed such that there is functional 20 cooperativity between the catalytic domain and targeting moiety, particularly resulting from appropriate selection of linker(s) between the two components, such that the affinity of the resulting adzyme is at least 2 times greater than the sum of the affinities of the catalytic domain and targeting moiety, and even more preferably at least 5, 10, 100 or even 500 times greater.

25 In some instances, the targeting moiety itself interferes with the activity of the targeted substrate. For example, the targeting moiety may be a blocking or neutralizing agent that inhibits an intrinsic activity or interaction mediated by the targeted substrate. In such cases, the adzyme will preferably be at least 5 times more potent an inhibitor, and even more preferably at least 10, 100 or even 1000 times more potent than the targeting 30 moiety alone.

In other embodiments, the targeting moiety does not itself have any significant effect on the activity of the targeted substrate.

Where there are more than one possible substrate site of the catalytic domain on a targeted substrate, such as more than one substrate recognition sequences for a proteolytic 35 domain, the targeting moiety can be selected to enhance the selectivity/preference of the adzyme for one of the sites. This can be accomplished, for example, by using a targeting moiety that binds to the targeted substrate in a manner that sterically interferes with the

catalytic domain's ability to act at one of the sites. In other embodiments, the targeting moiety can be used to increase the concentration of the catalytic domain in the proximity of the desired substrate site.

In certain embodiments, the adzyme may include two or more address/ targeting moieties, which may be the same or different (i.e., their respective K_d may be the same or different). In such embodiments, the effective K_d of the adzyme for the targeted substrate may be as low as 10^{-15} M (femtomolar), when the effective substrate concentration $[S]_{eff}$ is greater than the highest individual K_d of the addresses (or targeting moieties).

In certain embodiments, the targeting moiety binds to a targeted substrate which is soluble under the reaction conditions, such as a soluble protein. In many cases, these soluble protein substrates will be present in the reaction milieu at relatively low concentrations, such as less than 0.1 μ M, and often at less than 10 nM. In such embodiments, and certain others herein, it may be desirable to select a targeting moiety which, when provided in the adzyme, results in a direct adzyme having a relative fast k_{on} for binding to the targeted substrate, e.g., a k_{on} of 10^3 M $^{-1}$ s $^{-1}$ or greater, e.g., at least 10^4 M $^{-1}$ s $^{-1}$, 10^5 M $^{-1}$ s $^{-1}$ or even 10^6 M $^{-1}$ s $^{-1}$.

(i) Exemplary Targeted Biomolecules

In certain embodiments, the subject adzymes are directed to biologically active molecules ("targeted biomolecule"), e.g., including solvent accessible extracellular and intracellular substrates, as well as extracellular or cytoplasmic portions of membrane associated substrates. These include, but are not limited to, substrates from among such classes as protein and peptide substrates, nucleic acids, lipids, small molecules including extracellular factors (such as steroids and neurotransmitters) and intracellular second messengers (such as phosphorylated inositol and cAMP). By modifying the functional performance of a targeted substrate of biological relevance, the subject adzymes can be used to alter such cellular processes as gene expression, morphology, cell adhesion, growth, proliferation, migration, differentiation and/or viability of cell.

Taregeted substrates can be modified by the adzyme so as to produce one or more products having one or more differences in biological activities relative to the targeted substrate (including, for example, the elimination of all or near all biological activity of the targeted substrate). For instance, for targeted substrates which are themselves enzymes, the subject adzymes can be used to alter the intrinsic enzymatic activity of those targeted substrates. To illustrate, an adzyme can used to inhibit such proteases as elastase (in the treatment of cystic fibrosis, acute respiratory distress syndrome, and emphysema) or matrix metalloproteases involved in metastasis. In other embodiments, the adzyme

alters the ability of a targeted substrate to interact with other biological moieties, e.g., such as by altering receptor-ligand interactions, protein-protein interactions, protein-lipid interactions, protein-DNA or protein-RNA interactions to name but a few. In this respect, the adzyme can be used to increase or decrease the intrinsic activity or binding activity of the targeted substrate. Adzymes can also be used to alter the half-life or biodistribution of a targeted substrate.

In certain instances, the adzyme can be used to convert a targeted substrate into a functional antagonist of the unmodified biomolecule. Merely to illustrate, in the case of a polypeptide factor that acts through a receptor interaction, rather than generate a product that is unable to interact with the cognate receptor of the targeted substrate, the adzyme can be selected so as to alter the targeted substrate to produce a product that retains the ability to bind to the receptor but not induce the level of receptor activation possible by the unmodified targeted substrate. In this way, the adzyme inhibits the function of the polypeptide factor by (a) reducing the concentration of the polypeptide factor, and (b) generating an antagonist which reduces the effective concentration of receptor for the polypeptide factor. In preferred embodiments of this system, the product has a K_i of 10 μ M or less for inhibiting an activity of the targeted substrate, and even more preferably has a K_i less than 10 μ M, 100 nM, 10 nM or even 1 nM.

20 (a) Extracellular Targets

In certain embodiments, the adzyme is directed to an extracellular target, including target molecules that are typically located entirely outside of a cell and target molecules that are inserted into a cellular membrane but have a portion that is exposed to the extracellular environment. Several categories of extracellular targets are recognizable, including, for example, diffusible extracellular molecules (e.g., growth factors, serum proteins, antibodies, any diffusible small molecule, extracellular nucleotides, lipids), extracellular molecules that are part of an insoluble aggregate (e.g., β -amyloid protein, constituents of atherosclerotic plaques, insoluble fibrin fibers), membrane associated proteins and other membrane bound moieties (e.g., transmembrane proteins, lipids, membrane associated polysaccharides), and constituents of or associated with an organized extracellular matrix.

Accordingly, the subject adzymes can be used to alter, e.g., inhibit or potentiate, such cell-surface mediated signaling as autocrine signaling (self-signaling), paracrine signaling (between nearby cells), and/or endocrine signaling (over a long distance, usually via the bloodstream or other bodily fluid). The subject adzymes can also be used to alter juxtacrine signaling, e.g., signaling consequences of cell contact.

Various illustrative examples of different types of extracellular targets are provided in Table I, below, along with associated conditions that antagonistic adzymes may be used to treat.

5 **Table I: Examples of various extracellular targets and associated conditions.**

Target	Disease/Condition
TNF receptor	Inflammation, arthritis, autoimmune thyroid disease, ischemic heart disease
TNF- α and β	Inflammation, arthritis, autoimmune thyroid disease, ischemic heart disease
IL-2 receptor	Ischemic heart disease
Aldosterone	Cardiovascular heart disease
Amyloid beta-peptide [Abeta(1-42)]	Alzheimer's disease
Transthyretin	Alzheimer's disease
Erythropoietin	benign erythrocytosis
Prostaglandin	Neurodegeneration
Cholesterol	Heart disease
Retinoid X	hepatogastroenterological diseases
Apolipoprotein B-100	Coronary heart disease
Homocysteine	Cardiovascular disease
Insulin	Diabetes
Apolipoprotein A1	Heart disease
Apolipoprotein CII	Hyperlipidemia
Apolipoprotein CII	heart disease
Apolipoprotein E	Cardiovascular disease
Apolipoprotein E	Alzheimer's disease
CD4	Immune response

CD4 receptor	Immune response/ HIV infection
CCR5	Immune response/ HIV infection
SBR1	HDL receptor/coronary heart disease
Annexin V	Clot formation, Apoptosis
Fibrin	Wound healing, clot formation

Among the diffusible extracellular molecules, further subcategories are recognizable. In a preferred embodiment, a target of an adzyme is an extracellular signaling molecule, meaning a molecule that is produced by one cell with the primary effect of triggering a response in another cell. Examples of extracellular signaling molecules include most growth factors and cytokines, neurotransmitters, hormones, and prostaglandins. Many extracellular signaling molecules are actually part of a larger assemblage that carries out the signaling function; for example, TGF- β 1 contains two 112 amino acid chains that are linked by a disulfide bond, and either of the two polypeptide chains may be considered to be extracellular signaling molecules that are targeted by an adzyme. Antibodies are explicitly not included in the term "extracellular signaling molecule".

In certain embodiments, an extracellular signaling molecule is a molecule that binds to an extracellular portion of a membrane bound receptor and triggers a signal transduction event in the cell. In certain embodiments, an extracellular signaling molecule is a molecule that enters a cell and binds to an intracellular receptor to trigger a signal transduction event in the cell (e.g., steroid hormones, harpin proteins of various bacterial pathogens).

In a particularly preferred embodiment, the target of an adzyme is an extracellular polypeptide signaling molecule, e.g., as may be found in biological fluid(s), such as a growth factor, cytokine, polypeptide hormone or the like. In certain preferred embodiments, the targeted substrate is a signaling molecule, particularly a polypeptide signaling molecule, present in serum or other bodily fluid at a concentration of less than 1 μ M, and even more preferably less than 0.1 μ M, 10 nM, 1 nM, 0.1 nM, 10 pM or even 1 pM. The catalytic domain is chosen so as to modify the signaling molecule in a manner that alters its interaction with a cognate receptor (e.g., abrogating binding or limiting receptor activation), ability to form protein complexes with other soluble factors, half-life and/or biodistribution.

In certain preferred embodiments, the adzyme alters the level of signal transduction induced by an extracellular factor. The term "signal transduction" is intended

to encompass the processing of physical or chemical signals from the extracellular environment through the cell membrane and into the cell, and may occur through one or more of several mechanisms, such as activation/inactivation of enzymes (such as proteases, or enzymes which may alter phosphorylation patterns or other post-translational modifications), activation of ion channels or intracellular ion stores, effector enzyme activation via guanine nucleotide binding protein intermediates, second messenger generation (e.g., GTP hydrolysis, calcium mobilization, formation of inositol phosphates, cyclic nucleotides, sugar nucleosides or dissolved gases such as NO or O₃), redistribution of intracellular ions (Ca²⁺, Zn²⁺, Na⁺, K⁺), and/or direct activation (or inhibition) of a transcriptional factor. Signal transduction may result in physiological changes to the cell, such as changes in morphology, cell adhesion, chemotaxis, drug resistance, growth, proliferation, death (apoptosis or necrosis), effector function, secretion of matrix, etc.

The induction of intracellular signals by the binding of an extracellular signaling molecule, such as a soluble growth factor, to a membrane-spanning receptor is of considerable biological importance. In many cases, promotion of receptor-receptor interactions by protein factors is a key initial step in the induction of a signal transduction process. In certain preferred embodiments, the subject adzymes can be used to alter the biological function/performance of an inductive protein factor, such as a protein factor selected from one of the protein factor superfamilies known as (i) four-helix bundle factors, (ii) EGF-like factors, (iii) insulin-like factors, (iv) β -trefoil factors and (v) cysteine knot factors. Exemplary substrates within in these classes are listed in Table II.

Table II: Growth factor structural superfamilies

Family	Subclass	Examples
Four-helix bundle	Short chain	IL-2, IL-3, IL-4, IL-5, IL-7, IL-9, IL-13, IL-15, M-CSF, GM-CSF
	Long chain	GH, LIF, G-CSF, IL-6, IL-12, EPO, OSM, CNTF
	Interferon	IFN β , IFN γ
EGF-like		EGF, TGF α , heregulin
Insulin-like		Insulin, IGF1, IGF2
β -trefoil		FGF, IL-1
Cysteine knot		NGF, PDGF, TGF β proteins

Examples of particular extracellular signaling molecules and conditions associated with these targets which may be treated using an appropriate adzyme are listed in Table III, below.

5

Table III: Examples of Extracellular Signaling Molecules

Target	Disease/Condition
IL-1 α and β	Inflammation, Arthritis, inflammatory bowel disease
IL-4	Asthma, allergic airway disease
IL-5	Asthma, Allergic airway disease
IL-6	Inflammation, Kaposi's sarcoma
IL-7	Immune response
IL-8	Inflammatory disease, Crohn's disease
IL-18	Arthritis
IL-9	Asthma
IL-10	Colitis
IL-11	Crohn's disease, Ischemic heart disease
TNF- α and β	Inflammation, arthritis, autoimmune thyroid disease, ischemic heart disease
VEGF	Cancer, Angiogenesis, Arthritis, Eales' disease
Aldosterone	Cardiovascular heart disease
Somatostatin	Grave's disease
Fibronectin	Ullrich's disease
Angiotensin	Heart disease
Erythropoietin	Benign erythrocytosis
Prostaglandins	Neurodegeneration
Interferon α and β	Immune response
Retinoid X	hepatogastroenterological diseases

Adrenocorticotropic Hormone	Cushing's disease
Hepatocyte growth factor	Cardiovascular disease, periodontal disease
Transforming growth factor-beta1	Graft-versus-host disease, renal disease
Transforming growth factor-beta	Coeliac Disease
Insulin-like growth factor binding protein-1 (IGFBP-1)	macrovascular disease and hypertension in type 2 diabetes
VEGF-A	Paget's disease
Platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP)	Paget's disease
Insulin-like growth factor I (IGF-I)	Inflammatory bowel disease
IGF binding protein-3	Inflammatory bowel disease
Insulin	Diabetes
EGF	Oncogenesis, Wound healing
Vasoactive intestinal peptide	Inflammation

In certain particularly preferred embodiments, the targeted substrate is an inflammatory cytokine, such as tumor necrosis factor (TNF- α), interleukin-6 (IL-6) or interleukin-1b (IL-1b), and the adzyme can be used therapeutically to reduce inflammation.

In certain other preferred embodiments, the targeted substrate is a polypeptide hormone, such as Adrenocorticotropic Hormone, Amylin Peptide, Bombesin, Calcitonin, Cholecystokinin (CCK-8), Gastrin, Glicentin, GLP-1, GLP-2, PYY, NPY, GIP, Glucagon, Human Chorionic Gonadotrophin (α), Human Chorionic Gonadotrophin (β), Human Follicle Stimulating Hormone ($\beta 2$), Human Growth Hormone, Insulin, Luteinising Hormone, Pancreatic Polypeptide, Parathyroid Hormone, Placental Lactogen, Proinsulin, Prolactin, Secretogranin II, Somatostatin, Thyroglobulin, Thyroid Stimulating Hormone, Vasoactive Intestinal Polypeptide.

Other exemplary substrates for the subject adzymes include polypeptide factors selected from the group consisting of: Granulocyte-colony stimulating factor (G-CSF), Myelomonocytic growth factor, Interleukin-3, Interleukin-7, Leukemia inhibitory factor (LIF), Oncostatin M, Ciliary neurotrophic factor (CNTF), cholinergic differentiation factor (CDF), Interleukin-4, Interleukin-13, Interleukin-16, Interleukin-17, Interferon-alpha (IFN- α), Interferon-beta (IFN- β), IFN-tau (IFN- τ), Interferon-omega (IFN- ω), Interleukin-5, Granulocyte-macrophage colony-stimulating factor (GM-CSF), Macrophage colony-stimulating factor (M-CSF), Interleukin-10, Interleukin 1-alpha (IL1- α), Interleukin 1-beta (IL1- β), Gonadotropin, Nerve Growth Factor (NGF), platelet factor 4 (PF-4), bTG, GRO, 9E3, HLA-A2, macrophage inflammatory protein 1 alpha (MIP-1 α), macrophage inflammatory protein 1 beta (MIP-1 β), Melanoma growth stimulating activity (MGSA), 4-1BB Ligand, ADF, Autocrine Motility Factors, B61, Betacellulin, Cardiotrophin-1, CD27 Ligand, CD30 Ligand, CD40 Ligand, CeK5 Receptor Ligand, EMAP-II, ENA-78, Eosinophil Cationic Protein, Epiregulin, Erythrocyte-derived Growth-Promoting Factor, Erythropoietin, Fas Ligand, Fibrosin, FIC, GDNF, Growth/Differentiation Factor-5, Interleukin-1 Receptor Antagonist, Interleukin-3, Interleukin-6, Interleukin-7, Interleukin-9, Interleukin-11, Interleukin-12, Interleukin-13, Interleukin-14, Interleukin-15, Lymphotactin, LT-beta, Lymphotoxin, MCP-2, MCP-3, Megaprotein, Melanoma-derived Growth Regulatory Protein, Monocyte Chemoattractant Protein-1, Macrophage Migration Inhibitory Factor, Neu Differentiation Factor, Oncostatin M, OX40 Ligand, Placenta Growth Factor, PLF, Scatter Factor, Steel Factor, TCA 3, Thrombopoietin, Vascular Endothelial Cell Growth Factor, Bone Morphogenetic Proteins, Interleukin-1 Receptor Antagonist, Monocyte Chemoattractant Protein-1, c-Kit ligand (stem cell factor), CXC chemokines, CC chemokines, lymphotactin, and C-X3-C chemokines (fractalkine / neurotactin).

In other embodiments, the adzyme is directed to a substrate associated with a cell surface, such as for altering the activity of a cell surface receptor, ion channel, transporter, adhesion molecule, lipid, or extracellular matrix molecule such as a polysaccharide or glycosaminoglycan.

In certain preferred embodiments, the targeted substrate is a cell surface receptor protein or ion channel. For instance, the adzyme can be designed to modify a ligand-binding receptor protein in a manner that alters ligand binding kinetics and/or signal transduction activity of the receptor. Receptor proteins which can be substrates for the 5 subject adzymes include any receptor or channel which interacts with an extracellular molecule (i.e. hormone, growth factor, peptide, ion) to modulate a signal in the cell. To illustrate, the targeted substrate of the adzyme can be a site on a serpentine receptor (such as G protein coupled receptor), an enzyme-linked receptor (such as a receptor tyrosine kinase, receptor serine/threonine kinase, receptor protein tyrosine phosphatase, receptor 10 guanylyl cyclase, or receptor nitric oxide synthase), or an ion channel (including an ion-channel-linked receptor). Exemplary receptors which can be altered by an adzyme include cytokine receptors; multisubunit immune recognition receptors (MIRR), chemokine receptors; growth factor receptors, or chemoattractant peptide receptors, neuropeptide receptors, light receptors, neurotransmitter receptors, and polypeptide hormone receptors, 15 to name but a few. Further examples of cell surface receptors are provided in Table IV, along with associated conditions that may be treated by administration of an appropriately targeted adzyme.

Table IV: Examples of Cell Surface Receptors

Target	Disease/Condition
IL-1 receptor	Inflammation, Arthritis, inflammatory bowel disease
TNF receptor	Inflammation, arthritis, autoimmune thyroid disease, ischemic heart disease
IL-2 receptor	Ischemic heart disease
EGF receptor	Cancer
Vascular endothelial growth factor receptor	Arthritis
VEGF receptor	Cancer
Aldosterone receptor	Cardiovascular heart disease
Somatostatin receptor	Grave's disease
Fibronectin receptor	Ullrich's disease
Angiotensin receptor	Heart disease

SBR1	HDL receptor/coronary heart disease
------	-------------------------------------

Additional examples of cell surface associated or extracellular matrix targets for the subject adzymes include cellular adhesion molecules, such as selectins, integrins and other hemidesmosomal proteins, cadherins, laminins, CD44 isoforms, proteoglycans (such as syndecans), Ig superfamily (IgCAM) proteins, catenins (such as α , β and γ catenins) and cadherins (such as E-cadherin or P-cadherin), galectins, collagens, elastins, fibrins, and the like.

In certain embodiments, the adzyme acts on a Cluster of Differentiation (CD) protein, such as CD1a, CD2 (LFA-2), CD3, CD4, CD5, CD6, CD7, CD8, CD9 (Motility-Related Protein-1), CD10 (CALLA), CD11b (Mac-1), CD11b, CD13, CD14, CD15, CD16, CD18 (b2), CD19, CD20, CD21, CD22 (BL-CAM), CD23, CD25 (Interleukin-2 Receptor), CD27, CD29 (b1), CD30, CD31 (PECAM-1), CD34 (Endothelial Cell Marker), CD35, CD37, CD38, CD39, CD40, CD40L (CD154), CD41 (GPIIb/IIIa), CD42b (GPIb), CD43, CD44 (H-CAM), CD44 Variant 3, CD44 Variant 4, CD44 Variant 5, CD44 Variant 6, CD45 (Leucocyte Common Antigen), CD45RA, CD45RB, CD45RO, CD48, CD49b (VLA-2), CD49c (VLA-3), CD49f (VLA-6), CD50 (ICAM-3), CD51, CD54 (ICAM-1), CD56 (NCAM), CD57, CD58 (LFA-3), CD61 (GPIIIa), CD61 (GPIIIa), CD62E (E-selectin), CD62L (L-selectin), CD62P (P-selectin), CD63 (Melanoma Marker), CD66a (CEACAM1), CD66e (Carcinoembryonic Antigen), CD68, CD69, CD71 (Transferrin Receptor), CD72, CD74, CDw75, CD79a, CD81, CD82, CD83, CD95 (Fas), CD99 (MIC2), CD104, CD105 (Endoglin), CD106 (VCAM-1), CD117 (c-kit Oncoprotein), CD134 (OX40), CD137, CD138 (Syndecan-1), CD141 (Thrombomodulin), CD141 (Thrombomodulin), CD143 (ACE), CD146 (MCAM), CD147 (EMMPRIN), CDw150 (SLAM), CD151 (PETA-3), CD154 (CD40L), CD162, CD163, CD166 (ALCAM), CD168 (RHAMM), or CD179a.

In certain preferred embodiments, the adzyme substrate is a selectin, e.g., a CD62 family protein. In other preferred embodiments, the adzyme substrate is an immunoglobulin superfamily protein (IgCAM), such as a CD2 family protein, CD22, CD31, CD48, CD50, CD54, CD56, CD58, CD66a, CD83, CD106, CD146, CD147, CDw150 or CD166. In still other preferred embodiments, the adzyme substrate is an integrin, such as CD49 family, CD51, CD29, CD11b, CD18, CD41, CD61 or CD104.

Certain of the subject adzymes can be used to alter the activity of scavenger receptor class A (SR-A, CD204), scavenger receptor-BI (SR-BI) or CD36, which are cell surface proteins that mediate cell adhesion to, and endocytosis of, various native and

pathologically modified substances, and participate in intracellular signaling, lipid metabolism, and host defense against bacterial pathogens.

Collagenolytic adzymes can be prepared, e.g., using collagenase catalytic domains from hydrobionts, polycollagenase-K or Fermenkol, to cause deep hydrolysis of 5 polypeptide substrates (native or partially denatured collagen types, elastin, fibrin, hemoglobin, and casein). Such adzymes have use in both medical and cosmetological applications.

In certain embodiments, a ligand (or binding portion thereof) of a receptor or other 10 cell surface molecule may be employed as an address moiety. In certain embodiments, the adzyme can be associated with one or more ligands effective to bind to specific cell surface proteins or matrix on the target cell, thereby facilitating sequestration of the adzyme to target cells. For instance, the adzyme can be a fusion protein that also includes the ligand. Merely to illustrate, examples of ligands suitable for use in targeting the adzymes of the present invention to specific cell types are listed in the Table V below.

15 **Table V. Adzymes Specific for Various Cell Types**

<i>Ligand</i>	<i>Receptor</i>	<i>Cell type</i>
folate	folate receptor	epithelial carcinomas, bone marrow stem cells
water soluble vitamins	vitamin receptor	various cells
pyridoxyl phosphate	CD4	CD4 + lymphocytes
apolipoproteins	LDL	liver hepatocytes, vascular endothelial cells
insulin	insulin receptor	
transferrin	transferrin receptor	endothelial cells
galactose	asialoglycoprotein receptor	liver hepatocytes
sialyl-Lewis _x	E, P selectin	activated endothelial cells
Mac-1	L selectin	neutrophils, leukocytes
VEGF	Flk-1, 2	tumor epithelial cells
basic FGF	FGF receptor	tumor epithelial cells
EGF	EGF receptor	epithelial cells
VCAM-1	a ₄ b ₁ integrin	vascular endothelial cells

ICAM-1	$\alpha_L\beta_2$ integrin	vascular endothelial cells
PECAM-1/CD31	$\alpha_v\beta_3$ integrin	vascular endothelial cells, activated platelets
osteopontin	$\alpha_v\beta_1$ integrin $\alpha_v\beta_5$ integrin	endothelial cells and smooth muscle cells in atherosclerotic plaques
RGD sequences	$\alpha_v\beta_3$ integrin	tumor endothelial cells, vascular smooth muscle cells
HIV GP 120/41 or GP120	CD4	CD4 ⁺ lymphocytes

In certain embodiments of adzymes intended to be antagonists of a receptor ligand, the adzyme will alter the receptor in a manner that reduces the level of ligand-induced signal transduction, but will not substantially impair the ability of the receptor to bind to its cognate ligand. In this manner, the adzyme antagonizes the ligand not only as a consequence to the generation of loss-of-function receptors with regard to signal transduction, but also because the otherwise inactivated receptor can act as a competitive binding agent for sequestering the ligand from still functional receptors. Alternatively, the adzyme can be selected to generate a receptor product which is constitutively active, e.g., in which case the adzyme acts may as an agonist of the receptor's inductive ligand.

In certain embodiments, the intended substrate of the adzyme will be a heteromeric receptor complex, e.g., receptor complexes involving two or more different receptor subunits. For instance, receptors for most interleukins and cytokines that regulate immune and hematopoietic systems belong to the class I cytokine receptor family. These molecules form multichain receptor complexes in order to exhibit high-affinity binding to, and mediate biological functions of, their respective cytokines. In most cases, these functional receptor complexes share common signal transducing receptor components that are also in the class I cytokine receptor family, such as the gp130 protein. Adzymes which are specifically reactive with the unique receptor subunit(s), but which do not substantially impair the function of the common subunit, can be used to enhance the selectivity of the adzyme as an antagonist of a particular ligand.

Alternatively, adzymes that selectively inactivate the unique receptor subunits of other ligand-receptor complexes, e.g., those that compete with the formation of receptor complexes for the ligand of interest, can be agonists of ligand of interest.

In still other embodiments, an adzyme is targeted to an extracellular molecule that is part of a biomolecular accretion. A biomolecular accretion is any undesirable assemblage of biomolecules, usually one that brings together components that are not typically found in an assemblage together usually one that has grown over time by the successive addition of material. Accretions are generally large enough as to be non-diffusible (although clots are accretions that may diffuse in the circulatory system) and are generally larger than the size of a typical host cell. Biomolecular accretions will often contain dead and living cells as well as extracellular matrix. Examples of biomolecular accretions include amyloid deposits, *e.g.*, a β -amyloid peptide deposit characteristic of Alzheimer's disease or a type II diabetes amyloid deposit, a collagen deposit, a protein deposit, an atherosclerotic plaque, an undesirable fat mass, an undesirable bone mass, a blood clot, or a cyst. In certain embodiments, an adzyme is designed to target one or more extracellular molecules of a biomolecular accretion and act on such targets in such a way as to cause the partial or complete dissolution of the accretion. Examples of proteins that are often present in the amyloid deposits associated with Alzheimer's disease include amyloid β -peptide [A β (1-42)] and transthyretin. Protein aggregation has been linked to several human diseases, including Alzheimer's disease, Parkinson's disease, and systemic amyloidosis. Most of these diseases are associated with the formation of highly ordered and beta-sheet-rich aggregates referred to as amyloid fibrils. Fibril formation by WT transthyretin (TTR) or TTR variants has been linked to systemic amyloidosis and familial amyloid polyneuropathy, respectively. Amyloid fibril formation by α -synuclein (α -syn) has been linked to neurodegeneration in Parkinson's disease. Atherosclerotic plaque may contain a variety of different components. Examples of certain components include: calcified substances (*e.g.*, hydroxyapatite), cholesterol crystals, collagen matrix, macrophage foam cells, smooth muscle cells, lipid-rich atheromatous material (particularly rich in cholesterol and esters thereof), mast cells, matrix metalloproteinases (*e.g.*, MMP-1 collagenase, MMP-2 and -9 gelatinases). Given that atherosclerotic plaque rupture is associated with dangerous thrombotic events, it may be desirable to design an adzyme that stabilizes plaques (*e.g.* by targeting metalloproteinases in the plaque) or to employ a plaque-dissolving adzyme in combination with an anti-thrombotic agent, such as heparin.

Often, a biomolecular accretion combines various biomolecules that have appropriate roles in other parts of an organism; accordingly, it may be desirable to selectively target molecules that are primarily present in the accretion or to provide an adzyme with multiple different address moieties that enhance adzyme concentration in the vicinity of the accretion.

(b) Intracellular Targets

In certain embodiments, an adzyme may be directed against an intracellular target. Examples of intracellular targets include intracellular receptors (e.g., many steroid hormone receptors), enzymes that are overexpressed or otherwise participate in an 5 undesirable condition, intracellular signaling proteins that participate in an undesirable condition (e.g., oncoproteins, pro-inflammatory proteins) and transcription factors.

In an exemplary embodiment, the adzyme alters a nuclear receptor. Many nuclear receptors may be viewed as ligand-dependent transcription factors. These receptors provide a direct link between extracellular signals, mainly hormones, and transcriptional 10 responses. Their transcriptional activation function is regulated by endogenous small molecules, such as steroid hormones, vitamin D, ecdysone, retinoic acids and thyroid hormones, which pass readily through the plasma membrane and bind their receptors inside the cell. The subject adzymes can be used, for example, to alter the responsiveness 15 of a cell to a particular hormone or other nuclear receptor ligand, such as by degrading receptor complexes to inhibit response to a hormone of interest, or degrading subunits for other receptor dimers that otherwise compete with the formation of receptor complexes for the hormone of interest (such that the adzyme is an agonist of that hormone).

Examples of certain intracellular targets are provided in Table VI, along with associated conditions that may be treated with an appropriately targeted adzyme.

20

Table VI: Examples of Intracellular Targets

Target	Disease/Condition
aldosterone receptor	Cardiovascular heart disease
Erythropoietin	benign erythrocytosis
PPAR γ	hepatogastroenterological diseases
Adrenocorticotrophic Hormone	Cushing's disease
Huntingtin protein	Huntington's disease
estrogen receptor	Coronary heart disease, Liver disease

glucose-6-phosphatase	Glycogen storage disease type 1
erythrocyte antioxidant enzyme	Behcet's disease
androgen receptor	Paget's disease
platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP)	Paget's disease
Rb	Cancer
P16	Cancer
P21	Cancer
P53	Cancer
HIF-1	Cancer
NF-κB	Inflammatory disease
NF-κB	Cell Death
IκB	Immune response

In embodiments involving an intracellular target, it will generally be desirable to have an adzyme that is produced within cells or designed for entry into cells. In certain embodiments, the adzyme may include one or more functionalities that promote uptake by target cells, e.g., promote the initial step of uptake from the extracellular environment. In one embodiment, a subject adzyme includes an "internalizing peptide" which drives the translocation of the adzyme across a cell membrane in order to facilitate intracellular localization. The internalizing peptide, by itself, is capable of crossing a cellular membrane by, e.g., transcytosis, at a relatively high rate. The internalizing peptide is conjugated, e.g., to an adzyme. In certain embodiments, the adzyme may be expressed from a nucleic acid that is introduced into a cell, such as a viral vector or naked or

encapsulated nucleic acid vector. Nucleic acids for the intracellular productions of adzymes are described in the section entitled “*Nucleic acid compositions*”, below.

In one embodiment, an internalizing peptide is derived from the *Drosophila* antepennepedia protein, or homologs thereof. The 60 amino acid long homeodomain of 5 the homeo-protein antepennepedia has been demonstrated to translocate through biological membranes and can facilitate the translocation of heterologous peptides and organic compounds to which it is couples. See for example Derossi *et al.* (1994) *J Biol Chem* 269:10444-10450; and Perez *et al.* (1992) *J Cell Sci* 102:717-722. Recently, it has been demonstrated that fragments as small as 16 amino acids long of this protein are 10 sufficient to drive internalization. See Derossi *et al.* (1996) *J Biol Chem* 271:18188-18193. The present invention contemplates an adzyme including at least a portion of the antepennepedia protein (or homolog thereof) sufficient to increase the transmembrane transport.

Another example of an internalizing peptide is the HIV transactivator (TAT) 15 protein. This protein appears to be divided into four domains (Kuppuswamy *et al.* (1989) *Nucl. Acids Res.* 17:3551-3561). Purified TAT protein is taken up by cells in tissue culture (Frankel and Pabo, (1989) *Cell* 55:1189-1193), and peptides, such as the fragment corresponding to residues 37 -62 of TAT, are rapidly taken up by cell *in vitro* (Green and Loewenstein, (1989) *Cell* 55:1179-1188). The highly basic region mediates internalization 20 and targeting of the internalizing moiety to the nucleus (Ruben *et al.*, (1989) *J. Virol.* 63:1-8). Peptides or analogs that include a sequence present in the highly basic region, such as CFITKALGISYGRKKRRQRRRPPQGS (SEQ ID NO:), can be used in the adzyme to aid in internalization.

Another exemplary adzyme can be generated to include a sufficient portion of 25 mastoparan (T. Higashijima *et al.*, (1990) *J. Biol. Chem.* 265:14176) to increase the transmembrane transport of the adzyme.

While not wishing to be bound by any particular theory, it is noted that hydrophilic 30 polypeptides and organic molecules may be also be physiologically transported across the membrane barriers by coupling or conjugating the polypeptide to a transportable peptide which is capable of crossing the membrane by receptor-mediated transcytosis. Suitable internalizing peptides of this type can be generated using all or a portion of, e.g., a histone, insulin, transferrin, basic albumin, prolactin and insulin-like growth factor I (IGF-I), insulin-like growth factor II (IGF-II) or other growth factors. For instance, it has been 35 found that an insulin fragment, showing affinity for the insulin receptor on capillary cells, and being less effective than insulin in blood sugar reduction, is capable of transmembrane transport by receptor-mediated transcytosis and can therefore serve as an internalizing peptide for the subject adzyme. Preferred growth factor-derived internalizing peptides

include EGF (epidermal growth factor)-derived peptides, such as CMHIESLDSYTC (SEQ ID NO:) and CMYIEALDKYAC (SEQ ID NO:); TGF-beta (transforming growth factor beta)-derived peptides; peptides derived from PDGF (platelet-derived growth factor) or PDGF-2; peptides derived from IGF-I (insulin-like growth factor) or IGF-II; and 5 FGF (fibroblast growth factor)-derived peptides.

Another class of translocating/internalizing peptides exhibits pH-dependent membrane binding. For an internalizing peptide that assumes a helical conformation at an acidic pH, the internalizing peptide acquires the property of amphiphilicity, e.g., it has both hydrophobic and hydrophilic interfaces. More specifically, within a pH range of 10 approximately 5.0-5.5, an internalizing peptide forms an alpha-helical, amphiphilic structure that facilitates insertion of the moiety into a target membrane. An alpha-helix-inducing acidic pH environment may be found, for example, in the low pH environment present within cellular endosomes. Such internalizing peptides can be used to facilitate transport of the subject adzyme, taken up by an endocytic mechanism, from endosomal 15 compartments to the cytoplasm.

A preferred pH-dependent membrane-binding internalizing peptide includes a high percentage of helix-forming residues, such as glutamate, methionine, alanine and leucine. In addition, a preferred internalizing peptide sequence includes ionizable residues having pKa's within the range of pH 5-7, so that a sufficient uncharged membrane-binding 20 domain will be present within the peptide at pH 5 to allow insertion into the target cell membrane.

A particularly preferred pH-dependent membrane-binding internalizing peptide in this regard is Xaa1-Xaa2-Xaa3-EAALA(EALA)4-EALEALAA-amide (SEQ ID NO:), which represents a modification of the peptide sequence of Subbarao *et al.* (*Biochemistry* 25 26:2964, 1987). Within this peptide sequence, the first amino acid residue (Xaa1) is preferably a unique residue, such as cysteine or lysine, that facilitates chemical conjugation of the internalizing peptide to a targeting protein conjugate. Amino acid residues Xaa2-Xaa3 may be selected to modulate the affinity of the internalizing peptide for different membranes. For instance, if both residues 2 and 3 are lys or arg, the 30 internalizing peptide will have the capacity to bind to membranes or patches of lipids having a negative surface charge. If residues 2-3 are neutral amino acids, the internalizing peptide will insert into neutral membranes.

Yet other preferred internalizing peptides include peptides of apo-lipoprotein A-1 and B; peptide toxins, such as melittin, bombolittin, delta hemolysin and the pardaxins; 35 antibiotic peptides, such as alamethicin; peptide hormones, such as calcitonin, corticotrophin releasing factor, beta endorphin, glucagon, parathyroid hormone, pancreatic polypeptide; and peptides corresponding to signal sequences of numerous secreted

proteins. In addition, exemplary internalizing peptides may be modified through attachment of substituents that enhance the alpha-helical character of the internalizing peptide at acidic pH.

Pore-forming proteins or peptides may also serve as internalizing peptides herein.

5 Pore forming proteins or peptides may be obtained or derived from, for example, C9 complement protein, cytolytic T-cell molecules or NK-cell molecules. These moieties are capable of forming ring-like structures in membranes, thereby allowing transport of attached adzyme through the membrane and into the cell interior.

10 *(c) Infective or Foreign Targets*

An additional category of targets for an adzyme are targets that are associated with an infective or otherwise undesirable foreign agent, such as protists, yeasts, bacteria, viruses and prions and various complexes. In certain embodiments, an adzyme is targeted against a virulence factor that is exposed on the surface of a bacterium, such as a pilin or 15 other adhesive protein, a flagellin, or other motility protein, a protein that facilitates bacterial cell entry into the host cell cytoplasm. In certain embodiments, an adzyme is targeted so as to disrupt a structural component of a bacterial cell wall or membrane, sufficient to cause cell lysis. In certain embodiments, an adzyme is targeted against a protein or other component of a virus that is required for viral particle viability or entry 20 into a host cell, e.g., a protein of a viral coat or envelope. In another example, an adzyme may be targeted against a toxin, a venom, an undesirable foreign chemical or a heavy metal.

25 *(d) Molecules targeted by Developed Therapeutic Agents*

One novel approach to designing effective adzymes is to identify molecules that are targeted by therapeutically active agents that act by binding to the targeted molecules, such as monoclonal antibodies and soluble receptor portions. In a preferred embodiment, the target molecule is a target for a FDA-approved, commercially available therapeutic binding agent. It is expected that a molecule which can be effectively targeted by a 30 binding agent may also be targeted by an adzyme that provides increased effectiveness relative to the binding agent.

In certain embodiments, the adzyme is an antagonist of CD52. Such adzymes can be used as part of a treatment for B cell chronic lymphocytic lymphoma (CLL). CD52 is a 21-28 kD glycoprotein expressed on the surface of normal and malignant B and T 35 lymphocytes, NK cells, monocytes, macrophages, and tissues of the male reproductive system. Campath® (Alemtuzumab) is a recombinant DNA-derived humanized CD52

monoclonal antibody (Campath-1H). One problem associated with the use of Campath is hematologic toxicity, which tends to occur when single doses of greater than 30 mg or cumulative doses greater than 90 mg per week are administered. Thus the subject adzyme, which can be administered at a much lower dose because of its catalytic nature, is
5 expected to be a better therapeutic alternative. The adzyme address domain may use the same monoclonal antibody or functional derivative thereof (such as a scFv derivative as in the instant application), as is generally the case in adzyme treatment of other diseases described below. A panel of proteases that are capable of efficiently digesting CD52 may be used as the catalytic domain.

10 In certain embodiments, the adzyme is an antagonist of TNF-alpha. Such adzymes can be used as part of a treatment for Rheumatoid arthritis, inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Human TNF-alpha is a non-glycosylated protein of 17 kDa, while murine TNF-alpha is N-glycosylated. TNF-alpha shows a wide spectrum of biological activities, and is found to be the important part of the
15 whole IBD problem. Enbrel (etanercept; Immunex) and Remicade (infliximab; Centocor) are TNF-alpha antibodies that are used for severe cases of Rheumatoid arthritis and Crohn disease. The two drugs are very similar in mechanism, as is Humira (adalimumab; Abbott), a very recently approved TNF antibody which is much more faithful to human antibody structure. The subject adzyme, which can be administered at a much lower dose
20 because of its catalytic nature, is expected to be a better therapeutic alternative. The adzyme address domain may use the same monoclonal antibody or functional derivative thereof (such as a scFv derivative as in the instant application). A panel of proteases that are capable of efficiently digesting TNF-alpha may be used as the catalytic domain.

25 In certain embodiments, the adzyme is an antagonist of the HER2/neu receptor. Such adzymes can be used as part of a treatment for metastatic breast cancer and/or recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2. The HER2 (or c-erbB2) proto-oncogene encodes a transmembrane receptor protein of 185 kDa, which is structurally related to the epidermal growth factor receptor 1 (EGFR1). HER2 protein overexpression is observed in 25%-30% of primary breast
30 cancers. HERCEPTIN (Trastuzumab) is a recombinant DNA-derived humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay ($K_d = 5$ nM) to the extracellular domain of HER2. The antibody is a humanized murine IgG1 kappa. One problem associated with the use of HERCEPTIN administration is severe hypersensitivity reactions (including anaphylaxis), infusion reactions, and pulmonary
35 events. Thus the subject adzyme, which can be administered at a much lower dose because of its catalytic nature, is expected to be a better therapeutic alternative. The adzyme address domain may use the same monoclonal antibody or functional derivative thereof

(such as a scFv derivative as in the instant application). A panel of proteases that are capable of efficiently digesting HER2 may be used as the catalytic domain.

In certain embodiments, the adzyme is an antagonist of CD33. Such adzymes can be used as part of a treatment for Acute myeloid leukemia (AML), the most common type 5 of acute leukemia in adults. CD33 antigen is a sialic acid-dependent adhesion protein found on the surface of leukemic blasts and immature normal cells of myelomonocytic lineage, but not on normal hematopoietic stem cells. "Mylotarg" (gemtuzumab ozogamicin for Injection) is a chemotherapy agent composed of a recombinant humanized IgG4, kappa antibody conjugated with a cytotoxic antitumor antibiotic, calicheamicin, 10 isolated from fermentation of a bacterium, *Micromonospora echinospora* ssp. *calichensis*. The antibody portion of Mylotarg binds specifically to the CD33 antigen. Side effects associated with the use of Mylotarg includes hypersensitivity reactions, including anaphylaxis, infusion reactions, pulmonary events, and hepatotoxicity. Thus the subject 15 adzyme, which can be administered at a much lower dose because of its catalytic nature, is expected to be a better therapeutic alternative. The adzyme address domain may use the same monoclonal antibody or functional derivative thereof (such as a scFv derivative as in the instant application). A panel of proteases that are capable of efficiently digesting CD33 may be used as the catalytic domain.

In certain embodiments, the adzyme is an antagonist of CD3. Such adzymes can be 20 used as part of a treatment for transplant rejection, such as acute renal, steroid-resistant cardiac, or steroid-resistant hepatic allograft rejection. OKT3 (or "muromonab-CD3") is a murine monoclonal antibody to the CD3 antigen of human T cells which functions as an immunosuppressant. The antibody is a biochemically purified IgG2a immunoglobulin. It is directed to the CD3 glycoprotein in the human T cell surface which is essential for T 25 cell functions. Modulated cells, which reversibly lose the expression of the CD3 T cell receptor molecular complex but still share the CD4 and CD8 antigens, have been shown to be functionally immunoincompetent. Thus the subject adzyme, which can be administered at a much lower dose because of its catalytic nature, is expected to be a better therapeutic alternative. The adzyme address domain may use the same monoclonal antibody or 30 functional derivative thereof (such as a scFv derivative as in the instant application). A panel of proteases that are capable of efficiently digesting CD3 may be used as the catalytic domain.

In certain embodiments, the adzyme is an antagonist of gpIIb/IIIa. Such adzymes can be used as part of a treatment for Acute myocardial infarction/unstable angina. 35 Abciximab (ReoPro®), is the Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa ($\alpha_{IIb} \beta_3$) receptor of human platelets and inhibits platelet aggregation. Abciximab also binds to the vitronectin ($\alpha_v \beta_3$) receptor found on platelets and vessel wall endothelial and smooth muscle cells.

The subject adzyme, which can be administered at a much lower dose because of its catalytic nature, is expected to be a better therapeutic alternative. The adzyme address domain may use the same monoclonal antibody or functional derivative thereof (such as a Fab or scFv derivative as in the instant application). A panel of proteases that are capable of efficiently digesting gpIIb/IIIa may be used as the catalytic domain.

In certain embodiments, the adzyme is an antagonist of CD20. Such adzymes can be used as part of a treatment for Non-Hodgkin's lymphoma (NHL), such as CD20 positive, follicular, Non-Hodgkin's lymphoma. The CD20 antigen is found on the surface of normal and malignant B lymphocytes. The RITUXAN® (Rituximab) antibody is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab has a binding affinity for the CD20 antigen of approximately 8.0 nM. A second approved drug, ZEVALIN (Ibritumomab Tiuxetan), is the immunoconjugate resulting from a stable thiourea covalent bond between the monoclonal antibody Ibritumomab and the linker-chelator tiuxetan [N-[2-bis(carboxymethyl)amino]-3-(p-iso thiocyanatophenyl)-propyl]-[N-[2-bis(carboxymethyl)amino]-2-(methyl)-ethyl]glycine. This linker-chelator provides a high affinity, conformationally restricted chelation site for Indium-111 or Yttrium-90. The antibody moiety of ZEVALIN is Ibritumomab, a murine IgG1 kappa monoclonal antibody directed against the CD20 antigen. A third drug, Bexxar (tositumomab and iodine-131 tositumomab), is another approved drug for the treatment of patients with CD20 positive, follicular, Non-Hodgkin's lymphoma, with and without transformation, whose disease is refractory to Rituxan and has relapsed following chemotherapy. The subject adzyme, which can be administered at a much lower dose because of its catalytic nature, is expected to be a better therapeutic alternative. The adzyme address domain may use the same monoclonal antibodies or functional derivative thereof (such as a Fab or scFv derivative as in the instant application). A panel of proteases that are capable of efficiently digesting CD20 may be used as the catalytic domain.

In certain embodiments, the adzyme is an antagonist of RSV F Protein. Such adzymes can be used as part of a treatment for RSV infection. SYNAGIS® (PALIVIZUMAB) is a humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Palivizumab is a composite of human (95%) and murine (5%) antibody sequences. The subject adzyme, which can be administered at a much lower dose because of its catalytic nature, is expected to be a better therapeutic alternative. The adzyme address domain may use the same monoclonal antibody or functional derivative thereof (such as a Fab or scFv derivative as in the instant

application). A panel of proteases that are capable of efficiently digesting RSV F protein may be used as the catalytic domain.

In certain embodiments, the adzyme is an antagonist of CD25. Such adzymes can be used as part of a treatment for transplant rejection. Zenapax® (daclizumab) is an immunosuppressive, humanized IgG1 monoclonal antibody produced by recombinant DNA technology that binds specifically to the alpha subunit (p55 alpha, CD25, or Tac subunit) of the human high affinity IL-2 receptor that is expressed on the surface of activated (but not resting) lymphocytes. The drug binds to the high affinity IL-2 receptor, thus inhibiting the binding of Tac by IL-2, and the activation of lymphocytes. Therefore, the monoclonal antibody acts as a pure binder inhibitor. The subject adzyme, which can be administered at a much lower dose because of its catalytic nature, is expected to be a better therapeutic alternative. The adzyme address domain may use the same monoclonal antibody or functional derivative thereof (such as a Fab or scFv derivative as in the instant application). A panel of proteases that are capable of efficiently digesting CD25 may be used as the catalytic domain.

In certain embodiments, the adzyme is an antagonist of IL-1. Such adzymes can be used as part of a treatment for Rheumatoid arthritis. The pathogenesis of RA is a complex process that leads to significant and chronic joint inflammation. Interleukin-1 (IL-1) is a central mediator in RA and is a critical proinflammatory cytokine that has been found to be abundant in the synovial fluid of RA patients. Kineret® (anakinra) is a recombinant, nonglycosylated form of the human interleukin 1 receptor antagonist (IL-1Ra). Kineret® differs from native human IL-1Ra in that it has the addition of a single methionine residue at its amino terminus. Kineret® blocks the biologic activity of IL-1 by competitively inhibiting IL-1 binding to the interleukin-1 type I receptor (IL-1RI), which is expressed in a wide variety of tissues and organs. Therefore, Kineret® acts as a pure binder inhibitor. The subject adzyme, which can be administered at a much lower dose because of its catalytic nature, is expected to be a better therapeutic alternative. The adzyme address domain may use the same monoclonal antibody or functional derivative thereof (such as a Fab or scFv derivative as in the instant application). A panel of proteases that are capable of efficiently digesting IL-1 may be used as the catalytic domain.

In certain embodiments, IgE (immunoglobulin E) may be the target of an adzyme. IgE is a class of antibodies that protects the host against invading parasites. IgE interacts with mast cells and eosinophils to protect the host against the invading parasite. The IgE-immune cell complex is also responsible for many allergic or hypersensitivity reactions such as hay fever, asthma, hives and anaphylaxis. There are two major types of receptor for the Fc portion of the IgE on cells. A high affinity receptor is found primarily on mast cells and basophils. A low affinity receptor is found on CD23 cells. IgE attaches to these and acts as an antigen receptor. Xolair™ is a humanized monoclonal antibody directed to

the Fc portion of IgE and effective in treating asthma. An adzyme targeted to and reducing the activity of IgEs (generally by targeting the Fc portion) may be used to treat asthma. The adzyme address domain may use a monoclonal antibody or functional derivative thereof (such as a scFv derivative as in the instant application), or a soluble ligand binding portion of an IgE receptor. One or more of a panel of proteases that are capable of efficiently digesting IgE may be used as the catalytic domain.

5 In certain embodiments, VEGF (Vascular Endothelial Growth Factor) may be the target of an adzyme. VEGF plays a critical role in angiogenesis (the formation of new blood vessels), particularly in tumors and is also involved in the maintenance of
10 established tumor blood vessels. VEGF is homodimeric and disulfide linked. Four human splice variants of VEGF have been identified encoding, in the mature form, polypeptide monomers of 121, 165, 189, or 206 amino acids. Two receptor tyrosine kinases (RTKs), Flt-1 and Flk-1 bind VEGF with high affinity. AvastinTM is an investigational recombinant humanized antibody to VEGF, and shows effectiveness in improving the survival of
15 metastatic colorectal cancer patients. An adzyme targeted to and reducing the activity of VEGF may be used to treat a variety of cancers, particularly colorectal cancer. The adzyme address domain may use a monoclonal antibody or functional derivative thereof (such as a scFv derivative as in the instant application), or a soluble ligand binding portion of a VEGF receptor. One or more of a panel of proteases that are capable of efficiently
20 digesting VEGF may be used as the catalytic domain.

In certain embodiments, EGFR (Epidermal Growth Factor Receptor) may be the target for an adzyme. EGFR is expressed in a high percentage of many cancer types, including head and neck, colorectal, pancreatic, lung, esophageal, renal cell, prostate, bladder, cervical/uterus, ovarian and breast cancers. ERBITUXTM (formerly known as
25 IMC-C225) is a highly specific chimerized monoclonal antibody that binds to EGFR and blocks the ability of EGF to initiate receptor activation and signaling to the tumor. This blockade results in an inhibition of tumor growth by interfering with the effects of EGFR activation including tumor invasion and metastases, cell repair and angiogenesis. ERBITUXTM has been used in combination with chemotherapy and radiation in animal
30 models of human cancers. These preclinical findings indicate that when combined with chemotherapy or radiation, ERBITUXTM treatment provides an enhanced anti-tumor effect resulting in the elimination of tumors and the long-term survival of the animals. An adzyme targeted to and reducing the presence, ligand-binding or signaling capacity of EGFR may be used to treat or prevent a variety of cancers, particularly colorectal cancer,
35 and particularly when used in combination with one or more additional chemotherapeutic agents. The adzyme address domain may use a monoclonal antibody or functional derivative thereof (such as a scFv derivative as in the instant application), or a soluble

ligand (such as EGF) for EGFR. One or more of a panel of proteases that are capable of efficiently digesting extracellular portions of EGFR may be used as the catalytic domain.

In certain embodiments, one or more alpha-4 integrins, such as beta-1 and beta-7 may be the target(s) for an adzyme. Integrins are transmembrane proteins, and the alpha-4-
5 beta 1 (VLA-4) and alpha-4-beta-7 integrins help white blood cells, particularly T lymphocytes and eosinophils, move from through the blood vessel walls into the tissues of the body at sites of inflammation, where these cells then participate in the inflammatory process. Antegren® is a humanized monoclonal antibody that binds to and blocks both the beta-1 and beta-7 integrins, preventing the contribution of many cell types to
10 inflammation; Antegren® shows effectiveness for treatment of Crohn's disease. An adzyme targeted to and reducing the presence or ligand-binding capacity of these integrins may be used to treat or prevent a variety of inflammatory diseases, particularly Crohn's disease. The adzyme address domain may use a monoclonal antibody or functional derivative thereof (such as a scFv derivative as in the instant application), or a soluble
15 ligand for the targeted alpha-4 integrins. One or more of a panel of proteases that are capable of efficiently digesting extracellular portions of the targeted integrins may be used as the catalytic domain.

In certain embodiments, CCR-5 may be the target of an adzyme. The human CCR5 chemokine receptor is a member of the rhodopsin superfamily of G-linked receptors
20 having seven hydrophobic transmembrane domains. CCR5 binds RANTES, MIP-1 β and MIP-1 α . Raport, C.J. et al. (1996) J. Biol. Chem. 271:17161. CCR5 facilitates infection by the macrophage-tropic HIV-1 virus, RANTES, MIP-1 α and MIP-1 β can suppress the infection of susceptible cells by macrophage-tropic HIV-1 isolates. Choe, H. et al. (1996) Cell 85:1135. Cocchi, F. et al. (1995) Science 270:1811. Although no CCR-5 targeted
25 affinity agent has been approved, CCR-5 is implicated in HIV infection, and an adzyme targeted to and reducing the presence or HIV-binding capacity of CCR-5 may be used to treat or prevent asthma and other allergic reactions. The adzyme address domain may use a monoclonal antibody or functional derivative thereof (such as a scFv derivative as in the instant application), or a soluble ligand for CCR-5. One or more of a panel of proteases
30 that are capable of efficiently digesting extracellular portions of CCR-5 may be used as the catalytic domain.

In certain embodiments, interleukin-4 may be the target of an adzyme. Human IL-4 is a pleiotropic cytokine produced by activated T cells, mast cells, and basophils. The biological effects of IL-4 are mediated by the binding of IL-4 to specific cell surface receptors. The functional high-affinity receptor for IL-4 includes a ligand binding subunit (IL-4 R) and a second subunit (β chain) that can modulate the ligand binding affinity of the receptor complex. The gamma chain of the IL-2 receptor complex may also be a functional β chain of the IL-4 receptor complex. Mature IL-4 is a 129 amino acid protein

Yokota, T. et al., 1986, Proc. Natl. Acad. Sci. USA 83:5894. IL-4 activity may be measured, for example, in a cell proliferation assay employing a human factor-dependent cell line, TF-1. Kitamura et al., 1989 J. Cell Physiol. 140:323. Although no IL-4 targeted affinity agent has been approved, IL-4 is implicated in allergies and asthma, and an adzyme targeted to and reducing the activity of IL-4 may be used to treat or prevent asthma and other allergic reactions. The adzyme address domain may use a monoclonal antibody or functional derivative thereof (such as a scFv derivative as in the instant application), or a soluble ligand binding portion of an IL-4 receptor. One or more of a panel of proteases that are capable of efficiently digesting IL-4 may be used as the catalytic domain.

In certain embodiments, IL-13 may be the target of an adzyme. Although no IL-13 targeted affinity agent has been approved, IL-13 is widely recognized as a cytokine that is involved in asthma and various allergies. Mature human IL-13 is a 112 amino acid polypeptide having a sequence as described in GenBank accession no. P35225. McKenzie et al. 1993, PNAS USA 90:3735-3739. IL-13 activity may be measured, for example, in a cell proliferation assay employing a human factor-dependent cell line, TF-1. Kitamura et al., 1989 J. Cell Physiol. 140:323. An adzyme targeted to and reducing the activity of IL-13 may be used to treat or prevent asthma and other allergic reactions. The adzyme address domain may use a monoclonal antibody or functional derivative thereof (such as a scFv derivative as in the instant application), or a soluble ligand binding portion of an IL-13 receptor. One or more of a panel of proteases that are capable of efficiently digesting IL-13 may be used as the catalytic domain.

(i) *TNF α Antagonists*

In certain embodiments, the subject adzyme is a TNF α antagonist, e.g., a “TNF α antagonist adzyme”. TNF α is a soluble homotrimer of 17 kD protein subunits. A membrane-bound 26 kD precursor form of TNF α also exists. The pleiotropic activities of the potent proinflammatory cytokine TNF are mediated by two structurally related, but functionally distinct, receptors, p55 and p75, that are coexpressed on most cell types. To exert its biological activity, TNF α (a homotrimeric molecule) must bind to at least 2 cell surface receptors, causing cross-linking and cell signaling. The majority of biologic responses classically attributed to TNF α are mediated by p55. In contrast, p75 has been proposed to function as both a TNF antagonist by neutralizing TNF α and as a TNF α agonist by facilitating the interaction between TNF α and p55 at the cell surface. The roles of p55 and p75 in mediating and modulating the activity of TNF α in vivo have been examined in mice genetically deficient in these receptors. Selective deficits in several host defense and inflammatory responses are observed in mice lacking p55 or both p55 and

p75, but not in mice lacking p75. In these models, the activity of p55 is not impaired by the absence of p75, arguing against a physiologic role for p75 as an essential element of p55-mediated signaling. In contrast, exacerbated pulmonary inflammation and dramatically increased endotoxin induced serum TNF α levels in mice lacking p75 suggest 5 a dominant role for p75 in suppressing TNF α -mediated inflammatory responses.

The p55 receptor (also termed TNF-R55, TNF-RI, or TNFR α) is a 55 kd glycoprotein shown to transduce signals resulting in cytotoxic, antiviral, and proliferative activities of TNF α . The p75 receptor (also termed TNF-R75, TNF-RII, or TNFR α) is a 75 kDa glycoprotein that has also been shown to transduce cytotoxic and proliferative 10 signals as well as signals resulting in the secretion of GM-CSF. The extracellular domains of the two receptors have 28% homology and have in common a set of four subdomains defined by numerous conserved cysteine residues. The p75 receptor differs, however, by having a region adjacent to the transmembrane domain that is rich in proline residues and contains sites for O-linked glycosylation. Interestingly, the cytoplasmic domains of the 15 two receptors share no apparent homology which is consistent with observations that they can transduce different signals to the interior of the cell.

To further illustrate, a TNF α antagonist adzyme can be directed to TNF α , e.g., in biological fluids, by way of one or more TNF α targeting moieties. Exemplary TNF α targeting moieties include, but are not limited to, the extracellular domains of TNF α 20 receptors (or appropriate portions thereof), anti-TNF α antibodies or antigen binding fragments thereof, or peptides or small molecules that (selectively) bind TNF α .

In certain preferred embodiments, the targeting moiety is derived from the extracellular ligand binding domain of the p75 or p55 receptor, e.g., a portion sufficient to 25 specifically bind to TNF- α . For instance, the targeting moiety can include a ligand binding fragment of p75, such as from Leu23 – Asp257 of the human p75 protein (Swiss-Prot Accession P20333) or a ligand binding fragment of p55, such as from Ile22 – Thr211 of the human p55 protein (Swiss-Prot Accession P19438). In certain embodiments, the targeting moiety of the subject adzymes can be generated from Onercept (a fully human 30 soluble fragment of p55) or Etanercept (Enbrel \circledR , a dimeric construct in which two p75 extracellular fragments are linked to the Fc portion of human IgG1).

In other preferred embodiments, the targeting moiety is derived from an antibody that binds to TNF α , or an antigen binding domain thereof. For instance, the subject adzymes can be generated using the monoclonal anti-TNF α antibody is infliximab (Remicade \circledR), or the variable domains of one or both of the heavy and light chains thereof, 35 such as the Fv fragment. Infliximab is a chimeric human/mouse monoclonal anti-TNF α antibody composed of the constant regions of human (Hu) IgG1 κ , coupled to the Fv region of a high-affinity neutralizing murine anti-HuTNF α antibody. Likewise, the subject

adzyme can including a targeting moiety derived from the human anti-TNF antibody D2E7, also known as adalumimab.

In still other embodiments, the TNF α targeting moiety is a peptide. For instance, Guo et al. (2002) Di Yi Jun Yi Da Xue Xue Bao. 22(7):597 describes the screening of 5 TNF α -binding peptides by phage display. That reference teaches a number of short peptides that could be used to generate TNF α -targeted adzymes. Merely to illustrate, the TNF α targeting moiety can be a peptide having the sequence ALWHWWH or (T/S)WLHWWA.

The ability of any particular adzyme to act alter the activity of TNF α can be 10 assayed using any of a variety of cell-based and cell-free assay systems well known in the art. Exemplary assays include, but are not limited to, L929 assay, endothelial procoagulation assays, tumor fibrin deposition assays, cytotoxicity assay, tumor regression assays, receptor binding assays, arthritic index assays in mouse model systems, and the like. In certain preferred embodiments of TNF α antagonist adzymes, their biological 15 activities will include one or more of: inhibition of TNF- α cytotoxicity in L929 cells; blocking of prostaglandin E2 production and expression of cell-associated IL1 by human dermal fibroblasts; blocking of TNF- α binding to the promonocytic cell line U937; blocking of TNF- α induced respiratory burst in human neutrophils; blocking of TNF- α stimulated neutrophil lucigenin-dependent chemiluminescence response and superoxide 20 formation; significantly reducing the priming ability of TNF- α for a response to the chemotactic peptide fMLP; blocking of class I antigen expression in the human Colo 205 tumor cell line; affecting TNF- α synergism with HLA-DR antigen expression induced by IFN- γ (yet preferably having no effect on IFN- γ activity).

In certain embodiments, the TNF α antagonist adzyme will modify the substrate 25 TNF α protein in a manner that produces a product that is itself an antagonist of TNF α . For instance, the adzyme can include a catalytic domain that cleaves a site in the TNF α polypeptide to produce a product that retains the ability to bind, for example, to the p55 receptor but with a greatly reduced ability to activate the receptor (e.g., has an impaired ability to induce a cytotoxic response) so as to be an antagonist of native TNF α . For 30 instance, the cleavage product may retain the ability to interact with native TNF α to form stable mixed trimers that bind to receptors but are incapable of activating receptor signaling. To further illustrate, the sites within the human TNF- α molecule that can be targeted for cleavage by an adzyme may be located at or near residues 29 to 34, 71-73, 86, and 143-146. For instance, a catalytic domain having a trypsin-like specificity can be used 35 in an adzyme that selectively cleaves Arg⁴⁴ of human TNF α . Likewise, an adzyme including the catalytic domain of granzyme B can be used to target Asp¹⁴³. Residues within these regions are believed to be important for TNF- α cytotoxic activity. Adzyme

cleavage products having the combination of antagonist activity and reduced cytotoxicity can be identified by the screening assays described above.

The subject TNF α antagonist adzymes can be used to treat various TNF-associated disorders, e.g., disorders or diseases that are associated with, result from, and/or occur in response to, elevated levels of TNF α . Such disorders may be associated with episodic or chronic elevated levels of TNF α activity and/or with local or systemic increases in TNF α activity. Such disorders include, but are not limited to, inflammatory diseases, such as arthritis and inflammatory bowel disease, and congestive heart failure.

TNF α causes pro-inflammatory actions which result in tissue injury, such as degradation of cartilage and bone, induction of adhesion molecules, inducing procoagulant activity on vascular endothelial cells, increasing the adherence of neutrophils and lymphocytes, and stimulating the release of platelet activating factor from macrophages, neutrophils and vascular endothelial cells. In certain preferred embodiments, the TNF α antagonist adzyme reduces the inflammatory activity of TNF α .

Recent evidence also associates TNF α with infections, immune disorders, neoplastic pathologies, autoimmune pathologies and graft-versus-host pathologies. For instance, TNF α is understood to play a central role in gram-negative sepsis and endotoxic shock, including fever, malaise, anorexia, and cachexia. Endotoxin strongly activates monocyte/macrophage production and secretion of TNF α and other cytokines (Kombluth et al., *J. Immunol.* 137:2585-2591 (1986)). Circulating TNF α levels increase in patients suffering from gram-negative sepsis. Thus, the subject TNF α antagonist adzymes may be used as part of a treatment protocol for inflammatory diseases, autoimmune diseases, viral, bacterial and parasitic infections, malignancies, and neurogenerative diseases, such as for therapy in rheumatoid arthritis and Crohn's disease.

There is evidence that TNF α is also involved in cachexia in cancer, infectious pathology, and other catabolic states. Accordingly, the TNF α antagonist adzymes can also be used to reduce muscle wasting associated with such disorders, or any other in which cachexia is an issue in patient management.

Accordingly, the present invention provides methods in which the subject adzymes can be used as part of treatments for modulating or reducing the severity of at least one immune related disease, in a cell, tissue, organ, animal, or patient including, but not limited to, at least one of rheumatoid arthritis, juvenile rheumatoid arthritis, systemic onset juvenile rheumatoid arthritis, psoriatic arthritis, ankylosing spondilitis, gastric ulcer, seronegative arthropathies, osteoarthritis, inflammatory bowel disease, ulcerative colitis, systemic lupus erythematosus, antiphospholipid syndrome, iridocyclitis/uveitis/optic neuritis, idiopathic pulmonary fibrosis, systemic vasculitis/wegener's granulomatosis,

sarcoidosis, orchitis/vasectomy reversal procedures, allergic/atopic diseases, asthma, allergic rhinitis, eczema, allergic contact dermatitis, allergic conjunctivitis, hypersensitivity pneumonitis, transplants, organ transplant rejection, graft-versus-host disease, systemic inflammatory response syndrome, sepsis syndrome, gram positive 5 sepsis, gram negative sepsis, culture negative sepsis, fungal sepsis, neutropenic fever, urosepsis, meningococcemia, trauma/hemorrhage, burns, ionizing radiation exposure, acute pancreatitis, adult respiratory distress syndrome, rheumatoid arthritis, alcohol-induced hepatitis, chronic inflammatory pathologies, sarcoidosis, Crohn's pathology, sickle cell anemia, diabetes, nephrosis, atopic diseases, hypersensitivity reactions, allergic 10 rhinitis, hay fever, perennial rhinitis, conjunctivitis, endometriosis, asthma, urticaria, systemic anaphylaxis, dermatitis, pernicious anemia, hemolytic disease, thrombocytopenia, graft rejection of any organ or tissue, kidney transplant rejection, heart transplant rejection, liver transplant rejection, pancreas transplant rejection, lung transplant rejection, bone marrow transplant (BMT) rejection, skin allograft rejection, 15 cartilage transplant rejection, bone graft rejection, small bowel transplant rejection, fetal thymus implant rejection, parathyroid transplant rejection, xenograft rejection of any organ or tissue, allograft rejection, anti-receptor hypersensitivity reactions, Graves disease, Raynoud's disease, type B insulin-resistant diabetes, asthma, myasthenia gravis, antibody-mediated cytotoxicity, type III hypersensitivity reactions, systemic lupus erythematosus, 20 POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome), polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes syndrome, antiphospholipid syndrome, pemphigus, scleroderma, mixed connective tissue disease, idiopathic Addison's disease, diabetes mellitus, chronic active hepatitis, primary biliary cirrhosis, vitiligo, 25 vasculitis, post-MI cardiotomy syndrome, type IV hypersensitivity, contact dermatitis, hypersensitivity pneumonitis, allograft rejection, granulomas due to intracellular organisms, drug sensitivity, metabolic/idiopathic, Wilson's disease, hemachromatosis, alpha-1-antitrypsin deficiency, diabetic retinopathy; Hashimoto's thyroiditis, osteoporosis, hypothalamic-pituitary-adrenal axis evaluation, primary biliary cirrhosis, thyroiditis, 30 encephalomyelitis, cachexia, cystic fibrosis, neonatal chronic lung disease, chronic obstructive pulmonary disease (COPD), familial hematophagocytic lymphohistiocytosis, dermatologic conditions, psoriasis, alopecia, nephrotic syndrome, nephritis, glomerular nephritis, acute renal failure, hemodialysis, uremia, toxicity, preeclampsia, okt3 therapy, anti-cd3 therapy, cytokine therapy, chemotherapy, radiation therapy (e.g., including but 35 not limited to asthenia, anemia, cachexia, and the like), chronic salicylate intoxication, and the like.

In one embodiment, a TNF α adzyme is used to treat hypergastrinemia, such as Helicobacter Pylori-induced gastritis.

The present invention also provides methods for using the subject TNF α antagonist adzymes for modulating or treating at least one cardiovascular disease in a cell, tissue, organ, animal, or patient, including, but not limited to, at least one of cardiac stun syndrome, myocardial infarction, congestive heart failure, stroke, ischemic stroke, 5 hemorrhage, arteriosclerosis, atherosclerosis, restenosis, diabetic atherosclerotic disease, hypertension, arterial hypertension, renovascular hypertension, syncope, shock, syphilis of the cardiovascular system, heart failure, cor pulmonale, primary pulmonary hypertension, cardiac arrhythmias, atrial ectopic beats, atrial flutter, atrial fibrillation (sustained or paroxysmal), post perfusion syndrome, cardiopulmonary bypass inflammation response, 10 chaotic or multifocal atrial tachycardia, regular narrow QRS tachycardia, specific arrhythmias, ventricular fibrillation, His bundle arrhythmias, atrioventricular block, bundle branch block, myocardial ischemic disorders, coronary artery disease, angina pectoris, myocardial infarction, cardiomyopathy, dilated congestive cardiomyopathy, restrictive cardiomyopathy, valvular heart diseases, endocarditis, pericardial disease, cardiac tumors, 15 aortic and peripheral aneurysms, aortic dissection, inflammation of the aorta, occlusion of the abdominal aorta and its branches, peripheral vascular disorders, occlusive arterial disorders, peripheral atherosclerotic disease, thromboangiitis obliterans, functional peripheral arterial disorders, Raynaud's phenomenon and disease, acrocyanosis, erythromelalgia, venous diseases, venous thrombosis, varicose veins, arteriovenous fistula, 20 lymphedema, lipedema, unstable angina, reperfusion injury, post pump syndrome, ischemia-reperfusion injury, and the like.

The present invention also provides methods using the subject TNF α antagonist adzymes for modulating or treating at least one infectious disease in a cell, tissue, organ, animal or patient, including, but not limited to, at least one of: acute or chronic bacterial 25 infection, acute and chronic parasitic or infectious processes, including bacterial, viral and fungal infections, HIV infection/HIV neuropathy, meningitis, hepatitis (A, B or C, or the like), septic arthritis, peritonitis, pneumonia, epiglottitis, E. coli infection, hemolytic uremic syndrome/thrombolytic thrombocytopenic purpura, malaria, dengue hemorrhagic fever, leishmaniasis, leprosy, toxic shock syndrome, streptococcal myositis, gas gangrene, 30 mycobacterium tuberculosis, mycobacterium avium intracellulare, pneumocystis carinii pneumonia, pelvic inflammatory disease, orchitis/epididymitis, legionella, lyme disease, influenza a, epstein-barr virus, vital-associated hemophagocytic syndrome, vital encephalitis/aseptic meningitis, and the like.

The present invention also provides methods for modulating or treating at least one 35 malignant disease in a cell, tissue, organ, animal or patient, including, but not limited to, at least one of: leukemia, acute leukemia, acute lymphoblastic leukemia (ALL), B-cell, T-cell or FAB ALL, acute myeloid leukemia (AML), chronic myelocytic leukemia (CML),

chronic lymphocytic leukemia (CLL), hairy cell leukemia, myelodysplastic syndrome (MDS), a lymphoma, Hodgkin's disease, a malignant lymphoma, non-hodgkin's lymphoma, Burkitt's lymphoma, multiple myeloma, Kaposi's sarcoma, colorectal carcinoma, pancreatic carcinoma, nasopharyngeal carcinoma, malignant histiocytosis, 5 paraneoplastic syndrome/hypercalcemia of malignancy, solid tumors, adenocarcinomas, sarcomas, malignant melanoma, hemangioma, metastatic disease, cancer related bone resorption, cancer related bone pain, and the like.

The present invention also provides methods that use TNF α antagonist adzymes for modulating or treating at least one neurologic disease in a cell, tissue, organ, animal or 10 patient, including, but not limited to, at least one of: neurodegenerative diseases, multiple sclerosis, migraine headache, AIDS dementia complex, demyelinating diseases, such as multiple sclerosis and acute transverse myelitis; extrapyramidal and cerebellar disorders' such as lesions of the corticospinal system; disorders of the basal ganglia or cerebellar disorders; hyperkinetic movement disorders such as Huntington's Chorea and senile 15 chorea; drug-induced movement disorders, such as those induced by drugs which block CNS dopamine receptors; hypokinetic movement disorders, such as Parkinson's disease; Progressive supranucleo Palsy; structural lesions of the cerebellum; spinocerebellar degenerations, such as spinal ataxia, Friedreich's ataxia, cerebellar cortical degenerations, multiple systems degenerations (Mencel, Dejerine-Thomas, Shi-Drager, and Machado- 20 Joseph); systemic disorders (Refsum's disease, abetalipoproteinemia, ataxia, telangiectasia, and mitochondrial multi-system disorder); demyelinating core disorders, such as multiple sclerosis, acute transverse myelitis; and disorders of the motor unit' such as neurogenic muscular atrophies (anterior horn cell degeneration, such as amyotrophic lateral sclerosis, infantile spinal muscular atrophy and juvenile spinal muscular atrophy); Alzheimer's 25 disease; Down's Syndrome in middle age; Diffuse Lewy body disease; Senile Dementia of Lewy body type; Wernicke-Korsakoff syndrome; chronic alcoholism; Creutzfeldt-Jakob disease; Subacute sclerosing panencephalitis, Hallervorden-Spatz disease; and Dementia pugilistica, and the like.

The TNF α antagonist adzymes can be administered before, concurrently, and/or 30 after (referred to herein as "concomitantly with") other drugs, such as at least one selected from an antirheumatic (e.g., methotrexate, auranofin, aurothioglucose, azathioprine, etanercept, gold sodium thiomalate, hydroxychloroquine sulfate, leflunomide, sulfasalazine), a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, a neuromuscular 35 blocker, an antimicrobial (e.g., aminoglycoside, an antifungal, an antiparasitic, an antiviral, a carbapenem, cephalosporin, a fluorquinolone, a macrolide, a penicillin, a sulfonamide, a tetracycline, another antimicrobial), an antipsoriatic, a corticosteroid, an

anabolic steroid, a diabetes related agent, a mineral, a nutritional, a thyroid agent, a vitamin, a calcium related hormone, an antidiarrheal, an antitussive, an antiemetic, an antiulcer, a laxative, an anticoagulant, an erythropoietin (e.g., epoetin alpha), a filgrastim (e.g., G-CSF, Neupogen), a sargramostim (GM-CSF, Leukine), an immunization, an 5 immunoglobulin, an immunosuppressive (e.g., basiliximab, cyclosporine, daclizumab), a growth hormone, a hormone replacement drug, an estrogen receptor modulator, a mydriatic, a cycloplegic, an alkylating agent, an antimetabolite, a mitotic inhibitor, a radiopharmaceutical, an antidepressant, antimanic agent, an antipsychotic, an anxiolytic, a 10 hypnotic, a sympathomimetic, a stimulant, donepezil, tacrine, an asthma medication, a beta agonist, an inhaled steroid, a leukotriene inhibitor, a methylxanthine, a cromolyn, an 15 epinephrine or analog, domase alpha (Pulmozyme), a cytokine or a cytokine antagonist.

The subject adzymes can also be administered concomitantly with compounds that prevent and/or inhibit TNF receptor signaling, such as mitogen activated protein (MAP) kinase inhibitors; compounds which block and/or inhibit membrane TNF cleavage, such 15 as metalloproteinase inhibitors; compounds which block and/or inhibit TNF activity, such as angiotensin converting enzyme (ACE) inhibitors (e.g., captopril); and compounds which block and/or inhibit TNF production and/or synthesis, such as MAP kinase 20 inhibitors.

20 (ii) *IL-1 β antagonists*

In certain embodiments, the subject adzyme is an Interleukin-1 antagonist, e.g., an “IL-1 antagonist adzyme”. Interleukin-1 is a multi-functional proinflammatory cytokine that mediates innate and adaptive immune responses in multiple cell types. It is believed to play a role in numerous diseases including arthritis, asthma/allergy, osteoporosis, and 25 stroke (for review, see Dinarello (1998) *Int. Rev. Immunol.* 16, 457-499). The IL-1 family actually consists of two proteins with similar biological activity, IL-1 α and IL-1 β , as well as a nonsignaling ligand termed the IL-1 receptor antagonist (IL-1ra). All three proteins exhibit a similar tertiary structure comprised of 12 β strands that make up a barrel-shaped 30 β -trefoil with pseudo-3-fold symmetry. IL-1 β is thought to be the primary circulating cytokine that mediates the systemic effects of IL-1.

IL-1 exerts its biological action by binding and activating the membrane-associated IL1R-I. A second receptor, termed the IL-1R accessory protein (AcP), is not involved in direct ligand binding but is required for IL-1 signal transduction by complexing with IL-1 and the IL1R-I. IL1R-I and AcP both contain extracellular portions 35 with three Ig-like domains and cytoplasmic portions containing conserved signaling motifs. A third IL-1 receptor exists termed the type II IL-1R (IL1R-II) that has a

extracellular structure similar to that of IL1R-I and AcP but that contains a truncated cytoplasmic tail incapable of signaling. This receptor acts as a decoy by binding IL-1 with high affinity and neutralizing its activity. IL1R-II can also be proteolytically cleaved, which releases the extracellular domain from the cell surface. This creates a soluble form 5 of the receptor (sIL1R-II) that possesses high affinity for IL-1 β , but only low affinity for IL-1 α , and virtually no affinity for IL-1ra.

In certain preferred embodiments, the subject adzymes are IL-1 antagonist adzyme that act on IL-1, particularly IL-1 β , present in biological fluids. Exemplary IL-1 targeting moieties that be adapted for use in such adzymes include, but are not limited to, the 10 extracellular domains of IL-1 receptors or appropriate portions thereof, IL1R-II or a portion thereof, anti-IL-1 antibodies or antigen binding fragments thereof, or peptides or small molecules that (selectively) bind IL-1.

In certain preferred embodiments, the targeting moiety is derived from IL1R-II, e.g., a portion sufficient to specifically bind to IL-1 β . For instance, the targeting moiety 15 can include a ligand binding domain from IL1R-II from the human IL1R-II protein (GI Accession 640248, PRI Accession 2IRT_A).

The inhibitory activity of an IL-1 antagonist adzyme can be assayed using any of a variety of cell-based and cell-free assay systems well known in the art. For instance, IL-1 antagonist adzymes can be identified using the mixed lymphocyte response (MLR) and 20 phytohemagglutinin A (PHA) assay, which is useful for identifying immune suppressive molecules *in vitro* that can be used for treating graft-versus-host disease. The results obtained from these assays are generally predictive of their *in vivo* effectiveness.

Another assay that be used to assess the adzyme is with respect to inhibition of immune responsiveness involves the mitogenic stimulation of lymphocytes with mitogenic 25 substances of plant origin. The most widely used plant molecule is PHA. Although PHA stimulates DNA synthesis non-specifically in a large number of lymphocytes, unlike true antigenic stimulation which causes mitogenesis of sub-populations of lymphocytes, the susceptibility of a patient's lymphocytes to PHA stimulation has been shown to correlate with the overall immune responsiveness of the patient.

30 Thus, it will be appreciated as to both the mixed lymphocyte and PHA assay that they are valuable for identifying immune suppressive IL-1 antagonist adzymes.

In addition to the above immunosuppressive assays, a secondary mixed lymphocyte reaction assay may also be used. The secondary mixed lymphocyte assays differs from the primary mixed lymphocyte reaction assays in that they employ many 35 more primed responder cells that are responsive to the primary stimulating cells. The presence of such responsive cells is a reflection of immunological memory in an ongoing

immunological response. The protocol for carrying out a secondary mixed lymphocyte assay involves performing a primary lymphocyte assay as described above, and recovering viable cells about 9-10 days after the primary mixed lymphocyte reaction exhibits little or no cell proliferation. Generally between 10% to 50% of the original input cells are recovered in viable condition. These cells are then used in the secondary mixed lymphocyte reaction.

The subject adzymes can also be assessed for their ability to block IL-1 mediated cytokine production. Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes are well known in the art.

10 In still other embodiments, the subject adzymes can be assessed for their effect on proliferation and differentiation of hematopoietic and lymphopoietic cells.

In certain embodiments, the IL-1 antagonist adzyme will modify the substrate IL-1 β protein in a manner that produces a product that is itself an antagonist of IL1 β . For instance, the adzyme can include a catalytic domain that cleaves a site in the IL-1 β polypeptide to produce a product that retains the ability to bind, for example, to the IL1 receptor but with a greatly reduced ability to activate the receptor so as to be an antagonist of native IL-1 β . To further illustrate, the Arg¹²⁷ residue of human IL-1 β can be targeted for cleavage by an adzyme having a catalytic domain with trypsin-like specificity. Mutation of Arg¹²⁷ has been demonstrated to reduce the bioactivity of IL-1 β greatly while only having slight effect on receptor binding affinity.

The IL-1 mediated diseases which may be treated or prevented by the IL-1 antagonist adzymes of this invention include, but are not limited to, inflammatory diseases, autoimmune diseases, proliferative disorders, infectious diseases, and degenerative diseases. The apoptosis-mediated diseases which may be treated or prevented by the IL-1 antagonist adzymes of this invention include degenerative diseases.

Inflammatory diseases which may be treated or prevented include, but are not limited to osteoarthritis, acute pancreatitis, chronic pancreatitis, asthma, and adult respiratory distress syndrome. Preferably the inflammatory disease is osteoarthritis or acute pancreatitis.

30 Autoimmune diseases which may be treated or prevented include, but are not limited to, glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Graves' disease, autoimmune gastritis, insulin-dependent diabetes mellitus (Type I), autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, chronic active hepatitis, myasthenia gravis, multiple sclerosis, 35 inflammatory bowel disease, Crohn's disease, psoriasis, and graft vs. host disease.

Preferably the autoimmune disease is rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, or psoriasis,

Destructive bone disorders which may be treated or prevented include, but are not limited to, osteoporosis and multiple myeloma-related bone disorder.

5 Proliferative diseases which may be treated or prevented include, but are not limited to, acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, and multiple myeloma.

Infectious diseases which may be treated or prevented include, but are not limited to, sepsis, septic shock, and Shigellosis.

10 The IL-1-mediated degenerative or necrotic diseases which may be treated or prevented by the IL-1 antagonist adzymes of this invention include, but are not limited to, Alzheimer's disease, Parkinson's disease, cerebral ischemia, and myocardial ischemia. Preferably, the degenerative disease is Alzheimer's disease.

15 The apoptosis-mediated degenerative diseases which may be treated or prevented by the IL-1 antagonist adzymes of this invention include, but are not limited to, Alzheimer's disease, Parkinson's disease, cerebral ischemia, myocardial ischemia, spinal muscular atrophy, multiple sclerosis, AIDS-related encephalitis, HIV-related encephalitis, aging, alopecia, and neurological damage due to stroke.

20 *(e) Biomolecular Targets in Non-Therapeutic Contexts*

Adzymes may be used in a number of non-medical applications, including but are not limited to, agriculture, environmental protection, food etc., and such adzymes will be targeted accordingly.

25 Adzymes may be used to upgrade nutritional quality and removing anti-nutritional factors from feed components, such as barley- and wheat-based feeds. Targets for such adzymes may include gluten meal, fiber, prions (e.g., PrP, the causative agent for bovine spongiform encephalopathy), dioxin, pesticides, herbicides, starches, lipids, cellulose, pectin, certain sugars (e.g., lactose, maltose) and polysaccharides.

30 Adzyme may be used in industrial processes such as waste processing, textile manufacture or paper production, or essentially any other process that employs an enzyme, where the enzyme can be replaced by an adzyme with improved effectiveness. Examples of targets for such applications include cellulose, hemicellulose, pectin, lignin, starch, peroxides, phosphates and nitrates.

Adzyme may be used in detergents or other cleaning agents, providing targeted elimination of selected soils or stains. Targets for such adzymes may include chlorophyll, hemoglobin, heme groups, hydrocarbons, avidin, ovalbumin, and various pigments and dyes.

5 Adzymes may be used for the cleanup of various environmental contaminants, such oil, pesticides, herbicides and waste products from chemical manufacture. Targets for such adzymes include hydrocarbons, halogenated hydrocarbons (particularly halogenated hydrocarbons containing aromatic moieties), cyanides, carbon monoxide, nitrous oxides, heavy metals, organometallic compounds, organophosphates and carbamates.

10

B. Exemplary Catalytic Domains

As used herein, the term "catalytic domain" includes any moiety capable of acting on a target to induce a chemical change, thereby modulate its activity, i.e., a moiety capable of catalyzing a reaction within a target. The catalytic domain may be a naturally occurring enzyme, a catalytically active fragment thereof, or an engineered enzyme, e.g., a protein engineered to have an enzymatic activity, such as a protein designed to contain a serine protease active motif. A catalytic domain need comprise only the arrangement of amino acids that are effective to induce the desired chemical change in the target. They may be N- terminal or C- terminal truncated versions of natural enzymes, mutated versions, zymogens, or complete globular domains. The catalytic domain may be a non protein physiologically compatible catalyst.

25 The catalytic domain may comprise an enzymatically active site that alone is promiscuous, binding with a vulnerable site it recognizes on many different biomolecules, and may have relatively poor reaction kinetics. Both of these features are normally antithetical to sound drug development, but often are desireable in adzyme constructs, where the address specifies preference for the desired targeted biomolecule, and its binding properties often dominate kinetics, i.e., assure preferential collision between the catalytically active site and the target.

30 The catalytic domain also may be a protein that modifies the target so that it is recognized and acted upon by another enzyme (e.g., an enzyme that is already present in a subject). In another embodiment, the catalytic domain may be a moiety that alters the structure of the target so that its activity is inhibited or upregulated. Many naturally occurring enzymes activate other enzymes, and these can be exploited in accordance with the invention.

The catalytic moiety of the adzyme can be a protease, a glycosidase, a lipase, or other hydrolases, or other enzymatic activity, including isomerases, transferases (including kinases), lyases, oxidoreductases, oxidases, aldolases, ketolases, glycosidases, transferases and the like.

5 Other potentially useful enzymes include oxidoreductases such as those acting on groups donating CH-OH, aldehyde or oxo, CH-CH, CH-NH₂, CH-NH, NADH or NADPH, other nitrogenous compounds, sulfur, heme, diphenols, hydrogen, single donors with incorporation of molecular oxygen, paired donors, -CH₂ groups, reduced flavodoxin, iron-sulfur proteins, and oxidizing metal ions, and those acting on a superoxide radicals or
10 peroxide as acceptors (peroxidases). The term "oxidoreductase" encompasses enzymes which catalyze the reduction or oxidation of a molecule. Examples of oxidoreductases include dehydrogenases, reductases, oxidases, oxygenases, hydrolases, and peroxidases.

Transfases include enzymes that catalyze the transfer of a group of atoms from one molecule to another. Useful transferase catalytic domains transfer carbon groups, 15 nitrogenous groups, phosphorous-containing groups, sulfur-containing groups, selenium-containing groups, or aldehyde or ketone residues, and include acyltransferases or glycosyltransferases transferring alkyl or aryl groups. Examples of transferases include aminotransferases, kinases, and myristolases.

Other potentially useful enzymes include carbon-carbon, carbon-oxygen, carbon- 20 nitrogen, carbon-sulfur carbon-halide and phosphorus-oxygen lyases. Lyases add a small molecule to a double bond. Examples of lyases include synthases, decarboxylases and dehydratases.

The adzyme can include a ligase domain, e.g., a catalytic domain that catalyzes the formation of carbon-oxygen bonds, carbon-sulfur bonds, carbon-nitrogen bonds, carbon- 25 carbon bonds, and phosphoric ester bonds. Ligases catalyze bond forming reactions which join together two or more molecules. Examples of ligases include carboxylases and synthetases.

Isomerases, racemases, epimerases, cis-trans-isomerases, intramolecular oxidoreductases, intramolecular transferases (mutases), intramolecular lyases also are 30 potentially useful.

Glycosidases can also be a source for the catalytic domain of an adzyme. These enzymes are defined as glycolytic enzymes which can alter the carbohydrate structure of a protein substrate, and may be useful in instances such as when carbohydrate-mediated interaction of the targeted substrate with other proteins (such as a ligand-receptor 35 interaction) is important to biological activity, or where the carbohydrate influences the

half-life or biodistribution of the targeted substrate. Lysozyme is an example of a hydrolytic enzyme directed to polysaccharides.

Likewise, lipases can be employed in adzymes that alter membrane structure.

Many examples of each type of enzyme have been identified and can be found in public databases, *e.g.*, SwissProt, PIR, PRF, or the database maintained by the National Centers for Biotechnology Information (NCBI). Further, high resolution three dimensional structural coordinates for many enzymes can be found in the database maintained by the Research Collaboratory for Structural Bioinformatics (RCSB). The unresolved structures of proteins often can be predicted using a technique known as threading. Threading algorithms are described in the literature and can be found in Alexandrov N.N., *et al.*, (1998) *Bioinformatics* 14:206-11, Labesse G, *et al.* (1997) *Proteins* 1:38-42, Xu, Y. *et al.* (1999). *Protein Eng.*, 12: 899-907, Russel A. J., *et al.* (2002) *Proteins* 47:496-505, and Reva, B., *et al.* (2002) *Proteins* 47:180-93.

In a preferred embodiment, the catalytic domain is a protease. Examples of proteases, or catalytically active fragments thereof, that can be utilized to this end include serine proteases, cysteine proteases, aspartate or acid proteases, metalloproteases or any other protease capable of cleaving the amide backbone of the targeted substrate.

In certain preferred embodiments, the subject adzyme incorporates a peptidase catalytic activity, *e.g.*, such as may be derived using an enzyme which is designated by the International Union of Biochemistry and Molecular Biology (1984) as subclass E.C 3.4.-.-. For example, the subject method can be used to determine the specificity of an aminopeptidase (EC 3.4.11.-), a dipeptidase (EC 3.4.13.-), a dipeptidyl-peptidase or tripeptidyl peptidase (EC 3.4.14.-), a peptidyl-dipeptidase (EC 3.4.15.-), a serine-type carboxypeptidase (EC 3.4.16.-), a metallocarboxypeptidase (EC 3.4.17.-), a cysteine-type carboxypeptidase (EC 3.4.18.-), an omegapeptidase (EC 3.4.19.-), a serine proteinase (EC 3.4.21.-), a cysteine proteinase (EC 3.4.22.-), an aspartic proteinase (EC 3.4.23.-), a metallo proteinase (EC 3.4.24.-), or a proteinase of unknown mechanism (EC 3.4.99.-). Exemplary peptide hydrolyases which can be adapted for use in the subject adzymes include:

30

- 3.4.11.1 Leucyl aminopeptidase.
- 3.4.11.2 Membrane alanine aminopeptidase.
- 3.4.11.3 Cystinyl aminopeptidase.
- 3.4.11.4 Tripeptide aminopeptidase.
- 3.4.11.5 Prolyl aminopeptidase.
- 3.4.11.6 Aminopeptidase B.
- 3.4.11.7 Glutamyl aminopeptidase.
- 3.4.11.9 Xaa-Pro aminopeptidase.
- 3.4.11.10 Bacterial leucyl aminopeptidase.

3.4.11.13 Clostridial aminopeptidase.
 3.4.11.14 Cytosol alanyl aminopeptidase.
 3.4.11.15 Lysyl aminopeptidase.
 3.4.11.16 Xaa-Trp aminopeptidase.
 5 3.4.11.17 Tryptophanyl aminopeptidase.
 3.4.11.18 Methionyl aminopeptidase.
 3.4.11.19 D-stereospecific aminopeptidase.
 3.4.11.20 Aminopeptidase Ey.
 10 3.4.11.22 Vacuolar aminopeptidase I.
 3.4.13.3 Xaa-His dipeptidase.
 3.4.13.4 Xaa-Arg dipeptidase.
 3.4.13.5 Xaa-methyl-His dipeptidase.
 3.4.13.6 Cys-Gly dipeptidase.
 3.4.13.7 Glu-Glu dipeptidase.
 15 3.4.13.8 Pro-Xaa dipeptidase.
 3.4.13.9 Xaa-Pro dipeptidase.
 3.4.13.12 Met-Xaa dipeptidase.
 3.4.13.17 Non-stereospecific dipeptidase.
 3.4.13.18 Cytosol non-specific dipeptidase.
 20 3.4.13.19 Membrane dipeptidase.
 3.4.13.20 Beta-Ala-His dipeptidase.
 3.4.14.1 Dipeptidyl-peptidase I.
 3.4.14.2 Dipeptidyl-peptidase II.
 3.4.14.4 Dipeptidyl-peptidase III.
 25 3.4.14.5 Dipeptidyl-peptidase IV.
 3.4.14.6 Dipeptidyl-dipeptidase.
 3.4.14.9 Tripeptidyl-peptidase I.
 3.4.14.10 Tripeptidyl-peptidase II.
 3.4.14.11 Xaa-Pro dipeptidyl-peptidase.
 30 3.4.15.1 Peptidyl-dipeptidase A.
 3.4.15.4 Peptidyl-dipeptidase B.
 3.4.15.5 Peptidyl-dipeptidase Dcp.
 3.4.16.2 Lysosomal Pro-X carboxypeptidase.
 3.4.16.4 Serine-type D-Ala-D-Ala carboxypeptidase.
 35 3.4.16.5 Carboxypeptidase C.
 3.4.16.6 Carboxypeptidase D.
 3.4.17.1 Carboxypeptidase A.
 3.4.17.2 Carboxypeptidase B.
 3.4.17.3 Lysine(arginine) carboxypeptidase.
 40 3.4.17.4 Gly-X carboxypeptidase.
 3.4.17.6 Alanine carboxypeptidase.
 3.4.17.7 Transferred entry: 3.4.19.10.
 3.4.17.8 Muramoylpentapeptide carboxypeptidase.
 3.4.17.10 Carboxypeptidase H.
 45 3.4.17.11 Glutamate carboxypeptidase.
 3.4.17.12 Carboxypeptidase M.
 3.4.17.13 Muramoyltetrapeptide carboxypeptidase.
 3.4.17.14 Zinc D-Ala-D-Ala carboxypeptidase.
 3.4.17.15 Carboxypeptidase A2.
 50 3.4.17.16 Membrane Pro-X carboxypeptidase.
 3.4.17.17 Tubulinyl-Tyr carboxypeptidase.
 3.4.17.18 Carboxypeptidase T.
 3.4.17.19 Thermostable carboxypeptidase 1.
 3.4.17.20 Carboxypeptidase U.
 55 3.4.17.21 Glutamate carboxypeptidase II.
 3.4.17.22 Metallocarboxypeptidase D.
 3.4.18.1 Cysteine-type carboxypeptidase.
 3.4.19.1 Acylaminoacyl-peptidase.
 3.4.19.2 Peptidyl-glycinamidase.
 60 3.4.19.3 Pyroglutamyl-peptidase I.

3.4.19.5 Beta-aspartyl-peptidase.
 3.4.19.6 Pyroglutamyl-peptidase II.
 3.4.19.7 N-formylmethionyl-peptidase.
 3.4.19.8 Pteroylpoly-gamma-glutamate carboxypeptidase.
 5 3.4.19.9 Gamma-glutamyl hydrolase.
 3.4.19.11 Gamma-D-glutamyl-meso-diaminopimelate peptidase I.
 3.4.21.1 Chymotrypsin.
 3.4.21.2 Chymotrypsin C.
 3.4.21.3 Metridin.
 10 3.4.21.4 Trypsin.
 3.4.21.5 Thrombin.
 3.4.21.6 Coagulation factor Xa.
 3.4.21.7 Plasmin.
 15 3.4.21.8 Transferred entry: 3.4.21.34 and 3.4.21.35.
 3.4.21.9 Enteropeptidase.
 3.4.21.10 Acrosin.
 3.4.21.11 Transferred entry: 3.4.21.36 and 3.4.21.37.
 3.4.21.12 Alpha-lytic endopeptidase.
 20 3.4.21.19 Glutamyl endopeptidase.
 3.4.21.20 Cathepsin G.
 3.4.21.21 Coagulation factor VIIa.
 3.4.21.22 Coagulation factor IXa.
 3.4.21.25 Cucumisin.
 3.4.21.26 Prolyl oligopeptidase.
 25 3.4.21.27 Coagulation factor XIIa.
 3.4.21.32 Brachyurin.
 3.4.21.34 Plasma kallikrein.
 3.4.21.35 Tissue kallikrein.
 3.4.21.36 Pancreatic elastase.
 30 3.4.21.37 Leukocyte elastase.
 3.4.21.38 Coagulation factor XIIa.
 3.4.21.39 Chymase.
 3.4.21.41 Complement component C1r.
 3.4.21.42 Complement component C1s.
 35 3.4.21.43 Classical-complement pathway C3/C5 convertase.
 3.4.21.45 Complement factor I.
 3.4.21.46 Complement factor D.
 3.4.21.47 Alternative-complement pathway C3/C5 convertase.
 3.4.21.48 Cerevisin.
 40 3.4.21.49 Hypodermin C.
 3.4.21.50 Lysyl endopeptidase.
 3.4.21.53 Endopeptidase La.
 3.4.21.54 Gamma-renin.
 3.4.21.55 Venombin AB.
 45 3.4.21.57 Leucyl endopeptidase.
 3.4.21.59 Tryptase.
 3.4.21.60 Scutellarin.
 3.4.21.61 Kexin.
 3.4.21.62 Subtilisin.
 50 3.4.21.63 Oryzin.
 3.4.21.64 Proteinase K.
 3.4.21.65 Thermomycolin.
 3.4.21.66 Thermitase.
 3.4.21.67 Endopeptidase So.
 55 3.4.21.68 T-plasminogen activator.
 3.4.21.69 Protein C (activated).
 3.4.21.70 Pancreatic endopeptidase E.
 3.4.21.71 Pancreatic elastase II.
 3.4.21.72 IgA-specific serine endopeptidase.
 60 3.4.21.73 U-plasminogen activator.

5	3.4.21.74	Venombin A.
	3.4.21.75	Furin.
	3.4.21.76	Myeloblastin.
	3.4.21.77	Semenogelase.
10	3.4.21.78	Granzyme A.
	3.4.21.79	Granzyme B.
	3.4.21.80	Streptogrisin A.
	3.4.21.81	Streptogrisin B.
	3.4.21.82	Glutamyl endopeptidase II.
15	3.4.21.83	Oligopeptidase B.
	3.4.21.84	Limulus clotting factor C.
	3.4.21.85	Limulus clotting factor B.
	3.4.21.86	Limulus clotting enzyme.
	3.4.21.87	Omptin.
20	3.4.21.88	Repressor lexA.
	3.4.21.89	Signal peptidase I.
	3.4.21.90	Togavirin.
	3.4.21.91	Flavirin.
	3.4.21.92	Endopeptidase Clp.
25	3.4.21.93	Proprotein convertase 1.
	3.4.21.94	Proprotein convertase 2.
	3.4.21.95	Snake venom factor V activator.
	3.4.21.96	Lactocepin.
	3.4.22.1	Cathepsin B.
30	3.4.22.2	Papain.
	3.4.22.3	Ficain.
	3.4.22.6	Chymopapain.
	3.4.22.7	Asclepain.
	3.4.22.8	Clostripain.
35	3.4.22.10	Streptopain.
	3.4.22.14	Actinidain.
	3.4.22.15	Cathepsin L.
	3.4.22.16	Cathepsin H.
	3.4.22.17	Calpain.
40	3.4.22.24	Cathepsin T.
	3.4.22.25	Glycyl endopeptidase.
	3.4.22.26	Cancer procoagulant.
	3.4.22.27	Cathepsin S.
	3.4.22.28	Picornain 3C.
45	3.4.22.29	Picornain 2A.
	3.4.22.30	Caricain.
	3.4.22.31	Ananain.
	3.4.22.32	Stem bromelain.
	3.4.22.33	Fruit bromelain.
50	3.4.22.34	Legumain.
	3.4.22.35	Histolysain.
	3.4.22.36	Caspase-1.
	3.4.22.37	Gingipain R.
	3.4.22.38	Cathepsin K.
55	3.4.23.1	Pepsin A.
	3.4.23.2	Pepsin B.
	3.4.23.3	Gastricsin.
	3.4.23.4	Chymosin.
	3.4.23.5	Cathepsin D.
60	3.4.23.12	Neopenthesin.
	3.4.23.15	Renin.
	3.4.23.16	Retropepsin.
	3.4.23.17	Pro- <i>opiomelanocortin</i> converting enzyme.
	3.4.23.18	Aspergillopepsin I.
	3.4.23.19	Aspergillopepsin II.

	3.4.23.20	Penicillopepsin.
5	3.4.23.21	Rhizopuspepsin.
	3.4.23.22	Endothiapepsin.
	3.4.23.23	Mucoropepsin.
	3.4.23.24	Candidapepsin.
	3.4.23.25	Saccharopepsin.
	3.4.23.26	Rhodotorulapepsin.
	3.4.23.27	Physaropepsin.
	3.4.23.28	Acrocylindropepsin.
10	3.4.23.29	Polyporopepsin.
	3.4.23.30	Pycnoporopepsin.
	3.4.23.31	Scytalidopepsin A.
	3.4.23.32	Scytalidopepsin B.
	3.4.23.33	Xanthomonapepsin.
15	3.4.23.34	Cathepsin E.
	3.4.23.35	Barrierpepsin.
	3.4.23.36	Signal peptidase II.
	3.4.23.37	Pseudomonapepsin.
	3.4.23.38	Plasmepsin I.
20	3.4.23.39	Plasmepsin II.
	3.4.23.40	Phytepsin.
	3.4.24.1	Atrolysin A.
	3.4.24.3	Microbial collagenase.
	3.4.24.6	Leucolysin.
25	3.4.24.7	Interstitial collagenase.
	3.4.24.11	Neprilysin.
	3.4.24.12	Envelysin.
	3.4.24.13	IgA-specific metalloendopeptidase.
	3.4.24.14	Procollagen N-endopeptidase.
30	3.4.24.15	Thimet oligopeptidase.
	3.4.24.16	Neurolysin.
	3.4.24.17	Stromelysin 1.
	3.4.24.18	Meprin A.
	3.4.24.19	Procollagen C-endopeptidase.
35	3.4.24.20	Peptidyl-Lys metalloendopeptidase.
	3.4.24.21	Astacin.
	3.4.24.22	Stromelysin 2.
	3.4.24.23	Matrilysin.
	3.4.24.24	Gelatinase A.
40	3.4.24.25	Aeromonolysin.
	3.4.24.26	Pseudolysin.
	3.4.24.27	Thermolysin.
	3.4.24.28	Bacillolysin.
	3.4.24.29	Aureolysin.
45	3.4.24.30	Coccolysins.
	3.4.24.31	Mycolysin.
	3.4.24.32	Beta-lytic metalloendopeptidase.
	3.4.24.33	Peptidyl-Asp metalloendopeptidase.
	3.4.24.34	Neutrophil collagenase.
50	3.4.24.35	Gelatinase B.
	3.4.24.36	Leishmanolysin.
	3.4.24.37	Saccharolysin.
	3.4.24.38	Autolysin.
	3.4.24.39	Deuterolysin.
55	3.4.24.40	Serralysin.
	3.4.24.41	Atrolysin B.
	3.4.24.42	Atrolysin C.
	3.4.24.43	Atroxase.
	3.4.24.44	Atrolysin E.
60	3.4.24.45	Atrolysin F.

	3.4.24.46	Adamalysin.
5	3.4.24.47	Horrilysin.
	3.4.24.48	Ruberlysin.
	3.4.24.49	Bothropasin.
	3.4.24.50	Bothrolysin.
	3.4.24.51	Ophiolysin.
10	3.4.24.52	Trimerelysin I.
	3.4.24.53	Trimerelysin II.
	3.4.24.54	Mucrolysin.
	3.4.24.55	Pitrilysin.
	3.4.24.56	Insulysin.
	3.4.24.57	O-sialoglycoprotein endopeptidase.
	3.4.24.58	Russellysin.
15	3.4.24.59	Mitochondrial intermediate peptidase.
	3.4.24.60	Dactylysin.
	3.4.24.61	Nardilysin.
	3.4.24.62	Magnolysin.
	3.4.24.63	Meprin B.
20	3.4.24.64	Mitochondrial processing peptidase.
	3.4.24.65	Macrophage elastase.
	3.4.24.66	Choriolysin L.
	3.4.24.67	Choriolysin H.
	3.4.24.68	Tentoxilysin.
25	3.4.24.69	Bontoxilysin.
	3.4.24.70	Oligopeptidase A.
	3.4.24.71	Endothelin-converting enzyme 1.
	3.4.24.72	Fibrolase.
	3.4.24.73	Jararhagin.
	3.4.24.74	Fragilysin.
30	3.4.99.46	Multicatalytic endopeptidase complex.

In certain preferred embodiments, proteases that are useful as catalytic moieties in the present invention include: serine proteases such as chymotrypsin, trypsin, elastase, plasmin, tissue-type plasminogen activator (t-PA), urokinase (UK), single-chain urokinase (scu-PA), thrombin, kallikrein, acrosin, cathepsin G, coagulation factors VIIa, IXa and XIa; cysteine proteases such as cathepsin B, papain, ficin, chymopapain, clostripain and cathepsin L; and acid proteases such as the pepsins, chymosin and cathepsin D.

Many purified serine proteases are commercially available, including: leukocyte elastase from human leukocytes (Sigma Catalog No. E1508); pancreatic elastase from human sputum (Sigma Catalog No. E1633); plasmin from human plasma (Sigma Catalog No. P4895); single-chain t-PA from human melanoma cell cultures (Sigma Catalog No. T7776); recombinant two-chain t-PA (Sigma Catalog No. T4654); urokinase from human kidney cells (Sigma Catalog No. U5004); urokinase from human urine (Sigma Catalog No. U6876); Trypsin (Sigma Catalog No. T8003); and alpha-Chymotrypsin (Sigma Catalog No. C7762).

Other useful enzymes include: pancreatic lipase; lipoprotein lipases; monoglyceride lipase; sphingosyl-glucopyranoside; sphingomyelinase; phosphoinositides;

phospholipases; peptidases such as carboxypeptidases, aminopeptidases and dipeptidases; glucosidases; glucanases; galactosidases;mannosidases; amylases and dextrinases.

The catalytic domain of the adzymes can also be derived from an engineered enzyme, *e.g.*, a protein engineered to have an enzymatic activity, such as a protein 5 designed to contain a serine protease active motif (see, for example, Quemenur *et al.* (1998) *Nature* 391:301-304 and Liu *et al.* (1998) *Molecular Immunology* 15:1069-1077).

As a further example, the catalytic moiety can be a catalytic antibody. Because 10 antibodies can be generated that selectively bind almost any molecule of interest, this technology offers the potential to tailor-make highly selective catalysts. Methods for making catalytic antibodies are disclosed by Lerner *et al.* (1991) *Science* 252:659; Benkovic *et al.* (1990) *Science* 250:1135; Tramontano *et al.* (1986) *Science* 234:1566. Alternatively, tailoring of an antibody to create a catalytic antibody can be carried out by methods such as walk-through mutagenesis (see PCT application PCT/US91/02362, incorporated by reference herein).

15

C. Generating Chimeric Adzymes

The catalytic moiety can be linked to the targeting moiety in a number of ways including by cotranslation from a recombinant nucleic acid (*e.g.*, fusion proteins) or, in less preferred embodiments, chemical coupling.

20

(i) Generated as Recombinant Fusion Proteins

The adzymes of this invention can be constructed as a fusion protein, containing the catalytic moiety and the targeting moiety as one contiguous polypeptide chain. In preparing the fusion protein, a fusion gene is constructed comprising DNA encoding the 25 sequences for the targeting moiety, the catalytic moiety, and optionally, a peptide linker sequence to span the two fragments. To make this fusion protein, an entire enzyme can be cloned and expressed as part of the protein, or alternatively, a suitable fragment containing the catalytic moiety can be used. Likewise, the entire cloned coding sequence of a targeting moiety such as a receptor or antibody, or alternatively, a fragment of the 30 molecule capable of binding the surface component of the pathogen can be used. The use of recombinant DNA techniques to create a fusion gene, with the translational product being the desired fusion protein, is well known in the art. Both the coding sequence of a gene and its regulatory regions can be redesigned to change the functional properties of the protein product, the amount of protein made, or the cell type in which the protein is 35 produced. The coding sequence of a gene can be extensively altered--for example, by fusing part of it to the coding sequence of a different gene to produce a novel hybrid gene

that encodes a fusion protein. Examples of methods for producing fusion proteins are described in PCT applications PCT/US87/02968, PCT/US89/03587 and PCT/US90/07335, as well as Traunecker et al. (1989) *Nature* 339:68.

Signal peptides facilitate secretion of proteins from cells. An exemplary signal peptide is the amino terminal 25 amino acids of the leader sequence of murine interleukin-7 (IL-7; Namen et al., *Nature* 333:571; 1988). Other signal peptides may also be employed furthermore, certain nucleotides in the IL-7 leader sequence can be altered without altering the amino acid sequence. Additionally, amino acid changes that do not affect the ability of the IL-7 sequence to act as a leader sequence can be made. A signal peptide may be added to the fusion adzyme target domain or catalytic domain, such that when these domains are synthesized by cells from transfected nucleic acids, the secreted adzyme target and catalytic domains will oligomerize to form mature adzymes to act on extracellular targets, such as cytokines.

In some instances it may be necessary to introduce a polypeptide linker region between portions of the chimeric protein derived from different proteins. This linker can facilitate enhanced flexibility of the fusion protein allowing various portions to freely and (optionally) simultaneously interact with a target by reducing steric hindrance between the portions, as well as allowing appropriate folding of each portion to occur. The linker can be of natural origin, such as a sequence determined to exist in random coil between two domains of a protein. Alternatively, the linker can be of synthetic origin. For instance, the sequence (Gly₄Ser)_n can be used as a synthetic unstructured linker. Linkers of this type are described in Huston et al. (1988) *PNAS* 85:4879; and U.S. Patent Nos. 5,091,513 and 5,258,498. Naturally occurring unstructured linkers of human origin are preferred as they reduce the risk of immunogenicity.

The length and composition of the linker connecting the address and the catalytic domain may be optimized. For example, Zhou (J. Mol. Biol. 329: 1-8, 2003) describes in detail a quantitative theory for enhancing affinity for a first molecule by linking a second and a third molecule (such as two scFvs), each of which has affinity for the first molecule. The predicted affinity enhancement is found to be actually approached by a bi-specific antibody against hen egg lysozyme consisting of scFv fragments of D1.3 and HyHEL-10. The wide applicability of the theory is demonstrated by diverse examples of protein-protein interactions constrained by flexible linkers, and the theory provides a general framework for understanding protein-protein interactions constrained by flexible linkers.

In the simplest case of the theory, the linker is flexible such that its only effect is to provide a leash constraining the distances between the two antibody fragments. Then it was shown:

$$C_{\text{eff}} = p(d_0) \quad (\text{Eq. a})$$

where $p(r)$ is the probability density for the end-to-end vector of the flexible linker with L residues to have a distance r , and d_0 is the actual end-to-end distance when the linked fragments are bound to the antigen. A flexible peptide linker consisting of L residues can 5 be modeled as a worm-like chain, such that:

$$p(r) = (3/4l_p l_c)^{3/2} \exp(-3r^2/4l_p l_c)(1-5l_p/4l_c + 2r^2/l_c^2 - 33r^4/80l_p l_c^3 - 79l_p^2/160l_c^2 - 329r_2 l_p/120l_c^3 + 6799r^4/1600l_c^4 - 3441r^6/2800l_p l_c^5 + 1089r^8/12800l_p^2 l_c^6) \quad (\text{Eq. b})$$

where $b=3.8 \text{ \AA}$ is the nearest $C_{\alpha}-C_{\alpha}$ distance, and $l_c=bL$ and $l_p=3 \text{ \AA}$ are the contour length and persistence length, respectively, of the peptide linker. Typically $p(d_0)$ is in the 10 millimolar range or higher, and hence the linking strategy is expected to result in significant affinity enhancement, since the association constants of antibody fragments are much greater than 10^3 M^{-1} . Equation (a) has been found to predict well the affinity 15 enhancements of linking DNA-binding domains (Zhou, *Biochemistry* **40**, pp. 15069–15073, 2001).

15 Based on this theoretic model, Figure 2 of Zhou (incorporated by reference) describes the relationship of L and $p(d_0)$ at several given d_0 values, such as 10 \AA , 20 \AA , 30 \AA , 40 \AA , 50 \AA , and 60 \AA . This linker theory incorporates two important realistic aspects. First, in the bound state, the end-to-end distance of the linker is kept at around a specific 20 value (d_0) determined by the structure of the bound complex. Second, in the unbound state, the distribution $p(r)$ of the end-to-end distance is not uniform but is what is appropriate for a semi-flexible polymer chain, such as a polypeptide chain. For entropic reasons, a polymer chain very rarely samples conformations with end-to-end distances approaching either zero or the full contour length l_c , thus $p(r)$ has a maximum at an intermediate value of r . At a given end-to-end distance d_0 , there is also a value of l_c (or L) 25 at which $p(d_0)$ is maximal (see Figure 2 of Zhou). Therefore, the chain length of a peptide linker can be optimized to achieve maximal affinity enhancement.

In the context of the adzyme linker design, once the address and the catalytic domain is chosen, molecular model of the target – adzyme avid complex may be obtained. 30 d_0 , the distance between the point where the linker connects to the address and the point where the linker connects to the enzyme, while both the address and enzyme domain are in the avid complex, can be readily determined from, for example, the 3-D structure of the target – adzyme complex. Many cytokine structures are solved (see the Cytokine Web site at http://cmbi.bjmu.edu.cn/cmbidata/cgf/CGF_Database/cytweb/cyt_structs/index.html). The structure of those other cytokines with sequence homology to cytokines of known 35 structures, as well as the target – adzyme complex may be routinely obtained via molecular modeling.

Once the d_0 value is obtained, Figure 2 of Zhou may be used to find the optimum L for the highest possible $p(d_0)$ value. For example, if it is determined that d_0 is about 20 Å, Figure 2 of Zhou indicates that at this d_0 value, the highest possible $p(d_0)$ value is about 20 mM, and that $p(d_0)$ value corresponds to a linker length of about 10-15 amino acids. Note 5 that at d_0 value larger than 20 Å, the maximum $p(d_0)$ value peaks quickly and tapers off very gradually, thus allowing quite a bit of flexibility in choosing a proper linker length. In addition, the method here is rather tolerant of a relatively imprecise estimation of the d_0 value, since in Figure 2 of Zhou, curves for different d_0 values tend to converge, especially in long linker length (e.g., more than 40 amino acids) and large d_0 values (30-60 Å). For 10 example, when d_0 is 30 Å, the peak $p(d_0)$ value is about 3-4 mM. When d_0 is 40 Å, the peak $p(d_0)$ only decreases to about 1.5 mM, at about the same linker length of around 35 – 40 residues.

Techniques for making fusion genes are well known. Essentially, the joining of various DNA fragments coding for different polypeptide sequences is performed in 15 accordance with conventional techniques, employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR 20 amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed to generate a fusion gene sequence (see, for example, Current Protocols in Molecular Biology, eds. Ausubel et al. John Wiley & Sons: 1992).

Fusion proteins can comprise additional sequences, including a leader (or signal 25 peptide) sequence, a portion of an immunoglobulin (e.g., an Fc portion, see below) or other oligomer-forming sequences, as well as sequences encoding highly antigenic moieties, hexahistidine moieties or other elements that provide a means for facile purification or rapid detection of a fusion protein.

To express the fusion protein molecule, it may be desirable to include 30 transcriptional and translational regulatory elements and other non-coding sequences to the fusion gene construct. For instance, regulatory elements including constitutive and inducible promoters, enhancers or inhibitors can be incorporated.

(ii) Use of Chemical Coupling Agents

35 There are a large number of chemical cross-linking agents that are known to those skilled in the art. For the present invention, the preferred cross-linking agents are

heterobifunctional cross-linkers, which can be used to link proteins in a stepwise manner. Heterobifunctional cross-linkers provide the ability to design more specific coupling methods for conjugating proteins, thereby reducing the occurrences of unwanted side reactions such as homo-protein polymers. A wide variety of heterobifunctional cross-linkers are known in the art. These include: succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC), m-Maleimidobenzoyl-N-hydroxysuccinimide ester (MBS); N-succinimidyl (4-iodoacetyl) aminobenzoate (SIAB), succinimidyl 4-(p-maleimidophenyl) butyrate (SMPB), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC); 4-succinimidylloxycarbonyl-a-methyl-a-(2-pyridyldithio)-tolune (SMPT), N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP), succinimidyl 6-[(3-(2-pyridyldithio) propionate] hexanoate (LC-SPDP). Those cross-linking agents having N-hydroxysuccinimide moieties can be obtained as the N-hydroxysulfosuccinimide analogs, which generally have greater water solubility. In addition, those cross-linking agents having disulfide bridges within the linking chain can be synthesized instead as the alkyl derivatives so as to reduce the amount of linker cleavage in vivo.

In addition to the heterobifunctional cross-linkers, there exists a number of other cross-linking agents including homobifunctional and photoreactive cross-linkers. Disuccinimidyl suberate (DSS), bismaleimidohexane (BMH) and dimethylpimelimidate-2 HCl (DMP) are examples of useful homobifunctional cross-linking agents, and bis-[beta.-(4-azidosalicylamido)ethyl]disulfide (BASED) and N-succinimidyl-6(4'-azido-2'-nitrophenyl-amino)hexanoate (SANPAH) are examples of useful photoreactive cross-linkers for use in this invention. For a review of protein coupling techniques, see Means et al. (1990) Bioconjugate Chemistry 1:2-12. One particularly useful class of heterobifunctional cross-linkers, included above, contain the primary amine reactive group, N-hydroxysuccinimide (NHS), or its water soluble analog N-hydroxysulfosuccinimide (sulfo-NHS). Primary amines (lysine epsilon groups) at alkaline pH's are unprotonated and react by nucleophilic attack on NHS or sulfo-NHS esters. This reaction results in the formation of an amide bond, and release of NHS or sulfo-NHS as a by-product.

Another reactive group useful as part of a heterobifunctional cross-linker is a thiol reactive group. Common thiol reactive groups include maleimides, halogens, and pyridyl disulfides. Maleimides react specifically with free sulfhydryls (cysteine residues) in minutes, under slightly acidic to neutral (pH 6.5-7.5) conditions. Halogens (iodoacetyl functions) react with --SH groups at physiological pH's. Both of these reactive groups result in the formation of stable thioether bonds.

The third component of the heterobifunctional cross-linker is the spacer arm or bridge. The bridge is the structure that connects the two reactive ends. The most apparent

attribute of the bridge is its effect on steric hindrance. In some instances, a longer bridge can more easily span the distance necessary to link two complex biomolecules.

Preparing protein-protein conjugates using heterobifunctional reagents is a two-step process involving the amine reaction and the sulphydryl reaction, and such processes are,

5 in view of this specification, generally well known in the art. See, e.g., Partis et al. (1983) *J. Pro. Chem.* 2:263); Ellman et al. (1958) *Arch. Biochem. Biophys.* 74:443; Riddles et al. (1979) *Anal. Biochem.* 94:75); Blattler et al. (1985) *Biochem* 24:1517).

(iii) Multimeric Constructs

10 In certain embodiments of the invention, the subject adzyme is a multimeric complex in which the catalytic domain and targeting domain are on separate polypeptide chains. These two domains, when synthesized, can be brought together to form the mature adzyme.

For example, in one embodiment, the adzyme takes the form of an antibody (e.g.,
15 Fc fusion) in which the variable regions of the heavy (V_H) and light chain (V_L) have been replaced with the targeting and catalytic domains (either the targeting or the catalytic domain can replace either the V_H region or the V_L region). For example, soluble proteins comprising an extracellular domain from a membrane-bound protein and an immunoglobulin heavy chain constant region was described by Fanslow et al., *J.*
20 *Immunol.* 149:65, 1992 and by Noelle et al., *Proc. Nad. Acad. Sci. U.S.A.* 89:6550, 1992.

In certain embodiments, an adzyme comprises a first Fc portion that is connected to the appropriate heavy and light chains which may function as a targeting moiety, and a second Fc portion that is fused to a catalytic domain.

Fusion proteins comprising a catalytic domain or a targeting domain may be
25 prepared using nucleic acids encoding polypeptides derived from immunoglobulins. Preparation of fusion proteins comprising heterologous polypeptides fused to various portions of antibody-derived polypeptides (including the Fc domain) has been described, e.g., by Ashkenazi et al., (PNAS USA 88:10535, 1991) and Byrn et al., (Nature 344:677, 1990). In one embodiment of the invention, an adzyme is created by fusing a catalytic
30 domain to a first Fc region of an antibody (e.g., IgG1) and a targeting domain to a second Fc region of an antibody. The Fc polypeptide preferably is fused to the C-terminus of a catalytic or targeting domain. A gene fusion encoding each Fc fusion protein is inserted into an appropriate expression vector. The Fc fusion proteins are expressed in host cells transformed with the recombinant expression vector, and allowed to assemble much like
35 antibody molecules, whereupon interchain disulfide bonds form between Fc polypeptides, yielding the desired adzymes. If fusion proteins are made with both heavy and light chains

of an antibody, it is possible to form an adzyme with multiple catalytic and targeting domains.

In certain embodiments, an adzyme comprising one or more immunoglobulin fusion protein may employ an immunoglobulin light chain constant region in association with at least one immunoglobulin heavy chain constant region domain. In another embodiment, an immunoglobulin light chain constant region is associated with at least one immunoglobulin heavy chain constant region domain joined to an immunoglobulin hinge region. In one set of embodiments, an immunoglobulin light chain constant region joined in frame with a polypeptide chain of a non-immunoglobulin polypeptide (e.g., a catalytic domain or polypeptide targeting domain) and is associated with at least one heavy chain constant region. In a preferred set of embodiments a variable region is joined upstream of and in proper reading frame with at least one immunoglobulin heavy chain constant region. In another set of embodiments, an immunoglobulin heavy chain is joined in frame with a polypeptide chain of a non-immunoglobulin polypeptide and is associated with an immunoglobulin light chain constant region. In yet another set of embodiments, a polypeptide chain of a non-immunoglobulin polypeptide dimer or receptor analog is joined to at least one immunoglobulin heavy chain constant region which is joined to an immunoglobulin hinge region and is associated with an immunoglobulin light chain constant region. In a preferred set of embodiments an immunoglobulin variable region is joined upstream of and in proper reading frame with the immunoglobulin light chain constant region.

The term "Fc polypeptide" as used herein includes native and altered forms of polypeptides derived from the Fc region of an antibody. Truncated forms of such polypeptides containing the hinge region that promotes dimerization are also included. One suitable Fc polypeptide, described in PCT application WO 93/10151, is a single chain polypeptide extending from the N-terminal hinge region to the native C-terminus. It may be desirable to use altered forms of Fc polypeptides having improved serum half-life, altered spatial orientation, and the like. Immunoglobulin heavy chain constant region domains include C_H1, C_H2, C_H3, and C_H4 of any class of immunoglobulin heavy chain including gamma, alpha, epsilon, mu, and delta classes. A particularly preferred immunoglobulin heavy chain constant region domain is human C_H1. Immunoglobulin variable regions include V_H, V_{kappa}, or V_{lambda} DNA sequences encoding immunoglobulins may be cloned from a variety of genomic or cDNA libraries known in the art. The techniques for isolating such DNA sequences using probe-based methods are conventional techniques and are well known to those skilled in the art. Probes for isolating such DNA sequences may be based on published DNA sequences (see, for example, Hietter et al., Cell 22: 197-207, 1980). Alternatively, the polymerase chain reaction (PCR) method

disclosed by Mullis et al. (U.S. Pat. No. 4,683,195) and Mullis (U.S. Pat. No. 4,683,202), incorporated herein by reference may be used. The choice of library and selection of probes for the isolation of such DNA sequences is within the level of ordinary skill in the art.

5 Host cells for use in preparing immunoglobulin fusions include eukaryotic cells capable of being transformed or transfected with exogenous DNA and grown in culture, such as cultured mammalian and fungal cells. Fungal cells, including species of yeast (e.g., *Saccharomyces* spp., *Schizosaccharomyces* spp.), or filamentous fungi (e.g., *Aspergillus* spp., *Neurospora* spp.) may be used as host cells within the present invention.

10 Strains of the yeast *Saccharomyces cerevisiae* are particularly preferred.

In each of the foregoing embodiments, a molecular linker optionally may be interposed between, and covalently join, the rest of the adzyme construct and the dimerization domain.

15 In another embodiment, various oligomerization domains may be employed to bring together the separately synthesized targeting and catalytic domains.

One class of such oligomerization domain is leucine zipper. WO 94/10308 A1 and its related U.S. Pat. No. 5,716,805 (all incorporated herein by reference) describes the use of leucine zipper oligomerization domains to dimerize/oligomerize two separate heterologous polypeptides. Each of the two separate heterologous polypeptides is 20 synthesized as a fusion protein with a leucine zipper oligomerization domain. In one embodiment, the leucine zipper domain can be removed from the fusion protein, by cleavage with a specific proteolytic enzyme. In another embodiment, a hetero-oligomeric protein is prepared by utilizing leucine zipper domains that preferentially form hetero-oligomers.

25 Leucine zipper domains were originally identified in several DNA-binding proteins (Landschulz et al., *Science* 240:1759, 1988). Leucine zipper domain is a term used to refer to a conserved peptide domain present in these (and other) proteins, which is responsible for dimerization of the proteins. The leucine zipper domain (also referred to herein as an oligomerizing, or oligomer-forming, domain) comprises a repetitive heptad 30 repeat, with four or five leucine residues interspersed with other amino acids.

Examples of leucine zipper domains are those found in the yeast transcription factor GCN4 and a heat-stable DNA-binding protein found in rat liver (C/EBP; Landschulz et al., *Science* 243:1681, 1989). Two nuclear transforming proteins, fos and jun, also exhibit leucine zipper domains, as does the gene product of the murine proto-oncogene, c-myc (Landschulz et al., *Science* 240:1759, 1988).. The products of the nuclear oncogenes fos and jun comprise leucine zipper domains preferentially form a

heterodimer (O'Shea et al., Science 245:646, 1989; Turner and Tjian, Science 243:1689, 1989). The leucine zipper domain is necessary for biological activity (DNA binding) in these proteins.

The fusogenic proteins of several different viruses, including paramyxovirus, 5 coronavirus, measles virus and many retroviruses, also possess leucine zipper domains (Buckland and Wild, Nature 338:547, 1989; Britton, Nature 353:394, 1991; Delwart and Mosialos, AIDS Research and Human Retroviruses 6:703, 1990). The leucine zipper domains in these fusogenic viral proteins are near the transmembrane region of the proteins; it has been suggested that the leucine zipper domains could contribute to the 10 oligomeric structure of the fusogenic proteins. Oligomerization of fusogenic viral proteins is involved in fusion pore formation (Spruce et al, PNAS 88:3523, 1991). Leucine zipper domains have also been recently reported to play a role in oligomerization of heat-shock transcription factors (Rabindran et al., Science 259:230, 1993).

Accordingly, in certain embodiments, the dimerization domains of the adzyme 15 components comprise coiled-coil dimerization domains, such as leucine zipper domains. Preferably, the leucine zipper domains include at least four leucine heptads. In one preferred embodiment, the leucine zipper domain is a Fos or Jun leucine zipper domain.

Many other so-called "bundling domains" exist which perform essentially the same function of the above-described leucine zipper domains to bring together the 20 catalytic and target domains. For example, WO 99/10510 A2 (incorporated herein by reference) describes bundling domains include any domain that induces proteins that contain it to form multimers ("bundles") through protein-protein interactions with each other or with other proteins containing the bundling domain. Examples of these bundling domains include domains such as the lac repressor tetramerization domain, the p53 25 tetramerization domain, the leucine zipper domain, and domains derived therefrom which retain observable bundling activity. Proteins containing a bundling domain are capable of complexing with one another to form a bundle of the individual protein molecules. Such bundling is "constitutive" in the sense that it does not require the presence of a cross-linking agent (i.e., a cross-linking agent which doesn't itself contain a pertinacious 30 bundling domain) to link the protein molecules.

As described above, bundling domains interact with like domains via protein-protein interactions to induce formation of protein "bundles." Various order oligomers (dimers, trimers, tetramers, etc.) of proteins containing a bundling domain can be formed, depending on the choice of bundling domain.

35 In one embodiment, incorporation of a tetramerization domain within a fusion protein leads to the constitutive assembly of tetrameric clusters or bundles. The *E. coli*

lactose repressor tetramerization domain (amino acids 46-360; Chakerian et al. (1999) J. Biol. Chem. 266:1371; Alberti et al. (1993) EMBO J. 12:3227; and Lewis et al. (1996) Nature 271:1247), illustrates this class. Other illustrative tetramerization domains include those derived from residues 322-355 of p53 (Wang et al. (1994) Mol. Cell. Biol. 14:5182; 5 Clore et al. (1994) Science 265:386) see also U.S. Pat. No. 5,573,925 by Halazonetis.

In yet another embodiment, the catalytic domain and the target domain may each be fused to a “ligand binding domain,” which, upon binding to a small molecule, will bring the catalytic domain and the target domain together (“small molecule-mediated oligomerization”).

10 Fusion proteins containing a ligand binding domain for use in practicing this invention can function through one of a variety of molecular mechanisms.

In certain embodiments, the ligand binding domain permits ligand-mediated crosslinking of the fusion protein molecules bearing appropriate ligand binding domains. In these cases, the ligand is at least divalent and functions as a dimerizing agent by 15 binding to the two fusion proteins and forming a cross-linked heterodimeric complex which activates target gene expression. See e.g. WO 94/18317, WO 96/20951, WO 96/06097, WO 97/31898 and WO 96/41865.

20 In the cross-linking-based dimerization systems the fusion proteins can contain one or more ligand binding domains (in some cases containing two, three, four, or more of such domains) and can further contain one or more additional domains, heterologous with respect to the ligand binding domain, including e.g. a catalytic or target domain of the subject adzyme.

25 In general, any ligand/ligand binding domain pair may be used in such systems. For example, ligand binding domains may be derived from an immunophilin such as an FKBP, cyclophilin, FRB domain, hormone receptor protein, antibody, etc., so long as a ligand is known or can be identified for the ligand binding domain.

30 For the most part, the receptor domains will be at least about 50 amino acids, and fewer than about 350 amino acids, usually fewer than 200 amino acids, either as the natural domain or truncated active portion thereof. Preferably the binding domain will be small (<25 kDa, to allow efficient transfection in Viral vectors), monomeric, nonimmunogenic, and should have synthetically accessible, cell permeant, nontoxic ligands as described above.

35 Preferably the ligand binding domain is for (i.e., binds to) a ligand which is not itself a gene product (i.e., is not a protein), has a molecular weight of less than about 5 kD and preferably less than about 2.5 kD, and optionally is cell permeant. In many cases it

will be preferred that the ligand does not have an intrinsic pharmacologic activity or toxicity which interferes with its use as an oligomerization regulator.

The DNA sequence encoding the ligand binding domain can be subjected to mutagenesis for a variety of reasons. The mutagenized ligand binding domain can provide

- 5 for higher binding affinity, allow for discrimination by a ligand between the mutant and naturally occurring forms of the ligand binding domain, provide opportunities to design ligand-ligand binding domain pairs, or the like. The change in the ligand binding domain can involve directed changes in amino acids known to be involved in ligand binding or with ligand-dependent conformational changes. Alternatively, one may employ random
- 10 mutagenesis using combinatorial techniques. In either event, the mutant ligand binding domain can be expressed in an appropriate prokaryotic or eukaryotic host and then screened for desired ligand binding or conformational properties. Examples involving FKBP, cyclophilin and FRB domains are disclosed in detail in WO 94/18317, WO 96/06097, WO 97/31898 and WO 96/41865. For instance, one can change Phe36 to Ala
- 15 and/or Asp37 to Gly or Ala in FKBP12 to accommodate a substituent at positions 9 or 10 of the ligand FK506 or FK520 or analogs, mimics, dimers or other derivatives thereof. In particular, mutant FKBP12 domains which contain Val, Ala, Gly, Met or other small amino acids in place of one or more of Tyr26, Phe36, Asp37, Tyr82 and Phe99 are of particular interest as receptor domains for FK506-type and FK type ligands containing
- 20 modifications at C9 and/or C10 and their synthetic counterparts (see, e.g., WO97/31898). Illustrative mutations of current interest in FKBP domains also include the following:

F36A	Y26V	F46A	W59A
F36V	Y26S	F48H	H87W
F36M	D37A	F48L	H87R
F36S	I90A	F48A	F36V/F99A
F99A	I91A	E54A/F36V/F99G	F99G
F46H	E54K/F36M/F99A	Y26A	F46L
V55A	F36M/F99G		

Table III: Entries identify the native amino acid by single letter code and sequence position, followed by the replacement amino acid in the mutant. Thus, F36V designates a human FKBP12 sequence in which phenylalanine at position 36 is replaced by valine.

- 25 F36V/F99A indicates a double mutation in which phenylalanine at positions 36 and 99 are replaced by valine and alanine, respectively.

Illustrative examples of domains which bind to the FKBP:rapamycin complex ("FRBs") are those which include an approximately 89-amino acid sequence containing residues 2025-2113 of human FRAP. Another FRAP-derived sequence of interest comprises a 93 amino acid sequence consisting of amino acids 2024-2113. Similar 5 considerations apply to the generation of mutant FRAP-derived domains which bind preferentially to FKBP complexes with rapamycin analogs (rapalogs) containing modifications (i.e., are "bumped") relative to rapamycin in the FRAP-binding portion of the drug. For example, one may obtain preferential binding using rapalogs bearing substituents; other than -OMe at the C7 position with FRBs based on the human FRAP 10 FRB peptide sequence but bearing amino acid substitutions for one or more of the residues Tyr2038, Phe2039, Thr2098, Gln2099, Trp2101 and Asp2102. Exemplary mutations include Y2038H, Y2038L, Y2038V, Y2038A, F2039H, F2039L, F2039A, F2039V, D2102A, T2098A, T2098N, T2098L, and T2098S. Rapalogs bearing substituents; other than -OH at C28 and/or substituents other than =O at C30 may be used to obtain 15 preferential binding to FRAP proteins bearing an amino acid substitution for Glu2032. Exemplary mutations include E2032A and E2032S. Proteins comprising an FRB containing one or more amino acid replacements at the foregoing positions, libraries of proteins or peptides randomized at those positions (i.e., containing various substituted amino acids at those residues), libraries randomizing the entire protein domain, or 20 combinations of these sets of mutants are made using the procedures described above to identify mutant FRAPs that bind preferentially to bumped rapalogs.

Other macrolide binding domains useful in the present invention, including mutants thereof, are described in the art. See, for example, W096/41865, W096/136131 W096/0611 11 W096/061 1 01 W096/060971 W096/127961 W095/053891 25 WO95/026842.

The ability to employ in vitro mutagenesis or combinatorial modifications of sequences encoding proteins allows for the production of libraries of proteins which can be screened for binding affinity for different ligands. For example, one can randomize a sequence of 1 to 5, 5 to 10, or 10 or more codons, at one or more sites in a DNA sequence 30 encoding a binding protein, make an expression construct and introduce the expression construct into a unicellular microorganism, and develop a library of modified sequences. One can then screen the library for binding affinity of the encoded polypeptides to one or more ligands. The best affinity sequences which are compatible with the cells into which they would be introduced can then be used as the ligand binding domain for a given 35 ligand. The ligand may be evaluated with the desired host cells to determine the level of binding of the ligand to endogenous proteins. A binding profile may be determined for each such ligand which compares ligand binding affinity for the modified ligand binding

domain to the affinity for endogenous proteins. Those ligands which have the best binding profile could then be used as the ligand. Phage display techniques, as a non-limiting example, can be used in carrying out the foregoing.

In other embodiments, antibody subunits, e.g. heavy or light chain, particularly 5 fragments, more particularly all or part of the variable region, or single chain antibodies, can be used as the ligand binding domain. Antibodies can be prepared against haptens which are pharmaceutically acceptable and the individual antibody subunits screened for binding affinity. cDNA encoding the antibody subunits can be isolated and modified by deletion of the constant region, portions of the variable region, mutagenesis of the variable 10 region, or the like, to obtain a binding protein domain that has the appropriate affinity for the ligand. In this way, almost any physiologically acceptable hapten can be employed as the ligand. Instead of antibody units, natural receptors can be employed, especially where the binding domain is known. In some embodiments of the invention, a fusion protein comprises more than one ligand binding domain. For example, a DNA binding domain 15 can be linked to 2, 3 or 4 or more ligand binding domains. The presence of multiple ligand binding domains means that ligand-mediated cross-linking can recruit multiple fusion proteins containing transcription activation domains to the DNA binding domain-containing fusion protein.

Cross-linking/dimerization systems Any ligand for which a binding protein or 20 ligand binding domain is known or can be identified may be used in combination with such a ligand binding domain in carrying out this invention.

Extensive guidance and examples are provided in WO 94/18317 for ligands and other components useful for cross-linked oligomerization-based systems. Systems based on ligands for an immunophilin such as FKBP, a cyclophilin, and/or FRB domain are of 25 special interest. Illustrative examples of ligand binding domain/ligand pairs that may be used for cross-linking include, but are not limited to: FKBP/FK1012, FKBP/synthetic divalent FKBP ligands (see WO 96/06097 and WO 97/31898), FRB/rapamycin or analogs thereof:FKBP (see e.g., WO 93/33052, WO 96/41865 and Rivera et al, "A humanized system for pharmacologic control of gene expression", Nature Medicine 2(9):1028-1032 30 (1997)), cyclophilin/cyclosporin (see e.g. WO 94/18317), FKBP/FKCsA/cyclophilin (see e.g. Belshaw et al, 1996, PNAS 93:4604-4607), DHFR/methotrexate (see e.g. Licitra et al, 1996, Proc. Natl. Acad. Sci. USA 93:12817-12821), and DNA gyrase/coumermycin (see e.g. Farrar et al, 1996, Nature 383:178-181). Numerous variations and modifications to 35 ligands and ligand binding domains, as well as methodologies for designing, selecting and/or characterizing them, which may be adapted to the present invention are disclosed in the cited references.

In addition, small molecule dimerizers, such as those described in ARIAD Pharmaceutical's ARGENT™ homodimerization kit and ARGENT™ heterodimerization kit may be used for this purpose. The ARGENT™ Regulated Homodimerization Kit contains reagents for bringing together two molecules of an engineered fusion protein by 5 adding a small molecule "dimerizer." The kit can be used to bring together any two proteins that normally do not interact with each other.

There are two classes of dimerizers. Homodimerizers incorporate two identical binding motifs, and can therefore be used to induce association of two proteins containing the same dimerizer-binding motif. Heterodimerizers incorporate two different binding 10 motifs, one on each of the two proteins, and can therefore be used to induce association of the two proteins containing these dimerizer-binding motifs. The ARGENT™ Kits also provides a homodimerizer or a heterodimerizer, and DNA vectors for making appropriate fusion proteins.

The reagents in the ARGENT Kits are based on the human protein FKBP12 15 (FKBP, for FK506 binding protein) and its small molecule ligands. FKBP is an abundant cytoplasmic protein that serves as the initial intracellular target for the natural product immunosuppressive drugs FK506 and rapamycin. In the original homodimerizer system developed by the Schreiber and Crabtree laboratories (*Science* 262: 1019-24, 1993), a dimerizer was created by chemically linking two molecules of FK506 in a manner that 20 eliminated immunosuppressive activity. The resulting molecule, called FK1012, was able to crosslink fusion proteins containing wild-type FKBP domains.

A second generation FKBP homodimerizer, AP1510, was subsequently developed 25 (Amara et al., *Proc Natl Acad Sci U S A* 94: 10618-23, 1997). AP1510 has the advantages of being completely synthetic, as well as being smaller and simpler than FK1012 and more potent in many applications. Other improved versions have also been developed (Clackson et al., *Proc Natl Acad Sci U S A* 95: 10437-42, 1998; AP1903, AP20187). The AP20187-based system has the advantages of working at lower concentrations, and AP20187 has better pharmacokinetic properties than AP1510, allowing it to be used *in vivo*. Other similar systems may also be used to bring two macromolecules together. For example, Lin 30 et al., (*J. Am. Chem. Soc.*, 122, 4247-4248, 2000; also featured in *Chem. & Eng. News*, 78, 52, 2000) use Dexamethasone-Methotrexate as an efficient chemical inducer of protein dimerization *in vivo*.

iv. *General Methodologies*

In applications of the invention involving the genetic engineering of cells within 35 (or for use within) whole animals, the use of peptide sequence derived from that species is preferred when possible. For instance, for applications involving human therapy, the use

of catalytic or targeting domains derived from human proteins may minimize the risk of immunogenic reactions. For example, a single chain antibody to be used as a targeting moiety may preferably be a humanized or human-derived single chain antibody. Likewise, other portions of adzymes, such as Fc portions or oligomerization domains may be
5 matched to the species in which the adzyme is to be used.

E. Miscellaneous Features for Adzymes

(i) Serum Half-Life

In certain embodiments of the invention, the subject adzyme can be designed or
10 modified to exhibit enhanced or decreased serum half-life. Enhanced serum half-life may be desirable to reduce the frequency of dosing that is required to achieve therapeutic effectiveness. For example, the rate of reaction between an adzyme and a low-abundance (e.g., femto- or pico-molar) substrate, such as certain extracellular signaling molecules, may occur on a timescale of days to weeks; accordingly, a serum half-life allowing
15 adzyme to persist in the body for days or weeks would be desirable and would decrease the frequency of dosing that is needed. Accordingly, in certain embodiments, the serum half-life of an adzyme is at least one day, and preferably two, three, five, ten, twenty or fifty days or more. Decreased serum half-life may be desirable in, for example, acute situations, where swift alteration of a substrate will generally accomplish the desired
20 therapeutic effect, with little added benefit resulting from prolonged adzyme activity. In fact, it may be possible to deliver very high levels of an adzyme with a short half-life, such that a high level of therapeutic effectiveness is rapidly achieved, but the adzyme is quickly cleared from the body so as to reduce side effects that may be associated with high dosages. Examples of acute situations include poisonings with various toxins, where the
25 adzyme neutralizes or otherwise eliminates the toxin, as well as sepsis or other severe fevers, where removal of endogenous pyrogens, such as IL-1 or TNF- α , or exogenous pyrogens, such as bacterial lipopolysaccharides, may accomplish the therapeutic purpose.

Serum half-life may be determined by a variety of factors, including degradation, modification to an inactive form and clearance by the kidneys. For example, an effective
30 approach to confer resistance to peptidases acting on the N-terminal or C-terminal residues of a polypeptide is to add chemical groups at the polypeptide termini, such that the modified polypeptide is no longer a substrate for the peptidase. One such chemical modification is glycosylation of the polypeptides at either or both termini. Certain chemical modifications, in particular polyethylene glycols ("pegylation") and N-terminal
35 glycosylation, have been shown to increase the half-life of polypeptides in human serum (Molineux (2003), Pharmacotherapy 8 Pt 2:3S-8S. Powell et al. (1993), Pharma. Res. 10:

1268-1273). Other chemical modifications which enhance serum stability include, but are not limited to, the addition of an N-terminal alkyl group, consisting of a lower alkyl of from 1 to 20 carbons, such as an acetyl group, and/or the addition of a C-terminal amide or substituted amide group.

5 In certain embodiments, an adzyme may be modified, so as to increase the hydrodynamic volume of the adzyme, thereby, among other things, reducing elimination from the kidneys. For example, modification with an inert polymer, such as polyethylene glycol, tends to decrease elimination through the kidneys. A polymer may be of any effective molecular weight, and may be branched or unbranched. For polyethylene glycol, 10 the preferred molecular weight is between about 1 kDa and about 100 kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the 15 ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog). For example, the polyethylene glycol may have an average molecular weight of about 200, 1000, 5000, 15,000, 30,000 50,000, or 100,000 kDa or more. The polyethylene glycol may have a branched structure. Branched polyethylene glycols are described, for example, in U.S. Pat. No. 5,643,575; 20 Morpurgo et al., *Appl. Biochem. Biotechnol.* 56:59-72 (1996); Vorobjev et al., *Nucleosides Nucleotides* 18:2745-2750 (1999); and Caliceti et al., *Bioconjug. Chem.* 10:638-646 (1999). The polyethylene glycol molecules (or other chemical moieties) may be attached to the adzyme with consideration of effects on catalytic or targeting portions. There are a number of attachment methods available to those skilled in the art, e.g., EP 0 25 401 384, herein incorporated by reference (coupling PEG to G-CSF), see also Malik et al., *Exp. Hematol.* 20:1028-1035 (1992) (reporting pegylation of GM-CSF using tresyl chloride). For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid 30 residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N- 35 terminus or lysine group.

Adzymes may be designed to have a molecular weight of about 50 kilodaltons or greater so as to reduce elimination through the kidneys.

The presence of an N-terminal D-amino acid also increases the serum stability of a polypeptide that otherwise contains L-amino acids, because exopeptidases acting on the N-terminal residue cannot utilize a D-amino acid as a substrate. Similarly, the presence of a C-terminal D-amino acid also stabilizes a polypeptide, because serum exopeptidases 5 acting on the C-terminal residue cannot utilize a D-amino acid as a substrate. With the exception of these terminal modifications, the amino acid sequences of polypeptides with N-terminal and/or C-terminal D-amino acids are usually identical to the sequences of the parent L-amino acid polypeptide.

Substitution of unnatural amino acids for natural amino acids in a subsequence of a 10 polypeptide can confer or enhance desirable attributes including biological activity. Such a substitution can, for example, confer resistance to proteolysis by exopeptidases acting on the N-terminus. The synthesis of polypeptides with unnatural amino acids is routine and known in the art (see, for example, Coller, et al. (1993), cited above).

In another embodiment, adzyme peptides are fused to certain polypeptides to 15 achieve enhanced / increased serum stability or half life. For example, WO 97/34631 A1 describes recombinant vectors encoding immunoglobulin-like domains and portions thereof, such as antibody Fc-hinge fragments, subfragments and mutant domains with extended biological half lives. Such vectors can be used to generate large quantities of fusions with such domains following expression by host cells. These antibody Fc and 20 Fc-hinge domains have the same *in vivo* stability as intact antibodies. The application also discloses domains engineered to have increased *in vivo* half lives. These DNA constructs and protein domains can be adapted for use in the instant invention, such as for the production of recombinant adzymes (or adzyme components) with increased stability and longevity for therapeutic and diagnostic uses.

25 Specifically, WO 97/34631 A1 describes recombinant vectors encoding immunoglobulin-like domains and portions thereof, such as antibody Fc fragments and subfragments and Fc-hinge domains with extended *in vivo* half lives. As the invention is exemplified by the production of a variety of immunoglobulin-like domains, including antibody Fc-hinge, Fc, CH2-hinge and CH3 domains; and engineered Fc-hinge domains 30 with extended *in vivo* half lives, such as, for example, the mutant termed LSF. In addition, other immunoglobulin-like domains may be expressed employing the methods described therein.

Previous studies indicate that the CH2 domain may play an important role in the 35 control of catabolism of antibodies, and sequences in the CH3 domain may be involved (Ellerson et al., 1976, Mueller et al., 1990; Pollock et al., 1990; Kim et al., 1994a; Medesan et al., 1997). The presence of carbohydrate residues on the CH2 domain appears

to have a minor if significant effect on the stability, and the extent of the effect is dependent on the isotype (Tao and Morrison, 1989).

Recombinant CH2-hinge, CH3, Fc and Fc-hinge fragments derived from the murine IgG1 and human constant regions have been expressed from host cells. The CH3 domain, Fc fragment and Fc-hinge fragment were all found to be homodimeric proteins. For the Fc and CH3 domain, the dimers are non-covalently linked, and are presumably stabilized by non-covalent interactions. For the Fc-hinge dimer, the fragments are covalently linked by -S-S- bridges between the hinge region cysteines. These domains may also be used to dimerize the adzyme target and catalytic domains.

The immunoglobulin Fc-hinge and Fc fragments, purified following expression in host cells, have the same *in vivo* stability as a native antibody molecule. Results from previous studies demonstrated that the recombinant aglycosylated Fc-hinge or Fc fragments have similar stability *in vivo* as the complete glycosylated IgG1 molecule. The recombinant aglycosylated Fc-hinge fragment was found to have a 0 phase similar to that of a complete glycosylated IgG1 immunoglobulin molecule. In fact the removal of Fc-hinge resulted in a slight decrease in half life (Kim et al., 1995). These results indicate that for the murine IgG1 isotype the presence of carbohydrate residues does not appear to be necessary for *in vivo* stability, although it may still play a minor role. Previous data obtained using protein chemistry suggested that the CH2 domain is responsible for *in vivo* stability (Ellerson et al., 1976) although a recent study indicated that residues in the CH3 domain may also be involved in the catabolism control of the murine IgG2a and IgG2b isotypes (Pollock et al., 1990).

(ii) Dosing Frequency

In many instances, an adzyme may be administered by injection or another administration route that may cause some discomfort to a patient, or the adzyme may require the assistance of a physician or other medical professional for safe administration. In such instances, it may be desirable to design an adzyme that is therapeutically effective at dosing frequencies of once per day or less, and preferably the adzyme is effective when administered once per week, once every two weeks, once every four weeks, once every eight weeks or less frequently.

The range of effective dosing frequencies for an adzyme may depend on a variety of characteristics of the adzyme. For example, an adzyme with a shorter serum half-life will tend to be effective for a shorter period of time, leading to a more frequent dosing schedule. Various adzyme characteristics that can extend or decrease serum half-life are described above.

Drug reservoirs in the body may lengthen the time over which an adzyme is effective. Upon dosing, many drugs accumulate in body compartments, such as the fat reserves or various transcellular fluids, from which the drug is then released slowly over a long period of time. Similarly, a drug may be tightly bound by a serum protein, such as 5 albumin or alpha1-glycoprotein and thus retained in the serum in an inactive, protected bound form, from which it may be released slowly over time. Accordingly, an adzyme may be designed to encourage the formation of reservoirs that provide for extended periods of effectiveness of the adzyme. In such embodiments, the adzyme may be administered in a higher initial dose (a "loading dose"), followed by occasional smaller 10 doses ("maintenance doses").

An adzyme may also be formulated and administered so as to have an extended period of effect. For example, an adzyme may be formulated and administered to form a "depot" in the patient that slowly releases the adzyme over time. A depot formulations may be one in which the adzyme is encapsulated in, and released slowly from, 15 microspheres made of biodegradable polymers (e.g., polylactic acid, alginate). Other depot materials include gelfoam sponges and the ProLease® system (Alkermes, Inc., Cambridge, MA).

(iii) Selectivity

In many instances, an adzyme will be designed for delivery into a particular 20 milieu. For example, many adzymes for use in humans will be designed for delivery to and/or activity in the blood stream. As described herein, adzymes may be designed for other situations, such as for use in an industrial or environmental setting. In general, it will be desirable to design an adzyme so as to decrease interactions with non-target molecules that inhibit the effectiveness of the adzyme against the target, or, in other words, it will be 25 desirable to design an adzyme that is active against target in the presence of expected levels of other components of the milieu in which the adzyme will be used.

In certain embodiments, an adzyme is designed to be effective against a substrate located in the blood, such as, for example, many extracellular signaling molecules. Such 30 an adzyme may be designed to minimize interactions with other blood components that would interfere with the ability of the adzyme to affect the target. The adzyme may be so designed on the basis of theoretical understanding or on the basis of empirical study, or both. In certain embodiments, an adzyme retains effectiveness against a target in the presence of one or more relatively abundant blood components. An adzyme may be tested for activity against target in the presence of one or more blood components, and 35 particularly abundant blood components. For example, an adzyme may be tested for activity against target in the presence of one or more abundant serum proteins, such as serum albumin (e.g., human serum albumin or other organism-specific albumin),

transthyretin ("retinol binding protein"), α -1 globulins (e.g., α -1 protease inhibitor [α -1 antitrypsin], α -1 glycoprotein, high density lipoprotein [HDL]), α -2 globulins (α -2 macroglobulin, antithrombin III, ceruloplasmin, haptoglobin), β -globulins (e.g., beta and pre-beta lipoproteins [LDL and VLDL], C3, C-reactive protein, free hemoglobin, 5 plasminogen and transferrin), γ -globulins (primarily immunoglobulins). In certain embodiments, an adzyme of the invention is active against target in the presence of expected (i.e., physiological, depending on the physiological state of the patient) concentrations of one or more blood components, such as one or more abundant serum proteins. Optionally, the adzyme is active against target in the presence of expected 10 concentrations of an abundant serum protein, and optionally is not significantly affected by concentrations of an abundant serum protein that are one-quarter, one-half, two, five or ten or more times greater than the expected concentration of an abundant serum protein. In a preferred embodiment, the adzyme comprises a catalytic domain that interacts with a polypeptide target that is expected to be found in the blood, and optionally the catalytic 15 domain has protease activity. Other abundant blood components include any of the various cell types, and molecules found on the surfaces thereof. Common blood cell types include red blood cells, platelets, neutrophils, lymphocytes, basophils, eosinophils and monocytes.

(vi) Resistance to Autocatalysis

20 In certain embodiments, the catalytic domain of an adzyme may be able to catalyze a reaction with the adzyme itself, resulting in the alteration of the adzyme. This type of reaction, termed "autocatalysis" may be between a catalytic domain and some other portion of the same adzyme (e.g., a linker, targeting moiety or other part) or between a catalytic domain of one adzyme and a portion of a second adzyme (e.g., the catalytic 25 domain, linker, targeting moiety). The former will tend to be more significant relative to the latter at very low adzyme concentrations, such as may be expected to occur after an adzyme has been deployed in a patient or other setting. The inter-adzyme form of autocatalysis is most likely to occur at higher concentrations, such as during adzyme preparation (e.g., purification from cell cultures and subsequent concentration), storage 30 and in any mixture prepared for administration to a subject (e.g., a dose of adzyme mixed with saline for administration intravenously).

For most types of catalytic domains, autocatalysis will be a relatively unimportant phenomenon, if it occurs at all. For example, catalytic domains that mediate glycosylation, isomerization or phosphorylation may not affect the activity of an adzyme, even if it does 35 undergo autocatalysis. However, in certain situations, a modification of an adzyme could disrupt the ability of the adzyme to act effectively on its target, particularly a modification that occurs in the binding portion of an address moiety or in the active portion of a

catalytic domain. Many types of catalytic domains require some type of co-factor (e.g., ATP for a kinase, a sugar for a glycotransferase), and therefore autocatalysis will not occur in the absence of such co-factors. In these circumstances, autocatalysis may be avoided during preparation or storage by ensuring that there is little or no co-factor present

5 in the adzyme preparation.

Catalytic domains that have protease activity or are otherwise capable of degrading the adzyme are of particular concern. Proteases often do not require any co-factor, and therefore autoproteolytic activity may well occur at any stage of adzyme generation or use. A variety of approaches may be taken to prevent autoproteolysis.

10 In one embodiment, an adzyme may be designed, or a protease domain selected, such that the protease is active at low levels in the absence of the target. See, for example, the description of contingent adzymes provided herein.

15 In certain embodiments, protease vulnerable sites may be engineered out of the various portions of an adzyme, such as any polypeptide address domain, catalytic domain or linker. This may be achieved either by altering the sequence of the selected components, or by selecting components in the first place that show resistance to cleavage with the desired protease domain. Trypsin has an internal trypsin vulnerable site and is susceptible to trypsin action for inactivation, however trypsin-resistant trypsin mutants may be generated. Often theoretic protease sensitive sites are present in various domains

20 but are not, in practice, viable protease substrates, perhaps due to folding or other steric hindrances. For example, Applicants have found that a p55(TNFR)-thrombin fusion protein adzyme does not undergo autocatalytic proteolysis, despite the presence of a thrombin cleavage site within the p55(TNFR) polypeptide. Such folding may be adjusted by the presence or absence of agents such as monovalent or divalent cations (e.g.,

25 potassium, calcium, zinc, iron) or anions (e.g., phosphates, chloride, iodine), as well as nonionic, zwitterionic and ionic detergents.

30 In certain embodiments, an address domain, such as a single chain antibody or other scaffold-based address domain, may be arrived at by in vitro RNA selection. In vitro selection allows the selection for protease insensitive address domains and thereby building an address domain that will not be cleaved by the enzyme domain. Similar approaches may be used for linkers, immunoglobulin portions or other polypeptides to be incorporated in an adzyme.

35 Another means of limiting auto-proteolysis is to produce the catalytic domain as a zymogen and activate the adzyme just prior to use (e.g., delivery to a patient). A zymogen or pro-protein portion may also be designed to be cleaved upon use (e.g., by a known serum active protease). Cleavage of certain zymogens occurs in the N-terminal direction

from the protease domain, meaning that after activation, the protease domain will be separated from the portion of the polypeptide that is N-terminal to the cleavage site. Cleavage of a zymogen that occurs in the N-terminal direction from the protease domain, means that after activation, the protease domain will be separated from the portion of the polypeptide that is N-terminal to the cleavage site. Cleavage of certain zymogens occurs in the C-terminal direction from the protease domain, meaning that after activation, the protease domain will be separated from the portion of the polypeptide that is C-terminal to the cleavage site. Accordingly, a fusion protein comprising a zymogen should be designed such that the protease domain is not separated (unless that is the intent) from the other relevant portion of the fusion protein upon activation.

In further embodiments, reversible competitive inhibitors may be employed. Such inhibitors are preferably selected so as to be readily removable. An inhibitor for use in a pharmaceutical preparation may be selected to have a K_i that allows effective inhibition in the high concentrations of storage and pre-administration, but which readily releases the protease upon dilution in the site of action (e.g., in the patient's body). Preferably, the inhibitor is chosen to be non-toxic or otherwise clinically approved. Inhibitors may also be used during production and purification of adzymes. Many proteases require a metal cofactor, and such proteases can often be reversibly inhibited by formulation with a chelator, such as EDTA, EGTA, BHT, or a polyanion (e.g., polyphosphate).

In a further embodiments, protease vulnerable sites may be post-translationally modified. Protease vulnerable sites could be modified by phosphorylation or methylation or glycosylation or chemically (in vitro, as opposed to modifications post translationally during production) such that the protease domain can not bind.

As a merely illustrative example, the competitive inhibitor benzamidine has been used to block the action of trypsin in the trypsinogen-p55 anti-TNF adzymes. The benzamidine has increased the yield of adzyme in the transient transfection expression of the trypsinogen adzyme. Benzamidine, boronic acid or other protease inhibitors may be useful for manufacturing adzymes. With respect to the MMP7 catalytic domain, inhibitors such as Thiorphan, Ilomastat, FN 439, Galardin or Marimastat may be employed.

30

F. Exemplary Methods for Designing Adzymes

A significant advantage of adzymes is that they admits of an engineering and design approach that permits the biomolecular engineer to resolve several of the multiple engineering challenges inherent in drug design serially rather than simultaneously. A drug must not only bind the target with high potency, but also it must have one or a combination of medicinal properties. In a given drug discovery/design exercise, the

candidate molecule must exhibit various combinations of the following properties: a suitable solubility in blood, no significant inhibition of unintended targets (the higher specificity the better), achieve an effective concentration at the target, pass biological barriers such as the skin, gut, cell walls, or blood brain barrier, have no toxic metabolites, 5 be excreted at a rate permitting achievement of necessary bioavailability without kidney or liver damage, not interfere with commonly prescribed medications, avoid complexation with albumin or other biomolecules or sequestration in tissue compartments, and be synthetically tractable. A single molecular entity simultaneously displaying all necessary combinations of these properties is very hard to find or design.

10 In contrast, the individual molecular moieties that comprise the adzyme, *e.g.*, the address and the catalytic domain, can be screened individually for the ability to bind to or modify the target of interest, respectively. Candidate structures for these parts can be taken from the ever growing public knowledge of new biological molecules and engineering efforts supported by increased understanding of their molecular biology and 15 pharmacology. Existing active enzymes can be mutated to give them an address that will confer a new specificity. Nixon et al., in *Proc. Natl. Acad. Sci. USA*, Biochemistry Vol. 94, p.1069, 1997, have validated the approach of constructing an active enzyme from disparate functional parts of other enzymes. Good candidates for each function may be linked together using various types of linking strategies. For example, they may be 20 inserted into loops, attached via flexible or structured amino acid sequence or other covalent attachments. Candidate constructs are made by choosing amino acid sequence or other structure spaced apart from the binding or catalytic portion of each domain for their ability to non-covalently complex, or via candidate chaperone proteins that complex to both domains. It is contemplated that many experimental constructs will be made in 25 parallel, and that the library of constructs may be screened for desired activity, and active species evolved by mutagenesis or otherwise altered to explore adjacent chemical space for improved properties.

Address domains can be selected using *in vivo* or *in vitro* assays. The address can be tested for the ability to bind to the target of interest using assays for direct binding or 30 assays that measure the activity of the target molecule. Methods that can be used to measure binding of the address to the target molecule include biophysical and biochemical techniques. For example, biophysical methods include fluorescence techniques which rely on intrinsic fluorescence or which rely on the addition of an extrinsic label, *e.g.*, fluorescence energy transfer, fluorescence anisotropy, changes in intrinsic fluorescence of 35 the target molecule or address domain upon binding (see Lakowitz, J. R. (1983) *Principles of Fluorescence Spectroscopy*, Plenum Press, New York). Surface plasmon resonance (Sjolander, S. and Urbaniczky, C. (1991) *Anal. Chem.* 63:2338-2345 and Szabo *et al.*

(1995) *Curr. Opin. Struct. Biol.* 5:699-705) can be used to study biospecific interactions in real time, without labeling any of the interactants (e.g., BIACore). Changes in the optical phenomenon of surface plasmon resonance can be used as an indication of real-time reactions between biological molecules.

5 Biochemical techniques that can be used to test the ability of the address domain to bind to the target molecule include techniques such as immunoprecipitation and affinity chromatography.

Further, one of both of the molecules can be labeled using a radioisotope, e.g., 125I, 35S, 14C, or 3H or other detectable label, e.g., an enzyme, and the interaction

10 between the two molecules can be measured by specifically isolating one molecule and measuring the amount of the second molecule that is associated with the first molecule. In the case of a radiolabel, the amount of radio-labeled protein that is isolated can be measured by counting of radio emmission or by scintillation counting. Alternatively, compounds can be enzymatically labeled with, for example, horseradish peroxidase, 15 alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product.

Address domains (e.g., a target specific peptide, target specific single chain antibody) may be taken from known examples in the literature, preferably from examples of human proteins. Alternatively, address domains may be identified by any of a number

20 of recombinant display techniques, including but not limited to phage display, yeast display, ribosome display, and bacterial display. Methods for preparing and screening libraries of address domains, e.g., peptide or antibody libraries, are well known in the art and include those described in U.S. Patent Nos. 6,156,511; 5,733,731; 5,580,717; 5,498,530; 5,922,545; 5,830,721; 5,811,238; 5,605,793; 5,571,698; 5,223,409; 5,198,346; 25 5,096,815; 5,403,484; 6,180,336; 5,994,519; 6,172,197; 6,140,471; 5,969,108; 5,872,215; 5,871,907; 5,858,657; 5,837,242; 5,733,743; 5,962,255; 5,565,332; and 5,514,548, the contents of each of which are incorporated herein by reference. Libraries may be functionally selected or screened to identify specific address domains exhibiting the desired properties (e.g., affinity for a target, signal to noise ratio, etc.). A recombinant 30 display technique may also be used to identify candidate address domains. Useful recombinant display techniques include, but are not limited to, phage display (see Hoogenboom *et al.*, *Immunol Today* 2000 Aug;21(8):371-8), single chain antibody display (see Daugherty *et al.* (1999) *Protein Eng* 12(7):613-21; Makeyev *et al.*, *FEBS Lett* 1999 Feb 12;444(2-3):177-80), retroviral display (see Kayman *et al.*, *J Virol* 1999 Mar;73(3):1802-8), bacterial surface display (see Earhart, *Methods Enzymol* 2000;326:506-16), yeast surface display (see Shusta *et al.*, *Curr Opin Biotechnol* 1999 Apr;10(2):117-22), ribosome display (see Schaffitzel *et al.*, *J Immunol Methods* 1999 Dec

10;231(1-2):119-35), two-hybrid systems (see, e.g., U.S. Patent Nos. 5,580,736 and 5,955,280), three-hybrid systems, and derivatives thereof. Recombinant display techniques identify address domains capable of binding targets, e.g., proteins (see, for example, Baca *et al.*, Proc Natl Acad Sci U S A 1997 Sep 16;94(19):10063-8; Katz, Biomol Eng 1999 5 Dec 31;16(1-4):57-65; Han *et al.*, J Biol Chem 2000 May 19;275(20):14979-84 ; Whaley *et al.*, Nature 2000 Jun 8;405(6787):665-8; Fuh *et al.*, J Biol Chem 2000 Jul 14;275(28):21486-91; Joung *et al.*, Proc Natl Acad Sci U S A 2000 Jun 20;97(13):7382-7; Giannattasio *et al.*, Antimicrob Agents Chemother 2000 Jul;44(7):1961-3).

Catalytic domains can be screened based on their activity. Depending on the 10 specific activity of each molecule being tested, an assay appropriate for that molecule can be used. For example, if the catalytic domain is a protease the assay used to screen the protease can be an assay to detect cleavage products generated by the protease, e.g., a chromatography or gel electrophoresis based assay. In an alternative example, the targeted substrate may be labeled and cleavage of the labeled product may produce a detectable 15 product by, for example, a change in fluorescence of the targeted substrate upon cleavage.

In another example, the catalytic domain may be a kinase. The assay used to screen these catalytic domains could measure the amount of phosphate that is covalently incorporated into the target of interest. For example, the phosphate incorporated into the target of interest could be a radioisotope of phosphate that can be quantitated by 20 measuring the emission of radiation using a scintillation counter.

It should be noted that the pharmacodynamics (binding and kinetic properties) of the interactions among the molecular address domains, targets, substrates, inhibitors, and enzymatically active sites will often be important properties of candidate constructs embodying the invention. Thus, association and dissociation properties, on-rates, off-rates, 25 and catalytic reaction rates interplay in the various constructs to achieve the desired result. These properties are engineered into the molecules by a combination of rational, structure based design and manufacture of a multiplicity of candidate constructs, or sub-parts thereof, which are screened for appropriate activity, as disclosed herein.

Methods for preparing and screening catalytic domains for the desired activity are 30 well known in the art and described in, for example, U.S. Patent No. 6,383,775 and U.S. Provisional Patent Application Serial No. 60/414,688, the entire contents of each of which are incorporated herein by reference.

Once the address domain and the catalytic domain have been incorporated into a single molecule a library of adzymes may then be created. The resulting library can be 35 screened for the ability to modify the specific target of interest. An assay for the appropriate biological function can be used to quantitate the amount of modification the

catalytic domain carries out. In a preferred embodiment, the catalytic domain is a protease and the assay is one that measures the amount of cleavage product generated by cleavage of the target molecule. It may also be effective to measure biophysical parameters, *e.g.*, k_{cat} or K_m , of the select library members. In another embodiment, the assay to screen the 5 library of adzymes can be one which measures the biological activity of the target molecule or a downstream molecule that is regulated by the target molecule.

Once an adzyme, or group of adzymes, has been identified in a selection or screen, its properties may be further enhanced by one or more rounds of mutagenesis and additional selection/screening according to art known methods. Furthermore, a catalytic 10 domain of general utility, such as a protease, may be used in constructs designed for very different purposes.

A library of adzymes comprising combinations of address domains, linkers, and enzymes may be generated using standard molecular biology protocol. Either the address 15 domain or the enzyme domain may be at the N-terminal of the adzyme. The size / length, composition (amino acid sequence) may be varied. Nucleic acids encoding the address domain, the linker, and the enzyme domain can be recombinantly fused and cloned in suitable expression vectors, under the control of operatively linked promoters and transcription regulators. The construct may also include epitope tags to facilitate purification of the recombinant products.

20 The desired combination of different address domain, linker, and enzyme domain can be generated, for example, by brute force construction of a desired number of candidate adzymes. Each of these adzymes can then be individually tested and compared in one or more of in vivo and/or in vitro functional assays, either for the adzyme itself, or for the target of the adzyme, or both.

25 Once an adzyme, or group of adzymes, has been identified in a selection or screen, its properties may be further enhanced by one or more rounds of mutagenesis and additional selection/screening according to art known methods. Furthermore, a catalytic domain of general utility, such as a protease, may be used in constructs designed for very different purposes.

30 To illustrate, U.S. Pat. No. 6,171,820 describes a rapid and facilitated method of producing from a parental template polynucleotide, a set of mutagenized progeny polynucleotides whereby at each original codon position there is produced at least one substitute codon encoding each of the 20 naturally encoded amino acids. Accordingly, the patent also provides a method of producing from a parental template polypeptide, a set of 35 mutagenized progeny polypeptides wherein each of the 20 naturally encoded amino acids is represented at each original amino acid position. The method provided is termed "site-

saturation mutagenesis," or simply "saturation mutagenesis," and can be used in combination with other mutagenization processes described above. This method can be adapted to fine-tune / optimize the final chosen combination of address domain, linker, and enzyme domain, so that the adzyme exhibits desired the biological property.

5

G. Contingent Adzymes

In one important class of adzymes, the activity of the catalytic domain is modulated by the binding of the address to an address binding site (on the target or target associated molecule). Thus, the activity of the catalytic domain may be modulated by 10 target itself, by a target associated molecule, or by part of the adzyme molecule itself. In this class of constructs, the catalytic domain itself is "masked" or sterically hindered, thus mostly inactive, when the address is not bound by an address binding site. Once the address recognizes and binds an address binding site (e.g., when the adzyme reaches its 15 target), such hinderance is released, exposing the active catalytic domain to act on the target.

There could be many embodiments of this type of so-called "contingent adzymes."

In one embodiment, the contingent adzyme is simply kept in a conformation that masks the catalytically active site, due to, for example, the presence of a self inhibitory domain. Binding of the address to an address binding site triggers a conformation change 20 of the adzyme, thereby releasing the masking effect of the catalytic domain. Alternatively, the masking of the catalytic domain may be released by administering a molecule that binds to the self-inhibitory domain at a time and/or place where adzyme activity is needed. In fact, some transcription factors have adopted this strategy to regulate their activity. For example, a small domain of the *Drosophila* homeodomain transcription factor Bicoid 25 (Bcd), located immediately N-terminal to the homeodomain (residues 52-91), represses Bcd activity in *Drosophila* cells. This domain, referred to as a self-inhibitory domain, works as an independent module that does not rely on any other sequences of Bcd and can repress the activity of heterologous activators. This domain of Bcd does not affect its properties of DNA binding or subcellular distribution. A Bcd derivative with point 30 mutations in the self-inhibitory domain severely affects pattern formation and target gene expression in *Drosophila* embryos, suggesting that proper temporal and spacial regulation of the self-inhibitory domain is not only possible but crucial for certain biological functions. In fact, evidence suggests that the action of the self-inhibitory domain requires a *Drosophila* co-factor(s), other than CtBP or dSAP18. These results suggest that proper 35 action of Bcd as a transcriptional activator and molecular morphogen during embryonic development is dependent on the downregulation of its own activity through an interaction

with a novel co-repressor(s) or complex(es) (Zhao et al., *Development* 129, 1669-1680, 2002).

In another example, complement serine protease Factor D, which is essential for the activation of complement alternative pathway and displays a typical trypsin-like fold, 5 contains an atypical active site conformation due to the presence of a self-inhibitory loop, which overlaps with the binding positions of many peptidomimetic inhibitors in other serine protease complexes. Pro-factor D displays an active catalytic triad conformation, flipped conformation for the self-inhibitory loop, and similar conformation for the flexible activation domain as that in trypsinogen, chymotrypsinogen, and prethrombin-2.

10 In another embodiment, the adzyme might be held in a conformation that masks the catalytic domain by virtue of the presence of a self binding site (“SBS”) on the adzyme surface. The SBS may be within or nearby the catalytic domain, and it competes with the address binding site for binding to the address domain. In the absence of the address binding site, the otherwise enzymatically active catalytic site is inhibited sterically or 15 allosterically by an intramolecular interaction between, for example, the address and the SBS, or between an attached small molecule inhibitor and the SBS. In the presence of the address binding site, such as when the adzyme is at or near the target, the stability of the intramolecular interaction in the adzyme is reduced or eliminated, thereby increasing the activity of the enzymatically active catalytic site to act on the target. Thus, in this class of 20 embodiments, the catalytic domain of the adzyme is actuated, or turned on (exhibits a high reaction rate), or off (exhibits a lower reaction rate), depending on the presence of a address binder for the address, which acts as a switch or trigger. When the address binder is present, the intramolecular interaction is released (competed off), freeing up the catalytic domain to act on its target.

25 One prominent feature of the contingent adzyme is that it has a higher potential enzymatic activity in the locus of the target than elsewhere, or *when* the adzyme activity is most needed: This constitutes a significant engineering advantage helpful in drug development, as it can aid in the task of increasing specificity and decreasing toxicity, i.e., by reducing the chance that the construct reacts at unintended targets. In this type of 30 construct, the affinity of the address for the target or target associated molecule preferably is greater than the affinity of the address for the SBS.

In a related form of contingent adzyme, a small molecule inhibitor that is mobile on a molecular scale is attached to the catalytic domain by a flexible linker. Either the linker includes an address domain for the targeted biomolecule or other trigger molecule, 35 or a portion of the catalytic domain apart from the catalytically active site defines an address surface. In the absence of the trigger molecule or targeted biomolecule, the inhibitor inhibits the enzymatic activity of the catalytic domain by inserting within and

blocking access to its active pocket. In the presence of the trigger molecule or targeted biomolecule, the address domain on the linker or the address surface binds with a binding site on the trigger molecule or targeted biomolecule, and forms a complex which displaces the inhibitor away from the active pocket of the catalytic domain, increasing enzymatic 5 activity.

In still another form, an address domain is attached to the catalytic domain via a linker which, in the absence of the binding site on the target, sterically disposes the address domain in a position to impede access to or otherwise disrupts the activity of the catalytic domain. In the presence of the binding site, its association with the address 10 domain disrupts the secondary structure of the linker, permitting the address domain to move away from the catalytic domain, freeing it up to react with its targeted biomolecule.

Several exemplary embodiments of the contingent adzymes are described n more detail below. However, it should be understand that these illustrative examples are not exhaustive, and should not be construed to be limiting in any aspect. A skilled artisan 15 would readily appreciate the general principle of the invention and envision similar non-described embodiments with minor modifications.

Figure 3A is a schematic representation of an embodiment of a contingent adzyme comprising a single chain antibody (scFv) serving as an address domain, covalently attached by a flexible linker to a catalytic domain, which also defines an epitope or 20 binding site for the scFv, termed a “self binding site” because the address of the construct is binding with the catalytic domain of the construct, i.e., engaging in an intramolecular reaction. In the absence of the targeted biomolecule or other triggering molecule, the address binds to the self binding site of the catalytic domain and thereby inhibits its catalytic activity. When the targeted biomolecule or other trigger molecule displaying the 25 binding site is present, it competes for binding to the scFv address, thereby freeing the catalytic domain to act on the targeted biomolecule, and increasing its activity, e.g., at least by a factor of 100, and preferably by a factor of 10^3 to 10^9 .

In environments of zero or low target concentration, the address favors binding to the self binding site on the catalytic domain, and therefore the catalytic domain is inhibited 30 from inducing reaction with spurious targets. In addition to the requirement that the address domain bind with both the self binding site on the catalytic domain and the target, and that the self binding site be positioned so as to interfere with activity of the catalytic domain when bound, it is preferred that the affinity of the address domain for the target be greater than its affinity for the binding site. In this case, thermodynamics favors 35 displacement of the address from the self binding site by the target, and promotes activation of the catalytic domain. Furthermore, it is preferred that the off-rate of the target from the address domain be high (fast) so that the mean dwell time of the address on its

target is comparable to the enzyme reaction time, preferably slightly longer, but not a lot longer. Again, preferably the binding site on a target undergoes a chemical or allosteric change when the target is converted by the catalytic domain that decreases its affinity for the address. This promotes turnover.

5 The foregoing pharmacodynamic properties may be achieved conveniently by exploiting an antibody, antibody-like construct (scFv, etc.), or peptide which is selected, e.g., from a library, or designed to bind to a binding site on the targeted biomolecule. In this case, by epitope mapping or other conventional means, the sequence of amino acids constituting the binding site on the target can be determined, and that sequence or a
10 slightly altered, lower affinity sequence can be incorporated into various candidate positions in one or more loops of a catalytic domain. These positions are chosen based on the structural data characterizing the catalytic domain so as to maintain the structure of the enzymatic site, but to occlude or allosterically alter it when the inserted epitope is bound by the scFv or other address. After determination of which of the altered enzyme
15 candidates preserve the catalytic activity, the address, which binds both to the target and to a loop on the enzyme, is attached to the catalytic domain via a flexible polymeric leash or other flexible linear moiety. Again, various constructs are made for each of plural altered active enzymes, testing various linker lengths and attachment positions, until a structure is found that exhibits inactivation or significant reduction in the activity of the enzyme active
20 site in the catalytic domain. This type of construct, generally illustrated in Fig. 3A and following, has low activity in the absence of the target, as the scFv binds to the self binding site and sterically hinders the enzymatic site. In the presence of the target, the competitive binding between the target and the scFv liberates the enzymatic site.

Figure 3B is a schematic representation of another embodiment of a contingent adzyme comprising a small molecule or small peptide inhibitor attached covalently to a catalytic domain via a flexible linker that includes an address domain. The construct is enzymatically inactive (inhibited) in the absence or low concentration of a binder for the address domain as the inhibitor associates with the binding pocket of the catalytic domain, reducing or eliminating its activity. In the presence of a binding site, here illustrated as being on a surface of the targeted biomolecule, the inhibitor is sterically displaced from the enzyme pocket freeing it to interact with the target. Such small peptide may be similar in sequence to the enzyme binding domain of a substrate. The important feature is that the inhibitor is disposed within the enzyme site in the absence of the binder and spaced apart from it in its presence, and that the address serves to increase the local concentration of the
35 target.

Figure 3C is a schematic representation of another embodiment of a contingent adzyme similar to Figure 3B comprising a small molecule inhibitor (e.g., small peptide

inhibitor) attached covalently to a catalytic domain via a flexible linker that includes an address domain. Again, the construct is enzymatically inactive (inhibited) in the absence or low concentration of a binder for the address domain as the inhibitor associates with the binding pocket of the catalytic domain, reducing or eliminating its activity. In the presence 5 of a binding site, here illustrated again as being on a surface of the targeted biomolecule, the inhibitor is sterically displaced from the enzyme pocket freeing it to interact with the target. In this case, another molecule of the targeted biomolecule, or one just released from the address domain, reacts at the enzyme binding pocket. This type of adzyme may be similarly constructed as those in Figure 3B.

10 *Figure 3D* is a cartoon of a contingent adzyme embodiment similar to Figure 3A but showing an address domain non covalently complexed with a catalytic domain at a location comprising a self binding site which inhibits substrate access to the enzyme pocket of the catalytic domain. The targeted biomolecule and its substrate site are here illustrated as one part of a two part protein complex. The address domain is illustrated as 15 binding with a surface on the complex separate from the targeted biomolecule, to form a three part complex. As illustrated, the portion of the address domain which binds with the catalytic domain to inhibit its enzymatic activity may be different from the portion which binds with the trigger molecule binding site. Furthermore, while the illustration depicts steric interference as the mechanism of catalytic inhibition, the address domain may 20 allosterically inhibit the enzyme. This type of adzyme may be constructed by attaching to the address domain a catalytic domain binding sequence, such that when the address and the catalytic domain is complexed via non-covalent interaction, the active site on the catalytic domain is masked.

25 *Figure 3E* is a schematic representation of still another embodiment of a contingent adzyme. In this embodiment, the interfering address domain is not bonded covalently or non covalently to the catalytic domain, but rather to a chaperone protein that in turn is bonded to the catalytic domain. The construct is enzymatically inactive (sterically inhibited) in the absence of a binding site as the address domain associates with the catalytic domain near the binding pocket, reducing or eliminating its activity. In the 30 presence of a binding site, here illustrated as being on a surface of the targeted biomolecule, the address domain is sterically displaced from the interfering location near the enzyme pocket, freeing it to interact with the target. To construct this type of adzyme, a chaperon-binding domain may be incorporated into both the catalytic domain and the address to facilitate chaperone binding. The small-molecule induced dimerization section 35 of the instant specification describes various embodiments of how to bring together the address and the catalytic domain.

Figure 3F is a schematic representation of still another embodiment of an contingent adzyme. Here, an address domain is non covalently complexed with a catalytic domain through a chaperone protein. In the absence of the target or other molecule recognized by the address domain, the activity of the catalytic domain is hindered by a 5 small molecule inhibitor linked to the address domain and residing in the enzyme pocket. In the presence of the targeted biomolecule, the address domain is competed off the chaperone protein, extracting the inhibitor from the enzyme pocket. In the presence of the targeted biomolecule, there is competition between binding of the address domain to the target and to the chaperone protein, displacing the small molecule, thereby freeing the 10 catalytic domain to act on the target.

Figure 3G illustrates a contingent adzyme similar to the construct of Figure 3B, but here a single globular protein domain is illustrated as comprising both the address and the catalytic domain. In the presence of the triggering molecule displaying the binding site for the address, the small molecule inhibitor is competitively displaced from the binding 15 pocket of the catalytic domain, freeing it to induce chemical change in the targeted biomolecule.

To test if a candidate contingent adzyme is relatively inactive at the absence of the address binding site, while becoming activated at the presence of the address binder, the apparent catalytic activity of the contingent adzyme can be measured at these two 20 conditions, and the apparent catalytic activity at the presence of the address binder is expected to be at least 2-fold, 3-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, or even more than that without the address binder. For example, the activity of a contingent adzyme may be measured at the absence of any address binder, using a substrate that is incapable of exposing the catalytic domain (such as a substrate that does not bind to the 25 address). To measure the activity of the contingent adzyme at the presence of the address binder, the same substrate can be used, but the reaction system also contains an address binder which cannot itself be acted upon by the adzyme (such as resisting to proteolysis if the adzyme is a protease). In other words, the activity of the adzyme is compared by the same substrate, with or without the presence of an address binder that opens up the 30 catalytic domain.

H. Methods of Treatment Using Adzymes

The present invention also provides a method of treating a subject suffering from a disease, such as a disease associated with a soluble or solvent accessible molecule. The 35 method includes administering to the subject a therapeutically, prophylactically, or analgesically effective amount of an adzyme of the invention, thereby treating a subject

suffering from a disease. Generally, adzymes can be designed and used for treating any disease mediated by a solvent accessible signaling factor in extracellular body fluid or on a cell surface.

A disease associated with a soluble molecule includes a disease, disorder, or condition, which is caused by or associated (e.g., directly or indirectly) with a soluble or membrane bound biomolecule, such as a cytokine or a growth factor or a GPCR. Examples of such diseases include inflammatory diseases, such as asthma, psoriasis, rheumatoid arthritis, osteoarthritis, psoriatic arthritis, inflammatory bowel disease (Crohn's disease, ulcerative colitis), sepsis, vasculitis, and bursitis; autoimmune diseases such as Lupus, Polymyalgia, Rheumatica, Scleroderma, Wegener's granulomatosis, temporal arteritis, cryoglobulinemia, and multiple sclerosis; transplant rejection; osteoporosis; cancer, including solid tumors (e.g., lung, CNS, colon, kidney, and pancreas); Alzheimer's and other neurodegenerative disease; atherosclerosis; viral (e.g., HIV or influenza) infections; chronic viral (e.g., Epstein-Barr, cytomegalovirus, herpes simplex virus) infection; and ataxia telangiectasia.

Adzymes may be used for anti-TNF therapies in place of antibodies, artificial constructs, or small molecules. They can be used to treat Wegener's vasculitis, Psoriasis, ankylosing spondylitis, Psoriatic arthritis, Crohn's and other IBD, and rheumatoid arthritis. They may also be used for routine or rapid intervention in infectious disease cased by bacteria and virus, attacking the infectious agent directly via cell surface proteins or circulating toxins or immune complexes. Examples of particularly promising soluble targets in addition to TNF include IgE, C5, TGF β , VEGF, and Interlukines such as IL-1.

Adzymes can be used in warm-blooded animals, preferably mammals, including humans. In a preferred embodiment, the subject is a primate. In an even more preferred embodiment, the primate is a human.

As used herein, the term "administering" to a subject includes dispensing, delivering or applying an adzyme of the invention e.g., an adzyme in a pharmaceutical formulation, to a subject by any suitable route for delivery of the composition to the desired location in the subject, including delivery by either the parenteral or oral route, intramuscular injection, subcutaneous/intradermal injection, intravenous injection, buccal administration, transdermal delivery and administration by the rectal, colonic, vaginal, intranasal or respiratory tract route. The catalytic machines of the invention also may be administered by gene therapy approaches wherein nucleotides encoding the constructs are administered to a patient, migrate or are transported to target cells, enter the cells, and are expressed to provide the cells with a therapeutic engineered intelligent machine.

The adzymes of the present invention can be provided alone, or in combination with other agents that modulate a particular pathological process. For example, an adzyme of the present invention can be administered in combination with other known agents useful in the treatment of diseases associated with or caused by a soluble molecule.

5 Known agents that may be used in the methods of the invention can be found in Harrison's Principles of Internal Medicine, Thirteenth Edition, Eds. T.R. Harrison et al. McGraw-Hill N.Y., N.Y.; and the Physicians Desk Reference 50th Edition 1997, Oradell New Jersey, Medical Economics Co., the complete contents of which are expressly incorporated herein by reference. The adzymes of the invention and the additional agents may be administered

10 to the subject in the same pharmaceutical composition or in different pharmaceutical compositions (at the same time or at different times). In one embodiment, one or more adzymes which are specific for one or more targets, are administered to a subject simultaneously. In another embodiment, the separate domains of the adzymes (*i.e.*, the address domain and the catalytic domain) may be administered to a subject separately. In

15 such an embodiment, the address domain and the catalytic domain assemble *in vivo* to form the adzyme.

I. Non-medical Use of Adzymes

The present invention also provides various uses of adzymes in a number of non-medical applications, including but are not limited to, agriculture, environmental protection, food etc.

For example, the subject adzymes can find a wide range of uses in agriculture, including producing animal feed / pet food, grain milling, ethanol production, and food processing.

Animal Feed / Pet Food Adzymes may be used to upgrade nutritional quality and 25 removing anti-nutritional factors from feed components, such as barley- and wheat-based feeds. Corn processing co-products such as gluten meal and fiber can also be improved using the subject adzyme. In fact, a number of food safety crisis in recent history (BSE, dioxin scare, etc.) have made it clear that animal feed has to be considered a public hazard to public health and one that can lead to declining public confidence in the safety of food 30 of animal origin.

In one embodiment, a protease may be linked to an address specific for the undesirable nutritional factor present in feed components, thus leading to the degradation / elimination of such component. An added benefit of such adzyme-assisted digestion is that the degraded (inactive) protein factor is now a nutritious source of protein (peptide 35 fragments). For example, Caughey et al. (J. Virol. 2135-2141, Vol 68, No. 4, Apr 1994) reported that the apparent precursor of protease-resistant PrP (responsible for the Prion

disease BSE), protease-sensitive PrP, binds to Congo red and heparin, a highly sulfated glycosaminoglycan. Thus adzymes comprising an address domain of congo red or certain sulfated glycans, and an catalytic domain of a protease that can degrade the protease-sensitive PrP, may be used to pretreat certain animal feeds to reduce the risk of prion 5 disease transmission.

In a related embodiment, adzymes of the instant invention may be used with other enzyme as feed additives to improve nutrition and digestibility, reduce waste and lower feeding costs by increasing the solubility of fibers or proteins from grains such as corn, wheat, barley and soy used in typical feeds. The other enzymes that may be used with 10 adzyme include: protease (protein-digesting enzyme), amylase (carbohydrate-digesting enzymes), lipase (fat-digesting enzyme), cellulase (fiber-digesting enzyme), lactase (milk sugar digestive enzyme), invertase, maltase (sugar digestive enzyme), and/or alpha-galactosidase (bean digesting enzyme).

Fuel Ethanol Interest in ethanol as a clean-burning fuel is stronger than ever 15 before. Fossil fuels are finite, nonrenewable and cause harm to the environment through pollution and global warming, yet they supply over 80 percent of the world's energy needs. At the present rate of consumption, world oil reserves are expected to deplete in the next 50 to 100 years. Explosive population growth and improved living standards may shorten that timeframe. Ethanol, a chemical distilled from starch crops like corn, barley, 20 sorghum and wheat, is both more fuel-efficient and far less polluting than gasoline. The agriculture industry alone produces around 100 billion tons of biomass (unused crops, trees, grasses, and other agricultural "waste" product) worldwide each year, with an energy value five times that of all energy consumed globally. The starch from these grains is converted to fermentable sugars, which are then converted to alcohol by yeast.

25 While cellulase has been used in bio-fuel production, current estimate for cellulase cost ranges from 30 to 50 cents per gallon of ethanol produced. To be more competitive in price, the objective in bio-fuel production is to reduce cellulase cost to less than 5 cents per gallon of ethanol. This requires a tenfold increase in specific activity or production efficiency or combination thereof. Thus even a few fold increase in cellulase-specific 30 activity (relative to the *Trichoderma reesei* system) would be an important progress in this direction.

Thus in this embodiment, adzymes with cellulase and other enzymes that can digest biomass into simpler sugar moieties more suitable for fermentation may be used to facilitate the fuel ethanol production. The address domain may contain more than one 35 binding domains, such as the putative cellulose binding domains of \approx 100 amino acids encoded by the cbpA gene of the *Clostridium cellulovorans* cellulose binding protein (CbpA). As mentioned before, the effective K_d of an adzyme with two identical address

domains with K_d of about 1 nM would have a much tighter value of about 10^{-15} M, and may increase the catalytic efficiency of cellulose digestion.

Food Processing Adzymes may be used in the food industry for such purposes as to improve baking, to process proteins more efficiently, to preserve foods, to treat animal 5 hides in the leather industry, to recover silver residue in photographic film processing, and to improve pulp and paper processing. The use of adzymes offers treatment alternatives that are less harsh than traditional chemical processes. The primary benefit offered by is treatments under mild conditions of temperature and pH. Some adzymes useful for these 10 purposes are used for protein hydrolysis and in modification of cellulose and hemicellulose, others are useful to breakdown hydrogen peroxide in waste streams, or for oxygen and glucose removal in food applications.

All these adzymes may be engineered, at the minimum, by including multiple address domains that may enhance the binding specificity and/or affinity, thus increasing overall activity.

15 For example, adzymes can be used to improve gluten quality in baked goods, enhance the sensory and physical characteristics of breads, and to facilitate the solubility, functionality and nutrition of meat or vegetable proteins in a diverse range of products from infant formula to sports drinks. Adzymes can also be used to more efficiently convert starch to High Fructose Corn Syrup (HFCS), the sweetener widely used in many foods and 20 especially soft drinks.

Pulp and Paper Industry Adzyme comprising xylanases may be used for bleach boosting, adzyme comprising cellulases may be used for refining pulp and paper recycling, and adzyme comprising amylases may be used for starch removal and modification.

25 **In the brewing process**, adzymes may be used to improve process efficiency and the final products. For example, adzymes comprising alpha amylases can be used in the cooking of cereal adjuncts, adzymes comprising betaglucanases may be used to improve filtration in mashing and maturation, and adzymes comprising glucoamylase can be used to produce low calorie beers. In addition, adzymes comprising alpha amylase and glucomylase 30 may be used in the production of potable alcohol.

Textile Industry Adzymes are useful in a variety of applications within the cleaning and fabric care industries. The use of adzymes is beneficial because they often replace chemicals or processes that present environmental issues. But naturally occurring enzymes are quite often not available in sufficient quantities or enzymatic activity / 35 efficiency for industrial use.

The faded or worn look of denim that has a high contrast "stonewashed" look was originally achieved by washing denim with pumice stones in large industrial washing machines. In such a process, the lack of abrasion control, damage to the fabric, and wear and tear on the washing machines is considerable. The same effects can be efficiently 5 achieved using adzymes, in a more environmentally friendly manner. Adzymes may be useful in desizing (amylases), denim finishing (cellulases), biofinishing of cotton and cellulosics (cellulases), and hydrogen peroxide elimination (catalases).

Personal Care Products Proteases perform various macromolecular maturation or hydrolytic functions within the body. These functions may be enhanced or modified by the 10 application of exogenously supplied adzymes. For example, applying adzymes to the skin's surface may aid in the breakdown of surface oils and removal of dead skin. Thus, with the use of adzymes in skin, hair and oral care applications, it is possible to supplement the body's natural processes which will result in younger looking skin, more beautiful hair and healthier teeth and gums.

15 **Detergent / Cleaner Products** In other particularly preferred embodiments, the subject adzymes can be used to target and destroy particular preselected molecules whether or not they have a biological activity. Thus, for example, components of various soils or stains (e.g. milk, blood, eggs, grass stains, oil stains, etc.) can be specifically targeted. For example, avidin/egg protein can be specifically targeted by using a biotin as 20 a targeting moiety to specifically directed, e.g. a protease to the site. The stain is degraded/digested and thereby released from the underlying substrate. Such adzymes are particularly useful in various cleaning formulations.

The term "soil" or "stain" refers to the accumulation of foreign material on a substrate of interest (e.g. a textile). The "soil" or "stain" may have no biological activity, 25 but may serve to discolor, and/or degrade the underlying substrate. The "soil" need not be visible to the naked eye. Deposition of foreign materials that, while not visible to the naked eye, but that create odors or support bacterial growth are also considered "soils" in the context of this application. Typical stains or soils include, but are not limited to grass stains, blood stains, milk stains, egg, egg white, and the like.

30 The adzymes of this invention are useful in a wide variety of contexts where it is desired to degrade a target molecule and/or inhibit the activity of that target molecule. Thus, for example, in ex vivo applications, the catalytic antagonists can be used to specifically target and degrade a particular molecule. Thus, for example, in cleaning operations, the chimeric molecules of this invention can be utilized to specifically target

and degrade a component of a soil (e.g. a protein component, a lipid component, etc.). In chemical synthetic processes, or biochemical synthetic processes (e.g. in analytic or industrial preparations, in bioreactors, etc.) to specifically degrade particular preselected molecules. Thus, for example, where it is desired to eliminate a particular enzymatic 5 activity in a bioreactor (e.g. a glycosylation) the catalytic antagonist of this invention comprises, as a targeting moiety, a substrate for the enzyme mediating the activity (e.g. a glycosyltransferase). The enzyme (receptor) in the reactor binds the targeting moiety and the enzymatic component of the chimera (e.g. a hydrolase) degrades the enzyme reducing or eliminating its activity and also freeing itself from the enzyme binding site whereby it is 10 free to attack another target enzyme.

Silicon Biotechnology

In biological systems, organic molecules exert a remarkable level of control over the nucleation and mineral phase of inorganic materials such as calcium carbonate and silica, and over the assembly of crystallites and other nanoscale building blocks into 15 complex structures required for biological function (Belcher et al., *Nature* 381, 56-58, 1996; Falini et al., *Science* 271: 67-69, 1996; Cha, *Proc. Natl Acad. Sci. USA* 96: 361-365, 1999; Meldrum et al., *Proc. R. Soc. Lond. B* 251: 238-242, 1993). This ability to direct the assembly of nanoscale components into controlled and sophisticated structures has motivated intense efforts to develop assembly methods that mimic or exploit the 20 recognition capabilities and interactions found in biological systems (Colvin et al., *J. Am. Chem. Soc.* 144: 5221-5230, 1992; Brust et al., *Adv. Mater.* 7: 795-797, 1995; Li et al., *Chem. Mater.* 11: 23-26, 1999; Alivisatos et al., *Nature* 382: 609-611, 1996; Mirkin et al., *Nature* 382: 607-609, 1996; Brown, *Proc. Natl Acad. Sci. USA* 89: 8651-8655, 1992). Brown (*Proc. Natl Acad. Sci. USA* 89: 8651-8655, 1992; and *Nature Biotechnol.* 15: 269-272, 1997) describes the successful selection of peptides with limited selectivity for 25 binding to metal surfaces and metal oxide surfaces. In another study, using combinatorial phage-display libraries, Whaley et al. (*Nature* 405: 665-668, 2000) extend this approach and successfully screened and selected numerous peptides that bind to a range of semiconductor surfaces with high specificity, depending on the crystallographic 30 orientation and composition of the structurally similar materials used. Whaley et al. have extended this peptide recognition and specificity of inorganic crystals to other substrates, including GaN, ZnS, CdS, Fe₃O₄, and CaCO₃. Such peptides may be used as the address domains of the subject adzymes and specifically place / assemble a variety of functional

macromolecules (such as polypeptides) to pre-determined regions of micro-chips (such as protein arrays, etc.).

Such targeted adzymes may be used for targeted, sequential assembly/synthesis of nanomaterials, either inorganic or organic/inorganic hybrid materials. In one embodiment, 5 a first adzyme may be placed on the surface of a first region of a nano-assembly line / container (tank, flow through tube, and other appropriate designs) such that the functional domain – the catalytic domain – on the adzyme may carry out a first step of a series of processes on a reactant / substrate. The reactant can then be passed on to a second adzyme placed on the surface of a second region of a nano-assembly line / container to allow the 10 next step of the process to finish. This process can be repeated for subsequent steps of the processes until all the reactions are done and the final product emerge.

The protein silicatein, which is isolated from the marine sponge *Tethya aurantia*, catalyzes the *in vitro* polymerization of silica and silsesquioxanes from tetraethoxysilane and silica triethoxides, respectively. When tethered to a specific region of the nano- 15 assembly line, the protein may be used to carry out specific steps of a particular nano-assembly.

Alternatively, different adzymes may be attached to different chips, which can be automatically loaded into or taken out of a reaction container to carry out sequential catalytic steps.

20 Such targeted adzymes may also be used to construct arrays of (identical or different) molecules on silicon chips. In this regard, the subject adzyme technology can be combined with planned chemical assembly of 3-dimensional (3-D) organic / inorganic nanoscale architectures. This approach is based on processes of surface chemical derivatization and controlled self-assembly taking place on organic template scaffolds 25 produced via a hierarchical layer-by-layer self-assembly strategy. For example, arbitrary 2-D patterns can be generated using a novel nano-patterning process, referred to as "Constructive Nanolithography" [1], whereby electrical pulses delivered by a conductive AFM (atomic force microscope) tip induce local electrochemical transformations selectively affecting the top functions of certain highly ordered organosilane monolayers 30 or thicker films selfassembled on silicon. In this patterning process, the AFM tip plays the role of a nano-electrochemical "pen," with which chemical information is inscribed in a nondestructive manner on the top surface of the selected organic film. The patterned film or the product of its further chemical modification is then further utilized as a template

capable of guiding the subsequent surface self-assembly of various targeted adzymes, thus creating a gradually evolving self-assembling system in which each self-assembly step is subject to the control provided by a previously assembled template structure. This 5 of organic-inorganic nanocomposite architectures with variable dimensionality, from 0-D (individual dots) and 1-D (wires), to 3-D (superlattices) structures.

For example, the surface of an array may comprise a first material that cannot be bound by the addresses of any of a number of adzymes later to be attached. Using the above-described technology, a first area of the surface may be altered such that a first 10 address domain of an adzyme may now bind to the altered region. If the binding is saturating, after removing all of the first adzyme, the same process can be repeated for a second region on the surface to expose a second region, such that a second adzyme (may be with a different catalytic domain) may now bind. Since the ATM tip is controlling the exposure of the surface, various patterns can be etched on the surface sequentially, such 15 that different adzymes with different functions may be selectively attached to different areas of the surface in distinct patterns if necessary.

DNA motifs have been used to produce nanoscale patterns in 2D, including a 2D lattice from a junction with sticky ends (see Seeman and Belcher, Proc Natl Acad Sci U S A. 99 Suppl 2: 6451-5; Apr. 30, 2002; Epub 2002 Mar 05). Thus in other embodiments, 20 adzymes with address domains recognizing specific DNA sequences may be attached to such DNA lattice to create patterned adzyme arrays. The address domain can be naturally existing DNA binding domains, or can be selected for specific DNA binding using, for example, phage display or other similar techniques.

25 *J. Compositions Containing Adzymes*

(i) *Protein Preparations*

Another aspect of the invention pertains to pharmaceutical compositions containing the adzymes of the invention. The pharmaceutical compositions of the invention typically comprise an adzyme of the invention or nucleotides encoding the same 30 for transfection into a target tissue, and a pharmaceutically acceptable carrier. As used herein "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and anti-fungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. The type of carrier can be selected based upon the intended route of administration. In various embodiments, the carrier is

suitable for intravenous, intraperitoneal, subcutaneous, intramuscular, topical, transdermal or oral administration.

Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the pharmaceutical compositions of the invention is contemplated. Supplementary active compounds can also be incorporated into the compositions.

Therapeutic compositions typically must be sterile and stable under the conditions of manufacture and storage. The composition can be formulated as a solution, microemulsion, liposome, or other ordered structure suitable to high drug concentration. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example,

by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, monostearate salts and gelatin. Moreover, the adzymes can be administered in a time release formulation, for example in a composition which includes a slow release polymer. The adzymes can be prepared with carriers that will protect the compound against rapid release, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, polylactic acid and polylactic, polyglycolic copolymers (PLG). Many methods for the preparation of such formulations are generally known to those skilled in the art.

Sterile injectable solutions can be prepared by incorporating the adzyme in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the adzyme into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the

active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Depending on the route of administration, the adzyme may be coated in a material to protect it from the action of enzymes, acids and other natural conditions which may 5 inactivate the agent. For example, the adzyme can be administered to a subject in an appropriate carrier or diluent co-administered with enzyme inhibitors or in an appropriate carrier such as liposomes. Pharmaceutically acceptable diluents include saline and aqueous buffer solutions. Enzyme inhibitors include pancreatic trypsin inhibitor, diisopropylfluoro-phosphate (DEP) and trasylol. Liposomes include water-in-oil-in-water 10 emulsions as well as conventional liposomes (Strejan, *et al.*, (1984) *J. Neuroimmunol* 7:27). Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.

The active agent in the composition (*i.e.*, an adzyme of the invention) preferably is 15 formulated in the composition in a therapeutically effective amount. A "therapeutically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result, such as modulation of the activity of a target, to thereby influence the therapeutic course of a particular disease state. A 20 therapeutically effective amount of an adzyme may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the adzyme to elicit a desired response in the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. A therapeutically effective amount is also one in which any 25 toxic or detrimental effects of the adzyme are outweighed by the therapeutically beneficial effects. In another embodiment, the adzyme is formulated in the composition in a prophylactically effective amount. A "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result, for example, modulation of the activity of a target (*e.g.*, TNF α or 30 TNF β) for prophylactic purposes. Typically, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.

The amount of an adzyme in the composition may vary according to factors such as the disease state, age, sex, and weight of the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be 35 proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein

refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and 5 directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.

Another aspect of the invention provides aerosols for the delivery of adzymes to the respiratory tract. The respiratory tract includes the upper airways, including the 10 oropharynx and larynx, followed by the lower airways, which include the trachea followed by bifurcations into the bronchi and bronchioli. The upper and lower airways are called the conductive airways. The terminal bronchioli then divide into respiratory bronchioli which then lead to the ultimate respiratory zone, the alveoli, or deep lung.

Herein, administration by inhalation may be oral and/or nasal. Examples of 15 pharmaceutical devices for aerosol delivery include metered dose inhalers (MDIs), dry powder inhalers (DPIs), and air-jet nebulizers. Exemplary nucleic acid delivery systems by inhalation which can be readily adapted for delivery of the subject adzymes are described in, for example, U.S. patents 5,756,353; 5,858,784; and PCT applications WO98/31346; WO98/10796; WO00/27359; WO01/54664; WO02/060412. Other aerosol 20 formulations that may be used are described in U.S. Patents 6,294,153; 6,344,194; 6,071,497, and PCT applications WO02/066078; WO02/053190; WO01/60420; WO00/66206.

The human lungs can remove or rapidly degrade hydrolytically cleavable 25 deposited aerosols over periods ranging from minutes to hours. In the upper airways, ciliated epithelia contribute to the "mucociliary excalator" by which particles are swept from the airways toward the mouth. Pavia, D., "LungMucociliary Clearance," in Aerosols and the Lung: Clinical and Experimental Aspects, Clarke, S. W. and Pavia, D., Eds., Butterworths, London, 1984. In the deep lungs, alveolar macrophages are capable of phagocytosing particles soon after their deposition. Warheit et al. Microscopy Res. Tech., 30 26: 412-422 (1993); and Brain, J. D., "Physiology and Pathophysiology of Pulmonary Macrophages," in The Reticuloendothelial System, S. M. Reichard and J. Filkins, Eds., Plenum, New. York., pp. 315-327, 1985. The deep lung, or alveoli, are the primary target of inhaled therapeutic aerosols for systemic delivery of adzymes.

In preferred embodiments, particularly where systemic dosing with the adzyme is 35 desired, the aerosoled adzymes are formulated as microparticles. Microparticles having a diameter of between 0.5 and ten microns can penetrate the lungs, passing through most of

the natural barriers. A diameter of less than ten microns is required to bypass the throat; a diameter of 0.5 microns or greater is required to avoid being exhaled.

An adzyme of the invention can be formulated into a pharmaceutical composition wherein the compound is the only active agent therein. Alternatively, the pharmaceutical 5 composition can contain additional active agents. For example, two or more adzymes of the invention may be used in combination.

(ii) Nucleic Acid Compositions

Another aspect of the invention provides expression vectors for expressing the 10 subject adzyme entities. For instance, expression vectors are contemplated which include a nucleotide sequence encoding a polypeptide adzyme, which coding sequence is operably linked to at least one transcriptional regulatory sequence. Regulatory sequences for directing expression of the instant polypeptide adzyme are art-recognized and are selected by a number of well understood criteria. Exemplary regulatory sequences are described in 15 Goeddel; Gene Expression Technology: Methods in Enzymology, Academic Press, San Diego, CA (1990). For instance, any of a wide variety of expression control sequences that control the expression of a DNA sequence when operatively linked to it may be used in these vectors to express DNA sequences encoding the polypeptide adzymes of this invention. Such useful expression control sequences, include, for example, the early and 20 late promoters of SV40, adenovirus or cytomegalovirus immediate early promoter, the lac system, the trp system, the TAC or TRC system, T7 promoter whose expression is directed by T7 RNA polymerase, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase, e.g., Pho5, and the promoters of the yeast α -mating factors and other sequences known to control the expression of genes 25 of prokaryotic or eukaryotic cells or their viruses, and various combinations thereof. It should be understood that the design of the expression vector may depend on such factors as the choice of the target host cell to be transformed. Moreover, the vector's copy number, the ability to control that copy number and the expression of any other protein encoded by the vector, such as antibiotic markers, should also be considered.

30 As will be apparent, the subject gene constructs can be used to cause expression of the subject polypeptide adzymes in cells propagated in culture, e.g. to produce proteins or polypeptides, including polypeptide adzymes, for purification.

This invention also pertains to a host cell transfected with a recombinant gene in order to express one of the subject polypeptides. The host cell may be any prokaryotic or 35 eukaryotic cell. For example, a polypeptide adzyme of the present invention may be

expressed in bacterial cells such as *E. coli*, insect cells (baculovirus), yeast, or mammalian cells. Other suitable host cells are known to those skilled in the art.

Accordingly, the present invention further pertains to methods of producing the subject polypeptide adzymes. For example, a host cell transfected with an expression 5 vector encoding a protein of interest can be cultured under appropriate conditions to allow expression of the protein to occur. The protein may be secreted, by inclusion of a secretion signal sequence, and isolated from a mixture of cells and medium containing the protein. Alternatively, the protein may be retained cytoplasmically and the cells harvested, lysed and the protein isolated. A cell culture includes host cells, media and other byproducts.

10 Suitable media for cell culture are well known in the art. The proteins can be isolated from cell culture medium, host cells, or both using techniques known in the art for purifying proteins, including ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis, and immunoaffinity purification with antibodies specific for particular epitopes of the protein.

15 Thus, a coding sequence for a polypeptide adzyme of the present invention can be used to produce a recombinant form of the protein via microbial or eukaryotic cellular processes. Ligating the polynucleotide sequence into a gene construct, such as an expression vector, and transforming or transfecting into hosts, either eukaryotic (yeast, avian, insect or mammalian) or prokaryotic (bacterial cells), are standard procedures.

20 Expression vehicles for production of a recombinant protein include plasmids and other vectors. For instance, suitable vectors for the expression of polypeptide adzymes include plasmids of the types: pBR322-derived plasmids, pEMBL-derived plasmids, pEX-derived plasmids, pBTac-derived plasmids and pUC-derived plasmids for expression in prokaryotic cells, such as *E. coli*.

25 A number of vectors exist for the expression of recombinant proteins in yeast. For instance, YEp24, YIp5, YEp51, YEp52, pYES2, and YRp17 are cloning and expression vehicles useful in the introduction of genetic constructs into *S. cerevisiae* (see, for example, Broach *et al.*, (1983) in Experimental Manipulation of Gene Expression, ed. M. Inouye Academic Press, p. 83, incorporated by reference herein). These vectors can 30 replicate in *E. coli* due the presence of the pBR322 ori, and in *S. cerevisiae* due to the replication determinant of the yeast 2 micron plasmid. Autotrophic selection or counterselection is often used in yeast. In addition, drug resistance markers such as ampicillin can be used in bacteria.

35 The preferred mammalian expression vectors contain both prokaryotic sequences to facilitate the propagation of the vector in bacteria, and one or more eukaryotic transcription units that are expressed in eukaryotic cells. The pcDNA1/amp, pcDNA1/neo,

pRc/CMV, pSV2gpt, pSV2neo, pSV2-dhfr, pTk2, pRSVneo, pMSG, pSVT7, pko-neo and pHyg derived vectors are examples of mammalian expression vectors suitable for transfection of eukaryotic cells. Some of these vectors are modified with sequences from bacterial plasmids, such as pBR322, to facilitate replication and drug resistance selection

5 in both prokaryotic and eukaryotic cells. Alternatively, derivatives of viruses such as the bovine papilloma virus (BPV-1), or Epstein-Barr virus (pHEBo, pREP-derived and p205) can be used for transient expression of proteins in eukaryotic cells. Examples of other viral (including retroviral) expression systems can be found below in the description of gene therapy delivery systems. The various methods employed in the preparation of the

10 plasmids and transformation of host organisms are well known in the art. For other suitable expression systems for both prokaryotic and eukaryotic cells, as well as general recombinant procedures, see Molecular Cloning: A Laboratory Manual, 2nd Ed., ed. by Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press, 1989) Chapters 16 and 17. In some instances, it may be desirable to express the recombinant polypeptide

15 adzymes by the use of a baculovirus expression system. Examples of such baculovirus expression systems include pVL-derived vectors (such as pVL1392, pVL1393 and pVL941), pAcUW-derived vectors (such as pAcUW1), and pBlueBac-derived vectors (such as the beta-gal containing pBlueBac III).

In yet other embodiments, the subject expression constructs are derived by

20 insertion of the subject gene into viral vectors including recombinant retroviruses, adenovirus, adeno-associated virus, and herpes simplex virus-1, or recombinant bacterial or eukaryotic plasmids. As described in greater detail below, such embodiments of the subject expression constructs are specifically contemplated for use in various *in vivo* and *ex vivo* gene therapy protocols.

25 Retrovirus vectors and adeno-associated virus vectors are generally understood to be the recombinant gene delivery system of choice for the transfer of exogenous genes *in vivo*, particularly into humans. These vectors provide efficient delivery of genes into cells, and the transferred nucleic acids are stably integrated into the chromosomal DNA of the host. A major prerequisite for the use of retroviruses is to ensure the safety of their use,

30 particularly with regard to the possibility of the spread of wild-type virus in the cell population. The development of specialized cell lines (termed "packaging cells") which produce only replication-defective retroviruses has increased the utility of retroviruses for gene therapy, and defective retroviruses are well characterized for use in gene transfer for gene therapy purposes (for a review see Miller, A.D. (1990) Blood 76:271). Thus,

35 recombinant retrovirus can be constructed in which part of the retroviral coding sequence (gag, pol, env) has been replaced by nucleic acid encoding a polypeptide adzyme of the present invention, rendering the retrovirus replication defective. The replication defective

retrovirus is then packaged into virions which can be used to infect a target cell through the use of a helper virus by standard techniques. Protocols for producing recombinant retroviruses and for infecting cells *in vitro* or *in vivo* with such viruses can be found in Current Protocols in Molecular Biology, Ausubel, F.M. *et al.*, (eds.) Greene Publishing Associates, (1989), Sections 9.10-9.14 and other standard laboratory manuals. Examples of suitable retroviruses include pLJ, pZIP, pWE and pEM which are well known to those skilled in the art. Retroviruses have been used to introduce a variety of genes into many different cell types, including neural cells, epithelial cells, endothelial cells, lymphocytes, myoblasts, hepatocytes, bone marrow cells, *in vitro* and/or *in vivo* (see for example Eglitis *et al.*, (1985) *Science* 230:1395-1398; Danos and Mulligan, (1988) *PNAS USA* 85:6460-6464; Wilson *et al.*, (1988) *PNAS USA* 85:3014-3018; Armentano *et al.*, (1990) *PNAS USA* 87:6141-6145; Huber *et al.*, (1991) *PNAS USA* 88:8039-8043; Ferry *et al.*, (1991) *PNAS USA* 88:8377-8381; Chowdhury *et al.*, (1991) *Science* 254:1802-1805; van Beusechem *et al.*, (1992) *PNAS USA* 89:7640-7644; Kay *et al.*, (1992) *Human Gene Therapy* 3:641-647; Dai *et al.*, (1992) *PNAS USA* 89:10892-10895; Hwu *et al.*, (1993) *J. Immunol.* 150:4104-4115; U.S. Patent No. 4,868,116; U.S. Patent No. 4,980,286; PCT Application WO 89/07136; PCT Application WO 89/02468; PCT Application WO 89/05345; and PCT Application WO 92/07573).

Furthermore, it has been shown that it is possible to limit the infection spectrum of retroviruses and consequently of retroviral-based vectors, by modifying the viral packaging proteins on the surface of the viral particle (see, for example PCT publications WO93/25234, WO94/06920, and WO94/11524). For instance, strategies for the modification of the infection spectrum of retroviral vectors include: coupling antibodies specific for cell surface antigens to the viral env protein (Roux *et al.*, (1989) *PNAS USA* 86: 9079-9083; Julian *et al.*, (1992) *J. Gen Virol* 73:3251-3255; and Goud *et al.*, (1983) *Virology* 163: 251-254); or coupling cell surface ligands to the viral env proteins (Neda *et al.*, (1991) *J. Biol. Chem.* 266: 14143-14146). Coupling can be in the form of the chemical cross-linking with a protein or other variety (e.g. lactose to convert the env protein to an asialoglycoprotein), as well as by generating polypeptide adzymes (e.g. single-chain antibody/env polypeptide adzymes). This technique, while useful to limit or otherwise direct the infection to certain tissue types, and can also be used to convert an ecotropic vector in to an amphotropic vector.

Another viral gene delivery system useful in the present invention utilizes adenovirus-derived vectors. The genome of an adenovirus can be manipulated such that it encodes a gene product of interest, but is inactivate in terms of its ability to replicate in a normal lytic viral life cycle (see, for example, Berkner *et al.*, (1988) *Biotechniques* 6: 616; Rosenfeld *et al.*, (1991) *Science* 252: 431-434; and Rosenfeld *et al.*, (1992) *Cell* 68:

143-155). Suitable adenoviral vectors derived from the adenovirus strain Ad type 5 dl324 or other strains of adenovirus (e.g., Ad2, Ad3, Ad7 etc.) are well known to those skilled in the art. Recombinant adenoviruses can be advantageous in certain circumstances in that they are not capable of infecting nondividing cells and can be used to infect a wide variety 5 of cell types, including airway epithelium (Rosenfeld *et al.*, (1992) cited *supra*), endothelial cells (Lemarchand *et al.*, (1992) PNAS USA 89:6482-6486), hepatocytes (Herz and Gerard, (1993) PNAS USA 90:2812-2816) and muscle cells (Quantin *et al.*, (1992) PNAS USA 89:2581-2584). Furthermore, the virus particle is relatively stable and amenable to purification and concentration, and as above, can be modified so as to affect 10 the spectrum of infectivity. Additionally, introduced adenoviral DNA (and foreign DNA contained therein) is not integrated into the genome of a host cell but remains episomal, thereby avoiding potential problems that can occur as a result of insertional mutagenesis in situations where introduced DNA becomes integrated into the host genome (e.g., retroviral DNA). Moreover, the carrying capacity of the adenoviral genome for foreign DNA is 15 large (up to 8 kilobases) relative to other gene delivery vectors (Berkner *et al.*, *supra*; Haj-Ahmand and Graham (1986) J. Virol. 57:267). Most replication-defective adenoviral vectors currently in use and therefore favored by the present invention are deleted for all or parts of the viral E1 and E3 genes but retain as much as 80% of the adenoviral genetic material (see, e.g., Jones *et al.*, (1979) Cell 16:683; Berkner *et al.*, *supra*; and Graham *et* 20 *al.*, in Methods in Molecular Biology, E.J. Murray, Ed. (Humana, Clifton, NJ, 1991) vol. 7. pp. 109-127). Expression of the inserted chimeric gene can be under control of, for example, the E1A promoter, the major late promoter (MLP) and associated leader sequences, the viral E3 promoter, or exogenously added promoter sequences.

Yet another viral vector system useful for delivery of the subject chimeric genes is 25 the adeno-associated virus (AAV). Adeno-associated virus is a naturally occurring defective virus that requires another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle. (For a review, see Muzyczka *et al.*, Curr. Topics in Micro. and Immunol. (1992) 158:97-129). It is also one of the few viruses that may integrate its DNA into non-dividing cells, and exhibits a high 30 frequency of stable integration (see for example Flotte *et al.*, (1992) Am. J. Respir. Cell. Mol. Biol. 7:349-356; Samulski *et al.*, (1989) J. Virol. 63:3822-3828; and McLaughlin *et* *al.*, (1989) J. Virol. 62:1963-1973). Vectors containing as little as 300 base pairs of AAV 35 can be packaged and can integrate. Space for exogenous DNA is limited to about 4.5 kb. An AAV vector such as that described in Tratschin *et al.*, (1985) Mol. Cell. Biol. 5:3251-3260 can be used to introduce DNA into cells. A variety of nucleic acids have been introduced into different cell types using AAV vectors (see for example Hermonat *et al.*, (1984) PNAS USA 81:6466-6470; Tratschin *et al.*, (1985) Mol. Cell. Biol. 4:2072-2081;

Wondisford *et al.*, (1988) Mol. Endocrinol. 2:32-39; Tratschin *et al.*, (1984) J. Virol. 51:611-619; and Flotte *et al.*, (1993) J. Biol. Chem. 268:3781-3790).

Other viral vector systems that may have application in gene therapy have been derived from herpes virus, vaccinia virus, and several RNA viruses. In particular, herpes 5 virus vectors may provide a unique strategy for persistence of the recombinant gene in cells of the central nervous system and ocular tissue (Pepose *et al.*, (1994) Invest Ophthalmol Vis Sci 35:2662-2666)

In addition to viral transfer methods, such as those illustrated above, non-viral methods can also be employed to cause expression of a protein in the tissue of an animal.

10 Most nonviral methods of gene transfer rely on normal mechanisms used by mammalian cells for the uptake and intracellular transport of macromolecules. In preferred embodiments, non-viral gene delivery systems of the present invention rely on endocytic pathways for the uptake of the gene by the targeted cell. Exemplary gene delivery systems of this type include liposomal derived systems, poly-lysine conjugates, and artificial viral 15 envelopes.

In a representative embodiment, a gene encoding an adzyme-containing polypeptide can be entrapped in liposomes bearing positive charges on their surface (e.g., lipofectins) and (optionally) which are tagged with antibodies against cell surface antigens of the target tissue (Mizuno *et al.*, (1992) No Shinkei Geka 20:547-551; PCT publication 20 WO91/06309; Japanese patent application 1047381; and European patent publication EP-A-43075). For example, lipofection of neuroglioma cells can be carried out using liposomes tagged with monoclonal antibodies against glioma-associated antigen (Mizuno *et al.*, (1992) Neurol. Med. Chir. 32:873-876).

25 In yet another illustrative embodiment, the gene delivery system comprises an antibody or cell surface ligand which is cross-linked with a gene targeting moiety such as poly-lysine (see, for example, PCT publications WO93/04701, WO92/22635, WO92/20316, WO92/19749, and WO92/06180). For example, any of the subject gene constructs can be used to transfect specific cells *in vivo* using a soluble polynucleotide carrier comprising an antibody conjugated to a polycation, e.g. poly-lysine (see U.S. 30 Patent 5,166,320). It will also be appreciated that effective delivery of the subject nucleic acid constructs via -mediated endocytosis can be improved using agents which enhance escape of the gene from the endosomal structures. For instance, whole adenovirus or fusogenic peptides of the influenza HA gene product can be used as part of the delivery system to induce efficient disruption of DNA-containing endosomes (Mulligan *et al.*, 35 (1993) Science 260:926; Wagner *et al.*, (1992) PNAS USA 89:7934; and Christiano *et al.*, (1993) PNAS USA 90:2122).

In clinical settings, the gene delivery systems can be introduced into a patient by any of a number of methods, each of which is familiar in the art.

For instance, a pharmaceutical preparation of the gene delivery system can be introduced systemically, e.g. by intravenous injection, and specific transduction of the 5 construct in the target cells occurs predominantly from specificity of transfection provided by the gene delivery vehicle, cell-type or tissue-type expression due to the transcriptional regulatory sequences controlling expression of the gene, or a combination thereof. In other embodiments, initial delivery of the recombinant gene is more limited with introduction into the animal being quite localized. For example, the gene delivery vehicle can be 10 introduced by catheter (see U.S. Patent 5,328,470) or by stereotactic injection (e.g. Chen *et al.*, (1994) PNAS USA 91: 3054-3057).

The invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and published patent 15 applications cited throughout this application, as well as the Figures and the Sequence Listing are hereby incorporated by reference.

EXAMPLES

The following examples are for illustrative purposes only, and should not be 20 considered limiting in any respect.

Example 1 Chemical Cross-linking of Address and Enzyme Domains

An adzyme can be created in at least two ways: (A) by chemical crosslinking and (B) by recombinant DNA technology.

The cross linking is performed using techniques well known in the art. Briefly, the 25 N-termini (or surface accessible lysines) of one protein domain are reacted with SPDP, while the N-termini (or surface accessible lysines) of the other protein domain are reacted with SMCC. Subsequently, the two domains are allowed to react, thus, forming disulfide bridges that join the domains. When linked in the foregoing manner, the estimated distance between the two domains is approximately 14 Å.

30 Glutaraldehyde may also be used to cross link N-terminus of one protein with the C-terminus of the other protein.

These and similar methods well known in the art of chemical cross-linking can be used to link address (such as the scFv Ab mentioned below) with a catalytic domain (such as thrombin or its zymogen).

Example 2: A Model Adzyme Experimental System

In order to create an adzyme (*e.g.*, a bifunctional protein) that preserves the functions of both domains (address domain and catalytic domain) and confers greater target specificity, applicants designed the following model adzyme experimental system

5 using prethrombin as an enzyme domain and a single-chain antibody specific for the hemagglutinin peptide of influenza virus (HA) [18] as the address domain. Such an adzyme has heightened proteolytic activity on substrates bound by the address domain compared to the proteolytic activity of the enzyme domain alone. Proteolytic adzymes are expressed and purified as inactive zymogens. Frequently the zymogen has an amino

10 terminal sequence that blocks the catalytic site. Cleavage at a specific activation site removes the blocking peptide and leads to protease activation. To ensure that activation does not uncouple the two domains of the adzyme, the enzyme domain is preferably positioned N-terminal to the address domain. The following examples describe the construction, expression and purification (see below, Figs. 4 & 5) of components that

15 include the address domain alone, the enzyme domain alone and the ADYZME that coupled the address and enzyme domains through a flexible polypeptide linker. Following a partial one-step purification, these recombinant proteins were activated and tested for proteolytic activity against substrates that either contained or lacked a binding site for the address domain. Schematic model adzyme and individual components are shown in Fig. 4.

20 In Figure 4, all components were assembled in the pSecTag2A vector system (Invitrogen, Carlsbad, CA), which included an N-terminal leader peptide designed to enable secretion from a heterologous expression system and C-terminal tandem myc and His₆ tags to enable immunodetection and purification. The address domain was a single chain antibody (scFv α HA) derived from monoclonal antibody mAb26/9, which

25 recognized an influenza virus haemagglutinin (HA) epitope DVPDYA (SEQ ID NO:) [18]. The enzyme domain was prethrombin (residues 315 to 622 of human prothrombin; accession no. AAC63054) - a zymogen of thrombin that could be activated using Factor Xa. Address and enzyme domains were connected with a 15 amino acid linker ([GGGGS]₃, SEQ ID NO:). When tested against a target containing DVPDYA (SEQ ID

30 NO:) and a suboptimal thrombin cleavage site (*e.g.*, GGVR, SEQ ID NO:), the thrombin domain in the adzyme demonstrates accelerated cleavage because of the higher local concentration of peptide achieved through binding to DVPDYA (SEQ ID NO:) by the scFv domain (the address domain).

Both N-terminal and C-terminal fusions of adzymes are created with a variety of

35 tags (myc, His₆, V5). Different linker compositions and lengths are used. For example, the following constructs may be created: thrombin-tag-COOH; scFv α HA-tag-COOH; N-thrombin-linker-scFv α HA-tag-COOH; N-scFv α HA-linker-thrombin-tag-COOH; N-

scFv α HA-linker-thrombin-linker-scFv α HA-tag-COOH; or constructs with two thrombin units in tandem along with scFv anti-HA.

Prethrombin and the single chain antibody directed against the HA epitope are cloned individually into the HindIII and XhoI sites of the pSecTag2A vector from 5 Invitrogen to generate proteins that will be secreted into the medium for subsequent biochemical characterization. Prethrombin is the inactive form that is activated by Factor Xa or ecarin. Prethrombin(G₄S)₃-scHA and scHA(G₄S)₃-prethrombin are assembled by overlap / recombinant PCR (using the oligos described in Table X below) and cloned into the pSecTag2A vector as HindIII and XhoI fragments. They will contain myc and His₆ as 10 tags at the C-terminus. The slash shows where the cleavage occurs in the signal peptide. The amino acid sequence for Prethrombin(G₄S)₃ scFv α HA is:

METDTLLLWVLLWVPGSTG/DAAQPARRAVRSLMTATSEYQTFFNPRTFGSGEADCGLR
 PLFEKKSL EDKTERELLESYIDGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDR
 WVLTAAHCLLYPPWDKNFTENDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENL
 15 DRDIALMKLKKPVAFSDYIHPVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKQ
 PSVLQVNLPIVERPVCKDSTRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFN
 NRWYQMGIVSWGEGCDRGKYGYFYTHVFRLLKKWIQKVIDQFGEGGGGSGGGGSGGGGSME
 VQLLESGGDLVKPGGSLKLSCAASGFTFSTYGMSWVRQTPDKRLEWVATISNGGGYTYYP
 DSVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARRERYDENGFAYWGRGTLVTVSAG
 20 GGGSGGGGGGGSDIVMSQSPSSI AVSVGEKITMSCKSSQSLFNSGKQKNYL TWYQQKP
 GQSPKLLIYWASTRESGV PDRFTGSGSGTDFTLTISSVKAEDLAVYYCQNDYSHPLTFGG
 GTKLEIKRADAAPTARGGPEQKLISEEDLNSAVDHHHHHH* (SEQ ID NO:).

The amino acid sequence for scHA(G₄S)₃prethrombin as made from pSecTag2 is:

METDTLLLWVLLWVPGSTG/DAAQPARRAVRSLMEVQLLES GGDLVKPGGSLKLSCAAS
 25 GFTFSTYGMSWVRQTPDKRLEWVATISNGGGYTYYPDSVKG RFTISRDNAKNTLYLQMSS
 LKSEDTAMYYCARRERYDENGFAYWGRGTLVTVSAGGGGGGGGGSDIVMSQSPSS
 LAVSVGEKITMSCKSSQSLFNSGKQKNYL TWYQQKP GQSPKLLIYWASTRESGV PDRFTG
 SGSGTDFTLTISSVKAEDLAVYYCQNDYSHPLTFGGTKLEIKRADAAPTGGGGGG
 GGGGSMTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSL EDKTERELLESYIDGRIVEGS
 30 DAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTENDLLVRIGK
 HSRTRYERNIEKISMLEKIYIHPRYNWRENLD RDI ALMKLKKPVAFSDYIHPVCLPDRET
 AASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVNLPIVERPVCKDSTRIRITDNM
 FCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRGKYGYFYTHVFR
 LKKWIQKVIDQFGEARGGPEQKLISEEDLNSAVDHHHHHH* (SEQ ID NO:).

Oligo Name	Alternative name	Sequence (5' to 3')	Length	T m	Purpose
31	scHAfwdHindIII	CCCGGAAGCTTAatggagggtgcagctgttg	30	56	Fwd primer for amplifying ScHA for cloning into pSecTag2A using HindIII. A added after HindIII site to maintain reading frame.
32	scHArevXhol	acgcccCTCGAGCagtggtgcagcatcgc	31	56	Reverse primer for amplifying scHA for cloning into pSecTag2A using Xhol. C added prior to Xhol site to maintain reading frame.
33	prethrombinfwdH3	CCCGGAAGCTTAATGaccgccaccagtgagta	33	58	Fwd primer for amplifying prethrombin into pSecTag2A using HindIII. A added to keep frame after HindIII.
B4	prethrombinrevXhol	ggcccCTCGAGCctctccaaactgtcaatg	31	56	Rev primer to clone prethrombin into Xhol site of pSecTag2A. C added to keep frame.
B5	G4ScHAfwd	tttggagagggaggcggtggctggggggcggttgt gcggagggtggagcatggagggtgcagctgttg	72	56	Forward primer to introduce (G4S)3 at 5' end of scHA.
B6	prethrombinG4Srev	cacctccatgtcccaccctccgcccactaccggccccacca gaccaccgcctccctccaaactgtcaatg	73	54	Reverse primer to introduce (G4S)3 tag at the 3' end of prethrombin.
B7	G4Sprethrombinfwd	gcaccaactggaggcggtggctgtggggggcggttgt ggcgagggtggagcATGaccgccaccagtgtgat	75	58	Fwd primer to amplify prethrombin with (G4S)3 at 5' end to create overlap with ScHA.
B8	scHAG4Srev	ggtggcggtCATgctcccacccctccgcccactaccggcccc accagaccaccgcctccagttggtgcagcatcgc	75	56	Rev primer to amplify scHA with (G4S)3 at 3' end to create overlap with G4Sprethrombin.

Substrates tested include: S1, a high affinity epitope (DVPDYA, SEQ ID NO:) recognized by scFv α HA linked to the proteolytic target site (HAE-PT: NH₂-YPYDVPDYA-(SGSGS)₄-GGVR-p-nitroanilide, SEQ ID NO:); and S2, the proteolytic target alone (PT: NH₂-GGVR-p-nitroanilide). Other synthetic peptide substrates were also made with variable binding and cleaving substrate sequences. The Thrombin cleavage sites were chosen based on the teachings of Backes *et al.* (2000) *Nature Biotechnology* 18:187-193. Alternate choices include Ile-Thr-Pro-Arg as the best cleavage site and Ile-Thr-Leu-Arg as a poor target.

Cleavage of the peptide bond between the Arg residue in the substrates and the p-nitroanilide by thrombin activity releases free p-nitroaniline (pNA), which has a yellow color visible by spectrophotometric monitoring at 405 nm.

2.1. Production of model adzyme components: construction, expression, purification and activation.

Components were constructed in the pSecTag2A vector, expressed transiently in mammalian cells and purified from conditioned media as described below.

5 Briefly, mammalian expression vector pSecTag2A (Cat. No. V90020; Invitrogen, Carlsbad, CA) was used as the backbone for all constructs. Upstream of the polylinker is a murine Ig κ-chain V-J2-C signal peptide, and downstream are myc and His₆ tags, a TAA stop codon and a bovine growth hormone polyadenylation signal. Other notable features of the vector are a cytomegalovirus (CMV) promoter to drive expression of the inserted
10 coding sequence and the selectable markers zeocin and ampicillin. cDNAs corresponding to individual components were generated by PCR and cloned directionally into the polylinker to maintain the reading frame using HindIII at the 5' end and XhoI at the 3' end. The address component (scFvαHA) was amplified from a plasmid template containing the coding sequence of scFvαHA (engeneOS, Waltham, MA); prethrombin
15 was amplified from the full length human cDNA clone (ResGen; Cat. no. FL1001), and; the adzyme was created by overlap PCR designed to insert a 15 amino acid linker (GGGGS)₃ (SEQ ID NO:) between the N-terminal prethrombin domain and the C-terminal address domain. All constructs were sequence confirmed.

Transient transfections were carried out with 2 x 10⁶ 293T cells cultured in T175
20 flasks using Fugene (Roche, Indianapolis, IN). Conditioned media from 6 flasks containing the secreted components were harvested when expression reached maximum levels (day 4, 5 or 7-- depending on the construct), clarified and dialyzed against 50mM NaH₂PO₄, 300mM NaCl, 5mM imidazole (buffer A) overnight at 4°C with one change of buffer. For purification, the dialyzed supernatants were incubated for 16h at 4°C with Ni-
25 NTA (Qiagen, CA) resin (0.4ml resin or 0.8 ml of slurry per 200ml of the dialyzed supernatant). The resultant slurry was spun at 600g for 10mins at 4°C and the supernatant was removed and saved as a “flowthrough” sample. Then resin containing bound protein was re-suspended in 10ml buffer A, washed 3 times (10 minutes each at 4°C) and the beads were manually loaded on a 3 ml syringe fitted with 3 mm Whatman filter paper.
30 Three elutions (0.5 – 1ml each) were performed with 50 mM NaH₂PO₄, 300 mM NaCl, 1 M imidazole. Eluted material was dialyzed into phosphate-buffered saline overnight for storage or into Tris-buffered saline + 1mM CaCl₂ buffer for activation with Factor Xa.

As shown in Figure 5, the model adzyme prethrombin-(GGGGS)₃-scFvαHA (SEQ ID NO:) was expressed transiently in 293T cells and conditioned media harvested on day
35 7. The material was processed and purified as described above. Samples representing equivalent portions of each fraction were loaded onto 4-20% polyacrylamide gels and electrophoresed in Tris-glycine-SDS buffer (Novex). Panel A. Western blot—following

electrophoresis the gel was electroblotted to nitrocellulose membranes which were stained with an anti-myc antibody (Invitrogen, Carlsbad, CA). Lane (1) Load; (2) Flow through; (3) Wash 1; (4) Wash 3; (5) Elution 1; (6) Elution 2; (7) Elution 3; (8) Resin boiled in sample loading buffer; (9) Cruz mol. weight marker (Santa Cruz Biotechnology, Santa Cruz, CA). Panel B: Silver-stained gel. Lane (1) starting material; (2) Flow through; (3) Wash 1; (4) Wash 3; (5) molecular weight standard SeeBlue Plus 2; (6) Elution 1; (7) Elution 2; (8) Elution 3; (9) Resin boiled in sample loading buffer; (10) molecular weight standard SeeBlue Plus 2.

An example of an electrophoretic analysis of the model adzyme preparation is shown in Fig. 5. The secreted full-length adzyme was detected with an anti-myc antibody at ~70 kDa (panel A) as expected. Based on the silver-stained gel in this analysis (panel B), the estimated adzyme purity is about 10-20%. The individual address and enzyme components produced in parallel had yields and purity similar to the model adzyme (data not shown).

Purified adzyme components containing enzyme domains were activated using Factor Xa, which cleaves prethrombin at Arg 320 thereby releasing a 49 amino acid light chain from the N-terminus and generating the active thrombin heavy chain of 259 amino acids. In the example shown in Fig. 6, the activation process by Western blot indicated that activation using Factor Xa reduced the molecular weight of the model adzyme by ~6 kDa as expected.

Specifically, purified prethrombin and adzyme components were dialyzed at 4°C overnight against 50 mM Tris pH 8, 0.1M NaCl, 1mM CaCl₂, then protein concentrations were determined. Activation was performed using biotinylated Factor Xa (Roche). Applicant adapted the protocol to account for the estimated purity (~10%) of prethrombin to be activated, thus 1 μ g biotinylated Factor Xa was used per 4.44 μ g total protein for 3h at room temperature. Following activation, the biotinylated Factor Xa was removed using streptavidin beads supplied with the kit, and the activated components were analyzed by Western blot, and used for biochemical studies (see below).

As shown in Figure 6, a preparation of our model adzyme (see Fig. 5) was analyzed by Western blot using the anti-myc antibody before and after activation using Factor Xa: partially purified model adzyme dialyzed into TBS (lane 1); Factor Xa activation reaction (lane 2); activation reaction following removal of Factor Xa (lane 3); streptavidin beads used for removal (lane 4); and Cruz molecular weight standards (lane 5, Santa Cruz Biotechnology, CA).

These examples demonstrate that Applicants have developed reliable production methods for preparing and activating recombinant adzyme components. A typical

preparation from 2 to 6 T175 flasks yielded 2-3 mg of material recombinant protein. These materials were sufficient for all of the analytical studies on biochemical function described below.

2.2. Characterization of adzyme binding and enzymatic activity.

5 To ensure a meaningful comparison of the address domain, enzyme domain and adzyme properties (see Table 1), Applicants completed a series of control experiments designed to: 1) measure binding to a target epitope; 2) compare activities with well-characterized standards and; 3) normalize the proteolytic activity against control substrates.

10 Binding to a target epitope. This experiment assessed the binding characteristics of the adzyme address domain. Applicants assessed binding activity of various components using biotinylated peptides in a sandwich ELISA format. Purified components were dialyzed against PBS, captured on plates coated with anti-myc antibody (mAb 9E10; Sigma), then analyzed by ELISA for binding to biotinylated target peptide (NH₂-
15 YPYDVPDYAGSGDYKAFD, SEQ ID NO:), which contained the high affinity epitope (underline). Bound peptides were quantified using a streptavidin-horseradish peroxidase detection system (Quantablue; Pierce, Rockford, IL). The address domain alone and both the activated and zymogen forms of the adzyme bound comparable levels of the peptide per mole. However the enzyme domain alone failed to bind measurable amounts of the
20 peptide, as expected.

Model adzyme thrombolytic activity. Characterization of the proteolytic activity of the model adzyme helps to determine if either the address domain or the polypeptide linker affected its enzymatic properties.

25 Applicants compared the activities of the model adzyme against a commercially available thrombin preparation (Sigma, St Louis, Mo) on standard fluoro or colorimetric derivatives of the thrombin tripeptide substrate—tosyl-gly-pro-arg-(p-nitroaniline, pNA or amino methyl coumarin AMC, Sigma). Activity was monitored over a 5 min. time course in a cuvette-based fluorometric assay that measured released fluorophore AMC (excitation at 383 nm, emission at 455 nm) in a Perkin Elmer LS55 fluorescence spectrophotometer.
30 Based on a standard curve for free AMC, data obtained in terms of arbitrary fluorescence units vs time were converted into molecules of substrate hydrolyzed per unit time. Reaction velocities were determined over a range of substrate concentrations (0-50 μ M) and K_m values for the tripeptide substrate and were determined using a Line-Weaver-Burke plot. From these studies, it was confirmed that commercially available human
35 thrombin and the activated model adzyme had comparable K_m values for this standard

substrate, 4.2 μ M and 3.9 μ M, respectively, which were in good agreement with literature values.

Second, Applicants determined the specificity constants (K_{cat} / K_m) of thrombin for the substrates S1 and S2. Both substrates contain a thrombin cleavage site, and substrate 5 S1 also includes the high affinity epitope recognized by the anti-HA single chain antibody. A significant difference in thrombin selectivity for either S1 (HAE-PT) or S2 (PT) would require the selection of an alternative control substrate. Applicants measured the proteolytic activity of a standard human thrombin preparation (Sigma) at two different concentrations (0.0033 NIH Units/ml and 0.01NIH Units/ml) against a concentration 10 range between 3 μ M to 25 μ M of fluorometric derivatives of the substrates S1 and S2. Applicants followed the same protocol that was utilized to determine K_m values for the tosyl-GPR-AMC substrate (see above). Values for K_m and V_{max} were calculated from Line-Weaver-Burke plots. Active and total enzyme concentration (E_{total}) was determined from active site titration with D-Phe-Pro-Arg-ChloroMethylKetone (D-FPR-CMK), an 15 irreversible active site inhibitor. These experiments provided the data for a calculation of the absolute enzyme concentration (E_{total}) in 0.0033 NIH Units/ml and 0.01NIH Units/ml of Sigma thrombin proteolytic activity. From these data, Applicants calculated $K_{cat} = V_{max} / E_{total}$, then derived the specificity constants K_{cat} / K_m for the substrates as 8.9 μ M⁻¹sec⁻¹ and 10.3 μ M⁻¹sec⁻¹ for S1 and S2, respectively. The close match of these values indicated 20 that thrombin was acting at either substrate with equivalent specificity and proteolytic activity. Thus, the high affinity epitope has no effect on thrombin activity.

Normalization of proteolytic activity. Applicants needed to quantify the enzymatic activity of the model thrombin-(GGGGS)₃scFv α HA adzyme with reference to the standard human thrombin. The commercially available tripeptide tosyl-GPR-pNA 25 (Sigma), which lacked the high affinity HA binding site was used as substrate. Cleavage of the peptide bond following the Arg residue releases released the chromophore p-nitroaniline (pNA) which is visible at 405 nm. Applicants determined the relative proteolytic activity, in units of thrombin activity per ml, of adzyme components before and after activation with Factor Xa. Factor Xa has no activity on the commercial substrate. 30 Data from one such experiment are shown below in Fig. 7. This allowed normalization based on enzymatic activity of the adzyme preparation and comparison of equivalent activities for adzyme and native commercial thrombin against substrate S1 and S2.

Specifically, as shown in Figure 7, proteolytic activity was determined in a plate format using varying amounts of test components against a commercially available 35 enzyme standard (3.3 nM human alpha thrombin, Sigma) by monitoring the release of pNA absorbance at 405 nm in a Spectramax plate reader (Molecular Devices). Based on a standard curve for free p-nitroaniline, data obtained in terms of absorbance units vs. time

were converted into molecules of substrate hydrolyzed per molecule of enzyme per unit time.

Results of this experiment showed that this model thrombin-(GGGGS)₃scFv α HA adzyme preparation: 1) had no detectable activity prior to activation and; 2) could be normalized against a standard thrombin preparation—in this case 5 μ l/ml of the activated model adzyme was equivalent to 3.3 nM (0.1 NIH U/ml) of thrombin. Active site titration of activated samples with D-FPR-CMK provided independent verification of the normalization. Hence, the proteolytic activity for adzyme preparations were normalized relative to the thrombin standard.

In summary, these control experiments have shown that: 1) the address domain-mediated binding to the high affinity epitope and linkage of an enzyme domain did not interfere with binding activity; 2) the activated model thrombin-(GGGGS)₃scFv α HA adzyme had a K_m value comparable to thrombin for a standard thrombin substrate; 3) thrombin had equivalent specificity for substrates S1 and S2; 4) activation using Factor Xa was required to obtain detectable proteolytic activity; and 5) Applicants were able to normalize the proteolytic activities of adzyme preparations relative to a commercial thrombin standard. This series of control experiments have provided the basis for testing and comparing the adzyme and isolated components on substrates that contained or lacked a high affinity epitope for the address domain.

2.3. Test of Adzyme Function.

Applicants have designed an adzyme, thrombin-(GGGGS)₃scFv α HA, comprising a prethrombin enzyme domain linked by a 15 amino acid polypeptide to a single chain antibody to the HA epitope as the address domain. Thrombin does not bind or cleave the HA epitope but binds its targeted substrate site GGVR (SEQ ID NO:), whether in the context of S1 or S2, with the same affinity. The activated thrombin component of the thrombin-scFv α HA adzyme also binds the GGVR (SEQ ID NO:) of S1 with the same affinity; however the adzyme concept predicts that thrombin coupled to the anti-HA antibody will bind to substrates containing the HA epitope with the typical higher affinities of antibodies and may affect the adzyme reaction rate. It is predicted that the adzyme could have heightened enzymatic activity compared to thrombin.

In the reaction velocity experiments using the substrates S1 and S2 with either thrombin or thrombin-(GGGGS)₃scFv α HA adzyme; it is predicted that: 1) the address domain alone (A) would be inactive (-) on both substrates; 2) the enzyme alone (B) and the adzyme (D) would have equivalent (+) proteolytic activity on substrate S2, the thrombin cleavage site alone; 3) the adzyme would be more active (+++) against substrate S1 (S1 has both the high affinity epitope and the thrombin cleavage site) than against

substrate S2 or the enzyme alone against either substrate (+); and 5) a stoichiometric mixture (C) of the unlinked address domain and enzyme domain would be equivalent to the enzyme domain alone on both substrates (+) (see Table 1) and less than the adzyme.

5 Table 1: Model thrombin-(GGGGS)₃scFv α HA adzyme and components tested against linear peptide substrates

Test component	Substrate	
	S1: HAE-PT	S2:PT
A scFv α HA	-	-
10 B Thrombin	+	+
C A + B	+	+
D Thrombin-(GGGGS) ₃ scFv α HA	+++	+

15 Adzyme activity is driven by the address domain. The proteolytic activities of the model adzyme (D) to thrombin alone (B) were compared on substrates that either contained (on S1) or lacked (on S2) a high affinity epitope for the address domain. Results of this experiment are shown below in Fig. 8.

20 Specifically, in Figure 8, proteolytic release of pNA from substrates S1 and S2 was followed by monitoring absorbance at 405 nm over a two minute time course in a quartz cuvette. Reactions were carried out in thrombin running buffer (50mM Tris-HCl pH 8, 0.1M NaCl, 0.1% polyethylene glycol 8000) containing matched active enzyme concentrations (3.3 nM) as determined in normalization experiments (see Fig. 6). Reactions were initiated with the addition of substrate to 25 μ M.

25 Equivalent activities of the activated thrombin-(GGGGS)₃scFv α HA adzyme and activated commercial thrombin, as determined with the tosyl-GPR-pNA substrate and hence normalized, were tested against S1 and S2. As shown in Figure 8, the reaction rate for both the adzyme and thrombin are the same on the S2 substrate which contains just the thrombin cleavage site as expected, since both the adzyme preparations had been normalized to thrombin. However, as predicted, the model adzyme showed increased 30 activity towards substrate S1 which contained a high affinity epitope in addition to the thrombin cleavage site. There is a 2X increase in reaction rate. The presence of this high affinity epitope on the substrate did not alter the activity of the thrombin alone. In the absence of activation the adzyme did not show detectable proteolytic activity. Thus the enhanced activity of thrombin-(GGGGS)₃scFv α HA adzyme is driven by the presence of

an address domain that directed the enzyme activity to the substrate through binding a high affinity epitope.

Enhanced adzyme activity requires linkage of the address and enzyme domains. To determine if the enhanced adzyme activity requires linkage of the address and enzyme domain on the same polypeptide chain (D), or whether a stoichiometric mixture of the address domain and thrombin (C) perform equally well, Applicants compared these two proteolytic activities on substrate S1, which contained a high affinity epitope for the address domain. Data from this comparison are shown in Fig. 9.

Specifically, in Figure 9, purified address domain scFv α HA was used at 3.3 nM (concentration estimated based on Bradford assay and estimated percent purity from a Coomassie Blue stained gel).

The results of the experiment clearly show that mixing the individual address domain and enzyme thrombin together did not produce the accelerated rate of proteolysis observed with the model adzyme. Interestingly, applicants noted that the mixture was slightly less active than thrombin. Perhaps the unlinked address domain interfered slightly with access to the site of proteolysis by thrombin. Further, the address domain alone showed no detectable activity. Thus linkage of the address and enzyme domains produced a cooperative benefit in proteolytic rate over a stoichiometric mixture of the separated domains.

These studies have supported and validated the predicted adzyme function. The model adzyme design has preserved the functions of the individual components AND produced a cooperative advantage over the stoichiometric mixture. The technology can be equally applied to produce a proteolytic adzyme specific for a clinically relevant target protein, such as TNF- α or IL-1.

25

Example 3. Adzymes that selectively inactivates the bioactivity of TNF- α

This example describes the construction and optimization of adzymes that selectively inactivate the bioactivity of TNF α .

To illustrate, ninety-six (96) adzyme structures for selective catalytic inactivation of TNF α are designed, and at least half are constructed using standard molecular biology techniques. These adzyme structures include combinations of just two enzyme catalytic domains, three address domains and sixteen linkers (including zero linker).

Specifically, the enzymes are: cationic trypsin and MMP7; the addresses are: Sp55, Sp55_2.6, and scFv; the linkers are: linkers with 0, 10, 20, 30, 40, or 50 amino acids (corresponding to repeating units of GGGGS), FcIgG1 (knob mutation), FcIgG1 (hole

mutation), FcIgG2 (knob mutation), FcIgG2 (hole mutation), FcIgG3 (knob mutation), FcIgG3 (hole mutation), FcIgG2-(G₄S)₂ hole mutation, FcIgG2-(G₄S)₄ hole mutation, FcIgG2-(G₄S)₃ hole mutation, FcIgG2-(G₄S)₄ hole mutation. The knob and hole mutations refer to the paired mutations (S354C:T366'W/Y349C:T366S:L368'A:Y407'V) in CH3 domains that had been identified as giving rise to predominantly heterodimeric bispecific antibodies (Merchant et al. *Nature Biotechnology*, 1998, 16, p. 677-681).

Six of the adzymes are then produced, purified, and tested for bioactivity. One or more of these adzymes fulfills the essential criteria of a useful adzyme - preserve the function of individual components and yet produce a cooperative advantage through a polypeptide linkage of the two domains. Specifically, the adzyme(s) inactivates TNF α more effectively than either the address or enzyme alone, or a stoichiometric mixture of the individual domains.

Applicants have constructed, expressed and performed initial characterization of a series of three TNF α -targeted adzyme proteases, consisting of an address domain selected from soluble TNF receptor(s) linked to the catalytic domain of human cationic trypsin. The produced adzymes have been analyzed to quantify binding and proteolytic activities.

3.1. Design of TNF α -specific Adzymes

Three components - the enzyme, the linker and the address domain - work together effectively to produce a catalytic antagonist of TNF α . The enzyme domains are preferably positioned at the N-terminus in this particular example, although in other adzyme designs, the enzyme domain may be C-terminal or even internal to the fusion protein. The enzyme domain here is encoded as a zymogen and has proteolytic activity capable of inactivating TNF α . The address domains will bind TNF α with a high degree of selectivity, and the linkers will produce functional coupling of enzyme and address domains to support cooperativity in catalytic inactivation of TNF α .

a. Selection of the enzyme domains A survey of the literature and public domain databases (MEROPS: <http://www.merops.sanger.ac.uk>) for proteases that are commercially available, expressible as zymogens, and expected to cleave and inactivate TNF α [19-24] led to the selection of twenty candidate proteases, which were then tested for inactivation of TNF α using a TNF cytotoxicity assay. Specifically, TNF activation of functional TNF α receptor TNFR-1 [10, 25] leads to apoptotic cell death, which can be quantified in a cell-based assay [26]. This assay served as the basis to screen the 20 proteases for inactivation of TNF α bioactivity (see below, Fig. 10, Table 2).

Specifically, in Figure 10, L929 mouse connective tissue fibroblasts (ATCC catalog # CCL-1) were used to bioassay cell death induced by TNF α with the CellTiter 96[®] AQueous One Solution Cell Proliferation Assay system from Promega (Madison,

WI). This system provides a colorimetric assay method for determining the number of viable cells. Briefly, for each test protease, a solution of 5 μ M TNF α was digested overnight at 37°C, then bioactivity was determined for eight serial dilutions of the digestion solution. Data are mean values of triplicate determinations at each dilution of 5 TNF α . Examples of TNF α inactivation by trypsin and MMP7 are shown in the figure. Results from the tests on all twenty proteases are summarized in Table 2.

More specifically, 10,000 L929 cells per well were seeded in 96 well plates and cultured in DMEM + 10% FBS overnight in a humidified CO₂ incubator. Actinomycin D was added to all wells (final concentration 1 μ g/mL) and a standard TNF α survival curve 10 was generated by adding human TNF α (RDI, Flanders, NJ) to achieve final concentrations in the wells ranging from 100 pg/ml - 1 μ g/ml. Protease digestion samples of TNF α were similarly diluted and added to parallel rows of wells. Triplicate determinations were done for each dilution of TNF α . Following an overnight incubation in a humidified CO₂ 15 incubator 20 μ l of pre-mixed MTS/PES was added to each well and incubation continued for 2 – 4 hours at 37°C. Metabolically active viable cells reduced the assay reagent (MTS/PES includes a tetrazolium compound) into a formazan product that was soluble in tissue culture media. Absorbance was read at 490 nm in a plate reader after 4 hr to determine the number of viable cells. Complete details of the protocol were provided in Promega Technical Bulletin No. 245.

20 **Table 2: Proteases tested for inactivation of TNF α .**

<u>Proteases that inactivated TNFα</u>	<u>Proteases that did not inactivate TNF</u>		
MT1-MMP (0.86)	Furin	Urokinase	Plasmin
MMP12 (0.65)	Cathepsin G	Enterokinase	Kallikrein5
25 Tryptase (0.62)	HIV Protease	TACE	ADAMTS4
MT2-MMP (0.5)	ADAM10	MMP3	MT5-MMP
ELASTASE (1.45)			
MMP7 (1.22)			
CHYMOTRYPSIN (2.74)			
30 TRYPSIN (2.3)			

TNF α was digested with test proteases in overnight incubations at 37°C, then analyzed for bioactivity as described in Fig. 10. Twelve proteases had no activity against TNF α ; eight had varying levels of activity. Numbers in parentheses reflect log reduction in TNF α

activity calculated at the 50% survival level from inactivation curves similar to the ones shown in Fig. 10.

The survival curve for standard TNF α shows a steep reduction in survival from 100 pg/ml to 10 ng/ml (Fig. 10). In the presence of ~600 pg/ml TNF α reference standard 5 only 10% of the cells survive. This is in contrast to 40% and 70% survival for the equivalent dilution of TNF α digested with MMP7 or trypsin, respectively. The curve for dilutions of trypsin-digested TNF α showed a consistent shift to the right, indicating that the bioactivity of TNF α was reduced more than two logs compared to the TNF α reference standard. Similar studies were done with all of the enzymes listed in Table 2, including 10 MMP7 (Fig. 10). Chymotrypsin was the most active protease against TNF α (2.74 log reduction in TNF α bioactivity). However it also showed significant auto-degradation (not shown), which may be improved by eliminating autocleavage sites in the enzyme (see above). All of these enzymes are candidates for the enzyme component of anti-TNF adzymes.

15 **b. Selection of the address domains.** Address domains will preferably bind TNF α with high specificity, high affinity and will preferably be resistant to proteolytic cleavage by the catalytic domain. Quantitative models of how binding domains cooperate [27] and our experience with the thrombin model adzyme (above) suggested a range of binding affinities suitable for TNF α -specific adzymes. Address domains will be derived from two 20 independent sources that bind TNF α with K_{affinity} values in the nM range -- the TNFR-1 p55 extracellular domain and a single chain antibody to TNF α obtained from Genetastix (San Jose, CA) or generated in house from standard display technologies.

The sp55 address domains were constructed from the full-length human ectodomain of TNFR-1, and its binding to TNF α was characterized. Briefly, human 25 TNFR-1 encoded by the CD120A gene (accession no. NM_001065; IMAGE clone 4131360, Invitrogen, Carlsbad, CA) was used as the template to amplify residues 30-211 in the TNFR-1 ecto-domain (protein accession no. P19438) [28] to construct a full-length sp55. Alternative address domains that might be evaluated may include subdomains of sTNFR-1, such as sp55 Δ 4 (residues 22-167) [29] or sp55 domain 2.6 (residues 41-150) 30 [30]. These subdomains are smaller than the full ecto-domain, and hence might have reduced sensitivity to proteolytic degradation. Since a significant function of the address domain is to bind the target with high affinity, sp55 binding to TNF α was quantified using an indirect ELISA format to validate the presence of a functional address domain (Fig. 11).

35 Briefly, in Figure 11, address domains were expressed transiently in 293T cells and captured on Ni-NTA coated wells. Binding to TNF α was quantified using the S-TagTM system (Novagen, Madison, WI). The S-TagTM system is a protein tagging and

detection system based on the interaction of the 15 amino acid S-Tag peptide with ribonuclease S-protein, which is conjugated with horseradish peroxidase (HRP). Applicants constructed, expressed and purified a human TNF α fusion protein that included an N-terminal S-TagTM, then used this reagent (S-TNF) to quantify binding 5 activity of the sp55 address domains (vertical stripes). Background (control) binding of TNF α that lacks the S-tag is shown in the hatched boxes.

More specifically in Figure 11, conditioned media, harvested and clarified by centrifugation, was diluted 1:10 into buffer (0.5 % BSA Fraction V, 0.05 % Tween-20 in 1 X PBS pH 7.4). Expressed proteins were captured on Ni-NTA coated wells (HisSorb 10 plates, Catalog # 35061, Qiagen) for 1h at room temperature with shaking and washed four times in 0.05 % Tween-20 in 1 X PBS to remove un-bound materials. Binding to TNF α was determined by adding 100 μ L of S-TNF (or control TNF α) at 1 μ g/mL in assay 15 buffer per well, followed by incubation for 1 hr at room temperature with shaking. Plates were washed 4 times in 0.05 % Tween-20 in 1 X PBS, then S-protein HRP (1:2000 in assay buffer at 100 μ L/well, Novagen, Madison, WI) was added and incubated for 1 hr further at room temperature with shaking. A final wash step in 0.05 % Tween-20 in 1 X PBS was done 4 times to remove the S-protein-HRP, then 100 μ L HRP substrate 20 tetramethylbenzidine (TMB; Sigma T 4444, St. Louis, MO) was added per well. Color was allowed to develop for 5 – 45 minutes, then absorbance read at 370 nm in a Spectromax plate reader (Molecular Devices).

Figure 11 shows a three-fold elevation in S-TNF binding (vertical stripes) compared to non-specific binding in control samples (control: S-TNF; conditioned media from mock transfected cells). Binding appeared to saturate at 6-12 % of conditioned media in the assay, and the dilution series showed that binding was proportional to the amount of 25 expressed sp55 added. TNF α that lacked the S-tag was not detected with S-protein-HRP (hatched boxes). These results showed that the expressed sp55 address domain can bind TNF α .

As an alternative to using sp55 as an address domain, one anti-TNF α scFV antibody will be selected from a set of eighteen that were obtained from Genetastix (San 30 Jose, CA). These scFV antibodies were identified by Genetastix through use of their proprietary technology (www.genetastix.com) as having TNF α binding activity. Briefly, a human scFv cDNA library was produced from polyA RNA of human spleen, lymph nodes and peripheral blood lymphocytes through amplification of V_H and V_L sequences that were assembled in frame with a GAL4 activation domain (AD). The 18 scFvs were 35 identified as binding human TNF α -lexA DNA binding domain when co-expressed intracellularly in yeast. The Genetastix scFvs expression vectors were obtained in the form of bacterial periplasmic expression vector pET25B (Novagen, Madison, WI). Standard

recombinant DNA methods were used to subclone the scFv coding sequences into the pSecTag2A vector. The constructs were then sequenced to verify the structures. These scFv anti-TNF α antibodies is expressed and purified as described for the previous adzyme components, then analyzed for binding to TNF α . An indirect ELISA is used for TNF α based on the S-TagTM system (see above, Fig. 11) to identify one of the 18 scFvs that shows high affinity binding to TNF α for use as an address domain. The selection of a specific scFv is based on a ranking of their relative binding strengths of the various structures. Further quantitative determinations of binding affinities for TNF α may be included once a prototype adzyme has been identified.

c. Selection of the linkers A significant function of a linker is to connect a catalytic domain and an address domain in a fusion protein to yield cooperative function. The linker lengths can be experimentally investigated. Applicants found that a triple-repeat (or “3-repeat”) of the flexible pentapeptide GGGGS enabled a functional linkage of the enzyme and address domains. This linker can range in length from 23.60 Å in α -helical conformation to 50.72 Å as an extended chain. The initial adzymes have been built with 0 amino acids as linker (to minimize intramolecular digestion, 3 amino acids (AAA) and 20 amino acids (4 repeats of G₄S). Additional linker lengths under construction are 2 repeats of G₄S (10 amino acids), 6 repeats of G₄S (30 amino acids), 8 repeats of G₄S (40 amino acids) and 10 repeats of G₄S (50 amino acids).

	Extended form	α -helical form
(GGGGS) ₂ (SEQ ID NO:)	32.02 Å	15.96 Å
(GGGGS) ₄ (SEQ ID NO:)	64.04 Å	31.92 Å
(GGGGS) ₆ (SEQ ID NO:)	96.06 Å	47.88 Å
(GGGGS) ₈ (SEQ ID NO:)	128.08 Å	63.84 Å
(GGGGS) ₁₀ (SEQ ID NO:)	160.1 Å	79.8 Å

d. Adzyme Structures There are currently no reports in the literature for heterologous expression of trypsin in mammalian cells. Thus, it might be prudent to express the zymogen form that could be activated by enterokinase. Trypsinogen was thus cloned to be in frame with the leader sequence and N-terminal to the linker and address domain and in frame with the tandem myc-His₆ tags at the C-terminus.

N-murine Ig κ leader sequence-trypsinogen-0aa-sp55-myc-His6	tgn-0-sp55
N-murine Ig κ leader sequence-trypsinogen-AAA-sp55-myc-His6	tgn-3-sp55
N-murine Ig κ leader sequence-(G ₄ S) ₄ -trypsinogen-20aa-sp55-myc-His6	tgn-20-sp55

e. Self- or auto-proteolysis of the adzyme by the catalytic domain For

those adzymes that employ a protease as a catalytic domain, it will generally be preferable to generate an adzyme that is resistant to self- or auto-proteolysis, which may affect the integrity and activity of the address domain, the catalytic domain or the linker.

5 Accordingly, potential address domains may be tested for their susceptibility to protease attack. If the set of potential proteases and address domains is sufficiently large then there are likely to be combinations in which the protease attacks the target but not the address domain. Thus it may be advantageous to generate a relatively large library of potential adzymes, and screen among these candidate adzymes for the optimal
10 combination of address domain, linker, and enzyme domain. Single chain antibodies, due to their beta sheet structure, may be more resistant by nature to protease action. Once selected, the linkage arrangement of the address and enzyme domain can be used to minimize auto-proteolysis. Increasing the rigidity of the linker, limiting the degrees of freedom of each adzyme domain or applying a linker domain that orients the address and
15 enzyme toward target but away from each other is possible. Additionally, address domains may be designed on the basis of evolved protein scaffolds, such as that of the single chain antibody, and such scaffolds may be re-engineered at vulnerable conserved positions to remove protease sensitive sites by mutagenesis. Alternatively or in combination, protease sites within an address or linker region may be selected against by using, for example,
20 display evolutionary techniques.

Additionally, certain enzymes can undergo autolysis within the enzyme domain. For example, trypsin undergoes autolysis at R122. The autolysis site can be mutated to prevent autolysis (for example, R122H is a mutation in the human trypsin I gene which leads to inactivation of the autolysis pathway and thus overexpression of active trypsin
25 leading to hereditary pancreatitis [31]). Protease domains can be expressed as zymogens to minimize the level of auto-proteolysis and maintain the adzyme in an inactive form. Adzymes will be activated immediately prior to application, or adzymes could be stored with an inhibitor that blocks the catalytic site that can be diluted away to render the adzyme active.

30 **3.2. Production of adzymes**

Recombinant adzymes may be generated using the pSecTag2A vector system or any other equivalently functional system for transient expression in mammalian cells. The adzymes can be purified, for example, from conditioned media by binding the His₆ tags to a nickel resin. Additional technical details are described in example section 3.1.a., above.
35 All adzyme constructs generated in this section have been sequence confirmed.

a. Adzyme construction In this particular example, the enzyme domain is a zymogen of human trypsin, although similar constructs using human MMP7 are also obtained. Human trypsin I (cationic trypsin) is encoded by PRSS1 gene (Accession #NM_002769). The catalytic domain and part of the propeptide of trypsinogen I is 5 amplified (residues 16-247) from IMAGE clones 3950350 and 394971 (Invitrogen, Carlsbad, CA) and cloned into pSecTag2A. Human MMP7 (accession no. BC003635) residues 18-267, encoding the activation peptide (18-94) and catalytic domain (95-267) is amplified from IMAGE clone 3545760 (Open Biosystems, Huntsville, AL) and cloned into pSecTag2A (data not shown).

10 Also in this particular example, the address domain used is sp55, although other address domains such as scFV anti-TNF α antibody may also be used (both selected from a set of 18 potential candidates). All of these constructs when completed are verified by DNA sequencing.

The amino acid sequence of trypsinogen (tgn) is:

15 METDTLLLWVLLWVPGSTG↓DIAPFDDDDKIVGGYNCEENSVPYQVSLNSGYHFCGGSL
INEQWVVSAGHCYKSRIQVRLGEHNIEVLEGNEQFINAAKIIIRHPQYDRKTLNNDIMLIK
LSSRAVINARVSTISLPTAPPATGTKLISGWGNTASSGADYPDELQCLDAPVLSQAKCE
ASYPGKITSNMFCVGFLEGGKDSCQGDGGPVVCNGQLQGVVSWGDGCAQKNKPGVYTKV
YNYVKWIKNTIAANSTRGGPEQKLISEEDLNSAVDHBBBBB* (SEQ ID NO:)

20 The amino acid sequence of trypsinogen-0aa-sp55 (tgn-0-sp55) as expressed from pSecTag2A is:

METDTLLLWVLLWVPGSTG↓DIAPFDDDDKIVGGYNCEENSVPYQVSLNSGYHFCGGSL
INEQWVVSAGHCYKSRIQVRLGEHNIEVLEGNEQFINAAKIIIRHPQYDRKTLNNDIMLIK
LSSRAVINARVSTISLPTAPPATGTKLISGWGNTASSGADYPDELQCLDAPVLSQAKCE
25 ASYPGKITSNMFCVGFLEGGKDSCQGDGGPVVCNGQLQGVVSWGDGCAQKNKPGVYTKV
YNYVKWIKNTIAANSLVPHLGDRKDSVCPQGKYIHPQNNNSICCTKCHKGTLYND
PGQDTDCRECESGSFTASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTVCGRKNQYRH
YWSHENLFQCFNCSLCLNGTVHLSCQEKKQNTVCTCHAGFFLRENECVSCSNCKSLECTKL
CLPQIENVKGTEDSGTTRGGPEQKLISEEDLNSAVDHBBBBB* (SEQ ID NO:)

30 The amino acid sequence of trypsinogen-3aa-sp55 (tgn-3-sp55) as expressed from pSecTag2A is:

METDTLLLWVLLWVPGSTG↓DIAPFDDDDKIVGGYNCEENSVPYQVSLNSGYHFCGGSL
INEQWVVSAGHCYKSRIQVRLGEHNIEVLEGNEQFINAAKIIIRHPQYDRKTLNNDIMLIK
LSSRAVINARVSTISLPTAPPATGTKLISGWGNTASSGADYPDELQCLDAPVLSQAKCE
35 ASYPGKITSNMFCVGFLEGGKDSCQGDGGPVVCNGQLQGVVSWGDGCAQKNKPGVYTKV
YNYVKWIKNTIAANSAAALVPHLGDRKDSVCPQGKYIHPQNNNSICCTKCHKGTLYND

CPGPGQDTDCRECESGSFTASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTVCGCRKNQ
YRHYSSENLFQCFNCSLCLNGTVHLSCQEKKQNTVCTCHAGFFLRENECVSCSNCKSLEC
TKLCLPQIENVKGTEDSGTTRGGPEQKLISEEDLNSAVDHHHHH* (SEQ ID NO:)

5 The amino acid sequence of trypsinogen-20aa-sp55 (tgn-20-sp55) as expressed
from pSecTag2A is:

METDTLLLWVLLWVPGSTG↓DIAPFDDDKIVGGYNCEENSPYQVSLNSGYHFCGGSL
INEQWVVSAGHCYKSRIQVRLGEHNIEVLEGNEQFINAAKIIRHPQYDRKTLNNNDIMLIK
LSSRAVINARVSTISLPTAPPATGTKLISGWGNTASSGADYPDELQCLDAPVLSQAKCE
ASYPGKITSNMFCVGFLEGGKDSCQGDGGPVVCNGQLQGVVSWGDGCAQKNKPGVYTKV
10 YNYVKWIKNNTIAANSAAAGGGGGGGGGGGGGGGGGSRLVPHLGDRKDSVCPOGKYI
HPQNNSICCTKCHKGTYLYNDCPGPGQDTDCRECESGSFTASENHLRHCLSCSKCRKEMG
QVEISSCTVDRDTVCGCRKNQYRHYSSENLFQCFNCSLCLNGTVHLSCQEKKQNTVCTCHA
GFFLRENECVSCSNCKSLECTKLCLPQIENVKGTEDSGTTRGGPEQKLISEEDLNSAVD
HHHHH* (SEQ ID NO:)

15 In addition, sp55 was also cloned into pSecTag in similar fashion. The amino acid
sequence of sp55 as expressed from pSecTag2A is:

METDTLLLWVLLWVPGSTG↓DAAQPARRAVRSLVPHLGDRKDSVCPOGKYIHPQNNS
ICCTKCHKGTYLYNDCPGPGQDTDCRECESGSFTASENHLRHCLSCSKCRKEMGQVEISS
CTVDRDTVCGCRKNQYRHYSSENLFQCFNCSLCLNGTVHLSCQEKKQNTVCTCHAGFFLRE
20 NECVSCSNCKSLECTKLCLPQIENVKGTEDSGTTRGGPEQKLISEEDLNSAVDHHHHH
* (SEQ ID NO:)

25 The adzymes are constructed from the individual enzyme and address domains
connected via the three different linkers using an overlap PCR method; as was done for
the model thrombin adzyme (see previous examples). The constructs have been verified
by DNA sequencing.

b. adzyme Expression Transient expression in 293T cells are carried out in
T175 flasks. Benzamidine, a small molecule competitive inhibitor of trypsin activity with
a K_i of 18 μ M, is added to a final concentration of 1 mM to stabilize trypsinogen and
trypsinogen adzyme expression. Conditioned media is harvested at 24 hour intervals, or
30 allowed to accumulate upto 72 hrs.

35 An example of representative expression as analyzed by Western blotting with
anti-myc antibody is shown below in Figure 12. The increased intensity of anti-myc signal
in lane 2 demonstrates the stabilizing effect of the small molecule trypsin inhibitor,
benzamidine. Adzymes containing 0, 3 and 20 amino acids as the linker are expressed at
similar levels (lanes 3-5) and are also stabilized by the presence of benzamidine. The myc
reactive band is of the expected size of approximately 51 kDa. Finally, sp55 is also
-158-

produced in comparable amounts to trypsinogen and expression is not affected by the presence of benzamidine.

In brief, equal volumes of conditioned media after accumulation of secreted protein for 24 hours post transfection were electrophoresed on 4-20% TGS (Novex) gels, 5 electroblotted to nitrocellulose membrane and stained with anti-myc antibody.

c. adzyme Purification In one embodiment, His₆-nickel methodology is the preferred method of purification. This method is rapid, simple and available in either column format for large batches or in a 96 well format for parallel assay testing. However, many other alternative methods of purification can be used. For example, one option could 10 be benzamidine sepharose column chromatography (Pharmacia, NJ), which incorporates a protease inhibitor into the resin. Standard characterization of purified proteins will include Western analysis with anti-myc antibodies and silver-stained gels to assess purity and recovery of the adzyme preparations. The produced adzymes may be further analyzed to quantify binding and proteolytic activities.

d. Recombinant protein determination. In one embodiment, adzymes are constructed with a carboxy terminal tandem myc-His₆ tags. An ELISA method is developed to detect the c-myc tag for quantitating recombinant proteins bound to Ni-NTA on surfaces. This helps to normalize the amount of adzyme used in any biochemical analyses and bioassays.

20 The following method can be used to quantify heterologously expressed proteins containing tandem myc and His₆ tags using a sandwich ELISA approach. In summary, diluted conditioned medium containing recombinant proteins are incubated in wells of Ni-NTA coated HisSorb microtiter plates (catalog no. 35061 Qiagen, Valencia, CA) and then reacted with anti-myc-HRP (catalog no. R951-25, Invitrogen, Carlsbad, CA). Bound 25 recombinant material is then detected by incubation with a chromogenic substrate. A standard curve was established in parallel with purified recombinant sp55 (independently quantified using a commercially available ELISA (catalog no. QIA98, Oncogene Research Products, Madison, WI) containing tandem myc His₆ tag allowing quantification of captured material. Conditioned media from mock transfected cells served as a negative 30 control.

In brief, conditioned media from transfections was diluted directly into assay buffer (0.5 % BSA Fraction V, 0.05 % Tween-20 in 1 X PBS pH 7.4) to a final volume of 100 μ L / well. Known amounts of the standard, sp55, was serially diluted in similar fashion in assay buffer. Binding of the His₆ tag of the recombinant proteins to the Ni-NTA 35 surface was allowed to proceed at room temperature for half an hour with slow shaking. Anti-myc-HRP was then added to all wells at a final dilution of 1:1500 such that the final

volume in the wells was 150 μ L. Binding was allowed to proceed for two hours at room temperature with slow shaking. Following the binding of anti-myc to the His₆-captured proteins, the wells were washed 6 times with wash buffer (PBS containing 0.05% Tween 20) and blotted dry. Then, the chromogenic substrate TMB (Sigma Catalog #T-4444) was 5 added to each of the wells to a final volume of 100 μ L. The increase in absorbance at 370 nm was monitored by a microtiter plate UV/VIS reader (Molecular Devices SPECTRAmax 384 Plus). All samples are assayed in duplicate.

Using this method of quantification, average yield of trypsinogen adzymes were estimated at 1 μ g/mL.

10 **3.3. Biochemical analysis of TNF α -specific adzymes.**

This section describes methods to quantify binding and proteolytic activities of adzymes made against TNF α .

15 **a. Adzyme binding** Adzyme address domain functionality, e.g., binding to TNF α , is quantified by the TNF α binding assay described above and by the ability of the address domain to independently inhibit TNF α activity in the L929 assay prior to activation. Adzymes with the ecto-domain of p55 have been tested with recombinant p55 as parallel controls. The adzyme proteins exhibit specific binding characteristics (amount of TNF bound per mole of protein) and binding affinities similar to the address domains alone.

20 Alternatively, the following method can be used to establish the presence of a functional TNF α address domain within recombinantly expressed Adzymes by means of a modified ELISA-like assay. In summary, wells of a microtiter plate are precoated with TNF α and then reacted with diluted conditioned medium containing candidate adzymes. The detection of adzymes that express a functional, high-affinity TNF α binding domain 25 (and hence, are retained on the microtiter plate following washing of the microtiter plate) is effected by subsequent capture of a chromogenic enzyme conjugate that is specific for a detection tag within the adzyme and control constructs, followed by addition of a chromogenic substrate. The inclusion of control wells in which the capture and detection of adzymes is not expected to be present, and parallel evaluation of similar constructs that 30 do not encode the detection tag or TNF α -specific address domain provides evidence that the expressed adzymes contain a functional TNF α -specific address domain that binds specifically to the immobilized TNF α . Typically, one or more reversible or irreversible protease inhibitors may also be included in assay buffers to prevent autocatalysis or proteolytic activity of the adzyme, thereby restricting degradation of the adzyme and/or 35 assay reagents.

In an illustrative example, an assay for human trypsinogen-containing adzymes specific for TNF α is described. Wells of a microtiter plate (Nunc-ImmunoModule, MaxiSorp Surface) were precoated with 100 μ L/well of recombinant human TNF α (RDI Catalog #RDI-301X) at a concentration of 1 μ g/mL diluted into phosphate-buffered saline (PBS), pH 7.2. An equal number of wells received 100 μ L of PBS alone. The microtiter plate was then incubated at 4°C overnight (approximately 16 hours). The liquid from the wells was removed and the microtiter plate was washed twice with wash buffer (PBS containing 0.05% Tween 20). All wells of the microtiter plate were blocked by addition of 200 μ L/well of block/diluent buffer (PBS containing 0.05% Tween 20 and 0.05% bovine 5 serum albumin [BSA; Fraction V, RIA & ELISA-grade, Calbiochem Catalog #125593]). The microtiter plate was incubated at room temperature for 2 hours with slow shaking. The block solution was removed from the wells and 100 μ L/well of conditioned medium from transient adzyme transfections in 293T cells diluted 1:10 into block/diluent buffer containing 1 mM benzamidine (Sigma Catalog #B-6506) was added to TNF α -containing 10 wells and to wells that do not contain TNF α . The plate was incubated for 1 hour at room 15 temperature with slow shaking. Following removal of liquid, the wells of the microtiter plate were washed four times with wash buffer. Wells then received anti-myc antibody conjugated to horseradish peroxidase (anti-myc-HRP; Invitrogen Catalog #46-0709) diluted 1:2000 in block/diluent buffer containing 1 mM benzamidine. The microtiter plate 20 was incubated for 1 hour at room temperature with slow shaking. Following removal of liquid and washing as in the above, 100 μ L/well of substrate (TMB, Sigma Catalog #T-4444) was added to each of the wells. The increase in absorbance at 370 nm was monitored by a microtiter plate UV/VIS reader (Molecular Devices SPECTRAmax 384 Plus).

25 The results shown in Figure 15 are from a representative experiment and reveal the mean OD and standard deviation for samples and experimental controls evaluated in triplicate on a single microtiter plate. As illustrated, only Adzyme constructs and a control protein that are able to bind to immobilized TNF α and that also contain the c-myc antibody sequence generate a positive signal above background at 370 nm. Included in 30 this category is the trypsinogen-p55FL adzymes containing no linker (Tgn-0-p55FL) as well as those containing linkers of 3 amino acids (Tgn-3-p55FL) and 20 amino acids (Tgn-20-p55FL). As expected, a positive control sample containing the p55FL-myc-his construct (p55L) also binds and produces a positive signal above background. A construct 35 consisting of Trypsinogen-myc-his did not bind above background presumably due to significantly lower affinity for TNF α in the absence of a high affinity address domain (p55FL). Similarly, the conditioned medium from a transfection vector control (pSECTAG2A) did not demonstrate a positive signal above background. Background,

non-specific binding of the anti-myc antibody to wells that contain or do not contain TNF α was negligible as revealed by "Buffer Control."

It should be understood that, although the present illustrative example detects binding to TNF α , this assay format is generic to any of the target molecules. One 5 advantage of the assay described here is the inclusion of a reversible protease inhibitor in cell culture, during the expression of the adzymes and in assay buffers, to prevent inadvertent autoactivation / proteolytic breakdown of the adzyme and/or activation by endogenous proteases. This can be used as a general solution to expression of zymogens and/or active proteases. Importantly, one or more protease inhibitors can also be included 10 in assay buffers for the purposes of protein quantitation and confirmation of target specificity (as shown in this example). This general approach alleviates concerns regarding handling of autocatalytically-prone and/or active adzymes.

b. adzyme activation. Activation of the adzyme enzyme domain is carried out by incubating at 37°C following the manufacturer's recommendations. The progress may be 15 monitored by SDS-PAGE and Western blotting (e.g., see Fig. 7). Enterokinase (Novagen, Madison, WI) was used for activation of trypsinogen. For an in vitro TNF α assay, enterokinase need not be removed post activation, since it has been determined that enterokinase has no proteolytic activity towards TNF α and no effect in the L929 bioassay.

Applicants have developed a method for carrying out on-plate capture, activation 20 and proteolytic assays for recombinantly produced enzymes or adzymes containing a His₆ tag. In summary, diluted conditioned medium containing recombinant proteins are incubated in wells of Ni-NTA coated HisSorb microtiter plates, then treated with enterokinase and presented with suitable peptide substrates. The peptide substrate used in the current example is tosyl-GPR-AMC (Catalog no. 444228, Sigma, St. Louis, MO) 25 which has been described previously. Proteolysis of the peptide bond between the Arg residue in the substrate and the AMC leads to the release of free fluorescent AMC (excitation 383nm, emission 455 nm). Inclusion of conditioned media from sp55 or vector transfections provide important negative controls for the levels of adventitious protease expression in transfected cells and substrate background and hydrolysis under assay 30 conditions.

In brief, conditioned medium containing recombinant proteins was diluted directly 35 into assay buffer (0.5 % BSA Fraction V, 0.05 % Tween-20 in 1 X PBS pH 7.4) to a final volume of 100 μ L / well. Typically, 5-25% of conditioned medium per well yielded good linear response. Binding of the His₆ tag of the recombinant proteins to the Ni-NTA surface was allowed to proceed at room temperature for two hours with slow shaking. Following the binding of anti-myc to the His₆-captured proteins, the wells were washed 6 times with wash buffer (PBS containing 0.05% Tween 20 or PBST, 200 μ L per wash) and blotted

dry. This step also accomplishes the removal of benzamidine which would otherwise interfere with subsequent steps in the assay. Activation of zymogen is achieved by the addition of 1 U of enterokinase (EK, Catalog no. 69066, Novagen, Madison, WI) in a final volume of 100 μ L of PBST. Activation was carried out for 1 hour at 37°C. A parallel set of 5 samples received no enterokinase but underwent similar incubation. Finally, the wells were washed 6 times with PBST prior to the addition of trypsin digestion buffer (100 mM Tris pH 8, 5 mM CaCl₂) containing 10 μ M tosyl-GPR-AMC. Proteolytic activity was followed by monitoring the fluorescence at 455 nm following excitation at 383 nm using a Gemini EM microplate spectrofluorometer (Molecular Devices, CA).

10 Figure 13 shows a snapshot of representative experiments where the fluorescence detected at the end of 2 hours of incubation is compared for the different recombinant proteins. There is negligible proteolytic activity in the absence of enterokinase activation of captured recombinant trypsinogen and trypsinogen adzymes (striped bars). In this assay 15 format, conditioned media from sp55 and vector transfections do not contain detectable amounts of proteases which could give rise to artifacts as evidenced by the background levels of fluorescence. However, following enterokinase treatment trypsinogen and the adzymes (tgn-0-p55, tgn-20-p55, tgn-3-p55) exhibit significant amounts of proteolysis as evidenced by the 4-7 fold higher levels of fluorescence as compared to the no activation controls.

20 On the other hand, MMP7 is activated with organomercurial compound p-aminophenylmercuric acetate (APMA, Calbiochem 164610) and APMA can be (and will be) removed according to instructions provided by the supplier.

25 *c. Proteolysis assay using synthetic peptide substrates.* The adzyme catalytic domain's proteolytic activity post activation was determined with synthetic linear peptide substrates as described above. Proteolytic activity was determined in a plate format as described above using varying amounts of adzymes and substrates against a commercially 30 available enzyme standard. Substrate (tosyl-GPR-AMC) cleavage was monitored by the release of the fluorogen AMC. Data from a representative experiment is shown below in Figure 14, where conditioned media from transfections (24 hours post transfection) were bound to Ni-NTA plates, activated on plate, and assayed for proteolytic activity with a fixed concentration (10 μ M) of substrate (tosyl-GPR-AMC).

The assay for MMP7 proteolytic activity may use a fluorogenic substrate (dinitrophenyl-RPLALWRS; Calbiochem Cat. No. 444228).

35 Data from the biochemical analyses of adzymes can be used to normalize the concentration and proteolytic activity of adzyme preparations for assessment of bioactivity.

3.4. Testing adzymes for bioactivity.

To determine the bioactivity and selectivity of adzymes against TNF α , adzymes will be used to inactivate TNF α and bioactivity will be quantified in a TNF α -induced L929 cell death bioassay. Selectivity can be determined by comparing adzyme 5 inactivation of TNF α alone and mixed with human serum albumin (HSA). The soluble TNF α receptor p55 may serve as a stoichiometric blocker of TNF α .

The L929 bioassay is a stringent test for biologically active TNF α . Assays are done using preparations of all twelve adzymes, plus the four individual address and enzyme domains singly and in combinations. In each case, normalized quantities of 10 purified adzymes (as assessed above) will be mixed with TNF α alone or TNF α plus HSA and incubated at 37°C for 4 hr and overnight. The overnight digestion represents the standard protocol. Preliminary results may be followed by time course studies as needed. Residual activity may be assayed by the L929 bioassay.

It is expected that the enzyme domain alone will inactivate TNF α and shift the 15 survival curve to the right by 2 logs for the trypsin domain (Fig. 10, Table 2). In contrast, an effective adzyme will be expected to effect a larger rightward shift and/or do so at much lower concentrations or more rapidly (e.g., 4hr as opposed to overnight). A 10-fold enhancement in the inactivation of TNF α (a shift in the inactivation curve one log unit to the right) is a convincing demonstration of the potential of adzymes as catalytic protein 20 antagonists. Furthermore address domains alone should only minimally inactivate (by stoichiometric binding) TNF α , and mixtures of the address and enzyme domains should fare no better than the enzyme domains alone. The bioactivity of all adzymes may be ranked at matched molar concentrations, and the selectivity of those that inactivate TNF α can be analyzed.

25 Selectivity can be demonstrated in a mixing experiment (e.g., see Davis et al, 2003) -- adzymes will be used to digest TNF α alone and TNF α plus HSA, and the digests will be analyzed in the bioassay (see Fig. 10). Human serum albumin is the most logical choice for this mixing experiment. It is present in serum at high concentration and most likely to pose a challenge to the selective action of a TNF α -specific adzyme. Initial tests 30 of all adzymes can be done using a 10-fold molar excess of HSA over TNF α . Adzymes that are not selective are expected to show reduced bioactivity in the presence of the competing substrate. However selective adzymes should retain full bioactivity in the presence of excess HSA. Adzymes that pass this first test can be compared further by repeating the analysis in the presence of a higher concentration of HSA in the mixture. 35 Once again, adzymes can be ranked according to how much bioactivity is retained in the presence of HSA. Several rounds of competition should reveal structures that are both bioactive and selective catalytic antagonists of TNF α .

Example 4. Using Kinetic Modeling to Study the Adzyme System

Kinetic theory was applied to the reaction network of a direct adzyme, shown in (Eq-2), to develop a mathematical model of adzyme performance. Such a model can be 5 used to design and optimize the parameters of an adzyme, and to predict important functional properties of the adzyme such as the amount of substrate that it can inactivate.

In this example, a simulation of the total amount of inactivation of a substrate by three different drugs was performed with the objective of comparing the potency of the adzyme to the potency of its constituent domains individually. The three drugs were:

- 10 1. An address with $k_{on} = 10^6 \text{ M}^{-1} \text{s}^{-1}$ and $k_{off} = 10^{-3} \text{ s}^{-1}$ ($K_D = 1 \text{ nM}$)
2. An enzyme with $k_{on} = 10^3 \text{ M}^{-1} \text{s}^{-1}$, $k_{off} = 10^{-3} \text{ s}^{-1}$, and $k_{cat} = 1 \text{ s}^{-1}$ ($K_m = 10^{-3} \text{ M}$)
3. A direct adzyme with the properties of the address and enzyme above, and $[S]_{eff} = 10^{-6} \text{ M}$.

The initial concentrations of the drugs were 50 pM and the initial concentration of 15 target substrate was 5 pM. The total amount of substrate inactivated by each of these three drugs is shown in Figure 16.

Specifically, Figure 16 illustrates kinetic model results comparing the performance of an adzyme, an address, and an enzyme. The results indicate that the adzyme inactivates significantly more substrate than either the address or the enzyme alone.

20 For example, the enzyme is too weak by itself to inactivate a substrate at such low (pM) concentrations. Consequently, the total amount of substrate inactivation by the enzyme is not significantly different from zero. The address rapidly binds and inactivates some substrate, but because the concentration of substrate is much less than the K_D of the address, binding quickly becomes equilibrium limited and the address can only inactivate 25 about 0.25 pM, or 5 %, of the total substrate. The adzyme can rapidly bind and inactivate substrate like the address, but it can also convert the adzyme-substrate complex into product, removing the equilibrium limitation.

This example shows that the model adzyme combines address and enzyme 30 functionality in a synergistic way. Its potency is significantly higher than the sum of the address and the enzyme alone.

LITERATURE CITED

1. YG Kim, J.C., S Chandrasegaran, *Hybrid restriction enzymes-zinc finger fusions to Fok I cleavage domain*. Proc Natl Acad Sci U S A, 1996. 93: p. 1156-1160.

2. Zhou, P., Bogacki R., McReynolds L., Howley PM, *Harnessing the Ubiquitination Machinery to Target the Degradation of Specific Cellular Proteins*. Molecular Cell, 2000. 6: p. 751-756.

3. Bode, C., Runge M.S., Branscomb E.E., Newell J.B., Matsueda G.R. and Haber E. *Anitbody-directed Fibrinolysis*. The Journal of Biological Chemistry, 1989. 264(January 15): p. 944-948.

4. Runge, M.S.B., Christoph; Matsueda, Gary R.; Haber, Edgar, *Antibody-Enhanced Thrombolysis: Targeting of Tissue Plasminogen Activator in vivo*. Proceedings of the National Academy of Sciences of the United States of America, 1987. 84(21): p. 7659-7662.

5. Davis BG, S., RF, Hodgspm DRW, Ullman A, Khumtaveeporn K, Estell DA, Sanford K, Bott RR, Jones JB, *Selective protein degradation by ligand-targeted enzymes: towards the creation of catalytic antagonists*. ChemBioChem, 2003. 4: p. 531-540.

6. Zhou, H.-X., *Quantitative Account of the Enhanced Affinity of Two Linked scFvs Specific for Different Epitopes on the Same Antigen*. J. Mol. Biol. 2003: p. 1-8.

7. Choy EH, P.G., *Cytokine pathways and joint inflammation in rheumatoid arthritis*. N Engl J Med., 2001. 344(12): p. 907-16.

8. Feldmann M, M.R., *Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?* Annu Rev Immunol., 2001. 19: p. 163-96.

9. Feldman, M., *Development of anti-TNF therapy for rheumatoid arthritis*. Nature Publishing Group, 2002. 2.

10. Idriss, H.T.N., James H., *TNF α and the TNF Receptor Superfamily: Structure-Function Relationship(s)*. Microscopy Research and Technique, 2000: p. 184-195.

11. Bodmer, J.-L., Schneider P., Tschopp J., *The molecular architecture of the TNF superfamily*. Trends in Biochemical Sciences, 2002. 27(1): p. 19-.

12. Pennica D, K.W., Fendly BM, Shire SJ, Raab HE, Borchardt PE, Lewis M, Goeddel DV., *Characterization of a recombinant extracellular domain of the type 1 tumor necrosis factor receptor: evidence for tumor necrosis factor-alpha induced receptor aggregation*. Biochemistry, 1992. 31(4): p. 1134-41.

13. Nophar, Y., Brakebusch C., Englemann H., Zwang R., Aderka D., Holtzman H., Wallach D. *Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor*. EMBO J, 1990. 9(10): p. 3269-78.

14. Maini RN, Z.N., *Rheumatoid arthritis*, in *Rheumatology*, D.P. Klippe JH, Editor. 1994, Mosby: London. p. 3.1-3.14.8.

15. Warris, A., A. Bjorneklett, and P. Gaustad, *Invasive pulmonary aspergillosis associated with infliximab therapy*. N Engl J Med, 2001. **344**(14): p. 1099-100.

5 16. Keane, J., Gershon S., Wise R.P., mirabilke-Levens E., Kasznica J., Schwieterman W.D., Siegel J.N., Braun M.M. *Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent*. N Engl J Med, 2001. **345**(15): p. 1098-104.

10 17. Williams, R.O., M. Feldmann, and R.N. Maini, *Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis*. Proc Natl Acad Sci U S A, 1992. **89**(20): p. 9784-8.

18. Churchill ME, S.E., Pinilla C, Appel JR, Houghten RA, Kono DH, Balderas RS, Fieser GG, Schulze-Gahmen U, Wilson IA., *Crystal structure of a peptide complex of anti-influenza peptide antibody Fab 26/9. Comparison of two different antibodies bound to the same peptide antigen*. J Mol Biol., 1994. **241**(4): p. 534-56.

15 19. Calkins CC, P.K., Potempa J, Travis J., *Inactivation of tumor necrosis factor-alpha by proteinases (gingipains) from the periodontal pathogen, Porphyromonas gingivalis. Implications of immune evasion*. J Biol Chem, 1998. **273**(12): p. 6611-4.

20 20. Nakamura K, K.M., *Proteolysis of human tumor necrosis factor (TNF) by endo- and exopeptidases: process of proteolysis and formation of active fragments*. Biol Pharm Bull., 1996. **19**(5): p. 672-7.

21. Narhi LO, R.M., Hunt P, Arakawa T., *The limited proteolysis of tumor necrosis factor-alpha*. J Protein Chem, 1989. **8**(5): p. 669-77.

22. Kim YJ, C.S., Kim JS, Shin NK, Jeong W, Shin HC, Oh BH, Hahn JH., *Determination of the limited trypsinolysis pathways of tumor necrosis factor-alpha and its mutant by electrospray ionization mass spectrometry*. Anal Biochem., 1999. **267**(2): p. 279-86.

25 23. Magni F, C.F., Marazzini L, Colombo R, Sacchi A, Corti A, Kienle MG., *Biotinylation sites of tumor necrosis factor-alpha determined by liquid chromatography-mass spectrometry*. Anal Biochem., 2001. **298**(2): p. 181-8.

24. van Kessel KP, v.S.J., Verhoef J., *Inactivation of recombinant human tumor necrosis factor-alpha by proteolytic enzymes released from stimulated human neutrophils*. J Immunol., 1991. **147**(11): p. 3862-8.

30 25. Locksley RM, K.N., Lenardo MJ., *The TNF and TNF receptor superfamilies: integrating mammalian biology*. Cell, 2001. **104**(4): p. 487-501.

26. Humphreys, D.T. and M.R. Wilson, *Modes of L929 cell death induced by TNF-alpha and other cytotoxic agents*. Cytokine, 1999. **11**(10): p. 773-82.

27. Zhao, X.M., L; Song, K; Oliver, P; Chin, SY; Simon, H; Schurr, JR; Zhang, Z; Thoppil, D; Lee, S; Nelson, S; Kolls, JK, *Acute Alcohol Inhibits TNF-alpha Processing in Human Monocytes by Inhibiting TNF/TNF-alpha-Converting Enzyme Interactions in the Cell Membrane*. 2003: p. 2923-2931.

5 28. Marsters SA, F.A., Simpson NJ, Fendly BM, Ashkenazi A., *Identification of cysteine-rich domains of the type 1 tumor necrosis factor receptor involved in ligand binding*. J Biol Chem., 1992. **267**(9): p. 5747-50.

10 29. Chen PC, D.G., Chen MJ., *Mapping the domain(s) critical for the binding of human tumor necrosis factor-alpha to its two receptors*. J Biol Chem., 1995. **270**(6): p. 2874-8.

30. Rosenberg JJ, M.S., Seely JE, Kinstler O, Gaines GC, Fukuzuka K, Rose J, Kohno T, Boyle WJ, Nelson A, Kieft GL, Marshall WS, Feige U, Gasser J, St Clair J, Frazier J, Abouhamze A, Moldawer LL, Edwards CK 3rd., *Development of a novel, nonimmunogenic, soluble human TNF receptor type I (sTNFR-I) construct in the baboon*. J Appl Physiol., 2001. **91**(5): p. 2213-23.

15 31. Whitcomb, D.C., Gorry M.C., Preston R.A., Furey W., Sossenheimer M.J., Ulrich C.D., Martin S.P., Gates L.K., Amann S.T., Toskes P.P., Liddle R., McGrath K., Uomo G., Post J.C., Ehrlich G.D., *Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene*. Nat Genet, 1996. **14**(2): p. 141-5.

20

Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

What is claimed is:

1. An adzyme for enzymatically altering a substrate, the adzyme comprising: a catalytic domain that catalyzes a chemical reaction converting said substrate to one or more products, and a targeting moiety that reversibly binds with an address site on said substrate or with an address site on a second molecule that occurs in functional proximity to the substrate, wherein
 - 5 said targeting moiety and said catalytic domain are heterologous with respect to each other,
 - 10 said targeting moiety, when provided separately, binds to the substrate,
 - 15 said catalytic domain, when provided separately, catalyzes the chemical reaction converting said substrate to one or more products, and
 - 20 said adzyme has one or more properties, with respect to the reaction with said substrate, of (a) a potency at least 2 times greater than the catalytic domain or the targeting moiety alone; (b) a k_{on} of $10^3 \text{ M}^{-1}\text{s}^{-1}$ or greater; (c) a k_{cat} of 0.1 sec^{-1} or greater; (d) a K_D that is at least 5 fold less than the K_m of the catalytic domain; (e) a k_{off} of 10^{-4} sec^{-1} or greater, (f) a catalytic efficiency at least 5 fold greater than the catalytic efficiency of the catalytic domain alone, (g) a K_m at least 5 fold less than the K_m of the catalytic domain alone, and/or (h) an effective substrate concentration that is at least 5 fold greater than the actual substrate concentration.
2. An adzyme for enzymatically altering a substrate, the adzyme comprising: a catalytic domain that catalyzes a chemical reaction converting said substrate to one or more products, and a targeting moiety that reversibly binds with an address site on said substrate or with an address site on a second molecule that occurs in functional proximity to the substrate, wherein
 - 25 said substrate is an extracellular signaling molecule,
 - 30 said targeting moiety and said catalytic domain are heterologous with respect to each other,
 - 35 said targeting moiety, when provided separately, binds to the substrate,
 - 40 said catalytic domain, when provided separately, catalyzes the chemical reaction converting said substrate to one or more products, and
 - 45 said adzyme is more potent than said catalytic domain or targeting moiety with respect to the reaction with said substrate.
3. An adzyme for enzymatically altering a substrate, the adzyme comprising a polypeptide comprising: a catalytic domain that catalyzes a chemical reaction converting said substrate to one or more products, a targeting domain that reversibly binds with an address site on said substrate or with an address site on a

second molecule that occurs in functional proximity to the substrate, and a linker joining said catalytic domain and said targeting domain, wherein

5 said substrate is a receptor,

said targeting moiety and said catalytic domain are heterologous with respect to each other,

said targeting domain, when provided separately, binds to the substrate,

10 said catalytic domain, when provided separately, catalyzes the chemical reaction converting said substrate to one or more products, and

15 said adzyme is more potent than said catalytic domain or targeting moiety with respect to the reaction with said substrate.

4. An adzyme for enzymatically altering a substrate, the adzyme comprising: a catalytic domain that catalyzes a chemical reaction converting said substrate to one or more products, and a targeting moiety that reversibly binds with an address site

15 on said substrate or with an address site on a second molecule that occurs in functional proximity to the substrate, wherein one or more of said products is an antagonist of an activity of said substrate.

5. An adzyme for enzymatically altering a substrate, the adzyme comprising: a

20 catalytic domain that cleaves at least one peptide bond of said substrate to produce one or more products, and a polypeptide targeting domain that reversibly binds with an address site on said substrate or with an address site on a second molecule that occurs in functional proximity to the substrate, wherein

25 said adzyme is resistant to cleavage by the catalytic domain,

said targeting moiety, when provided separately, binds to the substrate,

30 said catalytic domain, when provided separately, cleaves at least one peptide bond of said substrate to produce one or more products, and

35 said adzyme is more potent than said catalytic domain or targeting moiety with respect to the reaction with said substrate.

6. An adzyme for enzymatically altering a substrate, the adzyme comprising a

polypeptide comprising: a catalytic domain that catalyzes a chemical reaction converting said substrate to one or more products, a targeting domain that

reversibly binds with an address site on said substrate or with an address site on a second molecule that occurs in functional proximity to the substrate, and a linker

35 joining said catalytic domain and said targeting domain, wherein

39 said substrate is an extracellular polypeptide signaling molecule,

said targeting moiety and said catalytic domain are heterologous with respect to each other,

 said targeting domain, when provided separately, binds to said substrate,

 said catalytic domain, when provided separately, catalyzes the chemical reaction converting said substrate to one or more products, and

 said adzyme is more potent than said catalytic domain or targeting moiety with respect to the reaction with said substrate.

7. The adzyme of any of claims 1-6, wherein the substrate is endogenous to a human patient.

8. The adzyme of claim 7, wherein the effect of the adzyme on the substrate is effective against the target molecule in the presence of physiological levels of an abundant human serum protein.

9. The adzyme of claim 8, wherein the abundant human serum protein is human serum albumin.

10. The adzyme of any of claims 2-6, wherein said adzyme has one or more properties, with respect to the reaction with said substrate, of (a) a potency at least 2 times greater than the catalytic domain or the targeting moiety alone; (b) a k_{on} of $10^3 M^{-1}s^{-1}$ or greater; (c) a k_{cat} of $0.1 sec^{-1}$ or greater; (d) a K_D that is at least 5 fold less than the K_m of the catalytic domain; (e) a k_{off} of $10^{-4} sec^{-1}$ or greater, (f) a catalytic efficiency at least 5 fold greater than the catalytic efficiency of the catalytic domain alone, (g) a K_m at least 5 fold less than the K_m of the catalytic domain alone, and/or (h) an effective substrate concentration that is at least 5 fold greater than the actual substrate concentration.

11. The adzyme of claim 10, wherein the potency of the adzyme is at least 5 times greater than the catalytic domain or the targeting moiety alone.

12. The adzyme of claim 10, wherein the k_{on} is $10^6 M^{-1}s^{-1}$ or greater.

13. The adzyme of claim 10, wherein the k_{cat} is $10 sec^{-1}$ or greater.

14. The adzyme of claim 10, wherein the K_D is at least 50 fold lower than the K_m of the catalytic domain.

15. The adzyme of claim 10, wherein the k_{off} is 10^{-3} s^{-1} or greater.
16. The adzyme of claim 10, wherein the catalytic efficiency is at least 20 fold greater than that of the catalytic domain alone.
5
17. The adzyme of claim 10, wherein the K_m is at least 20 fold less than that of the catalytic domain alone.
18. The adzyme of claim 1, wherein the potency of the adzyme is at least 5 times greater than the catalytic domain or the targeting moiety alone.
10
19. The adzyme of claim 1, wherein the k_{on} is $10^6 \text{ M}^{-1} \text{ s}^{-1}$ or greater.
20. The adzyme of claim 1, wherein the k_{cat} is 10 sec^{-1} or greater.
15
21. The adzyme of claim 1, wherein the K_D is at least 50 fold lower than the K_m of the catalytic domain.
22. The adzyme of claim 1, wherein the k_{off} is 10^{-3} s^{-1} or greater..
20
23. The adzyme of claim 1, wherein the catalytic efficiency is at least 20 fold greater than that of the catalytic domain alone.
24. The adzyme of claim 1, wherein the K_m is at least 20 fold less than that of the catalytic domain alone.
25
25. The adzyme of any of claims 1, 2, 4 or 5, wherein said adzyme is a fusion protein.
26. The adzyme of claim 25, wherein said fusion protein includes a linker between said catalytic domain and said targeting moiety.
30
27. The adzyme of claim 25, wherein said linker is an unstructured peptide.
28. The adzyme of claim 3 or 6, wherein said linker is an unstructured peptide.
35
29. The adzyme of claim 27, wherein said linker includes one or more repeats of Ser₄Gly or SerGly₄.

30. The adzyme of claim 3 or 6, wherein said linker includes one or more repeats of Ser₄Gly or SerGly₄.
31. The adzyme of claim 25, wherein said linker is selected to provide steric geometry between said catalytic domain and said targeting moiety such that said adzyme is more potent than said catalytic domain or targeting moiety with respect to the reaction with said substrate.
5
32. The adzyme of claim 3 or 6, wherein said linker is selected to provide steric geometry between said catalytic domain and said targeting moiety such that said adzyme is more potent than said catalytic domain or targeting moiety with respect to the reaction with said substrate.
10
33. The adzyme of claim 25, wherein said linker is selected to provide steric geometry between said catalytic domain and said targeting moiety such that said address moiety presents the substrate to the enzymatic domain at an effective concentration at least 5 fold greater than would be present in the absence of the address moiety.
15
34. The adzyme of claim 3 or 6, wherein said linker is selected to provide steric geometry between said catalytic domain and said targeting moiety such that said address moiety presents the substrate to the enzymatic domain at an effective concentration at least 5 fold greater than would be present in the absence of the address moiety.
20
25. 35. The adzyme of claim 25, wherein the fusion protein is a cotranslational fusion protein encoded by a recombinant nucleic acid.
36. The adzyme of claim 3 or 6, wherein the fusion protein is a cotranslational fusion protein encoded by a recombinant nucleic acid.
30
37. The adzyme of claim 1, 4 or 5, wherein the substrate is a biomolecule produced by a cell.
38. The adzyme of any of claims 1-5, wherein said substrate is a polypeptide.
35
39. The adzyme of claim 1, 4 or 5, wherein the substrate is a polysaccharide, a nucleic acid, a lipid, or a small molecule.

40. The adzyme of any of claims 1, 4 or 5, wherein the substrate is a diffusible extracellular molecule.
41. The adzyme of claim 40, wherein the diffusible extracellular molecule is an extracellular signaling molecule.
5
42. The adzyme of claim 41, wherein the extracellular signaling molecule is an extracellular polypeptide signaling molecule.
- 10 43. The adzyme of claim 40, wherein the extracellular signaling molecule is selected from among: interleukin-1 and TNF-alpha.
44. The adzyme of claim 41, wherein the extracellular signaling molecule binds to a cell surface receptor and triggers receptor-mediated cellular signaling.
15
45. The adzyme of any of claims 1, 4 or 5, wherein said substrate is a receptor.
46. The adzyme of claim 45, wherein said substrate is a unique receptor subunit of a heteromeric receptor complex.
20
47. The adzyme of claim 37, wherein the biomolecule is a component of a biomolecular accretion.
48. The adzyme of claim 47, wherein the biomolecular accretion is selected from among: an amyloid deposit and an atherosclerotic plaque.
25
49. The adzyme of claim 37, wherein the biomolecule is a biomolecule produced by a pathogen.
- 30 50. The adzyme of claim 49, wherein the pathogen is selected from among, a protozoan, a fungus, a bacterium and a virus.
51. The adzyme of claim 37, wherein the biomolecule is a prion protein.
- 35 52. The adzyme of any of claims 1, 2, 4 or 5, wherein said substrate comprises a polypeptide and wherein said catalytic domain is a protease that cleaves at least one peptide bond of the substrate.

53. The adzyme of claim 52, wherein said adzyme is resistant to cleavage by said catalytic domain.
54. The adzyme of claim 3 or 6, wherein said catalytic domain is a protease that cleaves at least one peptide bond of the substrate.
55. The adzyme of claim 54, wherein said adzyme is resistant to cleavage by said catalytic domain.
- 10 56. The adzyme of claim 52, wherein said protease is a zymogen.
57. The adzyme of claim 54, wherein said protease is a zymogen.
- 15 58. The adzyme of claim 52, wherein said adzyme is purified from a cell culture in the presence of a reversible protease inhibitor.
59. The adzyme of claim 54, wherein said adzyme is purified from a cell culture in the presence of a reversible protease inhibitor.
- 20 60. The adzyme of any of claims 1-6, wherein said catalytic domain modifies one or more pendant groups of said substrate.
61. The adzyme of any of claims 1-6, wherein said substrate includes a chiral atom, and said catalytic domain alters the ratio of stereoisomers.
- 25 62. The adzyme of claim 38, wherein said catalytic domain alters the level of post-translational modification of the polypeptide substrate.
63. The adzyme of claim 6, wherein said catalytic domain alters the level of post-translational modification of the polypeptide substrate.
- 30 64. The adzyme of claim 62, wherein the post-translation modification is selected from the group consisting of glycosylation, phosphorylation, sulfation, fatty acid modification, alkylation, prenylation and acylation.
65. The adzyme of claim 63, wherein the post-translation modification is selected from the group consisting of glycosylation, phosphorylation, sulfation, fatty acid modification, alkylation, prenylation and acylation.

66. The adzyme of any of claims 1, 2, 4 or 5, wherein the catalytic domain is selected from the group consisting of: a protease, an esterase, an amidase, a lactamase, a cellulase, an oxidase, an oxidoreductase, a reductase, a transferase, a hydrolase, an isomerase, a ligase, a lipase, a phospholipase, a phosphatase, a kinase, a sulfatase, a lysozyme, a glycosidase, a nuclease, an aldolase, a ketolase, a lyase, a cyclase, a reverse transcriptase, a hyaluronidase, an amylase, a cerebrosidase and a chitinase.
5
67. The adzyme of claim 3 or 6, wherein the catalytic domain is selected from the group consisting of: a protease, an oxidase, an oxidoreductase, a reductase, a transferase, a hydrolase, an isomerase, a lipase, a phospholipase, a phosphatase, a kinase, a sulfatase, a glycosidase, an aldolase, a ketolase, a lyase, a cyclase, a hyaluronidase, and a cerebrosidase.
10
68. The adzyme of any of claims 1-6, wherein the adzyme is resistant to autocatalysis.
15
69. The adzyme of claim 68, wherein the adzyme is resistant to autocatalysis at an adzyme concentration that is about equal to the concentration of adzyme in a solution to be administered to a subject.
20
70. The adzyme of claim 37, wherein said adzyme alters the half-life of the biomolecule in vivo.
71. The adzyme of claim 2, 3 or 6, wherein said adzyme alters the half-life of the substrate in vivo.
25
72. The adzyme of claim 37, wherein said adzyme alters the distribution of the biomolecule in vivo.
73. The adzyme of claim 2, 3 or 6, wherein said adzyme alters the distribution of the substrate in vivo.
30
74. The adzyme of claim 37, wherein said adzyme reduces a biological activity of said biomolecule.
35
75. The adzyme of claim 2, 3 or 6, wherein said adzyme reduces a biological activity of said substrate.

76. The adzyme of claim 37, wherein said biomolecule binds a plurality of different molecules in vivo, and said adzyme alters the binding specificity of said biomolecule.

5 77. The adzyme of claim 2, 3 or 6, wherein said substrate binds a plurality of different molecules in vivo, and said adzyme alters the binding specificity of said substrate.

78. The adzyme of claim 37, wherein said adzyme alters the interaction of said biomolecule with other molecules in vivo.

10 79. The adzyme of claim 2, 3 or 6, wherein said adzyme alters the interaction of said substrate with other molecules in vivo.

80. The adzyme of claim 78, which alters one or more of: a receptor-ligand interaction, 15 a protein-protein interaction and a DNA-protein interaction.

81. The adzyme of claim 79, which alters one or more of: a receptor-ligand interaction, a protein-protein interaction and a DNA-protein interaction.

20 82. The adzyme of claim 37, which reduces receptor-mediated or ion channel-mediated signal transduction.

83. The adzyme of claim 3, which reduces receptor-mediated or ion channel-mediated signal transduction.

25 84. The adzyme of claim 37, which alters proliferation, differentiation or viability of a cell in vivo or in vitro.

85. The adzyme of claim 2, 3, or 6, which alters proliferation, differentiation or 30 viability of a cell in vivo or in vitro.

86. The adzyme of any of claims 1-3, 5 or 6, wherein said product of said chemical reaction is an antagonist of said substrate.

35 87. The adzyme of any of claims 1-3, 5 or 6, wherein said product of said chemical reaction has an increased biological activity relative to said substrate.

88. The adzyme of claim 37, which alters an intrinsic enzymatic activity of said biomolecule.
- 5 89. The adzyme of claim 2, 3 or 6, which alters an intrinsic enzymatic activity of said substrate.
90. The adzyme of claim 1, 2, 4, or 5, wherein said substrate is a polypeptide.
- 10 91. The adzyme of claim 90., wherein said polypeptide is present in biological fluid of an animal.
92. The adzyme of claim 6, wherein said extracellular polypeptide signaling molecule is present in biological fluid of an animal.
- 15 93. The adzyme of claim 91, wherein said biological fluid is blood or lymph.
94. The adzyme of claim 92, wherein said biological fluid is blood or lymph.
95. The adzyme of claim 90, wherein said polypeptide substrate is a polypeptide hormone, a growth factor and/or a cytokine.
- 20 96. The adzyme of claim 92, wherein said extracellular polypeptide signaling molecule is a polypeptide hormone, a growth factor and/or a cytokine.
97. The adzyme of claim 91, wherein said polypeptide factor is selected from the group consisting of four-helix bundle factors, EGF-like factors, insulin-like factors, β -trefoil factors and cysteine knot factors.
- 25 98. The adzyme of claim 92, wherein said extracellular polypeptide signaling molecule is selected from the group consisting of four-helix bundle factors, EGF-like factors, insulin-like factors, β -trefoil factors and cysteine knot factors.
99. The adzyme of claim 91, wherein said polypeptide is a pro-inflammation mediator and said enzyme construct reduces the pro-inflammatory activity of said polypeptide factor.

100. The adzyme of claim 92, wherein said extracellular polypeptide signaling molecule is a pro-inflammation mediator and said enzyme construct reduces the pro-inflammatory activity of said polypeptide factor.
- 5 101. The adzyme of claim 91, wherein said polypeptide is Interleukin-1 or TNF α , and said adzyme reduces the activity of the substrate in vivo.
102. The adzyme of claim 92, wherein said extracellular polypeptide signaling molecule is Interleukin-1 or TNF α , and said adzyme reduces the activity of the substrate in vivo.
- 10 103. The adzyme of claim 1, 4, or 5, wherein the substrate is an intracellular biomolecule.
- 15 104. The adzyme of claim 103, wherein said adzyme further comprises a transcytosis moiety that promotes transcytosis of the adzyme into the cell.
104. The adzyme of claim 1, 2, 4 or 5, wherein the targeting moiety comprises a polypeptide or polypeptide complex.
- 20 105. The adzyme of claim 1, 2, 4 or 5, wherein said targeting moiety is a polyanionic or polycatonic binding agent.
106. The adzyme of claim 1, 2, 4 or 5, wherein said targeting moiety is an oligonucleotide, a polysaccharide or a lectin
- 25 107. The adzyme of any of claims 1-6, wherein the targeting moiety is an antibody or polypeptide(s) including an antigen binding site thereof.
- 30 108. The adzyme of claim 107, wherein the targeting moiety is selected from the group consisting of a monoclonal antibody, an Fab and F(ab)₂, an scFv, a heavy chain variable region and a light chain variable region.
109. The adzyme of any of claims 1-6, wherein said substrate is receptor ligand, and said targeting moiety includes a ligand binding domain of a cognate receptor of said ligand.
- 35

110. The adzyme of any of claims 1-6, wherein said targeting moiety is an artificial protein or peptide sequence engineered to bind to said substrate.
111. The adzyme of any of claims 1, 4 or 5, wherein said substrate is a receptor, and
5 said targeting moiety is a cognate ligand of said receptor.
112. The adzyme of claim 3, wherein said targeting moiety is a cognate ligand of said receptor.
- 10 113. The adzyme of claim 101, wherein the substrate is TNF α and wherein the targeting moiety binds to TNF α .
114. The adzyme of claim 102, wherein the substrate is TNF α and wherein the targeting moiety binds to TNF α .
- 15 115. The adzyme of claim 113, wherein the catalytic domain comprises a protease that decreases TNF α pro-apoptotic activity.
116. The adzyme of claim 114, wherein the catalytic domain comprises a protease that
20 decreases TNF α pro-apoptotic activity.
117. The adzyme of claim 115, wherein the protease is selected from among: MT1-MMP; MMP12; tryptase; MT2-MMP; elastase; MMP7; chymotrypsin; and trypsin.
- 25 118. The adzyme of claim 116, wherein the protease is selected from among: MT1-MMP; MMP12; tryptase; MT2-MMP; elastase; MMP7; chymotrypsin; and trypsin.
- 30 119. The adzyme of claim 113, wherein the targeting moiety is selected from among, a soluble portion of a TNF α receptor and a single chain antibody that binds to TNF α .
120. The adzyme of claim 114, wherein the targeting moiety is selected from among, a soluble portion of a TNF α receptor and a single chain antibody that binds to TNF α .
- 35 121. The adzyme of claim 113, wherein the targeting moiety is an sp55 portion of TNFR1.

122. The adzyme of claim 114, wherein the targeting moiety is an sp55 portion of TNFR1.
123. The adzyme of claim 101, wherein the substrate is IL-1 and wherein the targeting moiety binds to IL-1.
5
124. The adzyme of claim 102, wherein the substrate is IL-1 and wherein the targeting moiety binds to IL-1.
- 10 125. The adzyme of claim 123, wherein the catalytic domain comprises a protease that decreases an IL-1 bioactivity.
126. The adzyme of claim 124, wherein the catalytic domain comprises a protease that decreases an IL-1 bioactivity.
15
127. An adzyme preparation for therapeutic use in a human patient, the preparation comprising an adzyme of any of claims 1-6.
128. The adzyme preparation of claim 127, further comprising a pharmaceutically effective carrier.
20
129. The adzyme preparation of claim 127, wherein the adzyme preparation is formulated such that autocatalytic modification of the adzyme is inhibited.
- 25 130. The adzyme preparation of claim 129, wherein the adzyme comprises a catalytic domain that is a protease.
131. The adzyme preparation of claim 130, further comprising a reversible inhibitor of said protease.
30
132. The adzyme preparation of claim 131, wherein the reversible inhibitor is safe for administration to a human patient.
133. The adzyme preparation of claim 127, wherein said adzyme preparation is substantially pyrogen free.
35
134. The adzyme preparation of claim 127, wherein said adzyme preparation is packaged with instructions for administration to a patient.

135. A method of making a medicament for use in treating a disorder that is associated with an activity of the substrate of an adzyme of any one of claims 1-6, the method comprising formulating the adzyme for administration to a human patient.

5

136. A method of making a medicament for use in treating an inflammatory or allergic disorder, the method comprising formulating an adzyme of any one of claims 1, 2, or 4-6 for administration to a human patient in need thereof, wherein the substrate of the adzyme is an inflammatory cytokine.

10

137. A method of treating a disorder that is associated with an activity of the substrate of an adzyme of any one of claims 1-6, the method comprising administering a therapeutically effective dose of the adzyme to a human patient in need thereof.

15

138. A method of treating an inflammatory or allergic disorder, the method comprising administering a therapeutically effective dose of an adzyme to a human patient in need thereof, wherein the substrate of the adzyme is an inflammatory cytokine.

139. A nucleic acid comprising a coding sequence for the adzyme of claim 3 or claim 6.

20

140. A nucleic acid encoding a coding sequence for the adzyme of claim 25.

141. An expression vector comprising the nucleic acid of claim 139, wherein the expression vector directs expression of the adzyme in a suitable host cell.

25

142. An expression vector comprising the nucleic acid of claim 140, wherein the expression vector directs expression of the adzyme in a suitable host cell.

143. A cell comprising the expression vector of claim 141.

30

144. A cell comprising the expression vector of claim 142.

35

145. A cell comprising a first nucleic acid comprising a first coding sequence and a second nucleic acid comprising a second coding sequence, wherein the first coding sequence encodes a first fusion protein comprising an immunoglobulin heavy chain and a catalytic domain, and wherein the second coding sequence encodes a second fusion protein comprising an immunoglobulin heavy chain and a targeting domain.

146. The cell of claim 145, wherein, in appropriate culture conditions, the cell secretes an adzyme comprising an Fc fusion protein construct that is a dimer of the first fusion protein and the second fusion protein.

5

147. A method for manufacturing an adzyme, the method comprising
a) culturing a cell of claim 143 in conditions that cause the cell to produce the adzyme encoded by the expression vector; and
b) purifying the adzyme to substantial purity.

10

148. A method for manufacturing an adzyme, the method comprising
a) culturing a cell of claim 144 in conditions that cause the cell to produce the adzyme encoded by the expression vector; and
b) purifying the adzyme to substantial purity.

15

149. A method for manufacturing an adzyme, the method comprising
a) culturing a cell of claim 146 in conditions that cause the cell to produce the adzyme; and
b) purifying the adzyme to substantial purity.

20

150. The method of claim 147, wherein the purifying the adzyme to substantial purity includes the use of a reversible inhibitor that inhibits autocatalytic activity of the catalytic domain.

25 151. The method of claim 147, wherein the catalytic domain of the adzyme is a protease domain, and wherein purifying the adzyme to substantial purity includes the use of a reversible protease inhibitor that inhibits the protease activity of the catalytic domain.

30 152. A method of designing and constructing an effective adzyme, the method comprising:
a) selecting a substrate that is a known target for a therapeutically effective binding agent;
b) testing a plurality of catalytic domains for effectiveness in reducing an activity of the substrate to obtain a set of one or more candidate catalytic domains that are effective in reducing an activity of the substrate;

c) testing a plurality of binding moieties for effectiveness in binding to the substrate to obtain a set of one or more candidate targeting moieties that are effective in binding to the substrate;

5 d) constructing and producing a plurality of adzymes comprising one or more of the candidate catalytic domains and one or more of the candidate targeting moieties, wherein the one or more catalytic domains and the one or more candidate targeting moieties are associated in at least two different geometric conformations,

10 e) testing the plurality of adzymes for effectiveness in reducing an activity of the substrate to obtain a set of one or more candidate adzymes, wherein an adzyme that is effective for reducing an activity of the substrate is an effective adzyme.

153. The method of claim 152, further comprising testing the efficacy of the adzyme in an organism.

15 154. The method of claim 152, further comprising modifying an effective adzyme to improve one or more of the following properties:

a) reduce the amount of autocatalysis;

b) increase the potency of the adzyme;

c) increase the specificity of the adzyme;

20 d) improve the balance of the potency and specificity of the adzyme;

e) increase the serum half-life of the adzyme;

f) decrease the interactions between the adzyme and one or more abundant serum proteins.

25 155. A method of operating a therapeutic adzyme business, the method comprising:

a) designing an adzyme according to the method of claim 152;

b) testing the adzyme for safety and effectiveness in humans;

c) arranging for distribution and marketing of the adzyme.

1/16




Fig. 1

2/16




Fig. 2A




Fig. 2B




Fig. 2C




Fig. 2D

3/16




Fig. 2E




Fig. 2F




Fig. 2G




Fig. 2H

4/16




Fig. 2I




Fig. 2J




Fig. 3A




Fig. 3B

5/16




Fig. 3C




Fig. 3D




Fig. 3E

6/16




Fig. 3F




Fig. 3G

7/16




Fig. 4

8/16




Fig. 5

9/16




Fig. 6

10/16




Fig. 7

11/16




Fig. 8

12/16




Fig. 9

13/16




Fig. 10




Fig. 11

14/16




Fig. 12




Fig. 13




Fig. 14


DETECTION OF TNF α BINDING OF ADZYMES BY ELISA

Fig. 15

16/16




Fig. 16